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Haematopoietic stem cells (HSCs) exist in a fine balance between self-renewal 
and differentiation. The maintenance of this balance is critical for sustaining 
long term multilineage haematopoietic reconstitution. Quiescent HSCs heavily 
rely on glycolysis over oxidative phosphorylation (OXPHOS) to produce 
adenosine triphosphate (ATP). This is thought to be an adaptation to the 
hypoxic bone marrow (BM) microenvironment and reflects the low metabolic 
demands of quiescent HSCs, but also may allow for long-term survival. The 
transition from quiescent to active HSCs is accompanied by a metabolic switch 
towards OXPHOS which is essential for HSC differentiation. Stress stimuli 
such as infection initiate rapid expansion and differentiation of HSCs, which 
requires extensive ATP production. The underlying mechanisms involved in 
this process remain largely unknown. Here I examine the immuno-metabolic 
processes which facilitate HSC expansion in response to acute infection.  
 
This research shows that infection drives an increase in mitochondrial mass in 
HSCs, resulting in a metabolic switch from glycolysis towards OXPHOS. The 
initial mitochondrial mass increase occurred as a result of mitochondrial 
transfer from BM stromal cells (BMSCs) to the HSCs. This process was 
mediated by macrophage derived NADPH oxidase 2 (NOX2) reactive oxygen 
species facilitating the opening of connexin-43 channels. Moreover, 
mitochondrial transfer was regulated by activation of phosphoinositide3-kinase 
and this process occurred before the cells transcriptional program to generate 
new mitochondria. Furthermore, following infection HSCs also take up free 
fatty acids (FFA) and subsequently have an increased dependency on β-
oxidation. Mechanistically, CD36 upregulation mediates FFA uptake into 
HSCs, enabling CPT1A to transport fatty acyl chains into the mitochondria. 
Without uptake of FFA HSC expansion is reduced, leading to increased 
susceptibility and enhanced mortality in response to infection. Together, these 
findings provide mechanistic understanding of the interplay between HSCs 
and the BM microenvironment which supports the metabolic demands of 
HSCs during pathogenic stress. 
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1.1 Haematopoiesis  
 
On average, a healthy individual (70 kg in weight) is estimated to produce 
around 8 x 1011 mature blood cells daily (1). The process in which new blood 
cells are made is known as haematopoiesis. This can be broken down into 
various cell types including red cells, myeloid cells and lymphoid cells. It is 
estimated that we produce 2 x 1011 red cells, 1 x 1011 white cells and 4 
x 1011 platelets per day (2). Moreover, this production is increased when 
needed, in situations such as infections, trauma and severe blood loss (3). 
Thus, an efficient process is essential to generate large volumes of cells. This 
upregulation in adverse conditions is termed stress haematopoiesis.   
 
The bone marrow (BM) is the primary organ for haematopoiesis and bone 
formation (4). The BM not only contains haematopoietic cells, it also contains 
cells which contribute to bone homeostasis (5). Although the BM aims to 
maintain this homeostasis, the make-up of the BM can be displaced by 
aberrations such as malignancy or infection (6). The haematopoietic tissue 
comprises many different types of cells including; blood cells and precursor 
blood cells, barrier cells, adipocytes and macrophages. The arrangement of 
these cells is not arbitrary and show organisation within the BM (7). 
 
Haematopoiesis is the continuous, active process involved in the production 
of blood cells within the BM (8). The process originates at the haematopoietic 
stem cell (HSC), which is a multipotent stem cell (9, 10) HSCs give rise to 
haematopoietic progenitor cells (HPCs) through a series of lineage 
commitments. HPCs include common lymphoid and myeloid progenitors 
which can then differentiate into many different immune cells (11). Despite its 
complexity, haematopoiesis is one of the best defined human systems due to 
seminal animal experimentation (12). 
 
McCulloch and Till, 1960 were pioneers in first describing HSCs. Their 
research showed animals receiving a lethal dose of irradiation were rescued 
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from death via transplantation with unfractionated BM cells from non-irradiated 
mice (13). Interestingly, the transplanted irradiated mice developed small 
splenic lumps (14). They later went on to demonstrate that the colonies that 
formed in the spleen of the irradiated animals were formed by single cells 
capable of multilineage differentiation (15). These cells, now identified as 
HSCs, are regulated by many complex cellular and molecular signals at both 
a genetic and epigenetic level (16). Alterations to these highly regulated 
signals can lead to the dysfunction of haematopoietic cells causing them to 
become malignant stem cells (17). Thus, understanding more about the 
mechanisms behind how these highly regulated cells work is important in 
understanding the fundamentals of disease. 
 
The isolation of HSCs and HPCs, using distinct cell surface markers, allowed 
for the complex classification of the hierarchical structure of haematopoiesis 
to be identified (18). HSCs give rise to common lymphoid and myeloid 
progenitors, which can then differentiate into numerous different immune cells 
(11). Myeloid progenitors ultimately differentiate into granulocytes, monocytes 
and megakaryocytes (11). Granulocytes and monocytes play a key role in 
pathogen immunity and megakaryocytes can form platelets (11). Lymphoid 
progenitors give rise to the T cells, natural killer (NK) cells, dendritic cells and 
B cells, which are responsible for cell mediated immunity (11). This, however, 
is a simplified model and there is increasing evidence to suggest that the HSC 
does not strictly follow the hierarchical organisation but rather gradually 
acquire lineage biases along multiple directions (Figure 1.1) (19). 
 
Further analysis of the human haematopoietic system occurred after the 
emergence of severe combined immunodeficient (SCID) mice, these mice lack 
mature T and B cells (20). Transplanted human leukocytes from peripheral 
blood successfully engrafted into SCID mice and were able to produce 
functional human T and B cells (21). Furthermore, using a modified SCID 
model, the non-obese diabetic (NOD) SCID gamma (NSG) mouse allowed for 
more specific transplantation of HSCs isolated from human umbilical cord 
blood (22). Human CD45+ cells engrafted in the BM and the spleen of the 
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NSG mouse and mature human blood cells were found in the peripheral blood 
of the transplanted animal (23). Analysis of both human and murine 
haematopoietic systems has greatly aided in the understanding of 
haematopoiesis. 
 
Ordinarily, the BM is the sole site of haematopoiesis however, extramedullary 
haematopoiesis can occur in the spleen, liver and lymph nodes when 
compensatory mechanisms in the BM are compromised (1). In order for 
normal haematopoiesis to occur, support from the BM microenvironment is 
needed (24). The microenvironment provides the growth factors, neurological 
stimuli and cytokines required to aid proliferation, differentiation and 
maturation of stem cells along the lineage commitments (25). The BM 
microenvironment also provides the energy required for the rapid production 
of new blood cells (26). The haematopoietic microenvironment comprises the 
cells of the BM (27). Together, the BM microenvironment and the HSCs and 
progenitor cells constantly interact to allow for demands of new blood cells to 




















Figure 1.1. Hierarchical models of haematopoiesis. 
(A) A visualisation of the haematopoiesis model from around 2000. Long term 
haematopoeitic stem cells (LT-HSC) give rise to short term HSCs (ST-HSC), which 
can either revert back to LT-HSCs or differentiate and give rise to haematopoietic 
progenitor cells (HPCs). The multipotent progenitors (MPP) are the next stage of 
differentiation, which gives rise to both the common myeloid progenitor (CMP) and 
the common lymphoid progenitor (CLP). Myeloid cells include megakaryocyte-
erythrocyte progenitors (MEP) and the granulocyte-macrophage progenitors (GMP), 
which differentiate to form monocytes, macrophages, neutrophils, basophils, 
eosinophils, erythrocytes, and megakaryocytes. Whereas lymphoid cells include 
natural killer (NK) cells, T cells, and B cells. B cells also form the plasma cells 
(Created using BioRender.com). (B) From 2005 to 2015 the model expanded to 
incorporate new discoveries. The HSC pool is more heterogeneous and myeloid and 
lymphoid progenitors remain further down the hierarchy by the lymphoid-primed 
multipotent progenitors (LMPP) population. The eosinophil-basophil progenitor 
(EoBP)/ GMP population is fairly heterogeneous (28) (Created using 
BioRender.com). (C) From 2016, advances in single cell transcriptomics indicated 
cells gradually acquire lineage biases in a continuum of differentiation. The red dots 
represent a single cell. (Adapted from Laurenti and Göttgens, 2018 (29)). 
 
1.2  The human bone marrow 
 
The BM is an organ in which new blood cells are made in a process known as 
haematopoiesis (8). BM, found in the central cavities of the bone, is a sponge-
like tissue. It is comprised of blood vessels and a heterogeneous population 
of cells (30). The BM itself is made up of red marrow, also referred to as 
myeloid tissue, and yellow marrow (31). At birth, the BM consists of mostly red 
marrow, however with age, this is slowly displaced by yellow marrow which 
has a much higher level of adipocytes. In response to certain stress stimuli 
such as severe blood loss yellow marrow has the ability to revert back to red 
marrow (32). Red marrow is typically located either at the ends of the long 
bones or in the flat bones including; the hip, breastbone, skull, ribs, vertebrae 
and shoulder blades (Figure 1.2). The red marrow comprises the parenchyma, 
the haematopoietic stem and progenitor cells and vascular components 
including the supporting stromal cells (33). The main function of the red 
marrow is haematopoiesis, which is estimated to produce around 8 
x 1011 mature blood cells daily (1). Haematopoiesis is controlled by the central 
nervous system (CNS), which senses the body’s blood requirement, and 
increases or decreases blood production accordingly by its control of 
haematopoietic stem and progenitor cells located in the red marrow (34). The 
yellow marrow is mostly composed of fat cells, and operates as an energy 
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store in times such as severe starvation (35). Together, the red and yellow 
marrow function to support haematopoiesis.  
 
The human bone itself is comprised of the trabecular bone enclosed by a 
cortical bone layer and connective tissue (36). The BM cavity is comprised of 
at least four niches endosteal, subendosteal, central, and perisinusoidal (37). 
In terms of haematopoiesis histological and functional assays have shown that 
HSCs and multipotent progenitors preferentially reside in the endosteal and 
subendosteal regions, closely associated with the surface of the bone (27, 38). 
The more committed progenitors and mature cell types however colonise in 
the central and perisinusoidal regions, respectively. This complex organisation 
within the BM allows for efficient haematopoiesis. 
 
The BM is connected to the peripheral blood through vascular sinuses; pools 
of mixed arterial and venous blood dispersed within a trabecular bone network, 
which surrounds haematopoietic tissue islands and adipose cells (33). The 
venous sinuses are flat, thin-walled endothelial cells typically lacking a 
basement membrane. The venous sinuses receive arterial blood from the 
arteries and capillary networks connected by the Haversian canals. 
Consequently, blood flows in a circular process from the centre of the BM 
cavity toward the edge of the cavity and then back towards the centre (39) 
(Figure 1.2). The cavities are lined with a monolayer of flat “bone-lining cells”, 
which are reinforced with a thin layer of connective tissue (7). Neural 
innervation of bone, both myelinated and non-myelinated, permeates the BM 
through the nutrient foramina and is distributed similarly to the nutrient artery 
(40). The nerves run through the arterioles, innervating the vessels, and 
terminate at the haematopoietic tissue in the BM further suggesting blood 
production is regulated by the central nervous system. Taken together, this 





Figure 1.2. Cross section of the bone marrow. 
Anatomy of the bone, the diagram shows the trabecular, the spongy bone located at 
the end of the bone with the red marrow and the yellow marrow filling the cavities of 
the bone. A cross section of the bone shows the compact bone and blood vessels, 
the vascular sinuses. (Created using BioRender.com). 
 
1.3 Bone marrow microenvironment 
 
The BM microenvironment and its role in disease has recently been a research 
focus for many scientists. Several studies have demonstrated interactions 
between haematological malignancies and the non-haematopoietic cells 
within the BM aid the survival of these malignant cells both in vitro and in vivo 
(27). Studies have also shown that leukaemic cells compete for the BM 
resources creating a favourable environment for the progression of the 
disease (17, 41, 42).  
 
It has been theorised that the BM microenvironment can be categorised into 
compartments or niches which affect the differentiation and proliferation 
potential of HSCs (43). The two broad regions in the BM are the endosteal and 
the vascular niche (44). HSCs transition between the two niches. The 
endosteal niche maintains quiescence whereas the vascular niche enables 
differentiation and proliferation (45). This process ensures the HSC is in 




1.4  HSC niche  
 
A stem cell niche is defined as the location in which HSCs reside in an 
undifferentiated and self-renewable state (46). The idea of a niche was first 
described by Schofield in 1978 (47). However, since then considerable 
progress has been made in defining the structure and components of the niche 
(48). The best characterised BM microenvironment is the niche that regulates 
the HSC (49).  3D imaging of the mouse BM show dense populations of HSCs 
in micro-domains or niches (50). In the niche, cells interact with the HSCs, and 
either maintain quiescence or promote differentiation (51). Many studies have 
collectively established that the niche is mainly perivascular therefore, blood 
vessels and perivascular stromal cells are the key components of the niche 
(52). In addition, numerous other cell types have been shown to be 
components of the niche including osteoblasts and blood vessels (53). Thus, 
the HSC niche is a vastly complex network of cells functioning collectively for 
the production of BM cells (Figure 1.3). 
 
Within the niche, there is a relatively large number of maturing progenitor cells, 
for all lineages. This allows for prompt recruitment and reallocation of these 
cells under stressed conditions. The factors involved in the continuous 
turnover of mature cells in the BM are not well understood. There is however, 
evidence supporting the role of several growth factors and basic genetic 
controls in haematopoiesis regulation within the BM microenvironment (54). 
Together, the HSC niche is a highly organised microenvironment functioning 






Figure 1.3. The HSC Niche. 
Haematopoietic stem cells (HSCs) interaction with cells of the bone marrow (BM). 
The stromal cells release IL 6, IL 8 and CXCL12 which regulate the HSCs and can 
differentiate into the osteoblasts. The macrophage also can promote the release of 
CXCL12 from the stromal cells. The adipocytes release free fatty acids (FFA) which 
can provide the energy for HSC differentiation. The endothelial cells can regulate the 







































1.5 Cell compartments of the BM microenvironment 
 
1.5.1 Haematopoietic Cells 
 
1.5.1.1 Haematopoietic stem cells 
 
The key player in haematopoiesis is the HSC. McCulloch and Till findings 
introduced the two defining criteria of the HSC; self-renewal and differentiation. 
HSCs are the only cells of the haematopoietic system capable of both self-
renewal and differentiation. Specifically, HSC self-renewal is the ability to give 
rise to identical daughter cells whilst maintaining an undifferentiated state and 
differentiation is the ability of the HSCs to differentiate into all functional mature 
blood cells (55-58) (Figure 1.1). HSCs are first formed in early embryogenesis 
and their location changes during development (59). HSCs are a rare 
population within the BM making up around 0.05% of the total mouse BM cells 
(60, 61). Under normal conditions HSC numbers remain relatively unchanged 
and the majority of the HSCs primarily reside in G0 phase of the cell cycle (62).  
 
HSCs were first purified in 1988 from mouse BM cells using the then novel 
technology fluorescence activated cell sorting (FACS) and monoclonal 
antibodies (61). The enriched mouse HSC populations were sorted using the 
expression of two cell surface markers Thy-1low lineage marker (Lin) and Sca 
1, with HSCs being Lin negative (Lin-) and Sca 1 positive (60, 61). It was also 
demonstrated that these sorted Lin-Sca 1+ HSCs were the only mouse BM 
cells with the ability to reconstitute the entire haematopoietic system after 
transplantation into irradiated mice (61). It is important to note both Lin+Sca 1+ 
and Lin-Sca 1- cells were unable to reconstitute the BM (63). Following these 
initial findings, identifying additional cell surface markers CD117/c-Kit and 
CD34 allowed for more extensive purification of HSCs (64, 65). In 1996, it was 
demonstrated that injection of a single HSC (mCD34-, CD117, Sca 1+, Lin-) 
alone resulted in long-term repopulation of the haematopoietic system in 
lethally irradiated recipients (66). These additional cell surface markers also 
highlighted at least three distinct isolated populations; long term HSCs (LT-
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HSCs), short term HSCs (ST-HSCs) and multipotent progenitors (MPPs) (67). 
These cell populations are now well defined, with the additional cell surface 
markers, CD150 and CD48 (68).   
 
LT-HSCs are a subset of HSCs capable of undergoing asymmetric cell division 
to self-renew sustaining the HSC pool, and additionally differentiate into ST-
HSCs. (69). The ST-HSC is a multipotent HSC which is able to differentiate 
into the MPP. The MPP can differentiate to produce the common myeloid and 
lymphoid progenitors, which then differentiate further into mature, functional 
haematopoietic cells. LT-HSCs must sustain haematopoiesis for the lifespan 
of the organism, continually replenishing the haematopoietic system. 
However, the ST-HSCs and MPPs are only capable of maintaining 
haematopoiesis for a relatively short time of 6-8 weeks (70, 71). Taken 




Macrophages are immune effector cells and play a significant defensive role 
in the immune response (72). They participate in the host defence by 
phagocytosing microbes and parasites they come into contact with (73). The 
role of the macrophage also includes rapid and efficient removal of cell debris 
produced by cells undergoing apoptosis or during tissue modifications (74). 
The BM is an active site of myelopoiesis, a process in which monocytes and 
macrophages are produced (11). Within the BM, macrophages have been 
identified as being a vital element in modulating the HSC niche (75). Studies 
have reported depletion of macrophages, using clodronate-loaded liposomes 
or by using macrophage-Fas-induced apoptosis transgenic mice, led to HSC 
reallocation to the blood and a reduced number of HSC niche factor encoding 
genes (76). Winkler et al. 2010 also reported that CD169+ macrophages 
promoted the release of CXCL12 from the stromal cells causing HSCs to 
remain in their niche in a quiescent state (76). Other studies however, have 
shown using models of conditional depletion of macrophages, that a decrease 
in the number of macrophages causes a reduction of CXCL12 which leads to 
HSC retention by down regulation of the retention genes in the 
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Nestin+ mesenchymal stem cells (MSC) (77). Macrophages, therefore, are 
essential in the regulation of the HSCs. 
 
1.5.2 Non-haematopoietic Cells 
 
1.5.2.1 Osteolineage cells 
 
Alongside the haematopoietic system development, bone formation also 
occurs within the BM (78). Cells of the osteolineage include osteoblasts and 
osteoclasts which regulate bone formation. Osteoblasts are found at the 
surface of the new bone and are responsible for new bone formation (osteoid). 
They are phenotypically oval and elongated cells, stemmed from the MSCs 
(79). Osteoblast differentiation from MSCs is regulated by the transcription 
factor Runx2 (80). Both heterozygous and homozygous knockout of Runx2 in 
mice considerably disrupt osteogenesis, with homozygous knockout mice not 
surviving past birth (81). Mature osteoblasts form the bone by undergoing 
proliferation, matrix maturation and mineralisation (82). HSCs are found to be 
located close to osteoblasts whereas more mature progenitor cells are located 
further away (83). Initial studies into osteoblasts showed that osteoblasts 
promote the development of HPCs in culture (84). This was further reported 
by both Calvi et al. 2003 (85) and Zhang et al. 2003 (86). The authors showed 
activating osteolineage cells either pharmacologically or via genetic mutation, 
increased the number of HSCs in the BM. This suggests that osteoblasts have 
an important role in the maintenance of HSCs. An increase in the number of 
osteoblasts has also been positively correlated with an increased number of 
LT-HSCs in vivo (86, 87). Furthermore, it has been shown that in a conditional 
osteoblast knockout model there is an inability of the BM to sustain 
haematopoiesis (88, 89). However, there have been studies which disprove 
this and imaging of the BM has shown no relationship between HSCs and 
osteoblasts (90, 91). This could be due to osteolineage cells only having an 
indirect role in HSC regulation (27). The osteoblast population is heterogenic 
and there are many stages of differentiation of the osteoblasts. However, it 
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remains unclear which population is important in the maintenance of HSCs 
(92). 
 
Osteoclasts, on the other hand, are not derived from MSCs but do play an 
important role in the BM microenvironment. Osteoclasts are produced from the 
myeloid lineage specifically granulocyte macrophage progenitors (93). Bone 
formation is dynamic and relies on a balance between bone forming 
osteoblasts and bone resorbing osteoclasts (94). Osteoclasts are key in 
establishing a functional HSC niche. In an osteopetrotic (oc/oc) mouse, 
osteoclasts are not present and the BM of these mice lack any functional 
niches, which is thought to be due to the inability of HSC homing (95). There 
was also a reduced number of osteoblasts in the oc/oc mice. Overall, this 
suggests that the osteoclasts’ role in the maintenance of HSCs is linked 
indirectly though osteoblasts. 
 
1.5.2.2 Perivascular cells 
 
The BM needs to be highly vascularised to supply oxygen and nutrients for 
haematopoiesis. Perivascular cells, including pericytes and vascular smooth 
muscle cells (VSMCs) enclose the inner endothelial lining, providing support 
and stabilisation (96). Perivascular cells also surround the blood vessels 
promoting maturation of the vessel. This helps deter haemorrhaging or leaky 
vessels (97, 98). It is reported that the perivascular cells not only sustain the 
BM but also express high levels of major HSC niche factors making them a 
key component of the HSC niche (99, 100). 
 
1.5.2.3 Endothelial cells 
 
Endothelial cells make up the lining of the blood vessels and they have also 
been shown to modulate the trafficking of HPCs and HSCs in the HSC niche 
(101). Endothelial cells are derived from mesenchymal stem/stromal cells 
(MSC). Endothelial cells cultured in vitro have been shown to promote 
proliferation and differentiation of human CD34+ progenitor cells (102). They 
also regulate quiescence of HSCs via E-selectin, which is only expressed on 
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endothelial cells and activated by cytokines (103). Moreover, initial studies on 
endothelial cells with conditionally deleted gp130 receptor showed that this 
lead to a reduction of the HSC cell count in the HSC niches within the BM 
(104). Endothelial cells also release critical cytokines involved in HSC 
maintenance, including granulocyte colony stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 
(IL) 6 when stimulated with the proinflammatory cytokines IL 1 or tumour 
necrosis factor-alpha (TNF-a) (102). Additionally, vascular cell adhesion 
molecule 1 (VCAM-1) is expressed on endothelial cells (105). VCAM-1 binds 
to the leukocyte ligand VLA-4 present on HSCs causing HSC retention in the 
niche. Endothelial cells can also synthesise stem cell factor (SCF) in both its 
forms, soluble and membrane bound. Moreover, there is a depletion of HSCs 
when SCF is knocked out (106). Arterial vessels also promote HSC 
quiescence due to them being less permeable, thus maintaining the HSCs in 
a low reactive oxygen species (ROS) environment. High levels of ROS 
augment the differentiation and migration ability of HSC population (107). 
Therefore, endothelial cells and arterial vessels play a crucial role in the 




Adipocytes, often regarded as fat cells, are derived from MSCs and 
predominantly compose the BM adipose tissue (BMAT) (108). BMAT is an 
interesting form of adipocyte tissue which composes more than 10% of the 
total fat mass in normal healthy humans (109). Recent advances in imaging of 
the BM has shown BMAT has unique features highlighting physiological 
specificity in the BMAT (110). Alongside ageing (111, 112) BMAT is increased 
in osteoporosis (113) and obesity (114, 115). With age, the haematopoietic 
tissue within the BM is gradually replaced with adipocytes. Adipocytes make 
up around 15% of the BM in young adults, however, by age 65 this is increased 
to 60% (116). Thus, the number of HSC is negatively correlated with the 
increase of adipocytes in the BM (117). Adipocytes importantly contain large 
levels of fat and therefore play a significant role in regulating bone metabolism 
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(118). These cells store fat in lipid droplets in the form of triglycerides, which 
can be broken down by a catabolic process known as lipolysis into free fatty 
acids (FFA) and glycerol (119, 120) (Figure 1.4). These studies suggest that 
BM adipocytes are not just space fillers but play a substantial role.  
 
There have been many conflicting reports on adipocytes and whether they are 
directly involved in the maintenance of HSCs (78). These cells have been 
found to both generate and secrete SCF (121), they can also produce 
CXCL12, IL 8 and IL 3 (122), which are all key regulators in maintaining the 
HSC niche. Proteomic analysis of BM adipocytes showed, an upregulation of 
the pathways involved in sphingolipid signalling, arachidonic and cholesterol 
metabolism but a decrease in lipolytic enzymes compared to subcutaneous 
adipocytes (110). The physical location inside the niche may suggest BM 
adipocytes are an important energy source in response to stress. However, 
the full extent of the role of the adipocyte in the BM is not well established. 
This is due to the difficulties in isolating BM adipocytes from both humans and 
mice, which is partially due to the locality of the adipocyte. Additional studies 






Figure 1.4. The biochemical pathway governing lipolysis in the 
adipocyte. 
Triglycerides are broken down to glycerol and fatty acids in the adipocyte by the 
enzymes adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and 
monolglyceride lipase (MSL). (Created using BioRender.com). 
 
1.5.2.5 Stromal cells 
 
Another cell key to the establishment of the HSC niche is the BM 
mesenchymal stromal cell (BMSC). Often referred to as mesenchymal 
stem/stromal cells, the BMSC have the potential to differentiate into many 
different types of cells described above including adipocytes, osteoblasts, 
myocytes and chondrocytes (123, 124). The identification of the BMSC is one 
of the least understood areas in stem cell biology. Many studies have tried to 
define the role of the BMSC. However, they are universally recognised as 
connective tissue, which is phenotypically similar to skeletal progenitors and 
pericytes (30). Bianco et al. 2008, were the first to identify the progenitor to the 
BMSC and redefined them as a skeletal stem cell (124, 125). Saccehetti et al. 
2016, then help further the understanding of the stem cells proving that BMSC 
are not universal but in fact have varying differentiating capacities for different 
tissues of different origin (126). BMSC culture in vitro are characterised by 
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their differentiation ability, adherence to plastic and expression of fibroblast 
surface markers (127). The BMSCs have many importantant roles in the 
supporting the HSCs and heamatopoisis, which is dicussed further in section 
1.6. 
 
1.6 BMSC and normal haematopoiesis 
 
BMSC have been shown to release key cytokines and chemokines that 
regulate HSC maintenance (27). The potential of the HSCs to differentiate, 
self-renew, remain quiescent or proliferate is dependent on these factors 
secreted by adjacent cells in the BM microenvironment (128). BMSC 
specifically are a key source of SCF and CXCL12. Conditional deletion of the 
SCF (129) or CXCL12 (130) from stromal cells have also been shown to 
decrease the number of HSCs in the BM, solidifying the fact that BMSCs play 
a key role in the HSC niche compartment. 
 
SCF is a cytokine crucial in regulating the HSC niche (131). SCF can be 
present in both soluble and membrane bound forms and is activated when 
bound to the tyrosine kinase receptor CD117 expressed by HSCs to regulate 
proliferation (132, 133). It was reported that a small alteration in CD117 has a 
large effect on the functionality of HSCs (134). Thus, when culturing HSCs in 
vitro SCF proves vital. It has also been shown that maintenance of 
haematopoiesis by the membrane bound SCF is fundamental, as Sl/Sld mutant 
mice which only express the soluble SCF lack HSCs and progenitor cells 
(135). This data shows that SCF is a vital cytokine in HSC regulation. 
 
CXCL12 is a chemokine which regulates the HSC niche by promoting the 
retention of HSCs to maintain the HSC pool. CXLCL12 binds to and activates 
the C-X-C chemokine receptor type 4 (CXCR4) on the HSCs (136, 137). It has 
been shown that CXCL12 plays a key role in the regulation and reallocation of 
the HSC to the peripheral blood or spleen. The number of HSCs is reduced  in 
the niche when there is a deletion of CXCL12 in MSCs (100, 138) or CXCR4 
in HSCs (137). It has recently been found that BMSC secretion of CXCL12 
can be controlled by circadian oscillations (139). The sympathetic nerve fibres 
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release noradrenaline and this causes a downregulation of CXCL12 secretion 
from the BMSCs leading to HSC migration from the BM. Together, CXCL12 
plays a crucial role in the maintenance of haematopoiesis. 
 
BMSCs also secrete a variety of other growth factors and chemokines such 
as; Flt-3 ligand (FLT-3), thrombopoietin (TPO), IL 6, IL 7, IL 11, macrophage 
colony stimulating factor (mCSF), TNF-a, transforming growth factor- b1 
(TGF- B1) and leukaemia inhibitory factor (LIF) (140). These are all essential 
in the maintenance of haematopoietic homeostasis. 
 
BMSCs are a diverse cell population and there is increasing evidence about 
the number of different types of stromal cells (141, 142), which have different 
functions in regulating HSCs (90). However, there are three distinct 
populations which have been widely studied; CXCL12-abundant reticular 
(CAR) cells, nestin-GFP+ stromal cells and leptin receptor+ stromal cells (131). 
These stromal cell populations have substantial similarities as they were first 
found by transgene expression of stromal cell promotors. To identify CAR 
cells, GFP was knocked in to the CXC12 locus, similarly for nestin-GFP+ 
stromal cells GFP was knocked in to the nestin promoter(143, 144). Leptin 
receptor+ stromal cells were first found by lineage mapping of leptin receptor 
elements using Cre-recombinase expression (106). 
 
CAR cells are mesenchymal progenitors which can produce CXCL12 and can 
differentiate into adipocytes and osteoblasts (137, 145). Deletion of the CAR 
cells significantly decreases the amount of SCF and CXCL12 and also 
decreases the number of HSCs in the BM (145). BMSC express high levels 
Nestin-GFP+ transgene and deletion of this gene increases the translocation 
of HSCs from the BM to the spleen (100). Nestin-GFP+ cells, however, express 
both CXCL12 and SCF, and deletion of these cells leads to a decrease in HSC 
numbers (131). Similarly, leptin receptor+ stromal cells also express CXCL12 
and SCF and can differentiate into adipocytes however they are unable to 
differentiate into osteoblasts (145). HSC quiescence has been shown to be 
maintained by the NG2+ LepR− cells which contribute to the arteriolar niches. 
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Whereas NG2−LepR+ cells are thought to form perisinusoidal niches and 
regulate the proliferation of HSCs within the BM. Conditional depletion of NG2 
expressing cells has been found to induce HSC cycling (146). Whilst these 3 
cell types may be distinct, they have commonalities, including the ability to 
produce CXCL12 and SCF, and therefore can be classified as BMSCs.  
 
Intriguingly, intracellular HSC ROS levels can be reduced when in contact with 
BMSCs. This is via multiple mechanisms including CXCL12 and CXCR4 and 
ROS uptake via gap junctions (147). High levels of ROS enhance the 
differentiation ability and motility of the HSC population thus, BMSC are 
important in maintaining normal haematopoiesis (107). 
 
1.7 Pathological diseases of the BM 
 
An organism needs to achieve a balance between maintaining a sufficient 
HSC pool throughout its life span, whilst also consistently meeting the demand 
for replenishing the mature blood cells, many which only live for a short amount 
of time (58). The significance of maintaining this balance is highlighted by the 
many instances where abnormal HSC expansion causes severe disease. 
Examples of this are when HSC progenitors cannot fully differentiate into the 
more mature blood cell types or when HSCs do differentiate into more 
committed progenitors but do not lose their capacity for self-renewal (148). 
Examples of pathological diseases of the BM are discussed further in the 
sections below.  
 
1.7.1 Ageing  
 
Ageing is a process which affects all normal cells, tissues and organ systems; 
both the BM and the BM microenvironment are modified with age. 
Haematological changes within the BM are shown by a decrease in cellularity, 
a decline in adaptive immunity and a higher risk of developing 
myeloproliferative diseases (149) anaemia (150) autoimmune (151) and 
inflammatory disorders (152). The cellularity in the BM decreases dramatically 
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with age from 90% at birth to only 25% haematopoietic tissue at age 70 (153) 
(Figure 1.5). The haematopoietic tissue is replaced by adipocyte infiltration 
into the BM, which results in a decrease in the number of immune cells. These 
increased numbers of maturing adipocytes release factors that influence the 
neighbouring BMSC, driving further differentiation of the BMSCs towards 
adipocytes (154) creating a feedback loop and promoting ageing in the BM.  
 
Whilst extrinsic factors including an inflammatory microenvironment can 
accelerate ageing (155), they also effect the HSC, causing cell-intrinsic 
changes that can alter the self-renewal and differentiation potential, triggering 
lineage skewing (156). With ageing, the number of HSCs are increased, 
however, there is a reduced production of lymphoid cells and a preferential 
skewing towards myeloid cell production (27, 157-159). This age related loss 
of HSC function is thought to be due to telomere shortening (160), the accrual 
of nuclear and mitochondrial DNA damage (161) and changes in gene 
expression. Aged HSCs have upregulation of genes associated with stress 
and inflammation, whilst DNA repair and chromatin silencing genes are 
downregulated compared to young HSCs (157, 159). Furthermore, 
transcriptome analysis of aged HSCs showed a reduction in TGFβ signalling 
and impairment of genes involved in HSC differentiation and proliferation. 
Aged HSCs also showed elevated DNA methylation specifically at 
transcription factor binding sites. This was associated with an increase in 
genes promoting differentiation and a decrease in genes in sustaining HSC 
maintenance (162). Taken together this shift in HSC gene expression 
reinforces the diminished capacity for self-renewal and differentiation in aged 
HSCs.  
 
More recently it has been shown that the traits of HSC ageing and myeloid-
biased haematopoiesis in mice are initiated in middle-age. Moreover, the 
middle-aged BM microenvironment induces these haematopoietic ageing 
phenotypes, through a decreased production of IGF1 which accelerates BM 
ageing and stimulation with IGF1 rescues haematopoietic ageing (163). These 
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results indicate that the functional decline from young to aged HSCs may occur 
during middle age.  
 
Interestingly, although there are dramatic changes in the HSC niche with age, 
in the absence of disease HSCs are still able to repopulate the BM. When BM 
is transplanted from a 65-year-old donor into an HLA-matched younger 
recipient, the BM is still fully functional and maintains haematopoiesis, 
however, the only clinical change is an increased risk of rejection (164). 
Overall loss of HSC function with age majorly contributes to the decrease in 
function of the haematopoietic system and can lead to an impaired vaccination 
response, increased susceptibility to infection, clonal haematopoiesis and 
increased risk of developing haematological malignancies (163). 
 
 
Figure 1.5. The ageing bone marrow. 
Schematic diagram of decreased cellularity in the bone marrow with age. The red 
marrow is displaced by adipocyte rich yellow marrow with small changes percentage 




1.7.2 Haematological Malignancies 
 
Although the BM microenvironment is involved in promoting normal 
haematopoiesis, it also plays a significant role in the development and 
progression of disease, including different types of haematological cancer. 
Many malignant disorders develop in the BM when blood cells become 
cancerous and proliferate uncontrollably. Haematological malignancies can be 
classified into three broad groups; leukaemia, myeloma and lymphoma (166).  
Leukaemia can be further subdivided into acute myeloid leukaemia (AML), 
chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL) and 
chronic lymphoblastic leukaemia (CLL).  
Acute leukaemias are defined by the proliferation and accrual of malignant 
immature myeloid (AML) or lymphoid (ALL) progenitor cells whilst in chronic 
leukaemias there is proliferation of more mature monoclonal myeloid (CML) 
and lymphoid (CLL) cells. The myeloid malignancies generally have a lower 
survival outcome than lymphoid malignancies (167). Furthermore, the acute 
conditions progress faster and are more severe than the slower chronic 
conditions. These haematological malignancies result in the failure of normal 
haematopoiesis. Multiple myeloma (MM) is a malignancy of the plasma cells 
in the BM which leads to the production of non-functional monoclonal intact 
immunoglobulins or immunoglobulin chains (168). MM and leukaemia are 
liquid cancers present in the BM and peripheral blood, lymphoma however is 
a solid tumour made up of lymphocytes and resides in the lymphatic system. 
Lymphoma can be subdivided into either Hodgkin or Non-Hodgkin lymphoma. 
Hodgkin lymphoma is defined by the presence of malignant Reed-Sternburg 
cells whereas Non-Hodgkin lymphoma includes all other lymphomas (169). 
 
MM (170), AML (171), ALL (172), CLL (173) and CML (174) have all been 
shown to be heavily reliant on the BM microenvironment. The tumour 
microenvironment is vital for tumour cell proliferation, angiogenesis, 
invasion and metastasis. This is through its provision of survival signals, 
secretion of growth and pro-angiogenic factors and has been shown to 
provide a protective environment allowing malignant cells to evade 
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chemotherapy (43). Together, these studies demonstrate the significance of 
the BM microenvironment in the progression of haematological malignancies.  
 
1.7.2.1 Acute Myeloid Leukeamia 
 
AML is an aggressive malignancy defined by the proliferation and accrual of 
immature myeloid progenitors in the BM (175). AML is sustained by a pool of 
leukaemic stem cells (LSCs), which have the ability to evade chemotherapy 
and are often responsible for the relapse of this disease (176). AML is 
heterogeneous, there are many chromosomal translocations present in this 
disease (177). Similar to MM, AML primarily affects the older demographic 
with 71 being the average age at diagnosis (178).  
 
In the HSC niche, interactions between the BM microenvironment and 
leukaemia promote the survival, proliferation and chemotherapy resistance of 
AML (179-181). Many studies have now shown that primary leukaemia cells 
are not able to proliferate outside its disease microenvironment (30, 173, 182, 
183). Moreover, in many cases the interactions between the leukaemia and its 
microenvironment are hijacked from normal interactions between 
haematopoietic stem and progenitor cells (HSPCs) and the BM 
microenvironment. Thus, understanding the interactions between leukaemia 
cells and its BM microenvironment could also help us understand how normal 
HSPCs interact with the BM microenvironment. For example, AML has been 
shown to use the CXCR4/CXCL12 signalling axis to hone the BM (184) and 
blocking this interaction mobilises the AML into the peripheral blood (185). 
Discovering this mechanism in a malignant setting has allowed for the use of 
CXCR4 inhibitors to mobilise HSCs into the peripheral blood for isolation prior 
to stem cell transplantation (186, 187).  
 
In our laboratory we have shown that the BM microenvironment plays a key 
role in this disease. Specifically, the BM adipocytes have been shown to 
support the proliferation of AML. AML blasts reprogram the metabolism of the 
adipocytes to induce lipolysis, releasing FFA, which in turn are taken up by the 
AML (42). We have also shown that BMSC play a key role in the growth of 
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these malignant cells by facilitating interactions between the BM 
microenvironment and the leukaemic cell. A potential reason for this 
interaction is the tumours’ reliance on mitochondrial driven adenosine 
triphosphate (ATP) production which is provided by the microenvironment in 
the form of mitochondrial transfer (188). It has recently been reported that 
tumour derived nicotinamide adenine dinucleotide phosphate oxidase 2 
(NOX2) stimulates the generation of superoxide, causing the BMSCs within 
the microenvironment to donate their mitochondria to the AML through 
tunnelling nanotubes (TNTs), promoting tumour survival (41). Moreover, this 
study also showed that CD34+ HPCs could acquire mitochondria from the 
BMSC, but only when stimulated with hydrogen peroxide. Understanding 
these processes in normal and stressed haematopoiesis is one of the main 
objectives of this study.  
 
1.8 Stressed haematopoiesis 
 
Stress at the cellular and organism level arises in numerous forms. Intrinsic 
stress is defined as intercellular metabolic changes such as; the amalgamation 
of waste products, damage caused by repeated cell division with age and 
production of toxic metabolites, including ROS (189). Environmental stress 
causing potentially harmful alterations in the biological system is referred to as 
extrinsic stress (190). Stresses such as bacterial infections, viral infections, 
ageing, trauma or severe blood loss can affect the haematopoietic response. 
The ability of the haematopoietic system to adapt in response to this stress is 
critical for survival (191). 
 
1.8.1 Stress and ageing 
 
Ageing exhibits characteristics of both extrinsic and intrinsic stresses and thus, 
can be construed as a stress itself (189). Biological ageing, also known as 
senescence, is described as adverse alterations leading to increased mortality 
(192). In cellular senescence, cells ensue distinct phenotypic alterations and 
no longer undergo the process of cell division or proliferation (193). With 
50 
 
cellular senescence there is a release of many pro-inflammatory cytokines, 
chemokines, proteases and growth factors, this is considered the senescence-
associated secretory phenotype (SASP) (194). Senescence is thought to 
occur from the presence of alleles with harmful consequences, which manifest 
themselves as adverse phenotypes in later age (195). Immunosenescence is 
defined by a reduction of both innate and adaptive immunity in the peripheral 
blood and the BM (196). Both these processes are likely to have a significant 
impact on normal haematopoiesis.  
 
With ageing there is also an accumulation of  dysfunctional mitochondria (197, 
198) oxidative stress (199), proteotoxic stress (200), and inflammation (201) 
these all can alter normal HSC function. As HSCs have the ability to self-renew 
throughout their lifetime they are one of the only blood cells that can truly age 
(202). Although HSC expansion increases with age, their functionality 
decreases over time. Subsequently, there is a decrease in the production of 
blood and  engraftment after transplantation (203). However, the reason for 
this decline remains unknown (204). 
 
During ageing, HSCs acquire mutations which are passed to daughter cells, 
some mutations have no effect (205), whilst others can lead to increased 
proliferation, self-renewal and disproportionate expansion at the expense of 
other clones (206). This survival advantage is a hallmark of clonal 
haematopoiesis. Clonal haematopoiesis is often initiated by a skewed X 
chromosome inactivation or somatic mutations, most commonly in the 
DNM3TA, TET2, and ASXL1 genes (206, 207). These mutations represent a 
permissive state for leukaemia development and are commonly associated 
with myeloproliferative disorders, myelodysplatic syndrome and AML (148, 
208-210). Therefore, ageing itself is a stress, which can lead to functional 






1.8.2 Response to infection 
 
Alongside haematopoiesis, the BM is also an important site for granulopoiesis, 
erythropoiesis and lymphopoiesis which are all key to the response to 
infection. Microbial challenges, including acute infection, are linked to 
significant changes in the HSC compartment. This, in turn, has an impact on 
the differentiation and migration of  HSCs (211). The BM has a central role in 
maintaining this immune homeostasis; in infection the haematopoietic system 
drives the immune response necessary for host survival. HSC differentiation 
can be influenced by a variety of stimuli, including contact with pathogens, to 
combat the cellular needs of the immune response resulting in physiological 
changes within the BM (212). Infection can therefore dysregulate the 
progenitor cells and interfere with normal homeostasis in the BM, including the 
availability of blood cells (213). Under pathogenic challenge, emergency 
granulopoiesis and rapid mobilisation of neutrophils out of the BM is key to 
overcome pathogen invasion (191). Erythropoiesis similarly is increased in 
response to acute inflammation upon pathogen detection. Under systemic 
challenges such as malaria and toxoplasmosis, there is a preferential increase 
of granulocytes in the BM. This is at the expense of the lymphocyte, 
erythrocyte, and megakaryocyte populations (214).  
 
Increases in the number of progenitor or HSC populations within the BM is a 
trademark of infection (215). Immune challenges with Plasmodium 
chabaudi or Pneumocystis carinii increase the number of HPCs and HSCs in 
the BM and in the peripheral blood, which subsequently causes an increase in 
MPP cells (216). It has not been distinguished whether the changes in the BM 
are a consequence of the infection or part of the response to minimise the 
infection. It is also unclear whether the role of HSCs in infection includes 
immune sensing, however, it has been reported that the proliferation of HSCs 
could be a component of the primary response alongside replenishing 
depleted progenitors (217). Nevertheless, despite these drastic changes in the 
make-up of the BM microenvironment populations caused by infection, once 




The long-term effects of repeated infection on haematopoiesis and the 
function of life-long HSCs can however be detrimental. It has recently been 
shown that repeated inflammatory challenge with Poly IC results in depletion 
of functional HSCs and that these HSCs have an inability to self-renew. This 
depletion had no initial consequences on the mice however they developed 
clinically relevant features of ageing, comparable to elderly humans (218). 
Similarly, when mice were given daily low dose of lipopolysaccharide (LPS) 
for 1 month HSCs were unable to maintain quiescence, and following 
transplantation these HSCs skewed toward a myeloid lineage concurrent with 
ageing (219). Overall the haematopoietic system has an effective efficient 
reponse to immune challenges, however sustained or repeated infection can 
have an adverse effect and accelerate ageing.  
 
1.8.3 LPS as a surrogate for bacterial infection 
 
Bacterial LPS are a main component of the outer surface membrane of most 
gram-negative bacteria (220). They are strong activators of the innate and 
natural immune system in humans and murine models so are ideal in 
mimicking an infection (221). LPS comprises an oligosaccharide region which 
is attached to the outer membrane on the bacteria via a carbohydrate, lipid A 
(222). The main immunostimulatory effects of LPS is due to lipid A. In 
mammals, activation of the immune system with highly endotoxic forms of LPS 
have all been comprised of lipid A types of LPS (223). LPS can trigger a 
number of physiological immunostimulatory effects in mammals, however, if 
the dose is too high it can lead to the induction of septic shock (224).  
 
Myeloid lineage cells have been shown to be the primary sensors for LPS in 
the immune system (223). Significant progress been made to understand the 
signalling cascade caused by LPS in mammalian phagocytes. It is thought that 
the LPS is first recognised by the LPS binding protein (LBP), CD14 either 
membrane bound or soluble form and Toll-like receptor 4 (TLR4) *MD-2 
complex. This leads to the rapid activation of the intracellular signalling 
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network similar to the signalling of IL 1 and IL 18 (223). Whilst LPS alone 
activates the TLR4 immune response, whole bacterial cells secrete many 
virulence factors which activate numerous TLRs and pattern recognition 
receptors (PRR) that can modulate the immune response so LPS alone may 
not be truly representative of a bacterial infection. Whole bacterial cells also 
replicate and shed LPS, resulting in a more kinetic immune response rather 
than a direct activation of the immune system. However, to assess the effect 
of the host response to infection in a more standardised manner, in vivo and 
in vitro LPS can be used as a surrogate for simulating a bacterial infection. 
 
1.8.4  Salmonella   
 
Salmonella typhimurium (S. typhimurium) is the most common cause of 
invasive nontyphoidal Salmonella infection. Aggressive strains of non-
typhoidal salmonellae have been the main cause of infection of the 
bloodstream in African children and adults, with a fatality rate of 20–25% (225). 
S. typhimurium infections cause acute inflammation of the intestine in both 
human and mice hosts. The S. typhimurium can survive in this inflammatory 
environment and therefore has a selective growth advantage over the gut 
microbiota (226). Following adherence to the intestine the S. typhimurium then 
invades and crosses the intestinal epithelium (227). Toll like receptors (TLRs) 
are the first pathogen recognition receptors to recognise the presence of 
Salmonella (228). Salmonella has been shown to activate several TLRs 
including TLR1/2/6 in vitro by its bacterial lipoproteins; TLR4 by its LPS, TLR5 
by its flagellin and TLR9 by the CpG-rich repetitive elements in its DNA (226). 
When the ligands bind to the TLRs, MyD88 and TRIF signalling adaptors are 
activated initiating a signalling cascade in which transcriptional factors NFκB 
and IRF3 are also activated. This induces the production of several 
inflammatory cytokines including IL 8, IL 10, IL1β, IL 18 and type I interferon 
response (228). Mice infected with S. typhimurium have been shown to have 
upregulation of Sca 1 expression. Systemic infection with S. typhimurium also 
induced HSC activation and γH2AX+ and 53BP1+ foci formation indicating 
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proliferative stress caused by TLR4-TRIF signalling (229). S. typhimurium is 
the model of bacterial infection used in this study.  
 
1.8.5 NOX2  
 
It is interesting to note that, in some genetic diseases there exist a number of 
immunodefficiency syndromes (230). Nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX) isoforms have many important roles in 
the maintenance of normal functionality however, they have been connected 
to the pathogenesis of multiple diseases (231). NOX2 (Figure 1.6) is crucial in 
the host defence to microbes. One example of this inability to fight infection is 
NOX2 deficiency in several chronic granulomatous diseases (CGD), which are 
characterised by extreme inflammation and severe bacterial and fungal 
infection (232). This results from an inability of the phagocytes to produce ROS 
caused by a mutation in the genes encoding NOX2 (232, 233). The 
phagocytes, unable to produce reactive oxidant intermediates (ROI), have a 
low capability for phagocytosis. It has also been suggested that NOX2 plays a 
crucial role in the crosstalk between neutrophils and macrophages promoting 
neutrophilic apoptosis and clearance, to limit inflammation (231). NOX2-
deficient mice developed pro-inflammatory cytokine responses and 
neutrophilic lung inflammation in response to zymosan a ligand found on the 
surface of fungi. Wild type and transgenic mice which had NOX2 reconstructed 
in the monocytic and dendritic linages exhibited self-limited responses (234). 
These data show that NOX2 plays a critical role in fighting infection. However, 
we need to further understand if and how NOX2 signalling is required for the 






Figure 1.6. Diagram of NOX2. 
Activated complex of NADPH oxidase 2 (NOX2) also known as gp91phox. NOX2 is 
activated on phagosomes of phagocytic cells. NOX2 is formed of heterodimeric 
complexes and has a p22phox chain which is regulated by p47phox a homologous 
organiser protein and p67phox an activator protein. NOX2 also requires Rac bound 
to a GTP. When activated the preassembled cytosolic subunits p67phox, p40phox 
and p47phox translocate to the complex. Superoxide anions are produced by NOX2 
upon activation. (Adapted from Rada and Leto, 2008 (235)).  
 





The broad definition of metabolism is the sum of the biochemical processes 
which generate or consume energy in a living organism. This is a vast amount, 
more than 8,700 reactions and 16,000 metabolites (236). Pathways utilising 
abundant nutrients such as carbohydrates, fatty acids and amino acids are the 
basis of core metabolism and vital for energy homeostasis. Cells utilise these 
nutrients for energy in the form of ATP, primarily generated by aerobic 














Glucose is converted into pyruvate which generates two molecules of ATP in 
a process known as glycolysis. Pyruvate can then feed the tricarboxylic acid 
(TCA) cycle for further ATP production (238). Glycolysis is an oxygen 
independent reaction. Interestingly, recent studies have shown that lactate can 
also feed the TCA cycle via its conversion back to pyruvate by lactate 
dehydrogenase (239) (Figure 1.7). Within the mitochondria pyruvate is 
converted to acetyl CoA reducing nicotinamide adenine dinucleotide (NAD+) 
to NADH, which is later used by the cell to generate ATP (240). Acetyl CoA 
enters the TCA cycle where one molecule of ATP is generated, however three 
molecules of NADH and one molecule of reduced flavin adenine nucleotide 
(FADH2) are also produced (241). NADH and FADH2 provide the high energy 
electrons for the next stage in the process, oxidative phosphorylation 
(OXPHOS).  
 
OXPHOS is a process in which ATP is produced by electron transport from 
the NADH and FADH2 along protein Complex I, II, III and IV situated on the 
inner mitochondrial membrane (237). Electrons are removed from NADH in 
mitochondrial Complex I and FADH2 in Complex II and transferred to 
coenzyme Q (ubiquinone). Ubiquinone is reduced to ubiquinol in Complexes I 
and II transferring electrons to cytochrome C through Complex III. Electrons 
are removed from cytochrome C in Complex IV and transferred to oxygen 
molecules, generating water. As the electrons are transported through the 
complexes, mitochondrial matrix protons are passed across the inner 
mitochondrial membrane, creating an electrical potential gradient (242). This 
generates a proton-motive force, synthesising ATP from ADP and Pi by a 
rotation of the F0 subunit (243). Four protons are necessary for one molecule 
of ATP to be produced (244). NADH releases 10 protons whereas FADH2 
releases only six protons (237). Consequently, during this process many ATP 
molecules can be produced and therefore, OXPHOS is the most efficient way 





1.9.2 Glycolysis vs Oxidative phosphorylation 
 
The HSC niche in which the HSCs reside is known to be hypoxic, this 
maintains stem cell quiescence. Under normal conditions quiescent HSCs 
heavily rely on anaerobic glycolysis rather than OXPHOS to sustain ATP 
production (245). Metabolic analysis has shown that HSCs/HPCs have a 
different metabolic profile to that of the more committed cells (246). HSCs have 
been shown to have an increased pyruvate kinase activity and accrue high 
levels of fructose-1,6-bisphosphate, suggesting that the HSCs are 
metabolising by active glycolysis. They also have been shown to have high 
levels of pyruvate but low levels of phosphoenolpyruvate, which is the product 
and substrate of the glycolysis pathway (247). These data show that under 
normal conditions it is most likely that glycolysis is the metabolic pathway of 
choice for the HSCs.  
 
As HSCs differentiates into progenitor cells, they exit the niche and many of 
these cycling cells are situated near the vascular endothelial cells. The oxygen 
levels increase to a more normoxic level and the progenitor cells start to use 
OXPHOS to generate ATP (248). However, under stressed haematopoiesis, 
the primary source of ATP was thought to be glycolysis. During stress the BM 
becomes acidic due to an increased lactate production, a by-product of 
glycolysis (249). The BM is also full of triglyceride containing adipocytes, which 
release FFA and glycerol in response to stress conditions (250). The next two 
sections introduce how lactate and FFA could be the primary source of energy 




It is important to note that a by-product of glycolysis is lactate. It has recently 
been found that alongside pyruvate, glucose also feeds the TCA cycle through 
lactate produced in glycolysis (239). This study showed that in lung tumours 
circulating lactate was the primary substrate for the TCA cycle. Glucose is a 
vital nutrient which is broken down into pyruvate and lactate through glycolysis 
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or CO2 via the TCA cycle. Previously it was assumed that pyruvate was the 
primary source of circulating carbon from glycolysis for the TCA cycle and the 
amount of carbon provided by lactate remains unknown. In this study, to 
quantify glucose and lactate concentrations, 13C isotope labelled nutrients 
were administered intravenously to fasting mice. In the fasting mice, lactate 
had the highest flux of metabolites even when compared to glucose, indicating 
that in this model lactate was the primary source of carbon for the TCA cycle. 
Pyruvate was expended at a similar rate to lactate, however as it only exists 
in small quantities it did not have a substantial flux. It was previously presumed 
that the abundance of lactate over glucose was due to the interchange 
between pyruvate and lactate (Figure 1.7), which occurs under low oxygen 
conditions or when there is an large quantity of lactate (249). However, if this 
was the case the 13C labels would not be altered after infusion or during the 
conversion of lactate to pyruvate, therefore the large flux measured is from the 
lactate itself. It has also been shown that lactate can feed the TCA cycle under 
malignant conditions specifically in non-small cell lung cancer (251). 
Therefore, it is thought the lactate produced in glycolysis can be fed into the 




Figure 1.7. The conversion of pyruvate to lactate. 
NAD+ is regenerated from NADH by reduction of pyruvate to lactate, it is a reversible 
reaction catalysed by the enzyme lactate dehydrogenase. This reaction occurs in 

























1.9.4 Fatty acid oxidation  
 
Glucose and lactate contribute to around half of the carbon required for the 
TCA cycle. It is hypothesised that the remainder is provided by a combination 
of other amino acids and fat (239). Fatty acids (FAs) are released from the 
adipose tissue and are stored as triglycerides. Triglycerides are hydrolysed by 
lipolysis and secreted into the circulation as FFAs and glycerol (252). FFAs 
act as a substrate for beta (β)-oxidation and subsequent ATP production (253). 
Fatty acid β-oxidation (FAO) occurs in the both the mitochondria and 
peroxisomes and is the process by which FFAs are broken down to generate 
acetyl-CoA, which can feed the TCA cycle to produce energy in the form of 
ATP (Figure 1.8). The process of FAO can be broken down into four steps. 
Firstly, FFAs enter the cells and are activated by being coupled with coenzyme 
A (CoA) within the cytosol. This allows for the long-chain fatty-acyl-CoA to 
transfer the acyl group via carnitine palmitoyl transferase 1 (CPT1) producing 
acylcarnitine. It is then transported into the inner mitochondrial membrane by 
carnitine translocase. The final step is inside the mitochondria, the long chain 
acylcarnitine is oxidised by the carnitine palmitoyl transferase 2 (CPT2) and 
converted back to long-chain acyl-CoA which enters the TCA cycle for further 
ATP production (254). FAO is capable of providing a large amount of energy 
to fuel tumour growth by increasing production of ATP under metabolic stress 
(255). In vitro CPT1 has been shown to be upregulated in lung tumour models 
promoting tumour survival in metabolically stressed conditions (256). Previous 
studies have also shown cancer cells overexpress CTP1, which drives ATP 
production via FAO (257, 258). Taken together this data shows FAO could be 





Figure 1.8. Glycolysis and Beta oxidation feed the TCA cycle. 
Glucose is converted to pyruvate by a process called glycolysis. A by-product of this 
process is lactate which alongside pyruvate enters the mitochondria and is converted 
to acetyl CoA, which then feeds the tricarboxylic acid cycle (TCA) cycle. At the same 
time free fatty acids (FFA) are converted to acyl carnitine, which is then transported 
across the mitochondrial membrane and converted to acetyl CoA via beta (b) 
oxidation. The acetyl CoA produced during FAO is also used in the TCA cycle. The 
TCA cycle is a sequence of reactions which generates energy in the form of ATP 
during the process of aerobic respiration. 
 
1.9.5 Fatty acid transporters   
FAs not only serve as an energy source, but they also regulate the metabolism 
by transcriptional and enzymatic complexes which govern gene expression of 
many pathways such as cell survival, proliferation and metabolic responses 
(259-261). FA trafficking is a dynamic but complex process which affects many 
aspects of cell function (260). There are many transporters and receptors 
involved in FA transport including Macrophage scavenger receptor 1 (Msr1) 
(262), long chain acyl CoA synthetase (Acsl) (263), FA binding proteins 
(Fabp1, Fabp3, Fabp4, Fabp5) (264), fatty acid transporter proteins (Slc27a1, 
Slc27a4, Slc27a5) (265, 266) and fatty acid translocase (CD36) (267, 268) 
(Figure 1.9). FA binding proteins (FABPs) coordinate lipid trafficking and 
function in cells (261). It has been previously shown that AML can induces 
lipolysis in adipocytes releasing FFA which are transported into the cell by 
FABP4 (42). There are currently 9 distinctive isoforms of FABPs identified, and 
these are highly expressed in tissues with active lipid metabolism (269).  
61 
 
CD36 is a scavenger receptor which is expressed on many different types of 
cells. It is an integral membrane protein which is involved lipid metabolism, 
inflammation, thrombosis, atherogenesis and haemostasis (270). There are 
many members of the CD36 family of genes including lysosomal integral 
membrane protein II (LIMP II) and high-density lipoprotein receptor SR-B1. 
These all have a hairpin topology, which comprises two transmembrane 
domains a hydrophobic sequence adjacent to the COOH terminus and 
hydrophobic signal anchor adjacent to the NH2 terminus (271). The COOH 
terminal half contains three disulphide bridges and is heavily glycosylated, 
which is key for CD36 membrane recruitment (272). CD36 has been shown to 
be expressed on haematopoietic cells including monocytes, megakaryocytes, 
platelets and erythroid progenitor cells. Whilst CD36 has many roles its 
primary role is suggested to be a FA transporter; it has a high affinity for 
binding long chain fatty acids. CD36 has been shown to be the primary 
facilitator of FA transport in cardiomyocytes, skeletal myocytes enterocytes 
and adipocytes (273-276). In a malignant setting CD36 has also been 
implicated in the progression of many types of cancers (17, 277-279). A 
subpopulation of LSCs have been shown to express CD36 and to have an 
altered metabolic profile with high levels of fatty acid oxidation. These CD36 
expressing LSCs had a survival advantage and were able to evade 
chemotherapy (17). This study aims to elucidate the importance of CD36 for 




Figure 1.9. Transporters and receptors involved in FA transport.  
A schematic diagram of fatty acid (FA) trafficking into the cell regulated by transport 
proteins and receptors. Extracellular FAs are transported into the cell across the 
plasma membrane by CD36 and fatty acid transport proteins (FATPs). Inside the 
cytoplasm FFAs bind to fatty acid binding protein 4 (FABP4) and then long chain acyl 
CoA synthetase. They are then transported across the mitochondrial membrane by 
carnitine palmitoyltransferase 1 (CPT1) and transported for further metabolism by 
carnitine palmitoyltransferase 2 (CPT2) to be utilised by β oxidation which then feeds 
into the TCA cycle to generate ATP. (Adapted from Masarwi et al. 2019 (280) and 
created using BioRender.com). 
 
1.9.6 Mitochondria  
 
Mitochondria are regarded as the powerhouse of the cell. They maintain 
homeostasis of the cells by regulating energy production, cell metabolism and 
calcium signalling (281). Endosymbiotic theory states that mitochondria 
originated from eubacteria engaging in a symbiotic relationship with the host 
cell (282). As such, mitochondria have conserved many bacterial 
characteristics including the double membrane, its own DNA and the ability to 
self-sustain by generating the majority of ATP for cells, either by OXPHOS or 
aerobic respiration (283). The inner mitochondrial membrane is folded and 
forms the cristae, this increases the surface area, for the electron transport 
chain to maximise ATP production. The mitochondria has its own distinct 
mitochondrial DNA (mtDNA) which differs from genomic DNA (gDNA) (284). 
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The 16 kilobase circular mtDNA genome is circular contains 37 genes, 13 of 
which encode protein subunits of Complex I, III, IV, and V (285). 
 
Mitochondria are central to the metabolism of carbohydrates, lipids and amino 
acids in most cells including HSCs. Recent studies have shown that a key 
characteristic of HSCs is the maintenance of quiescence by limiting 
mitochondrial respiration (286). Although the role of mitochondria in stem cells 
is very complex, mitochondria in normal HSCs are somewhat inactive (287). 
ROS levels, related to mitochondrial activity, are also much lower in the HSCs 
compared to the committed progenitors (288) suggesting differentiation of 
HSCs requires a rapid burst of energy supplied via mitochondrial metabolism. 
As active cells require a different energy source to quiescent cells, the 
changes in cellular metabolism from dormant to cycling is important (59). 
Increasing ROS levels, as occurs with infection, promotes the differentiation 
of HSCs for repopulation, whereas low levels of ROS maintain quiescence 
(289).  
 
This suggests reprogramming of HSC metabolism can occur dependent on 
the demand. For example, normal HSCs rely on the maintenance of 
quiescence via anaerobic glycolysis but can rapidly turn on mitochondrial 
OXPHOS to meet the energy demands of repopulation under stressed 
conditions (246, 290, 291). Understanding these underlying changes in HSC 
metabolism from quiescence to proliferation can aid in the understanding of 
the development of diseases and response to infection. This ultimately is the 
aim of my PhD study. 
 
1.9.7 Mitochondrial transfer 
 
Mitochondria were typically thought to reside in one cell for the entirety of their 
life, undergoing fusion and fission generating networks of mitochondria until 
degradation by mitophagy (292). However, it has now been proven this is not 
the case and mitochondria are able to move intercellularly. Multiple structures 
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have been found to potentially mediate this transfer such as tunnelling 
nanotubules (TNTs), extracellular vesicles and gap junctions (Figure 1.10).  
 
Functional mitochondrial transfer was first described by Spees et al. 2006, 
where mitochondrial transfer between human stem cells and somatic cells in 
vitro rescued aerobic respiration of non-functional mitochondria-depleted 
recipient cells. A549 cells were treated long term with ethidium bromide to 
damage the mtDNA (ρ0) causing dysfunctional or deleted mitochondria. When 
cultured alone these A549 ρ0 cells did not survive monoculture. However, 
when co-cultured with human mesenchymal stem cells they obtained donor 
mitochondria and were able to respire aerobically (293). There was initial 
concern that intercellular mitochondrial transfer was not physiologically 
relevant as it was only observed in vitro. However, more recent studies 
disprove this and have reported that mitochondrial transfer does in fact also 
occur in vivo in tissue injury and cancer survival and proliferation (41, 294-
297).  Tan et al. 2015, showed mitochondrial transfer occurs in vivo, ρ0 tumour 
cells acquired mtDNA from cells in the tumour microenvironment, leading to 
recovery of mitochondrial function in these tumour cells (298).  
 
Intercellular mitochondria transfer has been shown to be crucial in the survival 
of cancer cells (299). Primary AML acquire functional mitochondria from the 
BMSC in a co-culture system increasing mitochondrial mass by 14%. 
Following co-culture, AML had a 1.5-fold increase in the production of 
mitochondrial ATP and were more resistant to mitochondrial depolarisation 
after chemotherapy, increasing cell survival. The mitochondrial transfer was 
cell to cell contact dependant (297).  
 
Mitochondrial transfer may also affect normal processes including stem cell 
differentiation, activation of inflammatory signalling pathways or differentiated 
cellular reprogramming (300). Intercellular mitochondrial trafficking has been 
shown to protect against acute lung injury following infection. Mice were 
airway-instilled with LPS and mouse BMSC. The mouse BMSC released 
mitochondria-containing extracellular vesicles which were taken up by the 
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alveolar epithelium. This transfer of mitochondria caused an increase in ATP 
in the alveolar preventing acute lung injury in response to infection (295). 
Similarly, neurons have been shown to transfer their dysfunctional 
mitochondria to astrocytes for reprocessing and this process is bi-directional. 
In mice with transient focal cerebral ischaemia astrocytes release and transfer 
functional mitochondria to neurons increasing cell survival (296).  
 
In a similar way, mitochondrial transfer occurs between MSC and human 
umbilical vein endothelial cells. Human umbilical vein endothelial cells were 
oxygen and glucose deprived and then reoxygenated, this stimulated 
mitochondrial trafficking from the MSC to the damaged endothelial cells 
resulting in rescued aerobic respiration and protection from apoptosis (301). 
Transfer of mitochondria from MSC to macrophages both in vitro and in vivo 
has been shown to enhance phagocytic capability of the macrophages in 
following Acute Respiratory Distress Syndrome and sepsis. Furthermore, 
inhibiting this process caused a decrease in macrophage functionality (302). 
These studies suggest intrinsic or extrinsic stress may be required to initiate 
intercellular mitochondrial transfer and that mitochondrial transfer is a 






Figure 1.10. Mechanisms of mitochondrial transfer. 
A schematic representation of the structure of the mechanism by which mitochondria 
can transfer intercellularly. 1. Tunnelling nanotubules 2. Gap junctions 3. Extracellular 
vesicles. (Created using Servier Medical ART). 
 
 
1.9.7.1 Tunneling Nanotubules 
 
One mediator of mitochondrial transfer are TNTs. TNTs have been shown to 
occur intercellularly both in vitro and in vivo. TNTs join the cytoplasm of two 
neighbouring cells directly via open tubes or channels (299). They enable the 
interchange of cellular organelles, membrane vesicles and small, cytoplasmic 
and membrane soluble molecules. A nanotubule is formed by the development 
of a membrane projection similar to the filopodium, which withdraws when it 
has reached the target cells leaving behind a very fine structure, separate to 
the substrate (300).  TNTs are able to bidirectionally transport proteins, lipid 






(303-305). There are two types of TNTs characterised by size, cytoskeletal 
design and functionality (306, 307). Type 1 TNTs tend to be longer and larger 
than type 2 TNTs and also have a clearer cytosolic tunnel. Interestingly, tubulin 
is not present in type 2 TNTs, however, type 1 TNTs are comprised of 
microfilaments and microtubules. Subsequently, organelle transporting only 
occurs by type 1 TNTs  and this is therefore, the type of TNT utilised in 
mitochondrial transfer (306). TNTs are vital in some types of mitochondrial 
transfer, TNT impairment either chemically or with stress can reduce 
mitochondria trafficking (308). Intercellular mitochondrial transfer via TNTs is 
facilitated by Milton adaptor proteins and kinesin motors (309-311).  
 
Stress agents have been shown to increase the formation of TNTs and 
subsequently induce mitochondrial transfer. Endothelial progenitors have  
increased mitochondrial transfer to mature endothelial cells when treated with 
doxorubicin (312). Similarly, ethidium bromide treatment increases TNT 
facilitated mitochondrial transfer from MSC to osteosarcoma cells (313). In 
vivo models of acute lung injury stimulated by rotenone or TNF-treatment also 
initiates mitochondrial transfer from the stem cells to lung epithelial cells via 
TNTs (294). Generally, mitochondrial transfer via TNTs is initiated by 
mitochondrial damage. However, serum starvation and hydrogen peroxide 
also promote TNT formation. Taken together, this signifies stress can induce 
the formation of TNTs and subsequently initiate mitochondrial transfer. 
 
1.9.7.2 Extracellular vesicles  
 
Another facilitator of intercellular mitochondrial transfer are extracellular 
vesicles. Most cell types release heterogeneous vesicles into the extracellular 
media. Extracellular vesicles range in size from 30 to 10000 nm and can be 
categorised into three broad subtypes microvesicles, exosomes and apoptotic 
bodies dependent on size, origin and composition (314). Extracellular vesicles 
also mediate intercellular communication in many physiological and 
pathological processes (315). These vesicles can move cellular materials and 
transport them over large distances (316). Mitochondrial proteins and DNA 
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have been found in extracellular vesicles and larger extracellular vesicles have 
been found to contain whole mitochondria.  
 
For example, both MSCs (317) and astrocytes (296) have recently been found 
to release mitochondria containing extracellular vesicles. BMSC have also 
been reported to use this mechanism to remove the dysfunctional depolarised 
mitochondria and transport them to surrounding macrophages for degradation 
(317).  
 
Extracellular vesicles have also been found to be considerably upregulated in 
the BM in haematological malignancies compared to their healthy counterparts 
(318). A recent study has shown isolation of extracellular vesicles from BMSC 
by ultracentrifugation, cocultured with CLL B cells decreased the amount of 
spontaneous apoptosis, increased migration capabilities and increased 
chemotherapy resistance to several drugs. The extracellular vesicles 
produced by the MSC in leukemic patients also protected the malignant cells 
from both spontaneous and drug induced apoptosis (173). Overall, these 
studies suggest that mitochondrial trafficking within extracellular vesicles is 
most likely the result of a cellular mechanism to rescue mitochondrial function. 
 
1.9.7.3 Gap Junctions  
 
Another intercellular transporter of mitochondria are gap junctions. Gap 
junctions are specialised intercellular channels directly connecting the 
cytoplasm of different cells (319). They allow for the interchange of ions and 
molecules smaller than ATP through a regulated gate (320). A gap junction 
consists of two connexons or half channels linked in the intercellular space 
forming a channel spanning both cell membranes (321). They were originally 
characterised as ion channels with low resistance, connecting nerve and 
muscle cells however, they have now been shown to be able to connect most 
cells. Gap junctions have evolved over time to have a range of different 




Mitochondrial transfer by gap junctions was shown to protect against acute 
lung injury. This process of mitochondrial transfer was shown to be regulated 
by connexins specifically, connexin-43 (CX43), which promotes the 
connection between MSCs and LPS damaged alveolar epithelial cells. This 
then led to the MSCs releasing extracellular vesicles containing the 
mitochondria, which were engulfed by the alveolar epithelial cells. This 
establishment of the CX43 gap junction channel was essential, MSC with 
dysfunctional CX43 could not attach to the alveolar epithelium cells and 
subsequently, no mitochondrial transfer occurred (295). It has also been 
shown that BMSCs transfer mitochondria through gap junctions to oxygen-
glucose deprivation injured neurons after spinal cord injury. The gap junction 
inhibitor 18β glycyrrhetinic acid reduced mitochondrial transfer from BMSCs to 
neurons whilst the gap junction potentiator retinoic acid enhanced the 
mitochondrial transfer (323). In the context of the haematopoietic system it has 
been shown that osteogenic BMSCs acquire mitochondria from the HSPC in 
a CX43 gap-junction dependent manner. This function of this process is  to 
reduce ROS levels in the HSC to maintain quiescence (324). 
 
Donor and acceptor cell connexin complementarity is essential in the 
mitochondrial transfer process (325). Previous studies have demonstrated that 
CX43 is key in the formation of gap junctions for TNTs (326). Connexin and 
gap junction channels have also been shown to be involved in the clathrin-
dependent endocytosis of extracellular vesicles (327). This data indicates gap 
junctions are important in mediating all mechanisms of intercellular 












The BM microenvironment regulates the production of both haematopoietic 
and non-haematopoietic cells for the maintenance of blood production under 
normal and stressed conditions. The ability to generate large amounts of 
energy in the form of ATP under stressed haematopoiesis is essential for the 
increase in proliferation of the required immune cells. Intercellular 
mitochondrial transfer has recently been reported in acute myeloid leukaemia 
as well as models of lung inflammation. In the context of bacterial infection, 
the haematopoietic system needs to drive the granulocytic response 
necessary for host survival. Whilst previous studies of the BM 
microenvironment have provided the foundation to characterise the interaction 
between haematopoietic stem and progenitor cells (HSPC) and their 
environment, this study aims to understand how mitochondrial transfer from 
the BM microenvironment to HSPC and, fatty acids as a substrate, facilitate 
the expansion of immune cells in response to infection. Understanding how 
the BM microenvironment responds to infection, will help broaden our 
understanding of the physiological processes that occurs after the disruption 
of BM homeostasis. Moreover, it is likely that these mechanisms, which 
support HSC metabolism are hijacked by haematological malignancies to 
support tumour growth and are a fundamental reason why blood cancers 
arising in the BM microenvironment are presently so difficult to treat. 
Developing our understanding of the effect of stress, on BM function in normal 





I hypothesise that under stressed haematopoiesis mitochondria move from the 
non-haematopoietic cells of the BM microenvironment to the haematopoietic 
stem/progenitor cells to rapidly support and sustain the host response to 
bacterial infection. I also hypothesise that HSCs within the BM 
microenvironment utilise both OXPHOS and β-oxidation to provide the 
necessary energy for the expansion of HSCs under stressed conditions. 
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1.12  Aims and Objectives 
1. To establish a model to track mitochondrial transfer in vivo. 
2. To determine if intercellular mitochondria trafficking from the BM 
microenvironment to HSCs is essential for the immune response to 
infection and establish the mechanisms governing this. 
3. To determine if fatty acids are transported to HSCs from the BM 
microenvironment and if fatty acid metabolism in the HSC is vital for 
generating cellular energy in response to bacterial infection.  
 






















The reagents and materials used in this study are described in the methods 
below. All reagents were obtained from Sigma Aldrich (St Louis, MO, USA), 
unless otherwise specified in the text. 
 
Table 2.1. Reagents used, with manufacturer and catalogue number. 
Agilent (Santa Clara, CA, USA), BioLegend (San Diego, CA, USA), , Clontech Takara Bio, 
Saint-Germain-en-Laye, France), Fisher Scientific (Hampton, New Hampshire, USA), GE 
Healthcare (Little Chalfont, UK), Ibidi (Munich, Germany), Machery-Nagel, Duren, Germany), 
Merck Millipore (Burlington, MA, USA), Miltenyi Biotec (Bergisch Gladbach, Germany), New 
England BioLabs (Ipswich, MA, USA), PCR Biosystems (London, UK), Peprotech (Rocky Hill, 
NJ, Promega (Madison, WI, USA), USA), Qiagen (Hilden, Germany), Sigma Aldrich (St Louis, 




Product Manufacturer Catalogue Number 
100 Base pair DNA ladder New England BioLabs N3231S 
10X RBC Lysis Buffer ThermoFisher 00-4300-54 
26G Butterfly Needles Fisher Scientific 12349169 






Sigma Aldrich 1004968350 
Ammonium Persulphate Sigma Aldrich A3678 
Amplex Red Assay ThermoFisher A22188 
AnnexinV Apoptosis Kit ThermoFisher 88-8005-72 
BL-Buthionine-sulfoximine Sigma Aldrich B2515 
BODIPY™ 493/503 ThermoFisher D3922 
Bovine Serum Albumin Fisher Scientific BP1600-100 
Bromophenol Blue Sigma Aldrich B0126 
CAL101 Selleck Chemicals S2226 
Calcein ThermoFisher C1430 
Carbenoxolone Selleck Chemicals S4368 
CD117 MicroBeads, mouse Miltenyi Biotec 130-091-224 
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Product Manufacturer Catalogue Number 
D-Luciferin Fisher Scientific 8829 
DAPI ThermoFisher 62248 
DMEM Medium ThermoFisher 10566016 
DMSO Fisher Scientific BP231-100 
EDTA Sigma Aldrich E9886 
Etomoxir Selleck Chemicals S8244 
Fetal Calf Serum ThermoFisher 105000056 
FIX & PERM Cell Fixation & 
Cell Permeabilization Kit 
ThermoFisher GAS004 
FlouroBrite DMEM ThermoFisher A1896701 
FLT 3 PeproTech 300-19 
FuGENE Promega E2691 
Gap 27 Sigma Aldrich G1794 
GeneJET Gel Extraction Kit ThermoFisher K0692 
GenElute Mammalian 
Genomic DNA Miniprep Kit 
Sigma Aldrich G1N70 
Glycine Fisher Scientific BP381-5 
H2DCFDA ThermoFisher D399 
H2O2 Sigma Aldrich H1009 
Heparin Sigma Aldrich H3393 
Histopaque-1077 Sigma Aldrich 10771 
Hoechst 33342 Solution ThermoFisher 62249 
Human CD105-FITC Miltenyi Biotec 130-098-774 
Human CD34 Microbead Kit Miltenyi Biotec 130-046-702 
Human CD34-VioBlue Miltenyi Biotec 130-113-744 
Human CD38-APC Miltenyi Biotec 130-110-345 
Human CD45-FITC Miltenyi Biotec 130-110-770 
Human CD45RA-PercyP Miltenyi Biotec 130-113-920 
Human CD49f-PeCy7 Miltenyi Biotec 130-107-832 
Human CD73 Miltenyi Biotec 130-095-183 
Human CD90-APC Cy7 Miltenyi Biotec 130-114-863 
Human IL3 PeproTech 200-03 
Human IL6 PeproTech 200-06 
Human TPO Miltenyi Biotec 130-094-011 
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Product Manufacturer Catalogue Number 




L-Glutamine Sigma Aldrich G7513 
Lipopolysaccharide Sigma Aldrich L2630 
LS columns Miltenyi Biotec 130-042-401 
MEM Medium ThermoFisher 11095080 
MethoCult STEMCELL Technologies 4434 
Mitotracker Green FM ThermoFisher M7514 
Mouse anti-connexin 43 ThermoFisher 13-8300 
Mouse CD105-APC BioLegend 120413 
Mouse CD105-Pe Miltenyi Biotec 130-102-548 
Mouse CD115-APCVio770 BioLegend 135531 
Mouse CD117-PeCy7 Miltenyi Biotec 130-108-355 
Mouse CD140a-APCVio770 Miltenyi Biotec 130-105-117 
Mouse CD150-BV510 BioLegend 115920 
Mouse CD16/32-BV510 BioLegend 101333 
Mouse CD31-PerCP BioLegend 102522 
Mouse CD34-PeCy5 BioLegend 103131 
Mouse CD36-VioBright Miltenyi Biotec 130-122-088 
Mouse CD4-PeCy7 BioLegend 100527 
Mouse CD45-VioBlue Miltenyi Biotec 130-119-130 
Mouse CD45.1-Pe Miltenyi Biotec 130-103-009 
Mouse CD45.2-VioGreen Miltenyi Biotec 130-102-312 
Mouse CD48-APC Cy7 BioLegend 103431 
Mouse CD8-PeCy5 BioLegend 301009 
Mouse F4/80-APC Miltenyi Biotec 130-116-525 
Mouse Gr1-PerCP Miltenyi Biotec 130-119-794 
Mouse IL3 PeproTech 213-13 
Mouse IL6 PeproTech 216-16 
Mouse Lineage Cell 
Depletion Kit 
Miltenyi Biotec 130-110-470 





Product Manufacturer Catalogue Number 
Mouse mCSF PeproTech 315-02 
Mouse pAKT-PE Miltenyi Biotec 130-105-343 
Mouse Sca 1-APC Miltenyi Biotec 130-102-343 
Mouse SCF PeproTech 250-03 
Mouse Ter119-APC Miltenyi Biotec 130-102-290 
N-Acetyl-L-cysteine Sigma Aldrich A7250 
ND1 Taqman Gene 
Expression Assay Human 
ThermoFisher 4331182_Hs02596873 
ND1 Taqman Gene 
Expression Assay Mouse 
ThermoFisher 4331182_Mm04225274 
Opti-MEM ThermoFisher 31985062 
OrangeG Gel Loading Dye New England BioLabs B7022S 
Ovation® PicoSL WTA 
System V2 
Tecan 3312-24 
Penicillin-Streptomycin GE-Healthcare SV30010 
PGE2 PeproTech 3632464 
Pierce ECL Western Blotting 
Substrate 
ThermoFisher 32106 
Poly-D-Lycine Solution Sigma Aldrich A-003-E 
Precision Plus Protien 
Standard Ladder 
Bio-Rad 1610373 
QBT Fatty Acid Uptake 
Assay 
Molecular Devices R8132 
qPCRBIO SyGreen Mix PCR Biosystems PB20.12-51 
RANKL PeproTech 315-11C 
ReliaPrep RNA Cell Miniprep 
System 
Promega Z6012 
RIPA Buffer ThermoFisher 89900 




RPMI Medium ThermoFisher 11875093 
Seahorse Mito Stress Test Agilent 103010-100 
Seahorse XFp Base Medium Agilent 1033335-100 
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Product Manufacturer Catalogue Number 
Seahorse XFp Mito Fuel 
Flex Test 
Agilent 103270-100 
Serum/Plasma Fatty Acid 
Detection Kit 
ZenBio Inc GFA-1 
Sodium Pyruvate Fisher Scientific 11501871 
StemMACS HSC expansion 
Medium 
Miltenyi Biotec 130-101-526 
Sulfosuccinimidyl Oleate Cayman Chemical 11211 
SYBR safe DNA Gel Stain ThermoFisher S33102 
TaqMan Human Tert ThermoFisher 4403316 
Taqman Mouse Tert ThermoFisher 4458368 
TaqPath ProAmp MasterMix ThermoFisher A30865 
TEMED Sigma Aldrich T9281 
Tris Base Fisher Scientific BP152-1 
Trypan Blue Solution Sigma Aldrich T8154 
Trypsin-EDTA ThermoFisher 25200056 
Tween-20 Fisher Scientific BP337-100 
UltraPure Agarose ThermoFisher U3750 
VECTASHIELD® mounting 
media 
Vector Laboratories H-1400-10 





2.2 Cell Culture 
 
2.2.1 Primary cell isolation  
 
2.2.1.1 Human cell isolation 
 
Primary bone marrow (BM) aspirates and umbilical cord blood were obtained 
from patients at the Norfolk and Norwich University hospital under the approval 
of the UK NHS Health Research Authority (LCREref07/H0310/146) following 
informed consent. The aspirate was collected in sample tubes containing 5 mL 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 100 units of 
Heparin. The cord blood was collected in sample tubes containing 15 mL 




Primary human BM mesenchymal stromal cell (BMSC) were isolated by 
density gradient centrifugation using Histopaque-1077. Cells differentially 
migrate through the Histopaque-1077 allowing for viable fractionation of cell 
populations. 10 mL of Histopaque-1077 per 15-20 mL of BM was added to a 
50 mL falcon tube. The BM aspirate was then gently layered on top of the 
Histopaque-1077 and centrifuged at 300 xg for 20 minutes with no brakes or 
acceleration, to allow for separation of the various BM components. Post 
centrifugation the red blood cells and heavy granulocytes are pelleted at the 
bottom of the tube, a layer of Histopaque-1077 sits atop. The ‘buffy coat’ 
containing mononuclear cells is formed on top of the Histopaque layer and 




Figure 2.1. Schematic of density gradient centrifugation using 
Histopaque-1077.  
Bone marrow aspirate was gently layered on top of Histopaque-1077 and centrifuged. 
Post centrifugation the BMSC of interest are located in the buffy coat. (Created using 
BioRender.com). 
 
The buffy coat comprising the leukocytes and BMSC was isolated using a 
pasture pipette and washed twice using 1 X PBS. The cells were then cultured 
in DMEM supplemented with 10% foetal calf serum (FCS), and 100 U/mL 
penicillin and 10 µg/mL streptomycin (penstrep) for 24 hours. The non-
adherent and non-viable cells were then washed off, fresh supplemented 
DMEM was added to the remaining adherent cells in the flask. The BMSC 
were situated in the adherent fraction. The media was replaced twice a week 
until BMSC colonies were visible. The BMSC were then passaged using the 
serine protease Trypsin-EDTA to allow for uniform coverage of BMSC in the 
flask. Briefly, the cells were washed with 15 mL of 1X PBS before addition of 
3 mL of Trypsin. The flask was then placed in the incubator to ensure adherent 
cells were lifted from the flask surface. Next, 7 mL of DMEM was added to the 
flask to inactivate the Trypsin, the cells were then pelleted to remove any 
excess Trypsin, resuspended in DMEM and plated into a fresh flask. The 
BMSCs were then expanded until around 70-80% confluent prior to 
experimental use. The BMSCs were characterised by expression of the cell 













2.2.1.1.2 CD34+ haematopoietic stem cells  
 
CD34+ haematopoietic stem cells (HSC) were isolated from the umbilical cord 
from caesarean section. The cord blood was collected by Dr Charlotte 
Hellmich and Dr Genevra Pillinger at the Norfolk and Norwich University 
hospital. Briefly, 2X 25 mL of cord blood was gently layered on top of 2X 15 
mL of Histopaque-1077 and separated by density centrifugation as described 
previously. The cells were then washed twice with 1X PBS and resuspended 
in MACS buffer (1X PBS pH 7.4 supplemented with 0.5% BSA and 1 mM 
EDTA). The CD34+ cells were then enriched using magnetic-activated sorting 
(MACS) and magnetically labelled CD34 microbeads. The CD34 magnetic 
microbeads were added to up to 200 million isolated cells and incubated at 
4˚C for 30 minutes. The cells were then centrifuged at 1400 rpm for 5 minutes 
and resuspended in 3 mL of MACS buffer. The cells were loaded onto a 
prewashed LS column (Miltenyi Biotec, Bergisch Gladbach, Germany) 
attached to a magnet. The column was washed a further three times with 
MACS buffer and the CD34+ cells were flushed from the LS column by 
removal from the magnet and firmly plunging the column. The cells were then 
used directly for experiments, cultured or cryopreserved (Section 2.2.2). 
CD34+ HSCs were injected into nonobese diabetic (NOD) severe combined 
immunodeficiency (SCID) Il2rg knockout NOD.Cg.PrkdscidIL2rgtm1Wji/SzJ 
(NSG) mice for the development of humanised mice or cultured in 
StemMACS™ HSC Expansion Medium (Miltenyi, Biotec, Bergisch Gladbach, 
Germany) supplemented with stem cell factor (SCF), Flt-3 ligand (FLT3), 
thrombopoietin (TPO), interleukin (IL) 3 and IL 6, all at 10 ng/mL concentration 
(PeproTech, Inc., Rocky Hill, NJ, USA). 
 
2.2.1.2 Mouse primary cell isolation  
 
The BM was extracted from the tibia, femur and hips of mice. Briefly, the bones 
were isolated, and all muscle were removed, the bone was the cut in half and 
placed in a perforated 0.5 mL Eppendorf tube. This was then placed in a 1.5 
mL Eppendorf tube and centrifuged at max speed for 5 seconds. The BM 
collected in the 1.5 mL Eppendorf tube was then pooled and washed in PBS. 
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The extracted BM was then plated in different culture conditions dependent on 
cell type.  
 
2.2.1.2.1 Mouse BMSC 
 
The BM cells were cultured in Minimum Essential Medium Eagle (MEM) 
supplemented with 20% FCS, and 1% penstrep for 96 hours. The non-
adherent and non-viable cells were then washed off, fresh supplemented MEM 
was added to the remaining adherent cells in the flask. The BMSC were 
situated in the adherent fraction. The media was replaced twice a week until 
BMSC colonies were visible. The BMSC were then passaged using the serine 
protease, Trypsin-EDTA as previously described for uniform coverage of 
BMSC in the flask. The BMSC were then expanded until around 70-80% 
confluent prior to experimental use. The BMSC were characterised by 
expression of the cell surface markers CD105 and CD140a but not the myeloid 
marker CD45 and the platelet endothelial cell marker CD31. The cells were 
then used directly for experiments. 
 
2.2.1.2.2 Mouse lineage negative cells 
 
The isolated BM cells were red cell lysed with remove any remaining red blood 
cells. The cells were centrifuged at 1400 rpm for 5 minutes the supernatant 
was removed and 1X red cell lysis buffer (1 mL) (ThermoFisher, Waltham, MA, 
USA) was added to the cell pellet. Following a 5-minute incubation 14 mL of 
PBS was added to the cells and the cells were centrifuged again at 1400 rpm 
for 5 minutes. The pellet was resuspended in MACS buffer and lineage 
depleted using direct lineage cell depletion kit, mouse (Miltenyi Biotec, 
Bergisch Gladbach, Germany), as previously described in section 2.2.1.1.2. 
The flow-through was collected which contained unlabeled cells representing 
the enriched lineage-negative (lin-) cells. The cells were then used directly for 
experiments or cultured in DMEM supplemented with 10% FCS, 1% penstrep, 
SCF (100 ng/mL), IL 3 (10 ng/mL) and IL 6 (10 ng/mL) (PeproTech, Inc., Rocky 




2.2.1.2.3 Mouse lineage negative, CD117 positive (LK) cells  
 
Once the cells were lineage depleted (section 2.2.1.2.2) the cells were 
resuspended in MACS buffer and CD117 enriched using (MACS) and 
magnetically labelled CD117 microbeads. The enriched CD117+ cells were 
flushed from the LS column by removal from the magnet and firmly plunging 
the column. The lin-, CD117+ cells (LK) were then used directly for 
experiments or cultured in DMEM supplemented with 10% foetal calf serum 
(FCS), and 1% penstrep, SCF (100 ng/mL), IL 3 (10 ng/mL) and IL 6 (10 
ng/mL) (PeproTech, Inc., Rocky Hill, NJ, USA). LK cells were injected into 
mice for transplantation. 
 
2.2.1.2.4 Mouse osteoblasts 
 
The isolated BM cells were red cell lysed to remove any remaining red blood 
cells. The pellet was resuspended in MEM containing 20% FCS and 1% 
penstrep supplemented with macrophage CSF (10 ng/mL) (PeproTech, Inc., 
Rocky Hill, NJ, USA) and Prostaglandin E2 (PGE2) (10−7M) (PeproTech, Inc., 
Rocky Hill, NJ, USA) and plated  at a density of 2 x 105 cells/well in a 24 well 
plate. After 3 days the media was changed to MEM containing 20% FBS plus 
1% penicillin-streptomycin supplemented with macrophage CSF (10 ng/mL), 
PGE2 (10−7M), and RANKL (10 ng/mL) (PeproTech, Inc., Rocky Hill, NJ, 
USA). The osteoblasts were visualised as a single layer of cuboidal or 
polygonal cells. The osteoblasts were then expanded until around 70-80% 
confluent prior to experimental use.  
 
2.2.1.2.5 Mouse macrophages 
 
The isolated BM cells were red cell lysed and the pellet resuspended in MEM 
containing 20% FCS and 1% penstrep supplemented with macrophage CSF 
(20 ng/mL) (PeproTech, Inc., Rocky Hill, NJ, USA). The cells were plated in at 
a density of 1 x 107 cells in a non-tissue culture treated 10cm dish. On day 3 
the cells were washed with 1X PBS and detached using a cell scraper. The 
cells were centrifuged at 1400 rpm for 5 minutes and resuspended in MEM 
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containing 20% FCS plus 1% penstrep supplemented with macrophage CSF 
(10 ng/mL) (PeproTech, Inc., Rocky Hill, NJ, USA) at a density of 1 x 105 
cells/well in a 24 well plate. The macrophages were characterised by 
adherence to tissue culture plastic and expression of the cell surface marker 
F4/80, intermediate CD115 expression but not the granulocyte marker GR1. 
The cells were then used directly for experiments. 
 
2.2.2 Cryopreservation and recovery of primary cells 
 
Continuous culturing causes cells to acquire genetic mutations and a higher 
risk of becoming senescent. To ensure cells are used at peak viability, cells 
are cryopreserved for long term storage. Aliquots of primary human BMSC 
were frozen after density separation (buffy coat), prior to plating and culturing. 
CD34+ HSC samples were directly preserved after MACS enrichment. The 
cells were pelleted and resuspended in freezing mix at a density of 5 x 106 
cells/mL in Freezing mix (10% dimethyl sulfoxide (DMSO) in FCS). DMSO 
reduces the freezing point of the freezing mix to allow for a delayed rate of 
cooling. Cells were then transferred to cryotubes and slowly frozen in a Mr. 
Frosty™ Freezing Container (ThermoFisher, Waltham, MA, USA) in a -80˚C 
freezer. The Mr. Frosty™ Freezing Container cools as a steady rate of around 
-1˚C/minute, which is the optimum rate for cell cryopreservation. 
 
To thaw, culture media was warmed to 37˚C, the cryotubes containing the cells 
were then removed from the -80˚C freezer. The cryotube was placed at 37˚C 
until partially defrosted. The cells were transferred into a 15mL falcon tube and 
10 mL of warm culture media slowly was added dropwise to the tube to dilute 
the DMSO. The cells were then centrifuged at 1400 rpm for 5 minutes and 
supernatant discarded to completely remove the DMSO. The pellet was 







2.3 Cell viability assays 
 
2.3.1 Cell counting by trypan blue exclusion 
The Trypan Blue exclusion assay is widely used to determine the number of 
viable cells. The non-viable cells do not have an intact cell membrane and 
therefore they take up the Trypan blue, but viable cells do not. 10 μL aliquot of 
the cell suspension was mixed in a 1:1 ratio with Trypan Blue. The cells were 
then pipetted onto a haemocytometer, and the healthy cells were counted. All 
four outer quadrants were counted and averaged, and cell/mL was calculated 
by the calculation below (Figure 2.2). 
Cell number 
(cells/ mL)=#
Number of viable cells  




Figure 2.2. Cell number determination using Trypan Blue exclusion. 
To calculate the number of cells required for a cell culture based experimental 
procedure the equation below was used.  
Volume of cells needed (mL) =#
Number of required cells  
Cell number (cells/mL) $ 
 
For animal experiments the automated cell counter Cellometer T4 Bright field 





used. The automated cell counter uses bright field microscopy and patten 
recognition software to identify and count single live, dead, and total cells. 
Briefly, cells isolated from the BM cells were diluted 1 in 10 in MACS buffer. 
The cells were then further diluted a 1:1 ratio with Trypan Blue and 20 μL was 
loaded onto a cell counting chamber (Nexcelom Bioscience LLC Lawrence, 
MA, USA). The cell concentration was calculated accounting for dilution 
factors. 
2.3.2 Annexin V/PI apoptosis assay 
 
Cell viability of lin- cells was assessed using eBioscienceTM Annexin V/PI 
detection kit (ThermoFisher, Waltham, MA, USA). The Annexin V FITC 
antibody preferentially bind to phosphatidylserine. Under normal condition this 
is located in the inner plasma membrane of the cell, however upon apoptosis 
the phosphatidylserine translocates across the lipid bilayer to the extracellular 
plasma membrane. This acts as a marker for cellular apoptosis and this 
phosphatidylserine can be detected by fluorescently labelled Annexin V. 
Propidium iodide (PI) is a viability dye which stains DNA. In late stage 
apoptosis, the cell membrane is no longer intact and PI stains the DNA, 
however in heathy cells the PI cannot cross the plasma membrane so is 
unable to stain the DNA. Annexin V allows for the detection of cells in early 
stage apoptosis and PI allows for the detection of cells which are in late stage 
apoptosis or necrotic. Early-stage apoptotic cells are Annexin V positive, PI 
negative, whereas late-stage apoptotic and necrotic cells are Annexin V 






Figure 2.3. Representative flow cytometry plot of Annexin V/PI staining. 
Cell were stained with Annexin V-FITC and PI and analysed by flow cytometry. Live 
cells (Annexin V- PI-), apoptotic cells (Annexin V+ PI-) and dead cells (Annexin V+ 
PI+). 
 
In the assay 2 x 104 lin- cells were pelleted by centrifugation and resuspended 
in 800 µl of 1X annexin/PI binding buffer. 2 µl of annexin V FITC antibody and 
4 µl of PI was then added to the buffer and left to incubate in the dark for 15 
minutes. The cells were then washed in MACS buffer and analysed on the 
Sysmex Cube 6 flow cytometer. The results were analysed using BD FlowJo 
10.7.0 software (FLowJo, LLC, Ashland, OR, USA). 
 
2.4 Methylcellulose Mouse Colony Forming Cell (CFC) Assay 
 
The methylcellulose assay or colony forming cell (CFC) assay can determine 
the differentiation capacity of the haematopoietic stem cells to progenitor cells. 
Haematopoietic progenitors can proliferate and differentiate into many 
different cell colonies, in this assay they are formed in a semi-solid media and 
can characterised by their specific morphologies and counted.  
 
5 x 104 isolated BM cells were washed in 1X PBS and resuspended in 400 µl 
of 1X PBS. The cells were added to 5 mL of mouse MethoCult™ GF M3434 
(Stemcell Technologies, Cambridge, UK) (a methylcellulose-based medium 
with recombinant cytokines) and briefly mixed by vortexing. Using a Pasteur 














replicated 3 times. Sterile water was added to the spaces between the wells 
of the 6-well plate to maintain the correct humidity for colony development. 
The plate was then incubated undisturbed at 37°C and 5% CO2 for 7-10 days 
to prevent colony shifts. Finally, the colonies were then assessed by light 
microscopy using a scoring grid. 
 
2.5 Cell culture assays  
 
Primary cells human BMSC (hBMSC), CD34+ HSCs, along with mouse BMSC 
(mBMSC), mouse BM osteoblast (mBM Osteoblast), mouse BM macrophages 
(mBM macrophages) and lin- or LK cells were cultured as described in section 
2.2 before use in any cell culture assays. 
 
2.5.1 Co-culture experiments 
 
Coculture systems were used to determine mitochondrial transfer between 
different cell types of the BM microenvironment and the consequence of this 
during infection. mBMSCs, mBM osteoblasts, or mBM macrophages were 
seeded in a 24-well plate at a density of 5 x 105 in normal growth media. The 
media was refreshed 24 hours after seeding. Once the cells were 70% 
confluent the media was removed and primary 1 mL of 2 x 105 lin- cells were 
added to the plate and treated. Lin- cells were added at 4:1 ratio of lin- cells to 
adherent cells. Following coculture the two different cells types were then 
separated and analysed individually. 
 
2.5.2 Mitochondrial DNA based transfer assay  
 
A mitochondrial DNA (mtDNA) based transfer method was developed to show 
specific mtDNA movement from the BM cells to the lin- cells. There are 2 
single-nucleotide polymorphisms (SNP) in the mitochondrial genome that can 
distinguish between murine strains, PepCboy and CBA. mBMSCs, mBM 
osteoblasts, or mBM macrophages were cocultured with the lin- cells in the 
absence or presence of 10 µM H2O2 for 24 hours. The lin- cells were then 
removed from the coculture and stained with CD45-FITC for 15 minutes in the 
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dark before washing and resuspending in MACS buffer. The lin- cells were 
then sorted into DNA cell lysis by fluorescence activated cell sorting (FACS) 
to ensure no BMSC remained. The DNA was extracted from these cells, and 
mtDNA quantification was performed using qPCR.  
 
To assess the driver of mtDNA transfer C57BL/6J mBM macrophages were 
treated with LPS (10 µg/mL) for 1 hour. BMSC were cocultured with the lin- 
cells in the absence or presence of this conditioned media for 24 hours. The 
lin- cells were then removed from the coculture and stained with CD45 - FITC 
for 15 minutes in the dark before washing and resuspending in MACS buffer. 
The lin - cells were then sorted into DNA cell lysis by FACS to ensure no BMSC 
remained. The DNA was extracted from these cells, and mtDNA quantification 
was performed using qPCR.  
 
The effects of pharmacological compounds on mtDNA transfer was assessed 
by comparing mtDNA transfer in the control, H2O2 alone and H2O2 with the 
drug (Table 2.2). These results are presented as mtDNA copy number of donor 
mtDNA compared to the non-drug treated baseline and H2O2 alone.  
 





2.5.3 rLV.EF1.mCherry mitochondrial transfer assay 
 
Mitochondrial transfer was also assessed using a stable lentiviral transduction 
of the BMSC mitochondria with a mCherry tag which fluoresces red. mBMSCs 
were isolated from the bone morrow and seeded at a density of 5 x 104 BMSCs 
Pharmacological Agent Target/effect Concentration used 
Carbenoxolone (CBX) Gap junction inhibitor 50μM
CAL101 PI3K inhibitor 25μM
Calcein AM Gap junction tracker 5μM
Gap27 CX43 peptide inhibitor 100μM
H2O2 ROS inducer 10μM
LPS Bacterial mimic 5μg/mL
Pharmacological Agent Target/effect Concentration used
Carbenoxolone (CBX) Gap junction inhibitor 50μM
CAL101 PI3K inhibitor 25μM
Calcein AM Gap junction tracker 5μM
Gap27 CX43 peptide inhibitor 100μM
H2O2 ROS inducer 10μM
LPS Bacterial mimic 5μg/mL
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in 500 μL of penstrep free MEM supplemented with 10% FCS. 0.5 μL of the 
rLV.EF1.mCherry-Mito-9 lentivirus (Clontech Takara Bio Europe, Saint-
Germain-en-Laye, France) (0.5 x 106 virus particles) was added to the BMSC. 
After 24 hours 1 mL of fresh MEM supplemented with 10% FCS was added, 
and mBMSCs were cultured for a further week to ensure that no residual 
lentivirus remained.  Successful transduction was confirmed by mCherry 
fluorescence in the mBMSCs detected by fluorescent microscopy.  
 
In addition, the rLV.EF1.AcGFP-Mem9 lentivirus was purchased from 
Clontech Takara Bio Europe, which allowed for stable tagging of the plasma 
membranes with a green fluorescent protein (GFP) fluorophore. Mouse lin- 
cells were depleted from mouse BM as previously described, and cells were 
transduced with rLV.EF1.AcGFP-Mem9 lentivirus. 24 hours later the cells 
were washed with DMEM and further cultured for 72 hours prior to use. 
Successful transduction was confirmed by GFP fluorescence in the lin- cells 
seen by fluorescent microscopy. 
 
Following successful transduction, tissue culture coverslips coated with 1 
μg/mL poly-D-lysine for 1 hour. The coverslips were washed with 1X PBS and 
placed in a 24-well plate. mBMSCs were seeded at 5 x 104 cells per well on 
the coverslips in the plate. The media was refreshed 24 hours after seeding 
and 2.5 x105 transduced lin- cells were cocultured with the mBMSCs for 24 
hours with or without of H2O2. Cells were then fixed using 4% 
paraformaldehyde and stained for 15 minutes in DAPI (ThermoFisher, 
Waltham, MA, USA). The coverslips were then washed 3 times with 1X PBS 
and mounted onto microscope slides with VECTASHIELD® mounting media 
(Vector Laboratories Ltd, Peterborough, UK).  
 
2.5.4 Visualisation of mitochondrial transfer  
 
To visualise the gap junctions formed between BMSC and the lin- cells, the 
gap junctions were stained with a CX43 antibody (ThermoFisher, Waltham, 
MA, USA). BMSCs successfully transduced with rLV.EF1.mCherry-Mito-9 
lentivirus were seeded at a density of 5 x 104 on a black walled imaging plate 
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(Ibidi, Munich, Germany). Lin- cells were stained with CD45-APC (Miltenyi 
Biotec, Bergisch Gladbach, Germany), in 500 µL FluoroBrite DMEM medium 
(ThermoFisher, Waltham, MA, USA) supplemented with 10% FCS, for 20 
minutes in the dark. The cells were then washed in 1X PBS and resuspended 
in DMEM supplemented with 10% FCS and 1% penstrep. 2.5 x 105 stained lin- 
cells were cocultured with the mBMSCs for 24 hours with H2O2 in the absence 
or presence of the CX43 peptide inhibitor Gap27. Cells were then fixed using 
4% paraformaldehyde and stained with the primary CX43 antibody in for 1 
hour. The plate was then washed 3 times with 1X PBS, and the cells were 
stained with secondary goat anti-mouse GFP and DAPI (ThermoFisher, 
Waltham, MA, USA) for 30 minutes in the dark. The plate was then washed a 
further 3 times with 1X PBS and 500 µL FluoroBrite DMEM medium was added 
to the wells. The plate was then imaged using confocal microscopy.  
 
2.6 Analysis of reactive oxygen species 
 
2.6.1 DCFDA / H2DCFDA (DCF) assay 
 
To quantify the level of reactive oxygen species (ROS) in the specific BM 
populations the DCF assay (ThermoFisher, Waltham, MA, USA) was used. In 
this assay H2DCFDA is added to the media containing cells and is internalised. 
Inside the cell the cellular esterases deacetylates the H2DCFDA to H2DCF, 
which is not fluorescent. H2DCF is then oxidised by any cellular ROS to 2’, 7’ 
–dichlorofluorescin (DCF) which is a highly fluorescent compound (Figure 2.4). 
DCF emits a wavelength of 529 nm and therefore can be detected in the FITC 





Figure 2.4. Schematic of the process occurring in DCF assay. 
H2DCFA is taken up by the cell and cellular esterases deacetylates the H2DCFDA to 
H2DCF. H2DCF is then oxidised by ROS DCF. 
 
To assess ROS in the in the specific BM populations 5 x 106 isolated BM cells 
were stained with 10 µM H2DCFDA in 500 µl of MACS buffer for 20 minutes in 
the dark. Next, the cells were washed three times with 1X PBS and 
resuspended in 300 µl of MACS buffer. The cells were then stained with any 
other necessary antibodies and ran on the flow cytometer. The results were 
analysed using BD FlowJo 10.7.0 software (FLowJo, LLC, Ashland, OR, USA). 
 
2.6.2 AmplexTM Red superoxide detection assay 
 
The DCF assay whist cellular specific has the ability to measure total cellular 
ROS including peroxide, hydroxyl radicals, hydroxyl ions and superoxide. To 
specifically assess superoxide production the AmplexTM Red superoxide 
detection assay (ThermoFisher, Waltham, MA, USA) was utilised. The assay 
is a one-step reaction whereby the Amplex Red reagent (10-acetyl-3,7-
dihydroxyphenoxazine) reacts with superoxide in the presence of horseradish 
peroxidase (HRP) to form resorifin (Figure 2.5). This reaction has an emission 
wavelength of 585nm which can be detected on a plate reader. The assay was 




Figure 2.5. Overview of the AmplexTM Red superoxide detection assay. 
In the presence of superoxide, the Amplex Red reagent is converted to fluorescent 
resorifin. 
 
Briefly, 2 x 105 BM cells was resuspended in 50 μL FluoroBrite DMEM 
supplemented with 10% FCS and plated on a black 96-well plate with a 
transparent base. 0.5 μL Amplex Red reagent, 1 μL horseradish peroxidase, 
and 48.5 μL 1X reaction buffer was mixed per sample to create a master mix. 
50 μL of master mix was then added to the BM cells. A standard curve was 
also performed on each 96-well plate for the hydrogen peroxide to ensure an 
accurate determination of superoxide concentration. The fluorescence was 
measured on the FLUOstar Omega microplate reader (BMG LABTECH, 
Ortenberg, Germany).  
 
2.7 Confocal Microscopy 
 
To visualise mitochondrial transfer between the BMSCs and HSCs and the 
mechanisms controlling this confocal microscopy was used. The microscope 
utilised was a Zeiss LSM 800 Axio Observer.Z1 confocal microscope with a 
63X water objective (Carl Zeiss, Oberkochen, Germany). The cells were 
cocultured as previously described in section 2.5.2 and 2.5.3 and fixed on 24 
well black walled imaging plate or coverslips on microscope slides. The plate 
or slide was placed on the culture plate or slide holder on the microscope. The 
ZEN Blue imaging software (Carl Zeiss) was used to acquire the images. 
Smart setup allowed for definition of the fluorophore wavelength acquisition 
parameters for mCherry, GFP, APC and DAPI. Relative mCherry positive lin- 











quantification. Fiji software was used to overlay, process and accurately 
quantify images. 
  
Zeiss LSM 800 Axio Observer.Z1 confocal microscope was also used to 
visualise lipid levels within the cell. BM from treated animals was lineage 
depleted and CD117 enriched (LK) as previously described. These LK cells 
were then stained with 5μM Hoechst 33342 (ThermoFisher, Waltham, MA, 
USA) and 4- difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene 
(BODIPY 493/503) (1μM) (ThermoFisher, Waltham, MA, USA) at room 
temperature for 20 minutes. The cells were then washed twice in 1X PBS by 
centrifugation at 1200rpm for 5 minutes. The cells were then stained with the 
cell surface antibody Sca 1-APC (Miltenyi Biotec, Bergisch Gladbach, 
Germany) for 20 minutes in the dark. The cell suspension was washed again 
with 1X PBS and resuspended in 200 μL of FluoroBrite DMEM medium 
supplemented with 10% FCS and plated in a black walled imaging plate. The 
cells were imaged using a 63X water objective, smart setup was performed for 
the fluorophore wavelength acquisition parameters for BODIPY 493/503, 
Hoechst and APC. Fiji software was used for image processing. 
 
2.8 Flow cytometry 
Flow cytometry was used for different purposes in this study:  
• To identify cell populations by surface receptors with antibodies 
conjugated to a detectable fluorophore.  
• To determine mitochondrial content, mitochondrial health, lipid content, 
ROS levels, pAKT and cell cycling in specific cell populations.  
• To sort specific cell populations by the cell surface receptors.  
To achieve these applications different flow cytometers were used dependent 
on the number of lasers determining the number fluorophores that can be 
detected in one sample and the ability to sort cells. Table 2.3 shows a 
comparison of the capabilities of the flow cytometers used in this study. Table 
2.4 shows the antibodies and panels used to detect cell populations. All 
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antibodies were purchased from Miltenyi Biotech (Bergisch Gladbach, 
Germany) or BioLegend (San Diego, CA, USA).  
2.8.1 Sysmex Cube 6 
 
The Sysmex Cube 6 flow cytometer (Sysmex, Gorlitz, Germany) is a 2-laser 
flow cytometer (blue 488nm and Red 633nm) and is capable of detecting four 
fluorophores FITC, PE, PERCP and APC. Whist this flow cytometer can detect 
four fluorophores it lacks the ability to do colour compensations and therefore 
cannot account for cross-over of emission spectre. Consequently, this 
machine was only used for single colour flow cytometry. This flow cytometer 
enabled the analysis of engraftment using CD45.1 Antibody, anti-mouse on 
the FITC channel and Calcein AM (ThermoFisher, Waltham, MA, USA) to track 
movement through gap junctions which is also detected on the FITC channel.  
 
The flow cytometer was primed prior to use ensuring the fluidics were clean 
and no blockages or air bubbles were present. 1 x 105 cells were stained with 
the either Calcein AM in 500 μL MACS buffer or CD45.1- FITC Antibody in 200 
μL MACS buffer for 20 minutes in the dark. The cells were then washed by 
centrifugation at 1500 rpm for 5 minutes and re-suspended in 1mL of MACS 
buffer and transferred into a flow tube. The samples were then ran on the flow 
cytometer and 1 x 104 cells were analysed in a pre-defined gated region. The 
flow cytometer was the cleaned after use and data was exported as an FCS 
file data and analysed using BD FlowJo 10.7.0 software (FLowJo, LLC, 
Ashland, OR, USA). 
 
2.8.2 Beckman Coulter CytoFLEX 
 
The Beckman Coulter CytoFLEX (Brea, CA, USA) is a multi-channel flow 
cytometer which also has 2 lasers (488 and 633nm), but with the addition of 
bandpass filters. This allows for the detection of FITC, PE, PERCP/Pe Cy5, 
Pe Cy7, APC and APC Cy7. It also has the ability to calculate colour 
compensations, therefore can detect up to four fluorophores in one sample. 
This flow cytometer was used to detect <4 fluorophores within in the one 
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sample in this study. This flow cytometer enabled the detection hCD45-FITC 
and mCD45-APC in the peripheral blood to show CD34+ HSC engraftment 
into NSG mice. 
 
The flow cytometer was cleaned and primed prior to use by a daily clean 
process on the cytometer. Before the samples were run, a compensation 
matrix was calculated using UltraComp eBeads™ Compensation Beads 
(ThermoFisher, Waltham, MA, USA) for each marker. This compensation 
calculation determines the cross-over of emission spectre and compensates 
to allow for any overlap. 1 x 105 cells were stained with the antibodies of 
interest or isotype controls for 20 minutes in the dark. The cells were then 
washed by centrifugation at 1500 rpm for 5 minutes and re-suspended in 400 
µl of MACS buffer and transferred into a flow tube. The samples were then run 
on the flow cytometer and 1 x 104 cells were analysed in a pre-defined gated 
region. The flow cytometer was the cleaned after use and data was analysed 
using the CytExpert 1.2 software. 
 
2.8.3 BD FACSCanto II  
The FACSCanto II flow cytometer (BD, Franklin Lakes, NJ, USA) was located 
in the Pathology Laboratory at the Norfolk and Norwich University Hospital and 
is maintained by Dr Allyson Tyler. This flow cytometer has three-lasers, 488, 
633 and 405nm and is therefore able to detect 7 fluorophores within the same 
sample including FITC, PE, PE Cy5, PE Cy7, APC, APC Cy7, BV421 and 
BV510. A compensation for each antibody panel was carried out to measure 
fluorophore emission cross-over using UltraComp eBeads™ Compensation 
Beads (ThermoFisher, Waltham, MA, USA) for each marker. The 
compensation was linked to each experiment before running the samples. This 
flow cytometer enabled the detection of mitochondrial content, mitochondrial 
potential, lipid content, ROS levels, pAKT, CD36, cell cycling and engraftment 
in various cell populations in mouse BM. The antibodies panels used to detect 
cell populations are shown in Table 2.4.  
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To analyse the mouse BM, 5 x 106 cells were used. For dyes including 
MitoTracker Green FM (200 nM) (ThermoFisher, Waltham, MA, USA) 
Tetramethylrhodamine, methyl ester (TMRM) (100 nM) (ThermoFisher, 
Waltham, MA, USA), H2DCFDA (10 µM) (ThermoFisher, Waltham, MA, USA) 
and BODIPY 493/503 (1 μM) the cells were stained with the dyes in 500 μL 
MACS buffer for 20 minutes in the dark. The cells were then washed by 
centrifugation at 1500rpm for 5 minutes and re-suspended in 200 μL of MACS 
buffer. An antibody master mix was prepared containing 1 μL of each antibody 
per sample and was added to the cells. Following a 20-minute incubation at 
4oC in the dark the cells were then centrifugation again at 1500rpm for 5 
minutes and re-suspended in 200 μL of MACS buffer. 
To analyse specific BM populations for antibody expression such as CD36 
VioBright 515 mouse (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
CD45.1 Antibody, anti-mouse FITC (Miltenyi Biotec, Bergisch Gladbach, 
Germany) or CD45.2 Antibody, anti-mouse PE (Miltenyi Biotec, Bergisch 
Gladbach, Germany) an antibody master mix was prepared containing 1μL of 
each antibody per sample and was added to 5 x 106 cells in 200 μL of MACS 
buffer. Following a 20-minute incubation at 4oC in the dark the cells were then 
centrifuged again at 1500rpm for 5 minutes and re-suspended in 200 μL of 
MACS buffer. 
To analyse cell cycling by Ki67 expression and phospo AKT levels in the BM 
populations the cells required fixing and permeabilising. The FIX & PERM Cell 
Fixation & Cell Permeabilization Kit (ThermoFisher, Waltham, MA, USA) was 
used. Briefly, 5 x 106 isolated BM cells were stained with an antibody master 
mix containing 1 μL of each surface marker antibody per sample and was 
added to the cells. Following a 20-minute incubation at 4oC in the dark the cells 
were then centrifuged at 1500rpm for 5 minutes and re-suspended in 100μL 
of 1X PBS, 100 μL of Reagent A (Fixation Medium) was then added to the cell 
suspension and incubated at room temperature for 15 minutes in the dark. The 
cells were then washed with 3 mL 1X PBS and centrifuged at 1500rpm for 5 
minutes. The pellet was resuspended in 100 μL of Reagent B 
(Permeabilisation Medium) and 1 μL of the intracellular antibodies, Anti-Ki-67 
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FITC human and mouse (Miltenyi Biotec, Bergisch Gladbach, Germany) or 
AKT pS473 Antibody, anti-human/mouse, PE-Vio® 770 mouse (Miltenyi 
Biotec, Bergisch Gladbach, Germany) was added. Following a 20 minutes 
incubation in the dark at room temperature, the cells were centrifuged again 
at 1500rpm for 5 minutes and re-suspended in 200μL of MACS buffer. 
The samples were all run on the FACSCanto II utilising the automated 
carousel and data were analysed using BD FlowJo 10.7.0 software (FLowJo, 
LLC, Ashland, OR, USA). The gating was set by using fluorescence minus one 
(FMO) controls for every fluorophore to establish the positive and negative 
gates for each cell marker. 
2.8.4 BD FACSMelody  
The FACSMelody (BD, Franklin Lakes, NJ, USA) is located at the Earlham 
Institute (Norwich, UK) and has the same number of lasers and fluorophore 
capabilities as the FACSCanto II, however has the additional ability to sort 
cells. This flow cytometer was used to sort the CD45.1 and CD45.2 lin- 
populations from the NSGC57Bl/6 mice. It was also used to sort the human 
and mouse haematopoietic progenitor cells from mouse BM. 
To sort the human and mouse haematopoietic progenitor cell populations the 
BM cells were isolated, and lineage depleted to isolate the lin- cells (section 
2.2.1.2.2). The cells were then stained with the HSC or progenitor panels for 
20-minute incubation at 4oC in the dark. The cells were centrifuged again at 
1500 rpm for 5 minutes and re-suspended in 1mL of MACS buffer. The 
samples were then run on the FACSMelody and sorted into lysis buffer for 
RNA or DNA analysis by qPCR or into culture media for culture, 
transplantation or the Seahorse extracellular flux assay. The positive and 
negative gating for the sorting of the haematopoietic progenitor cell 















Cube CytoFlex FACSCanto II FACSMelody
Number of lasers 2 2 3 3
Fluorophore 
capability
1 4 7 7
Colour 
compensation
No Yes Yes Yes
Automated No No Yes No
Cell sorting No No Yes Yes
Flourophore
Antibody panel FITC APC APC Cy7 Pe PeCy7 PeCy5 BV421 BV510
Bodipy HSC Bodipy Sca1 CD48 CD117 CD34 Lin Cocktail CD150
CD36 HSC CD36 Sca1 CD48 CD117 CD34 Lin Cocktail CD150
DCF
HSC DCF Sca1 CD48 CD117 CD34 Lin Cocktail CD150
Progenitor DCF Sca1 CD48 CD117 CD34 Lin Cocktail CD16/32
BMSC DCF Ter119 CD140a CD105 CD31 CD45
DsRed
Lin- DsRed
HSC Sca1 CD48 DsRed CD117 Lin Cocktail CD150
BMSC CD105 CD140a DsRed CD31 CD45
Macrophage F4/80 CD115 DsRed Gr1
Engraftment 
CD45.1/HSC Sca1 CD48 CD45.1 CD117 CD34 Lin Cocktail CD150
CD45.2/HSC CD45.2 Sca1 CD48 CD117 CD34 Lin Cocktail CD150
Myeloid CD45.2 CD45.1 Gr1
Lymphoid CD45.2 CD45.1 CD4 CD8
Humanised HSC/Prog MTG hCD38 hCD90 hCD49f hCD45RA hCD34 mCD45
Ki67 HSC Ki67 Sca1 CD48 CD117 CD34 Lin Cocktail CD150
MTG
HSC MTG Sca1 CD48 CD117 CD34 Lin Cocktail CD150
Progenitor MTG Sca1 CD48 CD117 CD34 Lin Cocktail CD16/32
BMSC MTG Ter119 CD140a CD105 CD31 CD45
pAKT
HSC Sca1 CD48 pAKT CD117 CD34 Lin Cocktail CD150
BMSC CD105 Ter119 CD140a pAKT CD31 CD45




2.9 Free FA and glycerol detection  
The level of free fatty acids (FFA) in the serum was detected using the 
Serum/Plasma Fatty Acid Detection Kit (ZenBio Inc., NC, USA). Serum or 
plasma levels of non-esterified fatty acids can be a sign of endogenous or 
induced adipocyte lipolysis. This assay detects non-Esterified Fatty Acids or 
FFA using a substrate to and causes a colorimetric change, which can be 
analysed using immunosorbance detection to calculate the concentration of 
FFA using a standard curve. 
To assess the level of FFA in the serum it is a three-step coupled reaction. 
The first step is catalysed by acyl-CoA synthetase, CoA, FFA released by 
adipocytes, and ATP produce acyl-CoA thiol ester. The acyl-CoA thiol reacts 
with oxygen and is catalysed by acyl-CoA oxidase to produce hydrogen 
peroxide. 3-methyl-N-ethyl-N-(β- hydroxyethyl)- and aniline4-aminoantipyrine 
undertakes oxidative condensation due to the hydrogen peroxide and 
peroxidase. This forms a purple product which can absorb light at 550nm. 
HCOOH (FFA) + ATP + CoA → Acyl-CoA + AMP + PPi 
Acyl-CoA + O2 → 2,3-trans-Enoyl-CoA + H2O2 
2 H2O2 + 3-methyl-C10 H15NO + C11H13N3O → Purple product + 4H2O 
For this assay C57Bl/6J mice were left untreated or infected with 
S.typhimurium by oral gavage for 72 hours or injected with LPS 16 hours. The 
mice were anaesthetized and 600 μL of blood was taken by cardiac puncture. 
To isolate the serum, the blood was centrifuged at 1600 xg for 10 minutes to 
remove cells. The supernatant was then centrifuged again at 16000 xg for 5 
minutes.  
From each sample, 5 μL of serum was placed in a 96 well plate and 50 μL of 
dilution buffer was added to each sample. 100 μL of FFA reagent A was then 
added to the well and mixed. The plate was then placed at 37oC for 10 minutes. 
Post incubation 50 μL of FFA reagent B was then added mixed and the plate 
was left at room temperature for 5 minutes. The optical density of each well 
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was measured using a FLUOstar Omega plate reader (BMG Labtech, 
Offenburg, Germany). A standard curve was also performed and measured on 
the 96-well plate from known standard concentrations provided in the kit to 
ensure an accurate determination of FFA concentration. 
2.10 Free Fatty Acid uptake assay  
FFA uptake was measured using the QBT Fatty Acid Uptake Assay (Molecular 
Devices San Jose, CA, USA). The assay is a single step process which uses 
a BODIPY®-dodecanoic acid fluorescent fatty acid analog which acts like a 
natural FA. The BODIPY label is activated by attachment to acyl-CoA and is 
incorporated into both diglycerides and triglycerides. It also then accrues 
inside the cell as lipid droplets. 
For this assay C57Bl/6J mice were left untreated or infected with 
S.typhimurium by oral gavage for 72 hours or injected with LPS 16 hours. The 
BM extracted, and the mouse lin- cells were depleted and CD117+ enriched 
(LK) as previously described. 5 x 104 LK cells were incubated with 4,4-Difluoro-
5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid (BODIPY™ 
FL C12) (1μM, Invitrogen) at room temperature for 20 minutes. The cells were 
then washed twice in 1X PBS and centrifuged at 1400rpm for 5 minutes. The 
cells resuspended in PBS and plated in a glass bottom 96 well plate. The 
absorbance was measured at 558/568 using a FLUOstar Omega plate reader 
(BMG Labtech, Offenburg, Germany). The cells were also visualised using 
Zeiss LSM 800 Axio Observer.Z1 confocal microscope and quantified 
fluorescence using Fiji software. 
 
2.11 Seahorse Extracellular Flux Assay 
To assess the metabolic activity of the LSK (Lin-, CD117+, Sca1+ cells) the 
Seahorse XFp Analyzer (Agilent Technologies, Santa Clara, CA, USA) was 
utilised with both the Seahorse XFp Cell Mito Stress Test Kit and the Seahorse 
XF Mito Fuel Flex Test.  
 
For these assays C57Bl/6J mice were left untreated or infected with 
S.typhimurium by oral gavage for 72 hours or injected with LPS 16 hours. Prior 
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to the experiment day XFp flux cartridges were hydrated in XF Calibrant 
overnight at 37°C the Seahorse Extracellular Flux analyser was also switched 
on overnight to allow equilibration to 37°C. On the day of the experiment the 
Seahorse XFp cell culture plates were coated with Poly-D-Lysine for 2 hours 
and then washed thre times. The animals were sacrificed, and the BM 
extracted, the mouse lin- cells were depleted and the LSK cells were isolated 
by FACS into conventional Seahorse base media supplemented with pyruvate 
(1mM), L-Glutamine (2mM), Glucose (10mM) as previously described. The 
cells for each condition were pooled and 1 x 105 cells in 180 µl were plated 
into the wells of the coated Seahorse XFp culture plate. The plate was 
centrifuged briefly to achieve a uniform monolayer of cells. The plate was then 
equilibrated in a humidified non-CO2 incubator until the start of the assay. All 
results were normalised to input cell number.  
 
2.11.1 Seahorse XFp Cell Mito Stress Test 
 
The quantification of mitochondrial respiration (oxidative phosphorylation 
(OXPHOS) measured by oxygen consumption rates (OCR)) and non-
mitochondrial respiration (glycolysis measured by extracellular acidification 
rates (ECAR)) that a cell undertakes can be determined using this kit. In this 
study the assay was used to determine the differences in oxidative 
phosphorylation of the LSK before and after infection. This method can be 
used to quantify basal mitochondrial respiration rates maximum respiration, 
spare capacity of a cell, proton leak and ATP production. This is done by 
microinjection of Oligomycin an inhibitor of ATP synthase which reduces OCR, 
carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) which targets 
the inner mitochondrial membrane and increases OCR and 
Rotenone/Antimycin A which targets complex 1 and 3, leading to a reduced 





Figure 2.6. Mitostress test experimental profile. 
Microinjection of Oligomycin an inhibitor of ATP synthase in Complex V of the 
mitochondria, FCCP which targets the inner mitochondrial membrane and 
Rotenone/Antimycin A which targets Complex 1 and III. (Source: Agilent 
Technologies (328)). 
 
Once the cells were plated and the machine were equilibrated, Oligomycin (2 
µM), FCCP (1 µM) and Rotenone/Antimycin A (0.5 µM) were loaded into the 
flux cartridges. The cartridge was then loaded into the Seahorse XFp Analyzer 
and the Mito Stress test protocol based on manufacturer’s instructions. The 
sensors in the analyser were equilibrated for 20 minutes and the plate was 
loaded into the analyser. The results were analysed using GraphPad Prism 
software (Version 7.0, GraphPad Software, San Diego, CA, USA) and 
Microsoft Excel. 
 
2.11.1.1 Seahorse XFp Mito Fuel Flex Test  
 
For fatty acid fuel dependency flux cartridges were loaded according to 
manufacturer’s instructions. Fatty acid dependency, capacity and flexibility 
values were obtained using the XFp Mito Fuel Flex Test Kit. Metabolic 
parameters were derived from calculations based on manufacturer’s 
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instructions. The Mito Fuel Flex Test was used to measure mitochondrial fuel 
usage, specifically long chain fatty acids in the LSK after infection. The Fuel 
Flex Test has the ability to measure the cells capacity, dependency, and 
flexibility to oxidize glucose, glutamine and long chain fatty acids (Figure 2.7). 
This is determined by the oxidation consumption rate of cells with and without 
specific fuel pathway inhibitors, UK5099, BPTES and Etomoxir. UK5099 
inhibits the glucose oxidation pathway by blocking the mitochondrial pyruvate 
carrier. BPTES inhibits the glutamine oxidation pathway by allosterically 
inhibiting glutaminase. Etomoxir inhibits long chain fatty acid oxidation 
specifically by inhibiting carnitine palmitoyl-transferase 1A (CPT1A). In the 
assay the pathway of interest is inhibited followed by the inhibition of the two 
alternative pathways, which allows for the determination of how dependent the 
cells are on a specific pathway to meet its basal energy requirements 
(Dependency). The dependency is the reliance of the cell on one pathway as 
the mitochondria is not able to compensate for the inhibition of the pathway by 
utilising other fuel sources. The two alternative pathways are also inhibited 
followed by the pathway of interest this allows for the determination of the cells 
mitochondrial capacity to meet energy requirements (capacity). The fuel 
flexibility is measured by subtracting the Fuel Dependency from the Fuel 
Capacity for the specific fuel pathway and demonstrates the cells are able to 
swich pathways to compensate for the inhibited pathway. If there is no 
flexibility this indicates the fuel pathway is required to maintain basal OCR. 
Only the fatty acid dependency, capacity and flexibility values were calculated 











Figure 2.7. Mito Fuel Flex Test experimental profile. 
Experimental profile and calculations to determine mitochondrial dependency and 
capacity for glutamine as a fuel source. Eto inhibits Fatty acid oxidation, BPTES 











To perform the assay, once the cells were plates and the machine was 
equilibrated, UK5099 (2 µM), BPTES (3 µM) and Etomoxir (4 µM) were loaded 
into the correct wells of the flux cartridges. The cartridge was then loaded into 
the Seahorse XFp Analyzer and the Mito Stress test protocol based on 
manufacturer’s instructions. The sensors in the analyser were equilibrated for 
20 minutes and the plate was loaded into the analyser. The results were 
analysed using GraphPad Prism software (Version 7.0, GraphPad Software, 
San Diego, CA, USA) and Microsoft Excel. 
 
2.12 Genetic knockdown of CPT1A 
 
To analyse the effect of CPT1A on lipid uptake and response to infection it 
was genetically knocked down using short hairpin (shRNA) targeted to CPT1A 
using a lentivirus. In a lentiviral system the cell of interest is transduced with a 
lentivirus which contains RNA encoding shRNA targeting the gene of interest. 
The RNA incorporates into the cells genome and the shRNA begins to 
transcribe using RNA polymerase III. The shRNA acts like the pri-miRNA and 
is therefore modified by the enzymes Drosha and Dicer, which removes the 
short hairpin, producing double stranded RNA. The RNA is then transported 
into the RNA-induced silencing complex (RISC) and where Argonaute-2 
degrades the sense strand. The anti-sense strand primes the RISC towards 
the complimentary mRNA. The mRNA is cleaved by the RISC and causes the 
gene of interest to be silenced. The lentiviral production process was carried 
out by Manar Shafat and is described below.  
 
2.12.1 Lentiviral production 
 
2.12.1.1 Plasmid preparation 
 
pLKO.1-amp vector Escherichia coli (E. coli) glycerol stocks containing the 
shRNA specific to the gene of interest were purchased from MISSION® 
shRNA library (Sigma Aldrich, St Louis, MO, USA). The primary step in 
lentivirus preparation is pLKO.1-amp plasmid generation from E. coli stocks. 
Luria Bertani (LB) agar was made up containing 50 µg/mL ampicillin and 
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poured into plates. Once set the MISSION® glycerol stocks were aseptically 
streaked onto the plate to isolate single colonies and incubated at 37oC for 16 
hours. A single colony was isolated and placed into 5 mL of sterile LB broth 
containing 50 µg/mL ampicillin and incubated in a shaker at 37oC for 24 hours. 
The culture was then centrifuged at 16000 xg for 10 minutes and the 
supernatant was discarded. The plasmid was purified by the NucleoSpin® 
Plasmid kit (Macherey-Nagel, Duren, Germany) as per manufacturer’s 
instructions. The DNA was quantified, and purity confirmed using the 
A260/230 and A260/280 ratio on the Nanodrop spectrophotometer 
(ThermoFisher, Waltham, MA, USA). This process was carried out by Manar 
Shafat. 
 
2.12.1.2 Transfection of packaging cells 
 
The plasmid DNA concentration required for transfection was 180 ng/µl or 
higher. 
293T packaging cells were used to produce the functional lentivirus encoding 
shRNA to target the CPT1A. 293T cells originated from the human embryonic 
kidney (HEK) 293 cells and were a kind gift from Dr Ariberto Fassati (University 
College London, UK). The cells were cultured tissue culture coated 10mm 
dishes in DMEM, supplemented with 10% FCS. They were split 90% 
confluency at a ratio of 1 in 3 using 0.25% Trypsin but were split 1 in 2 before 
transfection.  
 
Three plasmids, pLKO.1-amp plasmid, Vesicular stomatitis virus glycoprotein 
(VSV-G) (envelope proteins) and cytomegalovirus promoter (pCMV) 
(packaging protein promoter, and a transfection reagent were required to 
produce a functional lentivirus. FuGENE® 6 (Promega, Fitchburg, WI, USA) 
was the transfection reagent utilised. A mastermix containing the three 
plasmids and transfection reagent was made. First 1.5 µg of pLKO.1-amp 
plasmid and 1 µg of VSVG and pCMV plasmids were mixed in 15 µl TE buffer. 
This was then added to 18 µl of FuGENE® 6 mixed with 200 µl of Opti-MEM 
media (ThermoFisher, Waltham, MA, US) and added dropwise to the cells. 
The cells were incubated for 24 hours and the media was replaced. The media 
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was then collected 48, 72 and 96 hours after transfection and stored at -80oC. 
This process was carried out by Manar Shafat. 
 
2.12.1.3 Lentiviral knockdown 
 
LK cells were seeded at a density of 2 x 105 cells in 500 µl of pen-strep free 
medium in a 24 well plates. 20 µl of lentivirus was added to the cells. As a 
control 20 µl of empty construct virus (ShE) was added to LK cells the cells 
were then incubated at 37oC for 24 hours. The cells were then topped up with 
1 mL of fresh medium. The cells were then centrifuged at 1400rpm for 5 
minutes and resuspended in 1X PBS before transplantation into mice. 
Knockdown efficiency of the gene of interest was assessed using qPCR, if the 
knockdown was successful the mice were used for further experiments.  
 
2.13 Molecular biology   
 
2.13.1 DNA extraction  
To detect intraspecies and interspecies mitochondrial transfer, DNA was 
isolated from the relevant mice, the mtDNA was then quantified using qPCR. 
DNA was isolated using a GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma Aldrich, St Louis, MO, USA) as per manufacturer’s instructions. Cells 
from the BM were extracted, washed in 1X PBS and stained with antibodies 
for FACS as previously described. The sorted cells were then re-suspended 
in 200 μL of Resuspension solution. 20 μL of Proteinase K was then added for 
cell lysis, prior to addition of 200 μL of Lysis Solution C. The lysate was then 
vortexed followed by a 10 minutes incubation at 70 ̊C. 200 μL of absolute 
ethanol was added to the lysate post incubation. The column was pre-treated 
with column preparation solution to enable maximum yield. The lysate was 
loaded onto the column and centrifuged at 12000 xg for 1 minute. The flow 
though was discarded and 500 μL of Wash Solution was added to the column. 
This was then centrifuged again at 12000 xg for 1 minute. A second wash was 
carried out with 500 μL of Wash Solution and further centrifugation step for 3 
minutes and 16000 xg. To elute the DNA, 50 μL of Elution Solution was added 
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to the column and incubated for 5 minutes at room temperature. Finally, the 
column was centrifuged for 1 minute at 12000 xg. The DNA was stored at -
20oC until use. 
2.13.2 RNA extraction 
 
The gene expression levels in the HSC and LSK were also determined using 
qPCR. To extract the RNA from these cells for analysis the ReliaPrep™ RNA 
Cell Miniprep Kit (Promega, Fitchburg, WI, USA) was used as following the 
manufacturer’s instructions. The BM from animals were extracted, washed in 
1X PBS and stained with antibodies for FACS as previously described. The 
cells were sorted into 250 µl of BL+TG buffer and mixed thoroughly and 85µl 
of Isopropanol was then added and vortexed to mix. The cell lysate was then 
loaded onto the ReliaPrep™ mini-column and centrifuged at 13000 xg for 30 
seconds. The flow through was discarded and 200 µl of column wash solution 
was added to the column. The column was centrifuged at 13000 xg for 30 
seconds and 500 µl of RNA wash solution was then added. The column was 
centrifuged again using the same parameters before a second wash step with 
300 µl of RNA wash solution. The column was then centrifuged at 16000 xg 
for 3 minutes. To elute the RNA, 20 μL of nuclease free water was added to 
the column and centrifuged for 1 minute at 12000 xg. The RNA was stored at 
-80oC until use. 
 
2.13.3 Quantification of extracted DNA/RNA  
DNA and RNA yield were quantified using the NanoDrop spectrophotometer 
(ThermoFisher, Waltham, MA, USA). Breifly, the NanoDrop was blanked using 
1 μL of nuclease free water in which the RNA was eluted. 1 μL of sample was 
then measured, referenced to the blank sample and RNA or DNA 
concentration (ng/μL) determined. The sample with an A260/230 ratio 





2.13.4 cDNA synthesis 
 
To assess gene expression in the HSC and LSK the RNA extracted from 
section 2.13.2 it had to be synthesised to cDNA. This is by a process called 
reverse transcription and the RNA was synthesised using the qPCRBIO cDNA 
synthesis kit (PCR Biosystems, London, UK). The reaction occurs in 10 µl, a 
master mix was made with 2 µl of 5X cDNA Synthesis Mix and 0.5 µl of 20X 
RTase per sample. 300 ng of RNA was then added to each PCR tube and 
nuclease free water was added to make the sample up to 10 µl. The PCR 
tubes were then centrifuged and loaded into a Thermocycler (Bio-Rad, 
Watford, UK). A pre-defined program was run which consisted of 42oC 
incubation for 30 minutes followed by an 85oC incubation for 10 minutes. The 
reaction was held for 4oC for less than 3 hours and stored at -20oC until further 
use. 
 
2.13.5 RNA amplification and cDNA synthesis  
A high concentration of RNA was required to be able to assess gene 
expression. For isolation of RNA from sorted HSCs the RNA yield could be 
low as the frequency of HSCs in the BM is low. Therefore, the Ovation® 
PicoSL WTA System V2 (Tecan, Männedorf, Switzerland) was used to amplify 
cDNA from RNA for gene expression analysis. The Ovation® PicoSL WTA 
System V2 is a three-step process. The first step is generation of first strand 
cDNA, which is a reverse transcription process producing a hybrid 
cDNA/mRNA molecule containing a unique RNA tag sequence (SPIA tag) at 
the 5 prime end of the cDNA. The next step is a synthesis of a DNA/RNA 
heteroduplex double strand cDNA with the SPIA tag at one end. Finally, there 
is a SPIA® amplification which results in an amplification of cDNA. The 
Thermocycler (Bio-Rad, Watford, UK) was used for the reaction sand the 
program cycles are shown in the table below (Table 2.5). Breifly, 2 μL of First 
Strand Primer Mix and 5 μL of RNA was added to a PCR tube and mixed. This 
was then loaded on Thermocycler (Bio-Rad, Watford, UK) and program 1 was 
run. The first strand master mix was then prepared using 2.5 μL Buffer Mix 
and 0.5 μL Enzyme Mix per sample and mixed well. 3 μL of the master mix 
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was added to each tube and loaded onto the thermocycler using program 2. 
The second strand cDNA was then synthesised by preparing the second 
strand master mix with 9.7 μL Buffer Mix B1 and 0.3 μL Enzyme Mix per 
sample. 10 μL of the second strand master mix was then added to each tube 
and loaded onto the thermocycler using program 3. To purify the double 
stranded cDNA 32 μL of Agencourt® beads was added to each tube and 
incubated for 10 minutes at room temperature. The tubes were then placed on 
a magnet for 5 minutes and the buffer was removed. The beads were washed 
three times with 200 μL of 70% ethanol and left to air dry completely. The SPIA 
was then amplified by preparing the SPIA master mix with 20 μL of C2, 10 μL 
of C1 and 10 μL of C3 per tube and adding to the beads. The tubes were then 
loaded onto the thermocycler using program 4. The tubes were then placed 
back on the magnet and let stand for 5 minutes, the supernatant containing 
the cDNA was then transferred to a fresh tube. The PCR conditions for each 
program are specified in Table 2.5. 
Table 2.5. Table pf PCR conditions. 
 
The cDNA was then purified using the QIAGEN MinElute Reaction Cleanup 
Kit (Qiagen, Hilden, Germany) as per manufacturer’s instructions. Briefly, the 
cDNA was added to 300 μL of Buffer ERC and vortexed. The sample was then 
loaded onto MinElute spin column and centrifuged at 16000 xg for 1 minute. 
The flow through was discarded and 750 μL of Buffer PE was added to the 
column. It was then centrifuged again at 16000 xg for 1 minute and the flow 
through discarded. The column was centrifuged again at maximum speed for 
2 minutes to removed residual ethanol. The column was then placed into a 
FIRST STRAND cDNA SYNTHESIS 
Program 1 
Primer Annealing 65°C – 2 min, hold at 4°C 
Program 2 
First Strand Synthesis 4°C – 2 min, 25°C – 30 min, 42°C – 15 min, 70°C – 15 min, hold at 4°C 
SECOND STRAND cDNA SYNTHESIS
Program 3 
Second Strand Synthesis 4°C – 1 min, 25°C – 10 min, 50°C – 30 min, 80°C – 20 min, hold at 4°C 
SPIA AMPLIFICATION 
Program 4 
SPIA Amplification 4°C – 1 min, 47°C – 75 min, 95°C – 5 min, hold at 4°C 
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clean 1.5 mL microcentrifuge tube and eluted in 20 μL of Nuclease-free Water. 
The purified cDNA was stored at -20oC until use. 
2.13.6 Polymerase chain reaction 
In order to analyse the genetic sequence to confirm SNP between the DNA 
extracted in section 2.13.1 polymerase chain reaction (PCR) was performed 
using ND4 primers COX3 and ND3 primers (Details of PCR primers used 
provided in Appendix Table 8.3) 
A master mix was created using 5 μL TaqPath ProAmp enzyme 
(ThermoFisher, Waltham, MA, USA) 2.5 μL water and 1 μL forward and 
reverse primers. The mitochondrial primers used were ND4, COX3 and ND3. 
The 1.5 μL of DNA was mixed with 8.5 μL of master mix in PCR tubes, 
centrifuged and loaded into a Thermocycler (Bio-Rad, Watford, UK). The PCR 
was run using a pre-defined method as seen below: 
• Pre-amplification (98 oC for 1 minute).  
• Amplification over 25 cycles (98 oC for 30 seconds, 58 oC for 30 
seconds and 72 oC for 30 seconds). 
• Cooling (72 oC for 7 minutes and infinite hold at 4 oC).  
The samples were stored at -20 oC until further use.  
2.13.7 Agarose gel electrophoresis  
Agarose gel electrophoresis was utilised to isolate and analyse PCR product 
for sequencing. To cast a 60 mL 1.25% agarose gel, 0.75g of agarose was 
dissolved in 60 mL of 1X Tris Acetate EDTA (TAE) buffer and 6 μL of SYBR 
Safe (ThermoFisher, Waltham, MA, USA) was added to the solution. This was 
then microwaved for 60 seconds on full power to ensure all agarose was 
dissolved and left to cool slightly prior to pouring into gel casts. A well comb 
was added to create lane divides to allow for loading of the samples. Following 
setting, the gel was placed into an agarose gel running tank, the gel was then 
submerged in 1X TAE and the comb was removed. 2 μL of 6X Orange G 
loading dye was added to 10 μL of PCR products from section 2.13.6 and the 
111 
 
sample was loaded into the wells. 5 μL of 1KB DNA ladder (New England 
Biolabs, Ipswich, MA, USA) was also loaded into a well for PCR product size 
determination. The gel was run at 100V for 1 hour and imaged on the 
Chemdoc-It2 Imager (UVP, LLC, Upland, CA, USA) using the UV function 
(filter 1).  
2.13.8 Agarose gel isolation and purification 
PCR bands from 2.13.7 were excised using the UV function (filter 1) of the 
Chemdoc-It2 Imager (UVP, LLC, Upland, CA, USA) to gauge where the DNA 
was located. The DNA was then purified using GeneJET Gel Extraction Kit 
(ThermoFisher, Waltham, MA, USA) following manufacturer’s instructions. 
Briefly, the gel slice was excised close to the DNA. 1:1 volume of Binding 
Buffer was added to the gel slice and incubated at 50-60°C for 10 minute. The 
sample was vortexed and transferred into GeneJET purification column and 
centrifuged for 1 minute at 12000 xg and the flow though discarded. 100 μL of 
Binding Buffer to the column and centrifuged again for 1 minute at 12000 xg. 
The flow-through was discarded followed by the addition of 700 μL of Wash 
Buffer to the column and centrifuged for 1 minute at 12000 xg. The column 
was centrifuged for an additional 1 minute to completely remove residual wash 
buffer. The column was transferred to a fresh 1.5 mL Eppendorf and 50 μL of 
Elution Buffer was added to the centre of the column membrane. Finally, the 
column was centrifuged for 1 minute at 12000 xg.  
2.13.9 DNA preparation for sequencing  
 
The purified PCR product was re-quantified for DNA concentration the 
NanoDrop spectrophotometer (ThermoFisher, Waltham, MA, USA). 10ng/mL 
of purified PCR product was added to 3.2pmol/μL of ND4 or ND3 and COX3 
primer and made up to 5µl per reaction with nuclease free water. The solution 
was then sent to Source Bioscience for sequencing. Sequencing traces, 




2.13.9.1 Real time qPCR  
Real time quantitative PCR (qPCR) was carried out on the Roche Lightcycler 
480 (Roche, Basel, Switzerland). This technique was used to determine 
mitochondrial and fatty acid transporter gene expression and for detection of 
murine mtDNA transfer. Details of qPCR primers used provided in Appendix 
Table 8.1 and 8.2. 
2.13.9.2 Gene Expression 
 
To determine mitochondrial and fatty acid transporter gene expression in the 
LSK and HSC the synthesised cDNA was analysed by Sybr Green qPCR. In 
this reaction, when the cDNA is amplified the Sybr Green intercalates and 
becomes incorporated into the double stranded DNA. When the Sybr Green 
is bound it fluoresces and can be detected in real time of the qPCR machine. 
The reactions took place on a 384 well Roche Lightcycler reaction plates 
(Roche, Basel, Switzerland) using qPCRBIO SyGreen Mix (PCR Biosystems, 
London, UK). To perform the reaction a master mix comprising 4 µl of SyGreen 
Mix, 1 µl of 10 µM forward and reverse primer and 1 µl nuclease free water 
per sample was created. 6 µl of the master mix was plated into each well of a 
384 well plate and 4 µl of cDNA was then added to the wells. The plate was 
then sealed and briefly centrifuged for 1 minute at 1000rpm and loaded onto 
the Lightcycler 480. The PCR was run using the following pre-programmed 
method:  
• Pre-amplification (95 oC for 2 minutes). 
• Amplification 45 cycles (95 oC for 15 seconds, 60 oC for 10 seconds 
and 72 oC for 10 seconds). 
• Melting curve analysis confirms specificity of the PCR product (95 oC 
for 5 seconds, 65 oC for 1 minute and 97 oC continuous).  
• Cooling (40 oC for 30 seconds). 
 
The raw values on the qPCR machine are known as the cycle threshold (Ct) 
value. The gene of interest was normalised to a housekeeping gene GAPDH 
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which was present in every cell and expression is not changed with genetic 
alternations. To analyse the results ΔCt values for a specific gene was 
quantified by Ct GOI – Ct housekeeping gene. The ΔΔCt could then be 
calculated by ΔCt control – ΔCt test. The fold change in expression was then 
determined relative to untreated cells by 2-ΔΔCt. Each sample was replicated at 
least four times. 
 
2.13.9.3 Taqman® based mtDNA analysis  
To confirm the SNP genotyping assay, COX3 and ND3 primer efficiency and 
to quantify the levels of mitochondrial transfer occurring between BM 
microenvironment and HSCs after LPS treatment a TaqMan qPCR was 
developed. In this assay a sequence specific probe, which contains both a 
VIC/FAM fluorophore and TAMRA® quencher bind to the gene of interest. 
During amplification of the DNA the probe is cleaved which releases the 
fluorophore and quencher and allows for fluorophore detection. Pre-designed 
Taqman® assays were obtained from ThermoFisher, encompassing mouse 
COX3 and ND3 mtDNA, mouse ND1 mtDNA, human ND1 mtDNA and human 
and mouse genomic DNA (gDNA).  
2.13.9.3.1 Mouse SNP mtDNA detection  
The mouse mtDNA Taqman® assay was run in simplex reactions, as the 
probes had both 2′-chloro-7′phenyl-1,4-dichloro-6-carboxy-fluorescein (VIC) 
and 6- Carboxyfluorescein (FAM) fluorophores. The mouse gDNA Taqman® 
assays were also ran in simplex reactions. For the master mix: 0.25 μL of 
Taqman® reagent, which contained primers and probe was added to 2.5 μL 
of TaqPath ProAmp enzyme (ThermoFisher, Waltham, MA, USA) and mixed 
with 1.25 μL water. This master mix (4 μL) was then loaded onto each well of 
a 384 PCR plate. 1 μL of extracted DNA was then added to the master mix in 
the PCR plate. The plate was then sealed and briefly centrifuged for 1 minute 
at 1000rpm and loaded onto the Lightcycler 480. The PCR was run using the 




• Pre-amplification (60 oC for 30 seconds and 95 oC for 5 minutes).  
• Amplification over 50 cycles (95 oC for 15 seconds and 60 oC for 1 
minute).  
• Cooling (40 oC for 30 seconds).  
The Ct value was determined for the PCR run and from the Ct values obtained 
mouse mtDNA copy numbers were generated. Mouse COX3 and ND3 mtDNA 
and were normalised against the mouse gDNA Ct to obtain the ΔCt. ΔCt 
values was determined by Ct mouse COX3 or ND3 mtDNA – Ct mouse gDNA. 
The ΔCt value was used to generate mitochondrial copy number (2-ΔCt).  
The relative mtDNA:gDNA ratio was calculated using the ΔΔCt method 
described in section 2.13.9.2. The mitochondrial copy number values were 
used to determine the percentage of donor mouse mitochondria in recipient 
cells. 
 
2.13.9.3.2 Human and mouse mtDNA detection  
 
To assess mitochondrial transfer in the hu-NSG model a predesigned 
Taqman® assay which encompassing both human and mouse mtDNA and 
gDNA was used. The mtDNA Taqman assays for both human and mouse were 
ran in duplex reactions whereas the human and mouse gDNA were ran in 
simplex reactions. 
The simplex master mix was made as described in section 2.13.6. For the 
duplex reactions a master mix was made by mixing 0.5 μL of each Taqman® 
assay (human and mouse mtDNA) with 2.5 μL of TaqPath ProAmp enzyme 
and 0.5 μL water.  
 
This master mix (5 μL) was then added to the DNA (1 μL) on the PCR plate. 
The PCR plate was sealed, centrifuged at 1,000 xg for 1 minute and loaded 
into the Lightcycler 480 using the program previously described. mtDNA copy 
numbers were determined for both human and mouse mitochondria applying 
the ∆∆Ct method, using human genomic telomerase reverse transcriptase to 
normalise results. These values were used to generate the percentage of 
mouse mitochondria in the human cells to quantify mitochondrial transfer. The 
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master mix (4 μl) was then loaded onto each well of a 384 PCR plate. 1 μL of 
extracted DNA was then added to the master mix.  The plate was then sealed 
and briefly centrifuged for 1 minute at 1000rpm and loaded onto the Lightcycler 
480. The PCR was run using the following pre-programmed method: 
 
• Pre-amplification (60 oC for 30 seconds and 95 oC for 5 minutes). 
• Amplification over 50 cycles (95 oC for 15 seconds and 60 oC for 1 
minute). 
• Cooling (40 oC for 30 seconds). 
 
mtDNA copy number was determined for both human and mouse mitochondria 
and normalised to human gDNA. The Ct values for human and mouse were 
obtained and normalised against the human gDNA. The mouse genomic DNA 
should not have been detected to ensure no mouse cell contamination. To 
calculate the ΔCt = h/m mtDNA – Ct hgDNA. The copy number was then 
calculated by 2-ΔCt  this method was adapted from (330). These values were 
used to quantify the percentage of mouse mitochondria in the human cells to 
determine levels of mitochondrial transfer in the calculation below.  
 
% Mouse mitochondrial DNA= %
Mouse mtDNA copy number
m mtDNA copy number + h mtDNA copy number&×100 
 
2.13.9.4 Protein extraction 
 
To assess the protein levels in the lin- cells after coculture with BMSC the 
protein was extracted and analysed by western blotting. To extract the nuclear, 
cytoplasmic and membrane-bound protein, the whole cell lysate was isolated 
using radioimmunoprecipitation assay (RIPA) buffer, which was supplemented 
with protease and phosphatase inhibitors. The lin- cells we sorted after 
coculture and added to 30 µl of RIPA buffer. The solution was then incubated 
on ice for 20 minutes. The samples were then centrifuged at 16000 xg for 20 
minutes at 4ºC. The supernatant containing the protein was collected and the 




2.13.9.5 SDS page and immunoblotting 
 
A 12% polyacrylamide sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel was cast to quantify the presence of 
phosphorylated AKT. To make the SDS-PAGE gel 30% Polyacrylamide/Bis 
Solution (BioRad, Hercules, CA, USA) was added to 10% SDS, 10% 
ammonium persulphate, 1.5M Tris pH 8.8, TEMED and water. 5 mL of the gel 
mixture was added to the case and was left to set. The stacking gel was then 
prepared containing 30% Polyacrylamide/Bis Solution, 10% SDS, 10% 
ammonium persulphate, 1 M Tris, TEMED and water. The gel mix was then 
layer on top of the gel and a comb was added to create wells. The gel was left 
to set, and the protein sample was then prepared. 4x sample loading buffer, 
containing bromophenol blue, β-mercaptaethanol, glycine and a reducing 
agent was added to the samples. The samples were then incubated at 100oC 
for 5 minutes to denature the protein. 
 




Once the polyacrylamide SDS-PAGE gel was set the gel was placed in the 
tank filled with running buffer containing 10% SDS, 20µM glycine and 157µM 
Tris-Base. 10 µl of sample was loaded into the well alongside 5µl of Precision 
Plus Protein All Blue Prestained Protein standard ladder (BioRad, Hercules, 
CA, USA). The gels were run at 190V for around 1 hour, the protein was then 
transferred from the gel onto methanol pre-treated polyvinyladine fluoride 
(PVDF) membranes. The gel and the PVDF membrane were layered in a 
cassette and transferred to a tank filled with transfer buffer, 20µM Glycine and 













10% Ammonium persulphate 0.1
TEMED 0.001
12% separating gel 20mL 12% stacking gel 10mL
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overheating and was left to transfer at 100v for 45 minutes. The PVDF 
membrane was then blocked in TBST (1X PBS and 0.01% Tween) with 5% 
bovine serum albumin (BSA) on a shaker for 1 hour. The blocked membrane 
was then incubated with primary antibody overnight at 4˚C. The membrane 
was then washed with TBST 5 times and secondary anti rabbit horseradish 
peroxidase (HRP) was added to the membrane. The membrane was 
incubated for 1 hour at room temperature and washed a further 5 times in 
TBST. The membranes were also probed for total AKT as a loading control. 
 
2.13.9.6 Chemiluminescent detection of the western blot 
 
The antibody stained membranes were visualised using enhanced 
chemiluminescence (ECL) reagent (GE healthcare, Little Chalfont, UK). The 
solution A and B were first mixed in equal quantities and 500 µl was then 
added to the membrane. The membrane was incubated for 45 seconds and 
any excess solution remained was poured off. The membrane was imaged 
using the filter set on 3 on the Chemdoc-It2 Imager (UVP, LLC, Upland, CA, 
USA). 
 
2.14 Animal Procedures  
 
All animal work used in this thesis was carried out in accordance with 
regulations set by the UK Home Office and the Animal Scientific Procedures 
Act 1986 under project license 70/8814 (Prof. Kristian Bowles). All procedures 
were carried out by myself, under UK Home Office personal license 
I2777C6D5, with the aid of Dr Chris Marlein (IBB43C002), Dr Charlotte 
Hellmich, Jamie Moore (ID99A0852) and Dr Stuart Rushworth (ICD3874DB). 
Full training was conducted by Mr Richard Croft (IGEBEFB87) and Mrs Anja 
Croft (L8A2ACED) before undertaking the techniques described below. 
Animals were housed in a pathogen free, containment level 3 laboratory in the 




2.14.1 Maintenance of animal colonies  
Seven strains of mice were used in this study. C57BL/6J (originally purchased 
from stock at the DMU, UEA, UK), Non-obese diabetic (NOD) severe 
combined immunodeficiency (SCID) Il2rg knockout 
(NOD.Cg.PrkdscidIL2rgtm1Wji/SzJ) (NSG) mice, (originally purchased from the 
Jackson Laboratory, Bar Harbour, ME, USA), B6.SJL-PtprcaPep3b/BoyJ 
(PepCboy) mice (originally purchased from Jackson Laboratory), 
C57BL/6Nsu9-DsRed2 (DsRed) Mice (A kind gift from Professor Jiri Neuzil 
Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech 
Republic), B6.129S-Cybbtm1Din/J (Cybb) mice (originally purchased from 
Jackson Laboratory), CBA/J mice (originally purchased from stock at the 
DMU) and B6.129S1-Cd36tm1Mfe/J (CD36 knockout) mice (originally purchased 
from Jackson Laboratory). The mice were all maintained and bred in the “barn” 
of the DMU. Breeding pairs were kept together for 6 months before separation 
and the offspring weaned 3 weeks post birth. Animals were used for 
experimentation at 8 to 12 weeks of age (with the exception of mice used for 
transplantation in which case 3 to 4-week-old mice were used). Both genders 
were used for experiments. 
2.14.1.1 Wildtype C57BL/6J mice 
The C57BL/6J is the most commonly used inbred mouse strain, it is widely 
used as an all-purpose strain and a background strain for the generation of 
mice with spontaneous and induced mutations. The C57BL/6J mice are long-
lived and breed well. The C57BL/6J mice were used in this study to analyse 
the mitochondrial content, mitochondrial health, lipid content, ROS levels, 
pAKT and cell cycling in the HSC and progenitor populations after infection. 
The mice were also used for the generation of mouse BMSC, mouse 
macrophages, mouse osteoblasts and lin- or LK cells for in vitro experiments. 
To assess response to infection 1 mg/kg LPS or control PBS were injected IP 
into C57BL/6J mice. Following a 2 or 16 hours incubation the mice were 
sacrificed, and BM was extracted and analysed by flow cytometry, cell sorting 
and seahorse metabolic analysis. C57Bl/6J mice were also subjected to pre-
treatment with 500 mg/kg N-acetyl cysteine (NAC), 100 mg/kg buthionine 
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sulfoximine (BSO), 25 mg/kg cytochalasin B (CytoB), 30 mg/kg CAL 101, 50 
mg/kg carbenoxolone (CBX), 40 mg/kg sulfosuccinimidyl oleate (SSO) or 10 
mg/kg Etomoxir all diluted in PBS for 1 hour followed by 1 mg/kg LPS. After 
16 hours the mice were sacrificed, and the BM extracted for analysis. C57Bl/6J 
mice were also used to determine the HSC response to Salmonella 
typhimurium (S.typhimurium infection). C57Bl/6J mice were treated with 
streptomycin (20 mg/mL) 24 hours prior to S.typhimurium infection. Mice were 
then left untreated or infected with 100 μL of 1 x 108 CFU S.typhimurium 
(SL1344- JH3009) by oral gavage for 72 hours. 
2.14.1.2 NSG mice 
 
NSG mice have two mutations scid and an IL2 receptor common gamma chain 
(IL2rgnul) null allele on the NOD/ShiLtJ background. The mice are deficient of 
B and T cell as the scid mutation is in the Prkdc, a DNA repair complex protein. 
They are also deficient in functional natural killer cells due to the 
IL2rgnull mutation, which inhibits multiple receptor cytokine signalling. This 
severe immune deficiency allows for the engraftment of human CD34+ 
haematopoietic stem cells to create humanized mice. These mice were used 
for allograft and xenograft transplantations in this study. The mice were treated 
with busulfan rather than irradiation before transplantation, so the animals 
were relatively healthy.   
 
2.14.1.3 Wildtype PepCboy mice 
The B6.SJL-PtprcaPep3b/BoyJ (PepCboy) mouse is a C57BL/6J congenic strain 
which carries the differential pan leukocyte marker, Ptprca also known as 
CD45.1. Wildtype inbred C57BL/6J inbred mice express the Ptprcb or CD45.2 
allele. Therefore, these mice are commonly used for transplantation studies. 
These animals were used in this study to generate transplantation models in 
which a C57BL/6J or a CD36 mouse BM was transplanted into PepCboy mice. 
The mice were also used for the generation of mouse BMSC and lin- of LK 
cells for in vitro mtDNA transfer assay.  
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2.14.1.4 DsRed mice 
C57BL/6Nsu9-DsRed2 (DsRed) mice are transgenic mice which express a red 
fluorescent protein in the mitochondria of somatic cells (CAG/su9-DsRed2 
transgene). DsRed mice are based on a C57Bl/6 background and were 
generated at the Institute of Molecular Genetics (Prague, Czech Republic). 
DsRed mice were used in this study to assess mitochondrial transfer within 
the BM. DsRed mice were ear notched for phenotyping and identification and 
fluorescence was detected by fluorescent microscopy. Fluorescent 
microscopy was carried out on a Zeiss Axio Observer fluorescent microscope 
with 20X objectives (Carl Zeiss, Oberkochen, Germany). Tissue samples 
collected from ear notching were placed into 24 well plate and placed on the 
plate holder on the microscope. ZEN Blue imaging software was used to 
acquire fluorescent and bright field images. For characterisation of the DsRed 
animals, phenotypically positive animals were sacrificed, the BM was 
extracted and analysed by flow cytometry for specific cell populations. 
Phenotypically negative DsRed animals were used as a control. For 
mitochondrial transfer analysis 1 mg/kg LPS or PBS control were injected by 
intraperitoneal injection. After 2-hour of treatment the mice were sacrificed, 
and BM was extracted for flow cytometry analysis. 
2.14.1.5 Cybb mice 
B6.129S-Cybbtm1Din/J (Cybb) mice also known as gp91phox- have a C57Bl/6J 
background with a null allele in the gene involved in X-linked CGD. This gene 
encodes the oxidase cytochrome b in the 91 kD subunit and hemizygous male 
which are affected lack the ability to produce phagocytic superoxide and have 
an increased susceptibility to infection. The Cybb mice were used to analyse 
mitochondrial content in the HSC and progenitor populations after infection. 1 
mg/kg LPS or PBS control were interperitoneally injected. After 2 hours of 
treatment the mice were sacrificed, and BM was extracted for analysis. The 




2.14.1.6 CBA mice 
Wildtype inbred CBA/J mice are a commonly used as a general-purpose 
strain. CBA/J mice express the Ptprcb or CD45.2 allele similar to the WT 
C57BL/6J. These mice were used to assess mitochondrial transfer in in vitro 
mtDNA transfer assays. The mice were sacrificed, and the BM was extracted 
and used to generate mouse BMSC and lin- cells.  
2.14.1.7 CD36 knockout mice 
B6.129S1-Cd36tm1Mfe/J (CD36 knockout) mice have a number of lipid-related 
metabolic traits including an altered fatty acid uptake. The knockout mice have 
a targeted mutation a NEO cassette instead of exon 3 which encodes the 
translation initiation site and the first 40 amino acids. Homozygous mice are 
viable, tend to be smaller and have elevated fasting levels of non-esterified 
FFA compared wildtype controls. The CD36 knockout mice were used in this 
study to analyse the lipid content, and cell cycling in the HSC and progenitor 
populations after infection. The mice were also used in transplantation 
experiment. To assess response to infection 1 mg/kg LPS or control PBS were 
injected IP into CD36 knockout mice. Following a 16 hour incubation the mice 
were sacrificed and BM was extracted and analysed by flow cytometry and 
seahorse metabolic analysis. CD36 knockout mice were also used to 
determine the HSC response to S.typhimurium infection. CD36 knockout mice 
were treated with streptomycin (20 mg/mL) 24 hours prior to S.typhimurium 
infection. Mice were then left untreated or infected with 100 μL of 1 x 108 CFU 
S.typhimurium (SL1344- JH3009) by oral gavage for 72 hours. The mice were 
sacrificed, and BM was extracted and analysed by flow cytometry and 
seahorse metabolic analysis. 
2.14.2 Intraperitoneal injections  
Busulfan, LPS, NAC, BSO, etomoxir and D-luciferin were all administered 
using an intraperitoneal (IP) injection. The mice were restrained using a scruff 
technique and 200 μL for a 6-week old mouse and 100 μL for a 3-6-week-old 
mouse of the compounds were injected into the peritoneum with a sterile 26-
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gauge needle. In the case of busulfan where daily IP injection or pre-treatment 
was needed, the animals were injected in alternate flanks.  
2.14.3 Intravenous injections  
For transplantation models the donor LK cells were administered to the 
busulfan treated recipient mice via intravenous (IV) tail vein injection. The 
recipient mice were placed in a 37 ̊C hot box for 10 minutes to vasodilate the 
tail vein, prior to injection. The mice were then placed in a benchtop restrainer 
and 200 μL of 2 x 105 LK cells suspended in PBS was injected into the lateral 
tail vein with a sterile 26-gauge needle. The mice were then placed into a new 
cage for a short recovery period before being returned to their home cage.  
2.14.4 Blood Sampling  
Blood was taken from the tail vein of mice for engraftment and serum fatty acid 
analysis. For engraftment analysis the tail vein was vasodilated by placing the 
animals in a 37 oC hot box for 10 minutes. The mice were then placed in a 
benchtop restrainer, using a trimmed 26-gauge butterfly needle 200 μL of 
blood was collected in a 1.5mL Eppendorf tube containing 25 μL of 
monosodium citrate. The red cells were then lysed using 1X red blood cells 
lysis buffer (ThermoFisher, Waltham, MA, USA) and specific antibodies were 
added to the collected blood and stained for 20 minutes. The blood was then 
analysed using flow cytometry. For serum FFA analysis cardiac puncture was 
used to isolate the blood.  
Cardiac puncture was used as it is method which can obtain large quantities 
of good quality blood. The mice are placed under deep terminal anaesthesia 
and the blood samples were taken from the left ventricle of the heart using a 
25-gauge needle. The blood was withdrawn slowly to prevent the heart from 
collapsing and placed into EDTA coated tubes ready for analysis. 
2.14.5  Oral gavage  
For the administration of live S.typhimurium to C57BL/6J or CD36 knockout 
mice, oral gavage was utilised, this procedure was carried out by Dr Naiara 
Bezera. Glycerol stocks of S. typhimurium were aseptically streaked onto Luria 
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Broth agar plates, to isolate single colonies and incubated at 37˚C for 16 hours. 
A single colony was isolated and placed into 5 mL of sterile LB broth containing 
0.3 M NaCl (LBS) and incubated in a shaker at 37˚C for 24 hours. The 
overnight culture was diluted in LBS 1:100 and incubated until the culture 
reached the optical density (ΔOD600nm) of 1.2 to 1.4 which is the late 
exponential phase. At this ΔOD600nm the SPI1 invasion genes in the S. 
typhimurium are turned on. The culture was then centrifuged at 8000 xg for 7 
min and washed twice in 1X PBS, the pellet was resuspended at concentration 
of 1 to 5 x 108 CFUs per 100 μL in sterile 1X PBS. The mice were infected with 
100 μL of 1 x 108 CFUs of S. typhimurium by restraining the mouse in a scruff 
and administering the S. typhimurium down the oesophagus directly into the 
stomach of the mouse. 
2.14.6 Live animal imaging  
 
To assess fatty acid uptake in the haematopoietic compartment 
bioluminescent imaging of live mice was carried out. To ensure engraftment, 
the FFA-luciferase allograft mouse model was intraperitoneally injected 
with150mg/kg D-luciferin. The mice were then left for 15 minutes at room 
temperature for maximum detection of the luciferase signal. The mice were 
then anaesthetised using a chamber filled with isoflurane with a flow rate of 
3%. The mice were then transferred to the Bruker In-Vivo Xtreme (Bruker, 
Coventry, UK) an imaged using a pre-set method of 1-minute exposure 
bioluminescent image, x-ray and light image. The mice were transferred to 
their home cage to recover. Once engraftment was confirmed and the mice 
had sufficiently recovered the mice were injected with 100 μL of 200 μM FFA-
SS-luc (SwissLumix Sarl, Switzerland) (0.014 mg/mouse) bound to 0.1% (w/v) 
BSA in PBS, interperitoneally. The mice were imaged using the Bruker In-Vivo 
Xtreme with a 2-minute exposure. One week after the mice had recovered the 
animals were interperitoneally injected with 1 mg/kg LPS for 16 hours. The 
mice were injected with 100 μL of 200 μM FFA-SS-luc (0.014 mg/mouse) 
bound to 0.1% (w/v) BSA in PBS again and imaged using the Bruker In-Vivo 
Xtreme with a 2-minute exposure FFA uptake was visualised by light detection 
produced Oxyluciferin formation from luciferin. This reaction was catalysed by 
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the luciferase in the modified haematopoietic cells. The images were merged 
with the X-ray files and the densitometry was analysed using Fiji software. 
2.14.7 Schedule 1  
Mice were monitored daily and humanely sacrificed upon first sign of illness 
including; weight loss, reduced motility, signs of graft vs host disease, severe 
over grooming, hind limb paralysis, hunched posture and piloerection using 
schedule 1 methods. The mice were also sacrificed at the end point of the 
experiment. Mice were sacrificed by gradual CO2 asphyxiation followed by 
dislocation of the neck.  
2.14.8 Transplantation models  
For transplantation experiments engraftment was checked by expression of 
human CD45 or mouse CD45.1/2 on differentiated cells by blood sampling 4, 
8 and 12 weeks post transplantation (Appendix Figure 8.1 to 8.3). 12-16 weeks 
post transplantation animals were treated. Engraftment was also measured by 
expression of human CD45 or mouse CD45.1/2 detected in the BM after 
termination, if more than 40% donor cells were detected the cells were 
considered to be engrafted. 
2.14.8.1 NSGC57 allograft mouse model 
The NSG mouse model expressing the CD45.1 allele antigen was used in 
transplant experiments whereby isolated BM cells from C57Bl/6J mice 
expressing the CD45.2 allele was transplanted. 3-4-week-old NSG mice were 
treated with 25 mg/kg Busulfan interperitoneally every 24 hours over a 72-hour 
time period. 2 x 105 isolated BM cells from C57Bl/6J mice were lineage 
depleted then injected IV into the tail vein. Engraftment of the C57Bl/6 BM was 
analysed by flow cytometry through analysis of CD45.2 and CD45.2 cells in 
the peripheral blood. Once engrafted these animals were then treated with 1 
mg/kg LPS or control PBS for 2 hours. These transplanted mice were termed 
NSGC57. The BM was isolated and sorted for donor C57BL/6J LSK (Lin-, Sca 
1+, CD117) and donor C57BL/6J HSC (Lin-, Sca 1+ CD117 CD48−CD150+) 
and analysed for mtDNA transfer by qPCR. 
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2.14.8.2 CD34+ haematopoietic progenitor cell xenograft model  
For the CD34+ haematopoietic progenitor cell xenograft model (hu-NSG), 3-
4-week-old NSG mice were treated with 25 mg/kg Busulfan interperitoneally 
every 24 hours over a 72-hour time period. On the day of transplantation 2 x 
105 isolated CD34+ cord blood cells were injected into the tail vein of the 
busulfan treated NSG mice. CD34+ cell engraftment was checked by levels of 
human CD45+ cells in the peripheral blood. Post engraftment, the hu-NSG 
mice were treated with 1 mg/kg LPS for 2 hours and sacrificed. The BM was 
extracted, and the human HSCs (hHSCs) (mCD45−, hCD34+, hCD38−, 
hCD45RA−, hCD90+, hCD49f+), hMPPs (mCD45-, hCD34+, hCD38−, 
hCD45RA−, hCD90−, hCD49f−), and hGMPs (mCD45−, hCD34+, hCD38+, 
hCD45RA+, hCD90−, hCD49f−) was isolated by FACS. The BM was also 
analysed for human cell engraftment by human CD45+ cells. If more than 40% 
of human CD45 cells was detected in the BM, the CD34+ cells were deemed 
to be engrafted. 
2.14.8.3 FFA luciferase allograft mouse model 
 
For the FFA-luciferase allograft mouse model C57BL/6J and CD36 knockout 
mice expressing the CD45.2 allele antigen was used in the transplant 
experiments. C57BL/6J and CD36 knockout mice were sacrificed, BM was 
isolated, lineage depleted followed by CD117 enrichment using CD117+ 
enrichment kit. The cells were then seeded at a density of 2 x 105 cells/well in 
DMEM supplemented with 10% FBS plus 1% penstrep with mSCF, mIL 3, mIL 
6 (Peptrotech, NJ, USA). The cells were transduced with pCDH-luciferase-
T2A-mCherry virus, which was kindly provided by Professor Irmela Jeremias, 
(Helmholtz Zentrum München, Munich, Germany). Following a 24-hour 
incubation a successful transduction was confirmed by detection of mCherry 
fluorescence on a fluorescent microscope. The transduced cells were then 
transplanted into the tail vein of 3-4-week-old PepCboy mice by intravenous 
injection which had been preconditioned with 25 mg/kg/day for 3 days prior to 
transplantation. FFA-luciferase allograft mouse engraftment was monitored by 




2.14.8.4 CPT1A KD allograft mouse model 
In the CPT1A KD allograft mouse model PepCboy mice expressing the 
CD45.1 allele antigen was used in the transplant experiments to determine the 
role of CPT1A in the response to infection. C57BL/6J and CD36 knockout mice 
were sacrificed, BM was isolated, lineage depleted followed by CD117 
enrichment using CD117+ enrichment kit. The cells were then seeded at a 
density of 2 x 105 cells/well in DMEM supplemented with 10% FBS plus 1% 
penstrep with mSCF, mIL3, mIL6 (Peptrotech, NJ, USA). The cells were 
transduced with MISSION shRNA TRCN0000036279 (human carnitine 
palmitoyltransferase IA (CPT1A) shRNA). MISSION pLKO.1-puro Control 
Vector was used as the lentivirus control (control short hairpin RNA (shRNA)). 
The transduced cells were then transplanted into the tail vein of 3-4-week-old 
C57BL/6J mice by intravenous injection which had been preconditioned with 
25 mg/kg/day for 3 days prior to transplantation. Successful transduction was 
assessed using qPCR, if the knockdown was successful the mice were used 
for further experiments. Post engraftment the animals were treated with 1 
mg/kg LPS or control PBS for 16 hours and sacrificed. The BM was extracted 
and analysed by flow cytometry for cell cycling and lipid content. The BM was 
analysed for CD45.1 expression to determine cell engraftment.  
2.14.8.5 PepCboy CD36 allograft mouse model 
In the PepCboy CD36 allograft model PepCboy mice expressing the CD45.1 
allele antigen was used in this transplant experiment to assess the recovery 
of the haematopoietic system in CD36 knockout mice in response to infection. 
PepCboy mice were sacrificed and the BM was isolated, lineage depleted 
followed by CD117 enrichment (LK cells). 2 x 105 isolated LK PepCboy cells 
were then injected into the tail vein of 3-4-week-old CD36 knockout mice by 
intravenous injection which had been preconditioned with 25 mg/kg/day for 3 
days prior to transplantation. Post engraftment the animals were treated with 
1 mg/kg LPS or control PBS for 16 hours and sacrificed. The BM was extracted 
and analysed by flow cytometry for CD36 expression, lipid uptake and cell 
cycling and CD45.1 cell engraftment. The LSK cells were also isolated and 
metabolic changes were assessed by seahorse metabolic flux analysis.  
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2.14.8.6 CD36 PepCboy allograft mouse model 
 
In the CD36 PepCboy allograft model PepCboy mice expressing the CD45.1 
allele antigen was used in this transplant experiment to assess the role CD36 
in the haematopoietic system in response to infection. C57BL/6J (WT CD36+/+) 
and CD36 knockout (CD36-/-) mice were sacrificed, and the BM was isolated, 
lineage depleted followed by CD117 enrichment (LK cells). LK WT CD36+/+ 
and LK CD36-/- were then injected into tail vein of 3-4-week-old PepCboy mice 
by intravenous injection which had been preconditioned with 25 mg/kg/day for 
3 days prior to transplantation. These transplanted mice were termed WT(CD36-
/-) for CD36 knockout into WT and WT(CD36+/+) for WT into WT. Post engraftment 
the animals were infected with S. typhimurium for 4 days. The BM was 
extracted and analysed by flow cytometry for lipid uptake, cell cycling and 
CD45.2 cell engraftment.  
2.15 Quantification and Statistical Analysis 
 
All data produced in this study was analysed using Prism software (Version 
7.0, GraphPad Software, San Diego, CA, USA), BD FlowJo 10.7.0 software 
(FLowJo, LLC, Ashland, OR, USA), Fiji ImageJ 2.0.0. and Microsoft Excel 
(Albuquerque, NM, USA). Due data variability in vivo work, statistical 
comparison of two groups was performed without assumption of normal 
distribution using the Mann-Whitney U test. For comparison of more than two 
groups, One-way ANOVA followed by Tukey’s multiple comparisons test or 
Kruskal-Wallis statistical test followed by Dunn’s multiple comparisons or Two-
way Anova was performed using Prism software (GraphPad, La Jolla, CA, 
USA). Differences between group means were determined significant when 
the probability value, p, was less than 0.05* 0.01** 0.001*** 0.0001****.  The 
results represent the mean ± standard deviation of 4 or more independent 
experiments. Sample size (n) represents number of biological replicates. No 






3 Mitochondrial transfer occurs from the bone marrow 




The ability of the HSC to maintain the HSC pool and differentiate into the 
mature blood cells is vital for the maintenance of haematopoiesis throughout 
life (9, 331). The HSC whilst mostly quiescent, upon exposure to specific 
stimuli can rapidly become active and enter the cell cycle (332). The 
mammalian response to infection is reliant on this switch, initiating a rapid 
expansion of leukocytes to respond to the pathogen (11). This expansion 
requires large amounts of energy however, the mechanism underlying the 
regulation of HSC metabolism in response to the pathogenic challenge are not 
fully elucidated.  
 
HSCs reside in the BM microenvironment, within a specialised niche which 
helps maintain the production of mature blood cells under physiological 
conditions (51, 131). The HSC niche is a hypoxic environment, which supports 
the HSC for retention or expansion out of the niche. HSC expansion requires 
large amounts of energy and quiescent HSCs are thought to rely on anaerobic 
glycolysis (245, 333). It has been shown that quiescent HSCs have a low 
mitochondrial mass (245, 247, 334), which is maintained by mitophagy. This 
active removal of mitochondria has been shown to be vital for the maintenance 
of HSCs (334, 335). Furthermore, HSC mitochondrial mass has been shown 
to be stable over their lifetime with a lower turnover capacity of mitochondria 
than the more differentiated progenitors (336). HSC quiescence is maintained 
by the regulation of mitochondrial mass and a limited mitochondrial respiration 
(286). Taken together, the regulation HSC quiescence is reliant on specific 
metabolic conditions maintained by the HSC niche.  
 
It has previously been shown that intercellular mitochondrial transfer from 
BMSCs to AML blasts aids proliferation and survival of the malignant cell 
though an increase in OXPHOS (41, 297). Moreover, it has also been shown 
non-malignant cells can transfer mitochondria to rescue aerobic respiration. 
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Furthermore, it has been observed that under normal conditions human 
CD34+ haematopoietic progenitor cells do not obtain mitochondria from 
BMSCs, however under oxidative stress mitochondria can move between 
these cells (41). This suggests that the metabolic switch in AML, regulated by 
mitochondrial transfer could have originated from the normal physiological 
response of the HSC during infection. 
 
Pathogenic stress including bacterial infection is a major cause of oxidative 
stress in the human body (337) and therefore could stimulate the transfer of 
mitochondria to the HSC. LPS is found on the outer membrane of most gram-
negative bacteria and has been shown to initiate an immune response similar 
to a bacterial infection in mice (68). In this chapter of my thesis using S. 
typhimurium and LPS I will examine the mitochondrial change in HSCs and 
the metabolic consequences following acute bacterial infection. I also aim to 
determine if mitochondrial transfer from the BM microenvironment to the HSC 
occurs in vivo during LPS stimulation. 
 
3.2 Acute bacterial infection increases mitochondrial content in 
HSCs 
Firstly, to analyse the effect of acute bacterial infection on mitochondrial mass 
in HSCs, C57BL/6J mice were infected with S. typhimurium for 72 hours. At 
72 hours of S. typhimurium infection there is a significant increase of IL 6 in 
the serum compared to mice treated for 48 and 120 hours (Figure 3.1A). At 72 
hours the animals also begin to lose weight, a hallmark of S. typhimurium 
infection, this time point was therefore chosen as the endpoint (Figure 3.1B). 
The haematopoietic cell populations were analysed for mitochondrial levels 
with a panel of cell surface antibodies and MitoTracker Green (MTG) using 
flow cytometry (Figure 3.2A). This included all colour compensations and the 
gating strategy to isolate the specific cell populations of interest is shown in 
Figure 3.2B. All gating was determined using fluorescence minus one controls 




Figure 3.1. S.typhimurium infection induce an increase in IL 6 expression 
in the serum and weight loss.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 48,72 or 120 hours. 
Blood was taken from the animals by cardiac puncture and the serum was assessed 
for IL 6. n>3 in each group. Experiment performed by Dr Stuart Rushworth. (B) 
C57BL/6J mice were infected with S.typhimurium (Sal) for 5 days, the animals were 
weighed daily. n=6 in each group. Data shown are means ± SD **P < 0.01 P< 
****0.0001 Statistical test used was Kruskal-Wallis statistical test followed by Dunn’s 
multiple comparisons.  
 
Figure 3.2. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and 
LT-HSC. 
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, and the bone marrow was extracted. The cells were stained with a 
panel of antibodies to analyse specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC 
populations. (B) The gating strategy used is shown. 
 
 
Figure 3.1. Weight loss during S. typhimurium infection C57BL/6J mice were 








































Figure 5.6. S. typhimurium infection induce an increase in IL-6 expression in 
the serum and weight loss. 
(A) C57BL/6J mice were infected with S. typhimurium (Sal) for 48,72 or 120 hours. 
Blood was taken from the animals by cardiac puncture and the serum was assessed 
for IL-6. n>3 in each group. Experiment performed by Dr Stuart Rushworth. (B) 
C57BL/6J mice were infected with S. typhimurium (Sal) for 5 days, the animals were 
weighed daily. n=6 in each group. Data shown are means ± SD  **P < 0.01 
****0.0001 Statistical test used was One-way ANOVA followed by Tukey’s multiple 
comparisons test. 
Figure 4.1. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and LT-
HSC (A) C57BL/6J mice were infected with S. typhi urium (Sal) for 72 h, the 
animals were sacrificed and the bone marrow was extracted. The cells were stained 
with a panel of antibodies to analyse specific Lin-, LSK, HSC, MPP, ST-HSC and LT-





















































































Figure 3.3A shows that HSPC populations within the BM increase their 
mitochondrial mass after treatment with LPS. Specifically the LSK (Lin- Sca 
1+ CD117+), total HSCs (Lin- Sca 1+ CD117+ CD150+ CD48-), ST-HSC (Lin- 
Sca 1+ CD117+ CD150+ CD48- CD34+) and LT-HSCs (Lin- Sca 1+ CD117+ 
CD150+ CD48- CD34-) (68) populations all had a significant increase in 
mitochondrial fluorescence after S.typhimurium infection. In the other 
populations analysed Lin- and MPP (Lin- Sca 1+ CD117+ CD150- CD48+) 
there was no change in mitochondrial fluorescence after S. typhimurium 
infection (Figure 3.3A).  
As with any dye it has been reported that there are limitations to MTG. MTG 
stains live mitochondria within a cell enabling the identification of mitochondrial 
localisation (338). MTG has also been used to quantify mitochondrial mass 
within a cell (339). However, it has been reported that MTG flourecence 
intensity can be affected by ROS levels or mitochondrial potential. Thus, taking 
these limitations into account, to further prove that the mitochondrial content 
increases in the HSC population in response to S. typhimurium, the HSC 
population was sorted from control and S. typhimurium treated mice and 
analysed for mtDNA. The increase in mitochondrial mass was confirmed in the 
HSC population by an increase in mtDNA following S. typhimurium infection 






Figure 3.3. S.typhimurium induces an increase in mitochondrial content 
in the heamatopoetic stem and progenitor populations.  
C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and Mitotracker green (MTG) to analyse mitochondrial content in specific 
Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations. (A) Mitochondrial content 
(mitotracker green (mean fluorescence intensity (MFI)) in the specific populations of 
all animals examined. n=6. (B) The HSC (Lin-, Sca 1+, CD117+, CD48-, CD150+) 
population was sorted from control and S. typhimurium treated mice and analysed for 
mtDNA by qPCR. n=5 in each group. Data shown are means ± SD *P < 0.05 **P < 
0.01 
 
To examine mitochondrial content in the progenitor populations, C57BL/6J 
mice were infected with S.typhimurium by oral gavage for 72 hours. The mice 
were then sacrificed, and the haematopoietic progenitor populations were 
analysed for mitochondrial content (Figure 3.4A). The gating strategy shown 





























Figure 4.2. S. typhimurium induces an increase in mitochondrial content in 
the heamatopoetic stem and progenitor populations. C57BL/6J mice were 
infected with S. typhimurium (Sal) for 72 h, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies and Mitotracker
green (MTG) to analyse mitochondrial content in specific Lin-, LSK, HSC, MPP, 
ST-HSC and LT-HSC populations. (A) Mitochondrial content (mitotracker green 
(me  fluorescenc  intensity (MFI)) in the specific populations of all animals 
examined. n=6. (B) The HSC (Lin−, Sca-1+, c-Kit+, CD48−, CD150+) population 
was sorted from control and S. typhimurium treated mice and analysed for 
mtDNA by qPCR. n=5. Data shown are means ± SD  *P < 0.05 **P < 0.01







































Figure 3.4. Gating strategy for mouse, LS-K, GMP, CMP and MEP.  
(A) C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours, the animals 
were sacrificed, and the bone marrow was extracted. The cells were stained with a 
panel of antibodies to analyse specific LS-K, CMP, GMP and MEP populations. (B) 
The gating strategy used is shown. 
 
The more lineage committed cells such as the LS-K, CMP, GMP and the 
MEP populations showed no significant increase in mitochondrial content 
following S.typhimurium infection (Figure 3.5). Taken together, the results 
confirm that mitochondrial mass increases in the LSK and HSC populations 
in response to S. typhimurium but not in the downstream committed 























































































































































Figure 4.3. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and LT-
HSC (A) C57BL/6J mice were infected with S. typhimurium (Sal) for 72 h, the 
animals were sacrificed and the bone marrow was extracted. The cells were stained 
with a panel of antibodies to analyse specific LS-K, CMP, GMP and MEP 






Figure 3.5. S.typhimurium does not induce an increase in mitochondrial 
content in the haematopoietic progenitor populations. 
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies and 
Mitotracker green (MTG) to analyse mitochondrial content in specific LS-K, CMP, 
GMP and MEP populations. Mitochondrial content (mitotracker green mean 
fluorescence intensity (MFI)) in the specific populations of all animals examined. n=6 
in each group. Data shown are means ± SD  *P < 0.05 
 
 
To understand the kinetics at which mitochondrial content increases I used 
LPS as a surrogate for bacterial infection. Firstly, to assess the inflammatory 
response to LPS treatment a time course kinetic experiment was performed. 
C57BL/6J mice were treated with LPS for 2, 16 and 48 hours, serum was 
isolated from these mice and assessed for IL 6 expression. There was a 
significant increase of IL 6 in the serum of mice treated with LPS for 16 hours 
compared to the other time point (Figure 3.6).  
 
 
Figure 3.6. LPS treatment induce an increase in IL 6 expression in the 
serum. 
C57BL/6J mice were treated with 1 mg/kg LPS for 2, 16 or 48 hours. Blood was taken 
from the animals by cardiac puncture and the serum was assessed for IL 6. n>3 in 
each group. Data shown are means ± SD P< ****0.0001 Statistical test used was 






























Figure 4.4. S. typhimurium induces an increase in mitoc o drial c ntent in 
the haematopoietic stem and progenitor populations. 
C57BL/6J mice were infected with S. typhimurium (Sal) for 72 h, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and Mitotracker green (MTG) to analyse mitochondrial content in 
specific LS-K, CMP, GMP and MEP populations. (A) Mitochondrial content 
(mitotracker green (mean fluorescence intensity (MFI)) in the specific populations 
of all animals examined. n=6. Data shown are means ± SD  *P < 0.05
Figure 5.6. LPS t atment induce an increase in IL-6 expression i  the serum. 
C57BL/6J mice were treated with 1mg/kg LPS for 2, 16 or 48 hours. Blood was 
taken from the animals by cardiac puncture and the serum was assessed for IL-6. 
n>3 in each group. Data shown are means ± SD  ****0.0001 Statistical test used 
was One-way ANOVA followed by Tukey’s multiple comparisons test. Experiment 
performed by Dr Stuart Rushworth
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C57BL/6J at 8 weeks of age were then treated with LPS for 2 and 16 hours 
and analysed for MTG fluorescence (Figure 3.7A). An increase in 
mitochondrial content was observed in the LSK, HSC, ST-HSC and LT-HSC 
at both 2 and 16 hours post LPS treatment. Similar to Salmonella there was 
no increase in mitochondrial mass in the Lin- and MPP population at both 2 





Figure 3.7. LPS induces an increase in mitochondrial content in the 
haematopoietic stem and progenitor populations.  
(A) C57BL/6J mice were treated with 1 mg/kg LPS for 2 or 16 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies and 
Mitotracker green (MTG) to analyse mitochondrial content in specific Lin-, LSK, HSC, 
MPP, ST-HSC and LT-HSC populations. (B) Mitochondrial content (mitotracker green 
(mean fluorescence intensity (MFI)) in the specific populations of all animals 
examined after 2 hours of LPS treatment. n=5. (C) Mitochondrial content in the 
specific populations of all animals examined after 16 hours of LPS treatment. n=5 in 














































































































Figure 4.5. LPS induces an increase in mitoch ndrial content in the 
haematopoietic stem and progenitor populations. (A) C57BL/6J mice were
treated with 1mg/kg LPS for 2 or 16 h urs, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies and Mitotracker
green (MTG) to analyse mitochondrial content in specific Lin-, LSK, HSC, MPP, 
ST-HSC and LT-HSC populations. (B) Mitochondrial content (mitotracker green 
(mean fluorescence intensity (MFI)) in the specific populations of all animals 
examined after 2 hours of LPS treatment. n=5. (C) Mitochondrial content in the 
specific populations of all animals examined after 16 hours of LPS treatment. n=5 
Data shown are means ± SD  *P <0.05
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Next, to determine if the increase mitochondrial mass in the HSCs was due to 
mitochondrial biogenesis, we examined the expression of the genes known to 
be involved with mitochondrial biogenesis fission and fusion. Figure 3.8 shows 
that mRNA expression of the biogenesis genes PCG1 β, NRF1, NRF2, TFAM, 
tfb1m and tfb1m were not upregulated in response to LPS at 2 hours. 
Expression of these genes did increase at 16 hours post LPS infection. PGC1α 
was upregulated in the HSC after 2 and 16 hours of LPS treatment, however, 
upregulation of PGC1α alone cannot establish the cell’s ability to undertake 
mitochondrial biogenesis. Interestingly, expression of the fusion genes Opa1 
and MFN1 were also upregulated at both 2 and 16 hours following LPS 
infection. MFN2 another gene regulating mitochondrial fusion was only 
upregulated at 16 hours post LPS treatment. The mitochondrial fission gene 
DNM1I was only upregulated at 16 hours following infection. This data 
suggests that the increase in mitochondrial mass in the HSC 2 hours post LPS 
infection is not associated with mitochondrial biogenesis. The 2-hour LPS time 
point was used in the following experiments to try to specifically detect 





Figure 3.8. Mitochondrial biogenesis fission and fussion gene 
expression in response to LPS stimulation in the HSC. 
C57BL/6J mice were treated with LPS for 2 or 16 hours, the animals were sacrificed, 
the bone marrow was extracted and stained with a panel of antibodies to isolate the 
HSC population by FACS. RNA was analysed for gene expression of mitochondrial 




Figure 4.6. Mitochondrial biogenesis is not up-regulated t 2 hours post 
LPS stimul ti n. C57BL/6J mice were treated with LPS for 2 or 16 hours, the 
animals were sacrificed, the bone marrow was extracted and stained with a panel 
of antibodies to isolate the HSC population by FACS. RNA was analysed for 






































The xenobiotic efflux pumps in the HSC have high activity and this can lead to 
MTG dye extrusion (340). To ensure the mitochondrial mass increase was not 
affected by dye extrusion C56BL/6 mice were treated with LPS for 2 hours and 
the animals were sacrificed. The BM was extracted and stained with a panel 
of cell surface antibodies and combination of MTG with the addition of efflux 
inhibitor verapamil. Figure 3.9A and B show there is a significant increase in 
mitochondrial content in the LSK, HSC ST-HSC and LT-HSC populations, but 
not in the MPP population which is consistent with previous results. There 
were no differences observed between verapamil and non-verapamil treated 
cells. However, to ensure no dye leakage occurred after staining, verapamil 




Figure 3.9. MTG fluorescence intensity does report mitochondrial mass. 
C57BL/6J mice were treated with LPS for 2 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies and Mitotracker 
green (MTG) to analyse mitochondrial content in specific Lin-, LSK, HSC, MPP, ST-
HSC and LT-HSC populations. (A) Mitochondrial content (mitotracker green (mean 
fluorescence intensity (MFI)) in the specific populations of all animals examined after 
2 hours of LPS treatment. n=5. (B) The calcium channel inhibitor Verapamil was 
added to the cells prior to staining with MTG and antibodies. Mitochondrial in the 
specific populations after 2 hours of LPS treatment. n=5 in each group. Data shown 
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Figure 4.7. MTG fluorescence i  does report mitochondrial mass.
C57BL/6J mice wer  tr ated with LPS for 2 hours, the animals w re sacrificed, 
the bone marrow w s xtr cted d stained with a panel of antibodies and 
Mitotracker green (MTG) to analyse mitochondrial content in specific Lin-, LSK, 
HSC, MPP, ST-HSC and LT-HSC populations. (A) Mitochondrial content 
(mitotracker green (mean fluorescence intensity (MFI)) in the specific populations 
of all animals examined after 2 hours of LPS treatment. n=5. (B) (A) The calcium 
channel inhibitor Verapamil was added to the cells prior to staining with MTG and 
antibodies. Mitochondrial in the specific populations after 2 hours of LPS 





Expansion of the haematopoietic cells is a hallmark of the immune response 
to acute infection. Figure 3.10A and B confirms a significant increase in cell 
number of LSK, HSC, MPP, ST-HSC and LT-HSC populations per 100 000 
BM cells following both S.typhimurium and LPS treatment. There was no 
change in cell number observed in the Lin- population.  
 
 
Figure 3.10. S.typhimurium or LPS increases HSC numbers per 100 000 
BM cells counted. 
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to analyse cell number in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-
HSC populations (B) C57BL/6J mice were treated with LPS for 2 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to analyse cell number in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-












































































































Figure 4.8. S. typhimurium and LPS induces an expansion of the 
haematopoietic stem and progenitor populations. (A) C57BL/6J mice were 
infected with S. typhimurium (Sal) for 72 h, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to analyse cell 
number in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations (B) 
C57BL/6J mice were treated with LPS for 2 hours, the animals were sacrificed, 
the bone marrow was extracted and stained with a panel of antibodies to analyse 
cell number in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations. 
n=5 Data shown are means ± SD  *P < 0.05 **P < 0.01
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Interestingly, there is no change in the number of progenitor cells per 100 000 
BM cells (CMP, GMP and MEP) in the S.typhimurium or LPS treated animals 
compared to the control (Figure 3.11A and B). There is a trend towards a 
decrease in the number of GMPs after both S.typhimurium infection or LPS 
treatment compared to the control. This has previously been shown following 
infection (341, 342) and could be due to the 2-hour time point. As the GMPs 
produce granulocytes, the GMPs could be migrating to the spleen or peripheral 
blood to fight the infection. Taken together, following acute infection there is 
an increased number of the HSCs but no significant change in the downstream 
progenitor cells.  
 
Figure 3.11. S.typhimurium or LPS does not increase progenitor 
population numbers. 
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to analyse cell number in specific LS-K, CMP, GMP and MEP populations. 
(B) C57BL/6J mice were treated with LPS for 2 hours, the animals were sacrificed, 
the bone marrow was extracted and stained with a panel of antibodies to analyse cell 
number in specific LS-K, CMP, GMP and MEP populations. n=5 in each group. Data 


































































Figure 4.9. S. typhimurium and LPS does not induces an expansion of the 
more differentiated progenitor populations. (A) C57BL/6J mice were infected 
with S. typhimurium (Sal) for 72 h, th  anim ls were sacrificed, the bone marrow 
was extracted and stained with a panel of antibodies to analyse cell number in 
specific LS-K, CMP, GMP and MEP populations. (B) C57BL/6J mice were treated 
with LPS for 2 hours, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to analyse cell number in 
specific specific LS-K, CMP, GMP and MEP populations. n=5 Data shown are 





To determine if infection induced HSC cell cycling, C57BL/6J mice were 
treated with LPS for 16 hours. HSC cell cycle transit time is around 14 hours 
therefore the 16-hour time point was chosen as 2 hours post infection is too 
early for cell cycling to occur (343). The animals were then sacrificed, the BM 
extracted, and the cells were stained with the HSC panel of antibodies and 
Ki67. Ki67 is a protein in the cells which increases with cell division, therefore, 
the higher the levels of Ki67 the more quicky the cells are dividing. Ki67 
staining can be used in combination with DAPI to identify the specific phase of 
the cell cycle the cells are in. Unfortunately, due to the lack of an ultraviolet or 
violet laser on the flow cytometers available I was unable to detect DAPI 
staining and therefore, used Ki67 alone to identify cycling cells. Following 16 
hours of LPS treatment there was a significant increase in the percentage of 
cycling LSKs, HSC, ST-HSC and LT-HSCs (Figure 3.12A and B). 
 
Figure 3.12. LPS induces increase in Ki67 positive cells in 
haematopoietic stem and progenitor populations. 
C57BL/6J mice were treated with LPS for 16 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to analyse Ki67 
positive cells in the LSK, HSC, ST-HSC and LT-HSC populations. n=5 in each group. 






































LSK HSC ST-HSC LT-HSC
Figure 4.10. LPS induces an expansion of the haematopoietic stem and 
progenitor populations. C57BL/6J mice were treated with LPS for 2 hours, the 
animals were sacrificed, the bone marrow was extracted and stained with a panel 
of antibodies to analyse cell cycling as measured by Ki67 positive cells in the 
LSK, HSC, MPP, ST-HSC and LT-HSC populations. n=5 Data shown are means 




































To understand the colony forming ability of the haematopoietic compartment 
after LPS treatment, C57BL/6J mice were treated with control PBS or LPS for 
2 hours. The animals were sacrificed, the BM was extracted, the cells were 
seeded in a semisolid Methocult for 7 days. There was a significant expansion 
of the granulocyte monocyte progenitor population (GM) in the BM cells from 
LPS treated animals compared to the control (Figure 3.13).  
 
Figure 3.13. LPS increases CFCU in the granulocyte monocyte 
progenitor populations. 
C57BL/6J mice were treated with control PBS or LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted. 1 x 104 bone marrow cells were seeded 
in a semisolid Methocult for 7 days. Granulocytic progenitor (G), granulocyte 
monocyte progenitor (GM), and granulocyte monocyte megakaryocyte progenitor 
(GEMM) colonies were then counted. Data shown are means ± SD of n=5 *P < 0.05 
 
3.3 Bacterial infection causes an increase in mitochondrial 
membrane potential and OCR 
To determine the functional consequences of the increase in mitochondrial 
content after acute infection, C57BL/6J mice were first treated with control 
PBS or LPS for 2 hours. The animals were sacrificed, and the BM was 
extracted and analysed for mitochondrial membrane potential by flow 
cytometry. Figure 3.14 shows an increase in tetramethylrhodamine methyl 
ester (TMRM) staining as measured by mean flourecence intensity (MFI) in 
LPS treated LSK, HSCs and ST-HSCs. There was no change in mitochondrial 




















Figure 4.11. LPS induces an expansion of the granulocyte monocyte 
progenitor populations. C57BL/6J mice were treated with control PBS or LPS 
for 2 h urs, the animals were sacrificed, th bo e marrow w s ex racted. 1 x 104
bone marrow cells were seeded in a semisolid Methocult for 7 days. Granulocytic 
progenitor (G), granulocyte monocyte progenitor (GM), and granulocyte 
monocyte megakaryocyte progenitor (GEMM) colonies were then counted. Data 




Figure 3.14. LPS treatment increases mitochondrial membrane potential 
in HSCs. 
C57BL/6J mice were treated with LPS for 2 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies and 
Tetramethylrhodamine, methyl ester (TMRM) to analyse mitochondrial potential in 
specific Lin-, LSK, HSC, ST-HSC and LT-HSC populations. n=5 in each group. Data 
shown are means ± SD *P < 0.05 
 
Next, to better understand the metabolic changes in the HSC after bacterial 
infection I used the mitochondrial extracellular flux assay which measures 
oxygen consumption rate (OCR). I first sorted HSCs from the BM of control 
and LPS treated mice. Unfortunately, the proportion of HSCs in the BM is very 
low, and a high number of cells is needed for this assay. As a result it was not 
possible to sort sufficient cells from the BM and the time taken to sort greater 
numbers of cells affected cell viability. Therefore, there was no measurable 
level of OCR or extracellular acidification rate (ECAR) observed using sorted 
HSCs in this assay. Following optimisation this issue persisted and I therefore 
sorted the LSK population to represent the haematopoietic progenitor 
populations, as they are more abundant in the BM. LSKs isolated from S. 
typhimurium and LPS treated animals had an increased basal and maximal 






























Figure 4.12. LPS treatm nt increases mitochondrial potenti l of the HSC. 
C57BL/6J mice ere tre ted with LPS for 2 hours, the animals were acrificed, 
the bone marrow was extracted and stained with a panel of antibodies and 
Tetramethylrhodamine, methyl ester (TMRM) to analyse mitochondrial potential 
in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations. n=5. Data 




Figure 3.15. LSK have increased OCR after LPS and S.typhimurium 
infection. 
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to isolate the LSK population by FACS. OCR was measured in the LSK 
n=5. (B) C57BL/6J mice were treated with PBS or LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies to 
isolate the LSK population by FACS. OCR was measured in the LSK n=5. Data shown 
are means ± SD **P< 0.01 
 
In addition to measuring OCR the mitochondrial extracellular flux assay also 
analyses ECAR as a measure of glycolysis. Glycolysis is not significantly 



















































































































Figure 4.13. LSK have increased oxidative phosphorylation levels after LPS 
and S. typhimurium infection. (A) C57BL/6J mice were infected with S. 
typhimurium (Sal) for 72 h, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to isolate the LSK population by 
FACS. OXPHOS levels were measured by OCR. n=5.(B) C57BL/6J mice were 
treated with PBS or LPS for 2 hours, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to isolate the LSK 
population by FACS. OXPHOS levels were measured by OCR.





Figure 3.16. LSK have no change in ECAR after LPS and S.typhimurium 
infection. 
(A) C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours or LPS for 2 
hours, the animals were sacrificed, the bone marrow was extracted and stained with 
a panel of antibodies to isolate the LSK population by FACS. Glycolysis levels were 
measured by ECAR. (B) Basal OCR (normalised to rotenone) vs Basal ECAR of LSK 
after S. typhimurium and LPS treatment. n=5 in each group. Data shown are means 
± SD 
 
Taken together these data show infection with gram negative bacteria causes 
an increase in mitochondrial content and function in the HSC population. This 
increase in mitochondria, however, was not associated with a change in 
mitochondrial biogenesis in HSCs, with the exception of PGC1α. Moreover, 
the increased mitochondrial mass was associated with an increased OCR in 
the LSK population. This suggests that the cells require energy derived from 
increased mitochondria content for cellular proliferation and expansion to 
differentiate into the critically needed immune cells for host defence. 
 
 
Figure 4.14. LSK have no change in ECAR levels after LPS and S. 
typhimurium infection. (A) C57BL/6J mice were infected with S. 
typhimurium (Sal) for 72 h or LPS for 2 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK population by FACS. Glycolysis levels were measured by ECAR. (B) Basal 
OCR vs Basal ECAR of LSK after S. typhimurium and LPS tre tment 




3.4 Development of a humanised mouse model to study 
mitochondrial transfer  
 
To determine if the increase in mitochondrial content was a result of 
intercellular mitochondrial transfer to HSCs during infection, three models 
were developed to specifically track the movement of mitochondria in vivo. The 
first model utilised was a humanised nonobese diabetic (NOD) severe 
combined immunodeficiency (SCID) Il2rg knockout 
NOD.Cg.PrkdscidIL2rgtm1Wji/SzJ (NSG) mouse model (hu-NSG). In this model 
human umbilical cord blood CD34+ stem and progenitor cells were 
transplanted into 3-4-week-old NSG mice (huNSG). Once engrafted the hu-
NSG were treated with 1 mg/kg LPS or PBS for 2 hours, the animals were 
sacrificed and the BM was extracted. The haematopoietic cell populations 
were analysed using flow cytometry and the human common myeloid 
progenitor (CMP), granulocyte macrophage progenitors (GMPs) multipotent 
progenitors (MPPs) and HSCs were isolated and analysed (Figure 3.17). The 
model utilises species-specific mitochondrial DNA (mtDNA) detection as a 
tracker for intercellular mitochondrial transfer based on a similar method used 
by Dong et al. (344).  
 
 
Figure 3.17. Schematic diagram of experimental design. 
Recipient 3-4-week-old NSG mice were treated with 25 mg/kg busulfan for 3 days 
prior to tail-vein injections of human CD34+ donor cells. Post engraftment mice were 
treated with 1mg/kg LPS or vehicle PBS for 2 hours. BM was isolated and sorted for 
human CMP (mCD45−, hCD34+, hCD38+, hCD45RA-, hCD90−, hCD49f−), human 
GMP (mCD45−, hCD34+, hCD38+, hCD45RA+, hCD90−, hCD49f−), human MPP 
(mCD45−, hCD34+, hCD38−, hCD45RA−, hCD90−, hCD49f−), and human HSC 
(mCD45−, hCD34+, hCD38−, hCD45RA−, hCD90+, hCD49f+) using FACS. The 















To assess the engraftment of the humanised mice peripheral blood was 
analysed monthly after transplantation to detect human CD45+ cells. Figure 
3.18 confirms engraftment of human CD45+ cells in the huNSG mice.  Around 
3% engraftment was seen at 1-month post transplantation, the level of human 
CD45+ cells present in the peripheral blood increased to around 40% after 3 
months post transplantation confirming humanisation. 
 
 
Figure 3.18. Human CD45+ cells are present in the peripheral blood of 
huNSG mice. 
NSG mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein injections 
of human CD34+ cord blood donor cells. Engraftment was determined by CD45 
expression in the peripheral blood detected by flow cytometry analysis. The peripheral 
blood was monitored monthly for 3 months, prior to experimentation. n=6 
 
HuNSG mice produced were treated with either 1 mg/kg LPS or control PBS 
for 2 hours. A 2-hour time point was used in this assay to detect specific 
changes in mitochondrial content due to intercellular mitochondrial transfer 
rather than the cells own transcriptional mechanism to increase mitochondria. 
The mice were then sacrificed, the BM was extracted, and analysed for the 
presence of human CD45 using flow cytometry. Figure 3.19 confirms equal 
engraftment of human CD34+ HSCs in recipient NSG mice within both 



























Figure 3.19. Human CD45+ engraftment is seen in the bone marrow of 
huNSG mouse model. 
NSG mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein injections 
of human CD34+ cord blood donor cells. The mice were subjected to 1 mg/kg LPS or 
PBS intraperitoneal injections. After 2 hours the mice were sacrificed, and the bone 
marrow was extracted. Engraftment was determined by CD45 expression in the bone 
marrow detected by flow cytometry analysis. n=6 in each group. 
 
In addition to engraftment the BM was also stained with a panel of antibodies 
to  detect the human CMP (mCD45−, hCD34+, hCD38+, hCD45RA-, hCD90−, 
hCD49f−), human GMP (mCD45−, hCD34+, hCD38+, hCD45RA+, hCD90−, 
hCD49f−), human MPP (mCD45−, hCD34+, hCD38−, hCD45RA−, hCD90−, 
hCD49f−), and human HSC (mCD45−, hCD34+, hCD38−, hCD45RA−, 
hCD90+, hCD49f+) populations. This was carried out using 7 colour flow 
cytometry for the detection of six cell surface antibodies and a mitochondrial 
dye MTG. This included all colour compensations and the gating strategy to 
isolate the specific cell populations of interest is shown in Figure 3.20. All 































Figure 3.20. Gating strategy for human CMP, GMP, MPP, and HSC cell 
populations in huNSG mice. 
After 2 hours of 1 mg/kg LPS or PBS the huNSG mice were sacrificed, and the bone 
marrow was extracted and stained with a panel of antibodies to analyse specific HSC, 
MPP, CMP and GMP populations. The gating strategy used is shown. 
 
 
Figure 4. Gating strategy for human CMP, GMP, MPP, and HSC cell 
populations in huNSG mice. After 2 hours of 1mg/kg LPS or PBS the 
huNSG mice were sacrificed, and the bone marrow was extracted and stained 
with a panel of antibodies to analyse specific HSC, MPP, CMP and GMP 






































































To determine whether the LPS had an effect on mitochondrial content, the hu-
NSG BM was stained with MTG and the antibody panel. There was a 
significant increase in mitochondrial content within the human HSC and MPP 
populations after LPS treatment. There were no observed mitochondrial 
changes in the  human CMP or GMP populations (Figure 3.21)  
 
 
Figure 3.21. Mitochondria content is increased in the human HSC and 
MPP from huNSG mice after LPS treatment.  
HuNSG were subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 2 
hours the mice were sacrificed and the bone marrow was extracted, cells were 
stained with a panel of antibodies to analyse specific HSC, MPP, CMP and GMP 
populations. Mitochondrial levels (mitotracker green (mean fluorescence intensity 
(MFI)) in specific populations of all animals examined. n=6 in each group *P < 0.05 
 
Finally, to determine if this observed increase in mitochondrial content was 
due to intercellular mitochondrial transfer from the mouse BM 
microenvironment, species specific mitochondrial analysis was performed. 
After LPS treatment the BM was extracted and the human CMP, human GMP, 
human MPP and human HSC population were sorted by FACS using the 
gating strategy shown in Figure 3.20. The DNA was extracted and duplex 
Taqman qPCR analysis was carried out using species specific probes 
targeting mitochondrial gene ND1. The Ct values were normalised to human 
genomic DNA (Tert). Figure 3.22 shows that in the LPS-treated huNSG mice, 
mouse mtDNA is significantly increased in the human MPPs and HSCs but not 
in human GMPs or CMPs. These data show mtDNA is transferred from the 






































Figure 3.22. Mitochondrial DNA is transferred from the BM 
microenvironment to the HSC and MPP populations in the huNSG mice 
in response to LPS treatment. 
Human CMP, GMP, MPP and HSC populations were sorted from the BM of huNSG 
treated with either LPS or PBS. The DNA was isolated and analysed using species 
specific Taqman probes targeting ND1 and Tert by qPCR. Mouse or human 
mitochondrial DNA was measured by ΔΔCt and normalised to human tert. Data 
shows the percentage of mouse mitochondria detected in the isolated human cells. 
Data shown are means ± SD of n = 5 mice in each group. *P < 0.05. 
 
 
3.5 Development of a strain specific model to study mitochondrial 
transfer  
 
As a second model to confirm transfer of mtDNA, I used a transplant model 
whereby NSG, CD45.1 recipient animals were transplanted with C57BL/6J 
CD45.2 donor lineage-negative cells. The model developed was using the 
difference in CD45 antigen which is known to be commonly expressed on all 
haematopoietic cells. The CD45 antigen is made up of 2 differing allelic 
variants CD45.1 or CD45.2 (345). The CD45.1 allele antigen is expressed on 
NSG mice and CD45.2 is expressed on C57Bl/6J mice. The functionality of 
both these alleles are identical and have previously been recognised as a 
marker identifying haematopoietic cells after BM transplants in mice (346). 
Next, I needed to establish a method to detect the mtDNA changes between 
these two mice after transplantation. Yu et al. 2009 reported that there was a 
single nucleotide polymorphism (SNP) in the COX3 region of the mtDNA 
whereby in BalbC mice had adenine (A) in the 9348 nucleotide position, this 
was displaced by guanine (G) in the C57Bl/6J mice (347), a potential 
probability for a SNP change in the ND4 region of mtDNA between BalbC and 





































mtDNA, BalbC mice had a cytosine (C) in the 9461-nucleotide position, which 
was displaced by thymine (T) in the C57Bl/6J mice (Table 3.1). I therefore, 
designed primers to amplify and sequence the COX3 and ND3 region and 
ND4 transcripts from NSG and C57BL/6J DNA (Figure 3.23A and B).  
 







Figure 3.23. Genomic regions and primer targets for mitochondrial DNA.  
(A) Genomic region for mitochondrial NADH dehydrogenase 3 (mt-ND3) and 
mitochondrial cytochrome c oxidase 3 (mt-COX3) with primer targets (B) Genomic 







Nucleotide position Protein Nucleic acid change Balb/c C57BL/6
9348 mt-COX3 G/A A G 
10623 mt-ND4 T/T T T 















To determine the efficiency of the primers, NSG or C57BL/6J mice were 
sacrificed, and the BM was extracted. The DNA was isolated and qPCR with 
the specific primers targeted to COX3, ND3 and ND4 mtDNA was carried out. 
The PCR products were then visualised by using agarose gel electrophoresis. 
Figure 3.24 show that PCR amplicon was detected in both NSG and C57BL/6J 
mice using both COX3/ND3 and the ND4 primer.  
 
 
Figure 3.24. ND3, COX3 and ND4 PCR amplicons. 
DNA from NSG and C57BL6/J bone marrow cells was isolated and quantified. After 
isolation, DNA was analysed using qPCR with ND4 primers or COX3 and ND3 
primers. PCR products were detected by agarose gel electrophoresis and is 
presented in this figure. n=3. 
 
 
Next, the PCR bands were excised, and the DNA was purified. Sequencing of 
the mtDNA identified 2 SNPs that exist in the mitochondrial genomes of NSG 
and C57BL/6J mice which are capable of distinguishing the 2 strains of mice 
(Figure 3.25). In the COX3 region of the mtDNA NSG mice have an adenine 
(A) which is displaced by guanine (G) in the C57BL/6J mice. The SNP in the 
ND3 region of the mtDNA, NSG mice have a cytosine (C) which is displaced 
by thymine (T) in the C57BL/6J mice. There was no SNP observed between 









Figure 3. ND3, COX3 and ND4 PCR amplicons. DNA from NSG and 
C57 bone marrow cells was isolated and quantified. After isolation, DNA 
was analysed using qPCR with ND4 primers or COX3 and ND3 primers. 
PCR products were detected by agarose gel gel electrophoresis and is 




Figure 3.25. Sanger sequencing analysis to confirm SNP in mtDNA 
between C57 and NSG. 
PCR bands were excised, and DNA purified using GenElute Mammalian Genomic 
DNA Miniprep Kit. Isolated DNA was then sent to Source Bioscience alongside the 
primers for sequencing. Sequencing traces were analysed using Sequence Scanner 
Software.  
 
A TaqMan SNP genotyping assay was then designed to detect this difference 
in ND3 and COX3 mtDNA between NSG mice and C57BL/6J mice. TaqMan 
SNP PCR analysis of NSG DNA and C57BL/6J DNA with ND3 SNP Taqman 
probes show positive fluorescence on FAM for NSG cells but negative for 
C57BL/6J cells (Figure 3.26) confirming the effectiveness of the probe. 
Whereas, the COX3 show positive fluorescence on VIC for C57BL/6J cells but 
negative for NSG cells (Figure 3.26). This confirms that the COX3 SNP probe 
is effective at targeting the ‘A’ in the COX3 mtDNA from NSG mice but does 




Protein Nucleic acid change NSG C57BL/6
mt-COX3 G/A A G 
mt-ND3 C/T C T




Figure 3.26. TaqMan RT-qPCR analysis of NSG and C57BL/6 DNA. 
PCR using COX3 primer show positive fluorescence on VIC for C57Bl/6 DNA but 
negative for NSG DNA. Analysis with ND3 primer on FAM show positive fluorescence 
for NSG DNA but negative for C57BL/6 DNA.  
 
 
Subsequently, I transplanted isolated BM cells from C57BL/6J mice 
expressing the CD45.2 allele into non-irradiated bulsulfan treated NSG mice 
expressing the CD45.1 allele. Due to the fact that the donor C57BL/6J and the 
recipient NSG mice differ in their CD45 allele, the cells origin and the 
mitochondria within these cells can be characterised by cell surface staining 
for specific CD45.1 or CD45.2 markers which can be analysed by flow 
cytometry. C57BL/6J expressing CD45.2 mice were sacrificed, the BM 
extracted, and lineage depleted. The cells were then intravenously injected 
through the tail vein into recipient NSG CD45.1 mouse. Once the C57BL/6J 
engraftment into NSG was confirmed the animals were treated with LPS for 2 
hours. The BM was extracted and the C57BL/6J HSC and LSK populations 





































Figure 5. TaqMan RT-qP R analysis f NSG and C57Bl/6 DNA. (A) PCR 
using Cox3 primer show positive fluorescence on VIC for C57Bl/6 DNA but 
negative for NSG DNA. (B) Analysis with ND3 primer on FAM show positive 




Figure 3.27. Schematic diagram of experimental design. 
Recipient CD45.1 NSG mice were treated with 25 mg/kg busulfan for 3 days prior to 
tail-vein injections of lineage-negative CD54.2 C57BL/6J donor cells. Post 
engraftment mice were treated with 1 mg/kg LPS or vehicle PBS for 2 hours. BM was 
isolated and sorted for donor LSK (Lin-, Sca 1+, CD117+) and donor HSC (Lin-, Sca 
1+, CD117+, CD48−, CD150+) cell populations expressing CD45.2 using FACS. The 
sorted donor cells were analysed for specific donor or host mtDNA by TaqMan PCR 
using ND3 or COX3 probes designed to detect strain-specific SNPs in the 
mitochondrial genome. 
 
To determine engraftment, 12 weeks after transplantation recipient NSG mice 
were sacrificed and the BM was extracted and stained with CD45.1 PE and 
CD45.2 FITC conjugated antibody for flow cytometry analysis. The 12-week 
time point was chosen as at 12 weeks it has been shown there is stable 
engraftment and haematopoietic reconstitution (348). Figure 3.28 shows 
CD45.2 positive cells present in the NSG BM. This confirms engraftment of 




Figure 3.28. Engraftment data for NSGC57 mouse model. 
C57Bl/6J lineage negative cells were transplanted into NSG mice. The mice were 
subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 2 hours the mice 
were sacrificed, and the bone marrow was extracted, and cells were stained with 
CD45.2-FITC and analysed using flow cytometry to assess bone marrow 
engraftment.  
 
Figure 6. Schematic diagram of xperimental design. Recipient CD45.1 
NSG mice were treated with 25mg/kg busulfan for 3 days prior t  tail-vein 
injections of lineage-negative CD54.2 C57BL/6 donor cells. Post engraftment 
mice were treated with 1mg/kg LPS or vehicle PBS for 2 hours. BM was 
isolated and sorted for donor LSK (Lin−, Sca-1+, c-Kit+) and donor HSC (Lin−, 
Sca-1+, c-Kit+, CD48−, CD150+) cell populations expressing CD45.2 using 
FACS. The sorted donor cells were analysed for specific donor or host mtDNA
by TaqMan PCR using ND3 or COX3 probes designed to detect strain-specific 

















Figure 7. Engraftment data for NSGC57 mouse m del. (A) C57Bl/6 lineage 
negative cells were transplanted into NSG mice. The mice were subjected to 
1mg/kg LPS or PBS intraperitoneal injections. After 2 hours the mice were 
sacrificed, and the bone marrow was extracted, and cells were stained with 









CD45.2 - FITC 
156 
 
Next, NSGC57 mice generated were treated with either 1 mg/kg LPS or control 
PBS for 2 hours. The mice were then sacrificed, the BM was extracted, and 
stained with CD45.2 FITC lineage cocktail-pacific blue, Sca 1-APC, CD117-
PeCy7,  CD48-APC Cy7 and CD150-BV510 to monitor engraftment in the 
lineage positive (lin+), lineage negative (lin-), LSK and HSC populations. 
Figure 3.29 confirms equal engraftment of CD45.2 cells in recipient NSG mice 
within both treatment groups.  
 
Figure 3.29. Engraftment data for NSGC57 mouse model.  
(A) C57Bl/6J lineage negative cells were transplanted into NSG mice. The mice were 
subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 2 hours the mice 
were sacrificed, the bone marrow was extracted and cells were stained with CD45.2 
FITC and analysed using flow cytometry to assess bone marrow engraftment. (B) The 
cells were also stained with lineage cocktail-BV421, Sca 1-APC, CD117-PeCy7, 
CD48-APC Cy7 and CD150-BV510 to monitor engraftment in the lineage positive 
(lin+), lineage negative (lin-), LSK and HSC populations.  
 
 
Figure 7. Engraftment data for NSGC57 mouse model. (A) C57Bl/6 lineage 
negative cells were transplanted into NSG mice. The mice were subjected to 
1mg/kg LPS or PBS intraperitoneal injections. After 2 hours the mice were 
sacrificed, and the bone marrow was extracted, and cells were stained with 
CD45.2 FITC and analysed using flow cytometry to assess bone marrow 
engraftment. (B) The cells were also stained with lineage cocktail-pacific blue, 
Sca 1-APC, CD117-PeCy7,  CD48-APC Cy7 and CD150-BV510 to monitor 



























































































In addition to engraftment the BM was also stained with a panel of antibodies 
to assess intercellular mitochondrial transfer from the mouse BM 
microenvironment by strain specific mitochondrial analysis was performed. 
After LPS treatment the BM was extracted and the CD45.2 C57BL/6J HSC 
and LSK cell populations were sorted by FACS using the gating strategy 
shown in Figure 3.30.  
 
Figure 3.30. Gating strategy for the sorted LSK and HSC cell populations. 
NSGC57 mice were subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 
2 hours the mice were sacrificed and the bone marrow extracted. Cells were stained 
with lineage cocktail-BV421, Sca 1-APC, CD117-PeCy7, CD48-APC Cy7 and 
CD150-BV510 to isolate the sort the LSK population and HSC populations 
After the cells were sorted the DNA was extracted and analysed by qPCR 
using the COX3 SNP Taqman probe to detect the NSG SNP in the C57Bl/6J 
HSC and LSK CD45.2 C57BL/6J cell population. CD45.2 C57BL/6J donor 
cells from untreated mice had detectable mtDNA from CD45.1 NSG recipient-
derived mitochondria, with a significant increase in CD45.1 NSG mtDNA in the 
CD45.2 C57BL/6J HSC and LSK populations upon LPS treatment (Figure 
3.31). This suggests that mitochondria are being transferred from the host 
microenvironment into the donor cells under normal conditions, but when 
stimulated with LPS this transfer is significantly increased. The Ct values were 
Figure 5.  Gating strategy for the sorted LSK and HSC cell populations.
NSGC57 mice were subjected to 1mg/kg LPS or PBS intraperitoneal 
injections. After 2 hours the mice were sacrificed, and the bone marrow 
extracted. Cells were stained with lineage cocktail-pacific blue, Sca 1-APC, 
CD117-PeCy7,  CD48-APC Cy7 and CD150-BV510 to isolate the sort the LSK 







































normalised to CD45.2 C57BL/6J genomic DNA and was used to determine a 
percentage of mtDNA transferred from CD45.1 NSG to CD45.2 C57BL/6J 
cells.  
 
Figure 3.31. Mitochondria are transferred from the BM microenvironment 
to the HSC populations in vivo in response to LPS. 
NSGC57 mice were subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 
2 hours the mice were sacrificed, and the bone marrow extracted. The LSK and HSC 
CD45.2 population was sorted by FACS and analysed for SNP differences by qPCR 
(A) The percentage of recipient mtDNA in isolated donor cells after a 2-hour treatment 
with 1 mg/kg LPS compared to control (untreated) cells using the COX3 TaqMan 
probe. (B) The percentage of recipient mtDNA in isolated donor cells after a 2-hour 
treatment with LPS versus control (untreated) cells using the ND3 TaqMan probe. 
Donor genomic DNA was used to standardise mtDNA copy number. Data shown are 
means ± SD of n=5 mice in each group. *P < 0.05 **P < 0.01 ***P < 0.001. 
 
These data support the hypothesis that mitochondria are transferred from the 
BM microenvironment to the progenitor cells, a process shown to occur 
normally but significantly amplified in moments of stress, such as stimulation 
with LPS. This process occurs when an increased immune response is 

























Figure 6. Mitochondria are transferred from the BM microenvironment to 
the HS  populations in vivo in response to LPS. NSGC57 mice were 
subjected to 1mg/kg LPS or PBS intraperitone l injections. After 2 hours the 
mice were sacrificed, nd the one marrow extracted. The LSK and HSC 
CD45.2 population was sorted by FACS and analysed for SNP differences by 
qPCR (A)The percentage of recipient mtDNA in isolated donor cells after a 2-
hour treatment with 1 mg/kg LPS compared to control (untreated) cells using 
the COX3 TaqMan probe. (B) The percentage of reci ie t tDNA in is lated 
donor cells after a 2-hour tr tment with LPS versus control (untreated) cells 
using the ND3 TaqMan probe. Donor genomic DNA was used to standardize 
mtDNA copy number. Data shown are means ± SD of n = 5 mice. *P < 0.05 























































Figure 6. Mitochondria are transfer d from the BM microenvironment to 
the HSC populations in vivo in response to LPS. NSGC57 mice were 
subjected to 1mg/kg LPS or PBS intraperitoneal injections. After 2 hours the 
mice were sacrificed, and the bone marrow extracted. The LSK and HSC 
CD45.2 population was sorted by FACS and analysed for SNP differences by 
qPCR (A)The percentage of recipi t NA in isolate  d nor cells after a 2-
hour treatment with 1 mg/kg LPS comp r  to control (untreated) cells using 
the COX3 TaqMan probe. (B) The percentage of recipient mtDNA in isolated 
donor cells after a 2-hour treatment with LPS versus control (untreated) cells 
using the ND3 TaqMan probe. Donor genomic DNA was used to standardize 
mtDNA copy number. Data shown are means ± SD of n = 5 mice. *P < 0.05 





































3.6 Characterisation of the C57BL/6Nsu9-DsRed2 model to study 
mitochondrial transfer  
To further show that transfer from the BM microenvironment to the HSCs 
occurs within the BM in response to LPS, the C57BL/6Nsu9-DsRed2 (DsRed) 
mouse model was the third model used (344). First, to establish detection of 
DsRed labelled mitochondria in living cells, I ear notched the animals for 
phenotype analysis. Fluorescent microscopy imaging highlighted the presence 
of DsRed within the cell populations of some animals (Figure 3.32). The 
animals positive for DsRed flourecence were used in the following experiments 
and the negative phenotype animals were used as a control.  
 
Figure 3.32. Phenotype analysis of DsRed animals.  
DsRed mice were notched for phenotyping and identification of DsRed expression in 
the mitochondria of the mice. Representative fluorescent microscopy images 
of DsRed-/- and DsRed +/+ to detect DsRed mitochondria (Red).  
 
The DsRed model was used to characterise which cell populations have the 
DsRed mitochondria and to demonstrate where in the microenvironment the 
acquired mitochondria originated. The cell populations I chose to characterise 
was the lineage negative, stromal and macrophage cell populations as 
previous studies have shown these cells have been key in mitochondrial 
transfer within the BM microenvironment (41, 302, 324, 349).  
 
Figure 1. Phenotype analysis of DsRed animals. DsRed mice were notched for 
phenotyping and identification of DsRed expression in the mitochondria of the mice. 
Representative fluorescent microscopy images of DsRed-/- and DsRed +/+ to detect 






DsRed mice, with both positive (DsRed +/+) and negative (DsRed -/-) 
phenotype, were sacrificed and the BM extracted. The first population I 
characterised was the lineage negative cells (Figure 3.33). Cells were stained 
with lineage cocktail pacific blue and analysed for DsRed fluorescence (Ex 
561nM) by flow cytometry. Results showed that there was no difference in the 
DsRed fluorescence level between the DsRed-/- and DsRed +/+ mice in the 
lineage negative cell population (Figure 3.33).  
 
Figure 3.33. Characterisation of the DsRed in the lineage negative cell 
population. 
DsRed-/- and DsRed +/+ mice were sacrificed and the bone marrow extracted. Cells 
were stained with lineage cocktail-pacific blue. Data shows the level of mitochondrial 
DsRed fluorescence (Ex 561nM) in the lineage negative cell population. 
 
The next population that was characterised was the stromal cell population. 
DsRed-/- and DsRed+/+ mice were sacrificed the BM was extracted. The cells 
were stained with CD45-BV510, CD105-APC, CD140a-APC Cy7 and CD31-
PeCy5 and analysed by flow cytometry (Figure 3.34). However, again it was 
unclear if there was DsRed mitochondria in the stromal cell population as both 
the DsRed-/- and DsRed +/+ mice showed similar DsRed florescence (Figure 
3.34).  
Figure 2. Characteri ation of th  DsRed mitochondria in the lineag  negative 
cell population. DsRed-/- and DsRed +/+ m ce were sacrificed and th  bone marrow 
extracted. Cells were stained with lineage cocktail-pacific Blue. Data shows the level 


























Figure 3.34. Characterisation of the DsRed in the stromal cell population. 
DsRed-/- and DsRed +/+ mice were sacrificed and the bone marrow extracted. Cells 
were stained with CD45-BV510, CD105-APC, CD140a-APC Cy7 and CD31-PeCy5 
for analysis by flow cytometry. DsRed expression (Ex 561nM) in the stomal cell 
population CD45-, CD31-, CD105+ and CD140a+. 
 
Finally, the last population I characterised was the macrophage cell 
population. Cells were stained with the macrophage markers GR1+, CD115 
and F4/80+ as established previously (77) (Figure 3.35). The DsRed 
fluorescence level between the DsRed-/- and DsRed+/+ again remained 
relatively unchanged in the macrophage population (Figure 3.35). Thus, it 
remained unclear which cells contained the DsRed phenotype.  
Figure 3. Characterisation of the DsRed mitochondria in the stromal cell 
population. DsRed-/- and DsRed +/+ mice were acrificed and the bone marr w 
extracted. Cells were stained with CD45- BV51 , CD105-APC, CD140a-APC Cy7 
and CD31- PeCy5 for analysis by flow cytometry. DsRed expression in mitochondria 































Figure 3.35. Characterisation of the DsRed in the macrophage cell 
population.  
DsRed-/- and DsRed+/+ mice were sacrificed and the bone marrow extracted. Cells 
were stained with with GR1-PeCy5, CD115-APC Cy7 and F4/80-APC for analysis by 
flow cytometry. DsRed expression (Ex 561nM) in the macrophage cell population 
GR1-, CD115int and F4/80+.  
 
Next, as the lineage negative cells showed no DsRed flourecence I performed 
an assay using the DsRed mice to determine if HSPC acquire DsRed 
fluorescence in response to LPS. DsRed-/- and DsRed+/+ mice were treated 
with 1 mg/kg LPS or control PBS intraperitoneal injections. After 2 hours the 
mice were sacrificed, and the BM extracted. BM cells were stained with a 
lineage cocktail - pacific blue, Sca 1-APC, CD117-PeCy7, CD48-APC Cy7 and 
CD150-BV510. This enabled the detection the DsRed mean fluorescence 
intensity in the lineage negative, LSK, MPP and HSC populations by flow 
cytometry analysis (Figure 3.36 A). DsRed fluorescence in the specific cell 
populations which do not show fluorescence in the control mice, indicates 

























CD115 - APC Cy7
Figure 4. Characterisation of the DsRed mitochondria in the macrophage 
cell population. DsRed-/- and DsRed +/+ mice were sacrificed and the bone 
marrow extracted. Cells were stained with with GR1-PeCy5, CD115-APC Cy7 
and F4/80-APC for analysis by flow cytometry. DsRed expression in mitochondria 

























CD115 - AP  Cy7
Figure 4. Characterisation of the DsRed mitochondria in the macrophage 
cell population. DsRed-/- and DsRed +/+ mice w re s crificed and the bone 
marrow extracted. Cells were stain d with with GR1-PeCy5, CD115-APC Cy7 
and F4/80-APC for analysis by flow cytometry. DsRed expression in mitochondria 
in the macrophage cell population GR1-, CD115int and F4/80+. 
163 
 
Figure 3.36A shows that lineage negative, LSK, MPP and HSC populations 
within the BM of the DsRed mice do not have an increase in mitochondrial 
content (as measured by DsRed mean fluorescence intensity) after treatment 
with LPS. The number of cells increased in the LPS treated DsRed mice in the 
lineage negative, LSK and HSC cell populations however the number of MPPs 
decreased in response to LPS (Figure 3.36B).  
 
Figure 3.36. No DsRED was detected in HSPC population in vivo in 
response to LPS. 
DsRed+/+ mice were subjected to 1 mg/kg LPS or PBS intraperitoneal injections. After 
2 hours the mice were sacrificed and the bone marrow was extracted, cells were 
stained with lineage cocktail-pacific blue, Sca 1-APC, CD117-FITC, CD48-APC Cy7 
and CD150-BV510 and analysed using flow cytometry. (A) Representative histogram 
plots of the defined populations presenting DsRed fluorescence (Ex561nM)  and cell 
counts. (B) Cell counts of specific populations after LPS treatment. (n=1) 
 
There was no observed increase in DsRed fluorescence in all cell populations 
after LPS treatment. Moreover, it is unclear which specific cell populations 
within the BM contain the DsRed tag. Therefore, this model was not taken 
forward and I need to conduct this transfer assay in another model to identify 
























































Taken together, in this chapter I have investigated intercellular mitochondrial 
transfer in a non-malignant haematological system. I have shown that 
mitochondrial content is increased in response to infection. This leads to a 
metabolic shift from baseline quiescent glycolytic HSCs towards utilisation of 
OXPHOS to generate ATP which is subsequently followed by HSC expansion 
into the immune cells. Importantly I have discovered that mitochondrial transfer 
occurs before the transcriptional changes needed for mitochondrial biogenesis 
to occur in a system which has evolved in mammals to support the required 
rapid granulocytic response to acute bacterial infection. Moreover, using two 
different models I have shown using LPS to simulate bacterial infection that 
mitochondrial transfer occurs from the BM microenvironment to the HSC. This 
transfer is specific to the early stem and progenitor populations MPP, LSK and 
HSCs, there was no transfer observed to the more differentiated CMP or GMP 
population. These data show mitochondrial transfer to the HSC is a 
fundamental process which underlies the mammalian response to infection, 










4 Macrophage derived NOX2 ROS mediated PI3K activation 




In the previous chapter I have shown that mitochondrial DNA moves from the 
BM microenvironment to the HSC during infection and this transfer results in 
increased mitochondrial mass and increased levels of OXPHOS.  
 
In response to stress, such as infection, it is known quiescent HSCs rapidly 
shift towards OXPHOS with an increase ATP production (350). This increased 
ATP allows for rapid cycling of the HSCs to differentiate into the more mature 
progenitor cells required to fight the infection (351). The metabolic changes in 
the cells from quiescent to cycling is key in regulating HSC fate (59, 290, 291). 
Differentiation of the HSC is promoted by increased levels of ROS in response 
to the infection while low ROS levels maintain HSC quiescence (289). This 
suggests that the rapid burst of energy required for HSC differentiation is 
reliant on both oxidative stress and OXPHOS. 
 
HSCs interact with the cells of the BM microenvironment and the niche which 
can influence HSC quiescence, differentiation and lineage determination. 
Many of these cells have been shown to be vital in mitochondrial transfer 
including BMSC (301, 323) and macrophages (302, 352). In the second 
chapter of my thesis using S. typhimurium and LPS I will examine the specific 
cell of the BM that transfer their mitochondria to HSCs and the underlying 









4.2 Superoxide drives mitochondrial transfer to HSCs during 
infection 
Marlein et al. 2017 showed mitochondrial transfer to the AML is stimulated by 
AML derived NOX2 superoxide (41). To establish if there are elevated levels 
of superoxide in the BM of S.typhimurium and LPS treated C57BL/6J mice I 
used the Amplex red assay. Amplex red reacts with H2O2 and produces a 
fluorescent signal. There was an increase in H2O2 production in the BM of 
S.typhimurium (72 hours) (Figure 4.1A) or LPS (2 hour) (Figure 4.1B) treated 
mice.  
 
Figure 4.1. S.typhimurium and LPS induces an increase in H2O2 in the 
bone marrow.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted. 1 x 106 cells were analysed by 
Amplex Red assay n=5. (B) C57BL/6J mice were treated with 1 mg/kg LPS for 2 
hours, the animals were sacrificed, the bone marrow was extracted. 1 x 106 cells were 
analysed by Amplex Red assay. n=5 in each group. Data shown are means ± SD 
*P < 0.05 **P < 0.01  
 
Next, to determine if the elevated H2O2 in the BM caused an increase in ROS 
in the HSPC populations, ROS levels were measured using the DCF assay. 
Following inoculation of C57BL/6J mice with S. typhimurium for 72 hours, ROS 
levels (measured by DCF fluorescence) were elevated in the HSC, ST-HSC 
and LT-HSC populations (Figure 4.2A). Similarly, there was an increase in 
DCF fluorescence in the LSK, HSC, ST-HSC and LT-HSC in the LPS (2 hours) 













































Figure 4.16. S. typhimurium and LPS induces an increase in superoxide in 
the bone m rrow. (A) C57BL/6J mice wer  infected with S. typhimurium (Sal) 
for 72 h, the animals were sacrificed, the b ne marrow was extracted. 1 x 
106 cells were analysed by Amplex Red assay n=5. (B) C57BL/6J mice were 
treated with 1mg/kg LPS for 2 hours, the animals were sacrificed, the bone 
marrow was extracted. 1 x 106 cells were analysed by Amplex Red assay n=5 





Figure 4.2. S.typhimurium and LPS induce an increase in ROS in the 
haematopoietic stem and progenitor populations. 
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hour, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and H2DCFDA (DCF) to analyse ROS in specific LSK, HSC, ST-HSC and 
LT-HSC populations. n=6. (B) C57BL/6J mice were treated with 1 mg/kg LPS for 2 
hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and H2DCFDA (DCF) to analyse ROS in specific populations. n=5 
in each group. Data shown are means ± SD *P < 0.05 
 
Next, to examine if there was elevated ROS in the more downstream 
populations, ROS levels were again measured using the DCF assay. There 
was no increase in ROS production observed in the LS-K, CMP, GMP and 
MEP populations following S. typhimurium (Figure 4.3A) or LPS treatment 
(Figure 4.3B). 
Figure 4.17. S. typhimurium and LPS induce an increase in superoxide in 
the haematopoietic stem and progenitor populations. (A) C57BL/6J mice 
were infected ith S. typhimurium (Sal) for 72 h, the animals were s crificed, the 
bone marrow was extracted and stained with a panel of antibodies and 
H2DCFDA (DCF) to analyse ROS in specific LSK, HSC, MPP, ST-HSC and LT-
HSC populations. n=6. (B) C57BL/6J mice were treated with 1mg/kg LPS for 2 
hours, the animals were sacrificed, the bone marrow was extracted stained with 
a panel of ntibodies and H2DCF A (DCF) to analyse ROS in specific 
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Figure 4.3. S.typhimurium and LPS does not induce an increase in ROS 
in the more differentiated progenitor populations.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and H2DCFDA (DCF) to analyse ROS in specific LS-K, CMP, GMP and 
MEP populations n=6. (B) C57BL/6J mice were treated with 1 mg/kg LPS for 2 hours, 
the animals were sacrificed, the bone marrow was extracted stained with a panel of 
antibodies and H2DCFDA (DCF) to analyse ROS in specific populations. n=5 in each 
group. Data shown are means ± SD 
 
 
Next, to investigate if ROS alone caused an increase in mitochondrial content 
within the HSC, C57BL/6J mice were treated with L-buthionine-sulfoximine 
(BSO) for 2 hours (Figure 4.4A). BSO blocks the rate-limiting step of L-
glutathione (GSH) biosynthesis and therefore can be used to induce an 
increase in intracellular ROS in vivo (3). The dose of BSO used was confirmed 
to cause an increase in DCF fluorescence in the LSK, HSC, ST-HSC and LT-
HSC populations similar to the increase observed in LPS and S. typhimurium 

































































Figure 4.18. S. typhimurium and LPS does not induce an increase in 
superoxide in the more differentiated progenitor populations. (A) C57BL/6J 
mice were infect d with S. typhimurium (Sal) for 72 h, the animals were 
sacrificed, the bone marrow was extracted a d stained with a panel of antibodies 
and H2DCFDA (DCF) to analyse ROS in specific LS-K, CMP, GMP and MEP 
populations n=6. (B) C57BL/6J mice were treated with 1mg/kg LPS for 2 hours, 
the animals were sacrificed, the bone marrow was extracted stained with a panel 
of antibodies and H2DCFDA (DCF) to analyse ROS in specific populations n=5. 




Figure 4.4. BSO induces an increase in ROS in the haematopoietic stem 
and progenitor populations. 
(A) C57BL/6J mice were treated with 100 mg/kg L-buthionine-sulfoximine (BSO) for 
2 hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and H2DCFDA (DCF) to analyse ROS in specific LSK, HSC, ST-
HSC and LT-HSC populations. (B) Superoxide levels (DCF (mean fluorescence 
intensity (MFI)) in the specific populations of all animals examined. n=5 in each group. 
Data shown are means ± SD *P < 0.05 
 
Moreover, the LSK, HSC, ST-HSC and LT-HSC populations all had a 
significant increase in mitochondrial mass after BSO treatment compared to 
the control mice (Figure 4.5). 
 
 
Figure 4.5. BSO induces an increase in mitochondrial content in the 
haematopoietic stem and progenitor populations. 
(A) C57BL/6J mice were treated with 100 mg/kg L-buthionine-sulfoximine (BSO) for 
2 hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and Mitotracker green (MTG) to analyse mitochondrial content 
(mitotracker green (mean fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC 
and LT-HSC populations n=5 in each group. Data shown are means ± SD *P < 0.05 
















































Figure 4.18. BSO induc s an ncrease in super xide in the haematopoietic 
stem and progenitor populations. (A) C57BL/6J mice were treated with 
100mg/kg L-buthionine-sulfoximine (BSO) for 2 hours, the animals were 
sacrificed, the bone marrow was extracted stained with a panel of antibodies and 
H2DCFDA (DCF) to analyse ROS in specific LSK, HSC, MPP, ST-HSC and LT-
HSC populations. (B) Superoxide levels (DCF(mean fluorescence intensity 
(MFI)) in the specific populations of all animals examined. n=5. Data shown are 
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Figure 4.20. BSO induces an increase in mit chondrial content in the 
haematopoietic stem and progenitor populations. (A) C57BL/6J mice were 
treated with 100mg/kg L-buthionine-sulfoximine (BSO) for 2 hours, the animals 
were sacrificed, the bone marrow was extracted stained with a panel of 
antibodies and Mitotracker green (MTG) to analyse mitochondrial content 
(mitotracker green (mean fluorescence intensity (MFI)) in specific LSK, HSC, 
MPP, ST-HSC and LT-HSC populations n=5. Data shown are means ± SD  *P < 
0.05 **P < 0.01
170 
 
Next, to confirm that ROS was the stimulus for the mitochondrial transfer from 
the BM microenvironment to the HSC the huNSG model was used. Once 
engrafted the huNSG mice were treated with BSO for 2 hours, the animals 
were sacrificed, and the BM was extracted. The human MPP (hMPP) and 
human HSC (hHSC) were sorted and analysed for mouse mtDNA (Figure 
4.6A). The gating used for the sorting was determined by fluorescence minus 
one and is shown in Figure 4.6B. 
  
 
Figure 4.6. Schematic and gating strategy for human MPP and HSC cell 
populations in huNSG mice. 
(A) NSG mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein 
injections of human CD34+ cord blood donor cells. The mice were subjected to 100 
mg/kg BSO or PBS intraperitoneal injections. After 2 hours the mice were sacrificed, 
the bone marrow was extracted and stained with a panel of antibodies to isolate and 
sort specific human HSC and MPP populations by FACS. (B) The gating strategy 



















































Figure 4.20. Schematic and gating strategy for human MPP and HSC cell 
populations in huNSG mice. (A) NSG mice were treated with 25mg/kg 
busulfan for 3 days prior to tail-vein injections of human CD34+ cord blood 
donor cells. The mice were subjected to 100mg/kg BSO or PBS intraperitoneal 
injections. After 2 hours the mice were sacrificed, and the bone marrow was 
extracted and stained with a panel of antibodies to isolate and sort specific 






The BM was also analysed for the presence of human CD45 using flow 
cytometry. Figure 4.7 confirms equal engraftment of human CD34+ HSCs in 
recipient NSG mice within both treatment groups. 
 
 
Figure 4.7. Human CD45+ engraftment is seen in the bone marrow of 
huNSG mouse model. 
NSG mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein injections 
of human CD34+ cord blood donor cells. The mice were subjected to 100 mg/kg BSO 
or PBS intraperitoneal injections. After 2 hours the mice were sacrificed, and the bone 
marrow was extracted. Engraftment was determined by human CD45 expression in 
the bone marrow detected by flow cytometry analysis. n=5 in each group. 
  
Finally, to determine if intercellular mitochondrial transfer occurred from the 
mouse BM microenvironment to the HSC in response to elevated ROS alone, 
species specific mitochondrial analysis was performed. After BSO treatment 
the BM was extracted and the human MPP and human HSC population were 
sorted by FACS using the gating strategy shown in Figure 4.6. The DNA was 
extracted and duplex Taqman qPCR analysis was carried out using species 
specific probes targeting mitochondrial gene ND1. The Ct values were 
normalised to human genomic DNA (Tert). Figure 4.8 shows that in the BSO-
treated hu-NSG mice, mouse mtDNA is significantly increased in the human 
MPPs and HSCs. These data show elevated ROS alone causes the transfer 
of mtDNA from the BM microenvironment to the HSCs. 
Figure 4.21. Human CD45+ engraftment is seen in the bone marrow of 
huNSG mouse model. NSG mice were treated with 25mg/kg busulfan for 3 
days prior to tail-vein injections of human CD34+ cord blood donor cells. The 
mice were subjected to 100mg/kg BSO or PBS intraperitoneal injections. After 
2 hours the mice were sacrificed, and the bone marrow was extracted. 
Engraftment was determined by CD45 expression in the bone marrow 

















Figure 4.8. Mitochondrial DNA is transferred from the BM 
microenvironment to the HSC and MPP populations from the huNSG 
mice in response to BSO treatment. 
Human MPP and HSC populations were sorted from the bone marrow of huNSG 
treated with either BSO or PBS. The DNA was isolated and analysed using species 
specific Taqman probes targeting ND1 and Tert by qPCR. Mouse or human 
mitochondrial DNA was measured by ΔΔCt and normalised to human tert. Data 
shows the percentage of mouse mitochondria detected in the isolated human cells. 
Data shown are means ± SD *P < 0.05 **P < 0.01 
 
For further assurance that ROS mediates the LPS-driven increase in 
mitochondrial content within the HSCs, we used the ROS scavenger N-acetyl-
cysteine (NAC) to reduce ROS levels. C57BL/6J mice were pre-treated with 
NAC for 1 hour before treatment with LPS for 2 hours (Figure 4.9A). Pre-
treatment with NAC led to reduced ROS levels in the LSK, HSC, ST-HSC and 

























































Figure 4.23. Mitochondria are transferred from the BM microenvironment to 
the HSC and MPP population  from the huNSG mice in response to BSO 
treatment. Human MPP and HSC populations were sorted from the bone marrow of 
huNSG treated with either BSO or PBS. The DNA was isolated and analysed using 
species specific Taqman probes targeting ND1 and Tert by qPCR. Mouse or human 
mitochondrial DNA was measured by ΔΔ t and normalised to human tert. Data 
shows the percentage of mouse mitochondria detected in the isolated human cells. 




Figure 4.9. NAC reduces the LPS elicited increase in ROS in the 
haematopoietic stem and progenitor populations. 
(A) C57BL/6J mice were pre-treated with 500 mg/kg N-acetyl-cysteine (NAC) for 1 
hour before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the 
bone marrow was extracted stained with a panel of antibodies and H2DCFDA (DCF) 
to analyse ROS in specific LSK, HSC, ST-HSC and LT-HSC populations. (B) ROS 
levels (DCF (mean fluorescence intensity (MFI)) in the specific populations of all 
animals examined. n=5 in each group. Data shown are means ± SD *P < 0.05 
 
 
Furthermore, NAC treatment inhibited LPS elicited increase in mitochondrial 
content within the LSK, HSC, ST-HSC and LT-HSC populations (Figure 4.10). 
Taken together these data suggests that ROS is the stimulus responsible for 








































































Figure 4.23. NAC reduces the LPS elicited increase in superoxide in the 
haematopoietic stem and progenitor populatio s. (A) C57BL/6J mice were pre-
treated with 500mg/kg N-acetyl-cysteine (NAC) for 1 hour before treatment with 
1mg/kg LPS for 2 hours. The animals were sacrificed, the bone marrow was 
extracted st ined with a p nel f antibodies and H2DCFDA (DCF) to analyse ROS 
in specific LSK, HSC, MPP, ST-HSC and LT-HSC populations. (B) Superoxide 
levels (DCF(mean fluorescence intensity (MFI)) in the specific populations of all 






Figure 4.10. NAC reduces the LPS elicited increase in mitochondrial 
content in the haematopoietic stem and progenitor populations. 
C57BL/6J mice were pre-treated with 500 mg/kg N-acetyl-cysteine (NAC) for 1 hour 
before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green (MTG) 
to analyse mitochondrial content (MTG mean flourecence intensity (MFI)) in specific 
LSK, HSC, ST-HSC and LT-HSC populations n=5 in each group. Data shown are 
means ± SD *P < 0.05 
 
4.3 NOX2 derived superoxide mediate mitochondrial transfer to the 
HSC. 
 
To determine if the ROS generated in the BM after bacterial infection was 
NOX2 derived, we investigated mitochondrial transfer in the CGD or Cybb 
mouse model. In Cybb mouse the gp91 subunit of NOX2 has been deleted 
(353) and therefore they cannot produce NOX2 derived superoxide. Wildtype 
C57BL/6J or Cybb mice were treated with LPS for 2 hours, the BM was 
extracted and assessed for H2O2 production using the Amplex red assay 
(Figure 4.11A). As expected, there was an increase in H2O2 production in the 
BM of LPS treated mice (Figure 4.11B). Conversely, in the BM of Cybb mice 


















































Figure 4.24. NAC reduces the LPS elicited increase in mitochondrial content 
in the haematopoietic stem and progenitor populations. C57BL/6J mice were 
pre-treated with 500mg/kg N-acetyl-cysteine (NAC) for 1 h r before tre tment with 
1mg/kg LPS for 2 hours. The animals were sacrificed, the bone marrow was 
extracted stained with a panel of antibodies and Mitotracker green (MTG) to analyse 
mitochondrial content (MTG MFI) in specific LSK, HSC, MPP, ST-HSC and LT-HSC 




Figure 4.11. LPS induces an increase in H2O2 in the bone marrow. 
(A) C57Bl/6J mice or Cybb mice were treated with 1 mg/kg LPS or control PBS 
intraperitoneal injections. After 2 hours the mice were sacrificed, and the bone 
marrow extracted.  (B) 1 x 106 bone marrow cells were analysed by Amplex Red 
assay n=5. Data shown are means ± SD *P < 0.05 
 
Next, to determine if NOX2 derived superoxide was driving the increase in 
ROS in the HSPC populations ROS levels were measured using the DCF 
assay. Cybb mice were treated with LPS for 2 hours. The mice were sacrificed, 
and the haematopoietic cell populations were analysed for mitochondrial 
content using flow cytometry. The gating strategy to analyse the cell 
populations of interest is shown in Figure 4.12. All gating was determined 


















































Figure 4.25. LPS induces an increase in superoxide in the bone marrow. (A) 
C57Bl/6 mice or Cybb mice were treated with 1 mg/kg LPS or control PBS 
intraperitoneal injections. After 2 hours the mice were sacrificed and the bone 
marrow extracted.  (B) 1 x 106 bone marrow cells were analysed by Amplex Red 





Figure 4.12. Gating strategy for mouse LSK, HSC, ST-HSC and LT-HSC.  
Cybb mice were treated with LPS for 2 hours, the animals were sacrificed, and the 
bone marrow was extracted. The cells were stained with a panel of antibodies to 
analyse specific LSK, HSC, ST-HSC and LT-HSC populations. The gating strategy 
used is shown. 
Following treatment with LPS for 2 hours, there was no change in the ROS 
levels (measured by DCF fluorescence) within the LSK, HSC, ST-HSC and 
LT-HSC populations of the Cybb mice (Figure 4.13).  
 
Figure 4.13. HSC ROS levels do not increase in Cybb animals in response 
to LPS.  
Cybb mice were treated with LPS for 2 hours, the animals were sacrificed, and the 
bone marrow was extracted. The cells were stained with a panel of antibodies and 
H2DCFDA (DCF) to analyse superoxide levels (DCF (mean fluorescence intensity 
(MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in each group 










































Figure 4.26. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and LT-
HSC. Cybb mice were treated with LPS for 2 hours, the animals were sacrificed and 
the bone marrow was extracted. The cells were stained with a panel of antibodies to 
analyse specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations. The 






























Figure 4.28. HSC superoxide levels do not increase in Cybb animals in 
response to LPS. Cybb mice were treated with LPS for 2 hours, the animals were 
sacrificed and the bone marrow was extracted. The cells were stained with a panel 
of antibodies and H2DCFDA (DCF) to analyse superoxide levels (DCF(mean 
fluorescence intensity (MFI)) in specific LSK, HSC, MPP, ST-HSC and LT-HSC 
populations n=5 Data shown are means ± SD
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Moreover, Figure 4.14A shows in the Cybb mice the HSPC populations do not 
have an increased mitochondrial mass after treatment with LPS. To confirm 
there was no increase in mitochondrial content in the LSK and HSC population 
in response to LPS, the LSK and HSC population were sorted from control and 
LPS treated mice and analysed for mtDNA. As expected, there was no 
increase in mtDNA in both the LSK and HSC population from the LPS treated 




Figure 4.14. HSC mitochondrial content does not increase in Cybb 
animals in response to LPS.  
(A) Cybb mice were treated with LPS for 2 hours, the animals were sacrificed, and 
the bone marrow was extracted. The cells were stained with a panel of antibodies 
and Mitotracker Green (MTG) to analyse superoxide levels (MTG (mean fluorescence 
intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations (B) The LSK 
and HSC populations were sorted from control and LPS treated animals by FACS 
and analysed for mtDNA by qPCR n=5 in each group. Data shown are means ± SD 
 
Next, to see if exogenous ROS could cause an increase in mitochondrial 
content in the HSC, Cybb mice were treated with BSO for 2 hours (Figure 
4.15A). BSO was confirmed to cause an increase in ROS in the HSC and ST-



























































Figure 4.28. HSC mitochondrial content does not increase in Cybb animals in 
response to LPS. (A) Cybb mice were treated with LPS for 2 hours, the animals 
were sacrificed and the bone marrow was extracted. The cells were stained with a 
panel of antibodies nd Mitotrack r Green (MTG) to analys  superoxide levels 
(MTG(mean fluorescence intensit  (MFI)) in specific LSK, HSC, MPP, ST-HSC and 
LT-HSC populations (B) The LSK and HSC populations were sorted form control 
and LPS treated animals by FACS and analysed for mtDNA by qPCR n=5. Data 




Figure 4.15. HSC ROS levels increase in Cybb animals in response to 
BSO.  
Cybb mice were treated with 100 mg/kg BSO for 2 hours, the animals were sacrificed, 
and the bone marrow was extracted. (B)The cells were stained with a panel of 
antibodies and H2DCFDA (DCF) to analyse ROS levels (DCF mean fluorescence 
intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in each 
group. Data shown are means ± SD *P < 0.05 
 
Moreover, unlike LPS there was a significant increase in the mitochondrial 
content of the LSK, HSC, ST-HSC and LT-HSC populations in the Cybb mice 
after BSO treatment compared to the control mice (Figure 4.16). Together, 
these data show NOX2 derived ROS mediates transfer of mitochondria to 
HSCs during infection. 
 
 
Figure 4.16. HSC mitochondrial content increases in Cybb animals in 
response to BSO.  
Cybb mice were treated with 100 mg/kg BSO for 2 hours, the animals were sacrificed, 
and the bone marrow was extracted. The cells were stained with a panel of antibodies 
and Mitotracker Green (MTG) to analyse mitochondrial mass (MTG (mean 
fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations 



































Figure 4.29. HSC superoxide levels increase in Cybb animals in response to 
BSO. Cybb mice were reated with 100mg/kg BSO for 2 hours, th  animals were 
sacrificed and the bone marrow was extracted. (B)Th  cells were stained with a 
panel of antibodies and H2DCFDA (DCF) to analyse superoxide levels (DCF(mean 
fluorescence intensity (MFI)) in specific LSK, HSC, MPP, ST-HSC and LT-HSC 

































Figure 4.31. HSC mitochondrial content increases in Cybb animals in 
response to BSO. (A) Cybb mice were treated with 100mg/kg BSO for 2 hours, the 
animals were sacrificed and the bone marrow was extracted. The cells were stained 
with a panel of antibodies and Mitotracker Green (MTG) to analyse superoxide 
levels (MTG(mean fluorescence intensity (MFI)) in specific LSK, HSC, MPP, ST-
HSC and LT-HSC populations n=5. Data shown are means ± SD *P < 0.05
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4.4 BMSCs donate mitochondrial DNA to the HSC during infection 
 
The BM microenvironment is made up of multiple different cell types (354), 
many of which have been shown to be key in mitochondrial transfer within the 
BM (41, 302, 324, 349, 352). To establish the cell of the BM which transfers 
their mitochondria to the HSC during infection I used a co-culture assay which 
took advantage of the SNP differences in the mtDNA. A TaqMan SNP 
genotyping assay was designed to detect this difference in ND3 and COX3 
mtDNA between PepCboy and CBA mice. TaqMan SNP PCR analysis of 
PepCboy DNA and CBA DNA with COX3 SNP Taqman probes show positive 
fluorescence on FAM for CBA cells but negative for PepCboy cells (Figure 
4.17A). The ND3 also shows positive fluorescence on FAM for CBA cells but 
negative for PepCboy cells (Figure 4.17B).  
 
 
Figure 4.17. TaqMan RT-qPCR analysis of CBA and PepCboy mtDNA.  
(A) PCR using COX3 primer shows positive fluorescence on FAM for CBA DNA but 
negative for PepCboy DNA. (B) Analysis with ND3 primer on FAM shows positive 
fluorescence for CBA DNA but negative for PepCboy DNA.  
 
To investigate the cell which transferred their mitochondria to the HSC during 
infection, CBA lineage negative cells were cocultured with PepCboy BM-
derived macrophage cells, BM osteoblast or BMSCs for 24 hours with and 
without H2O2. The lineage negative cells were then analysed for PepCboy 





































Figur  4.31. TaqMan RT-qPCR analysis of BA and PepCboy mtDNA. (A) 
PCR using Cox3 primer shows positive fluorescence on FAM for CBA DNA but 
negative for PepCboy DNA. (B) Analysis with ND3 primer on FAM shows 




Figure 4.18. Schematic diagram of experimental design.  
CBA lineage-negative cells (recipient) were cocultured with PepCboy bone marrow-
derived macrophage cells, bone marrow osteoblasts, and BMSCs (donor) for 24 
hours with and without H2O2. The lineage negative cells were removed and analysed 
for PepCboy SNP mtDNA in CBA lineage negative cells by TaqMan PCR using ND3 
probes. 
 
Figure 4.19 shows that only the BMSCs transferred mtDNA to lineage negative 
cells when cultured with H2O2. There was no transfer of mtDNA observed from 




Figure 4.19. BMSCs supply mitochondrial DNA to HSCs in response to 
elevated H2O2.  
CBA lineage-negative cells (recipient) were cocultured with PepCboy bone marrow-
derived macrophage cells, bone marrow osteoblasts, and BMSCs (donor) for 24 
hours with and without H2O2. The lineage negative cells were removed and analysed 
for PepCboy SNP mtDNA in CBA lineage negative cells by TaqMan PCR using ND3 
probes. Donor PepCboy mtDNA copy number in CBA lineage negative cells. CBA 
gDNA was used to standardise mtDNA copy number. Data shown are means ± SD 
**P < 0.01 
Figure 4.33. Schematic diagram of exp rimental design. CBA lineage-
negative cells (recipient) were cocultured with PepCboy bone marrow-derived 
macrophage cells, bone marrow osteoblasts, and BMSCs (donor) for 24 hours 
with and without H2O2. The lineage negative cells were removed and analysed 









































































































Figure 4.34. BMSCs supply mitochondria to HSCs in resp se to elevated 
superoxide. CBA lineage-negative cells (recipient) were cocultured with 
PepCboy bone marrow-derived macrophage cells, bone marrow osteoblasts, and 
BMSCs (donor) f r 24 h urs with and without H2O2. Th  lineage-negative cells 
were removed and analysed for PepCboy SNP mtDNA in CBA lineage-negative 
cells by TaqMan PCR using ND3 probes. The percentage of PepCboy mtDNA in 
CBA lineage-negative cells. CBA gDNA was used to standardize mtDNA copy 
number. Data shown are means ± SD **P < 0.01
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Next to determine if mitochondria are transferred from the BMSC to the HSPCs 
primary mBMSC were transduced with an rLV.EF1.mCherry lentivirus for 
stable incorporation of mCherry protein tagged mitochondria. Lineage 
negative cells were transduced with rLV.EF1.AcGFP-Mem9 lentivirus were 
cultured on the mBMSCs for 24 hours with H2O2 and imaged using 
fluorescence microscopy (Figure 4.20A). BMSC labelled mitochondria 
transferred to the lineage negative cells in the presence of H2O2, quantified by 
the acquisition of the mCherry fluorescence in the lineage negative cells 
(Figure 4.20B).  
 
Figure 4.20. BMSCs supply mitochondria to HSCs in response to 
elevated H2O2 treatment.  
(A) Representative fluorescent microscopy images of lin- cells (white arrow) 
lentivirally transduced with the rLV.EF1.AcGFP-Mem9 virus cultured with mBMSCs 
transduced with rLV.EF1.mCherry-Mito-9 in the absence or presence of 10 µM H2O2 
for 24 hours. (B) Quantification of rLV.EF1.mCherry-Mito-9 in lin- cells from images 
shown taken from 3 independent experiments and 20 lineage cells from each 
experiment. Data shown are means ± SD *P < 0.05 
 





























Figure 4.35. BMSCs supply mitochondria to HSCs in response to elevated 
superoxide. (A) Representative flu rescent microsc py imag s of lin- cells 
(white arrow) lentivirally ransduced with the rLV.EF1.AcGFP-Mem9 virus 
cult r  it  mBMSCs transduced with rLV.EF1.mCherry-Mito-9 in the absence 
or presence of 10 µM H2O2 for 24 h. (B) Quantification of rLV.EF1.mCherry-Mito-
9 in lin- cells from images shown taken from 3 independent experiments and 20 
lineage cells from each experiment. Data shown are means ± SD *P < 0.05
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To ensure that the H2O2 concentration did not cause lineage negative cell 
death, cell viability was assessed using the Annexin V assay. No change in 




Figure 4.21. H2O2 does not cause lineage negative cell death.  
Lin- cells were cultured with mBMSCs in the absence or presence of 10 µM H2O2 for 
24 hours, stained for Annexin V-FITC and analysed by flow cytometry. Data shown 
are means ± SD 
 
 
Next, to examine the effects of infection on the BMSC in vivo C56BL/6J mice 
were treated with LPS for 2 hours. The mice were sacrificed, and the BMSCs 
were analysed for mitochondrial content and ROS using flow cytometry (Figure 
4.22A). The gating strategy to analyse the BMSC is shown in Figure 4.36B. 




Figure 4.22. Schematic and gating strategy for BMSC. 
C57BL/6J mice were treated with 1 mg/kg LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies to 




















Figure 4.36. H2O2 does not cause cell death lineage negative cell death. (A)
Lin- cells were cultured with mBMSCs in the absence or presence of 10 µM 
H2O2 for 24 hours, stained for Annexin V-FITC and analysed by flow cytometry. 
Dat  sho n are means ± SD
Figure 4.36. Schematic and gating strategy for BMSC (A) C57BL/6J mice 
were treated with 1mg/kg LPS for 2 hours, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to analyse the 

































Figure 4.36. Schematic and gating strategy for BMSC (A) C57BL/6J mice 
were treated with 1mg/kg LPS for 2 hours, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to analyse the 



































To investigate if infection also induced ROS in the BMSC in vivo we analysed 
ROS levels using DCF. Increased ROS levels were observed in the BMSC 
from LPS treated mice compared to the control mice (Figure 4.23).  
 
 
Figure 4.23. LPS induces an increase in ROS levels in the BMSC.  
C57BL/6J mice were treated with 1 mg/kg LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies and 
H2DCFDA (DCF) to analyse ROS (DCF (mean fluorescence intensity (MFI)) in the 
BMSC population n=5 in each group. Data shown are means ± SD *P < 0.05 
 
Furthermore, after treatment with LPS mitochondrial content was reduced in 




Figure 4.24. LPS induces a decrease in mitochondrial content in the 
BMSC.  
C57BL/6J mice were treated with 1 mg/kg LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies and 
Mitotracker green (MTG) to analyse the Mitochondrial content (mitotracker green 
(mean fluorescence intensity (MFI)) in the BMSC population n=5 in each group. Data 



























Figure 4.37. LPS induces an increase in superoxide levels in the BMSC (A) 
C57BL/6J mi e were treated with 1mg/kg L S for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies 
and H2DCFDA (DCF) to analyse ROS (DCF (mean fluorescence intensity (MFI)) 






















Figure 4.39. LPS induces a decrease in mitochondrial content in the BMSC
(A) C57BL/6J mice were treated with 1mg/kg LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies 
and Mitotracker green (MTG) to analyse the Mitochondrial content (mitotracker
green (mean fluorescence intensity (MFI)) in the BMSC population n=5. Data 
shown are means ± SD *P < 0.05
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To ensure ROS mediates the LPS-driven decrease in mitochondrial content 
within the BMSCs, we used the ROS scavenger NAC to reduce ROS levels. 
C57BL/6J mice were pre-treated with NAC for 1 hour before treatment with 
LPS for 2 hours (Figure 4.25A). As expected, pre-treatment with NAC inhibited 
the LPS elicited increase in ROS levels in the BMSC (Figure 4.25B). 
 
 
Figure 4.25. NAC reduces the LPS elicited increase in ROS in the 
haematopoietic stem and progenitor populations.  
(A) C57BL/6J mice were pre-treated with 500 mg/kg N-acetyl-cysteine (NAC) for 1 
hour before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the 
bone marrow was extracted stained with a panel of antibodies and H2DCFDA (DCF) 
to analyse ROS in the BMSC. (B) ROS levels (DCF (mean fluorescence intensity 
(MFI)) in the specific populations of all animals examined n=5 in each group. Data 
shown are means ± SD *P < 0.05 
 
 
Next, I examined if pre-treatment with NAC had an effect on mitochondrial 
content in the BMSC. Figure 4.26 shows the reduction in the mitochondrial 
mass cause by the LPS was inhibited by the addition of NAC. Using both in 
vitro and in vivo models, these data show that BMSC provide the mitochondria 
to the HSC during acute infection.  
 
Figure 4.40. NAC reduces the LPS elicited increase in superoxide in the 
haematopoietic stem and progenitor populations. (A) C57BL/6J mice were 
pre-treat d with 500mg/kg N-acetyl-cysteine (NAC) for 1 our before treatment 
with 1mg/kg LPS for 2 hours. The animals were sacrificed, the bone marrow was 
extracted stained with a panel of antibodies and H2DCFDA (DCF) to analyse 
ROS in the BMSC. (B) Superoxide levels (DCF(mean fluorescence intensity 
(MFI)) in the specific populations of all animals examined n=5. Data shown are 


































Figure 4.26. NAC inhibits the LPS elicited decrease in mitochondrial 
content in the BMSC.  
C57BL/6J mice were pre-treated with 500 mg/kg N-acetyl-cysteine (NAC) for 1 hour 
before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green (MTG) 
to analyse mitochondrial content (MTG mean fluorescence intensity (MFI)) in the 
BMSC n=5 in each group. Data shown are means ± SD *P < 0.05 
 
 
4.5 BM macrophage derived superoxide coordinates mitochondrial 
increase in the HSCs in response to infection 
 
In the previous sections I found that mitochondria are transferred from the 
BMSC to the HSC during infection and this transfer is mediated by superoxide. 
Next I aimed to determine the source of the superoxide following infection. BM 
macrophages have previously been shown to regulate HSC location (77, 355), 
erythropoiesis (356, 357) and steady state granulopoiesis (358, 359). 
However, the full mechanism by which HSCs expansion is regulated by 
macrophages remains unknown. BM derived macrophages (BMDM) produce 
H2O2 in response to LPS in vitro (360). Moreover, selective mutations in the 
H2O2 generating complex of the macrophage, have been shown to be vital in 
the immune response to infection (233, 361). I therefore investigated the role 
of BMDM in mediating mitochondrial content during infection.  
 
First, to look at specific macrophage derived H2O2 I isolated BMDM from 
C57BL/6J and Cybb mice. We treated the BMDM with LPS for 30 minutes and 
analysed the media for H2O2 production by the Amplex Red assay (Figure 
4.27A). In vitro, C57BL/6J BMDM generated increased extracellular H2O2 in 
Figure 4.41. NAC inhibits the LPS elicited decrease in mitochondrial 
content in he BMSC. C57B /6J mice were pre-treated with 500mg/kg N-acetyl-
cysteine (NAC) for 1 hour before treatment with 1mg/kg LPS for 2 hours. The 
animals were sacrificed, the bone m rrow was extracted stained with a panel of 
antibodies and Mitotracker green (MTG) to analyse mitochondrial content (MTG 

























response to LPS. In contrast, following LPS treatment the Cybb BMDM had a 




Figure 4.27. Bone marrow derived macrophages produce NOX2 derived 
H2O2 in response to LPS  
(A) Bone marrow derived macrophages from C57Bl/6J mice or Cybb mice were 
treated with 1 µl/ml of LPS for 30 minutes the media was removed and were analysed 
for H2O2 production by Amplex Red assay. (B) H2O2 produced by the bone marrow 
derived macrophages after LPS treatment from C57Bl/6J mice or Cybb mice n=5. 
Data shown are means ± SD *P < 0.05 **P < 0.01 
 
 
Next, to examine the effects of infection on the BM macrophage in vivo 
C57BL/6J mice were treated with LPS for 2 hours. The mice were sacrificed, 
and the BM macrophages were analysed using flow cytometry (Figure 4.28A). 
The gating strategy to analyse the macrophages is shown in Figure 4.28B. 
The gating was determined using fluorescence minus one controls. We 
observed there was a significantly increased number of macrophages in the 




















































Figure 4.41. Bone marrow derived macrophage produce NOX2 derived superoxide in 
response to LPS (A) Bone marrow derived macrophages fro  C57Bl/6 mice or Cybb mice were 
treated with 1µl/ml of LPS for 30 minutes the media was removed and were analyzed for 
H2O2 production by Amplex Red assay. (B) H2O2 produced by the bone marrow derived 
macrophages after LPS treatment from C57Bl/6 mice or Cybb mice n=5. Data shown are means 








Figure 4.28. Macrophage number increases after LPS infection. 
(A) C57Bl/6J mice were treated with 1 mg/kg LPS or control PBS intraperitoneal 
injections. After 2 hours the mice were sacrificed and the bone marrow extracted. The 
cells were analysed for GR1, CD115, F4/80 expression to analyse the macrophage 
population. (B) The gating strategy used is shown. (C) Macrophage cell number after 
treatment with LPS. Data shown are means ± SD of n=4 in each group. *p<0.05. 
 
 
Next, to examine if the H2O2 produced by the BMDM could stimulate 
mitochondrial DNA transfer I used a coculture assay which took advantage of 
the SNP differences in the mtDNA described in Figure 4.17 and 4.18. Instead 
of using H2O2 directly, the co-culture with BMSC and lineage negative cells 
were stimulated with conditioned media from LPS activated BMDM for 24 
hours. The CBA lineage negative cells were isolated and analysed for the 
presence of PepCboy SNP mtDNA by TaqMan qPCR using ND3 probes 
(Figure 4.29A).  
 
Figure 4.42. Macrophage number increases after LPS infcetion (A) C57Bl/6 
mic  were tre ted with 1mg/kg LPS or control PBS intraperitoneal i jections. 
After 2 hours the mice were sacrificed and the bone marrow extracted 
and analysed the animals were sacrificed, The cells were analysed for GR1, 
CD115, F4/80 expression to analyse the macrophage population. (B) The gating 
strategy used is shown. (C) Macrophage cell number after treatment with LPS. 








































Conditioned media from LPS activated C57BL/6J macrophages induced 
mitochondrial transfer from the PepCboy BMSC to the CBA lineage negative 
cells (Figure 4.29B). No transfer of mtDNA was observed in the coculture 
cultured with conditioned media from LPS activated Cybb macrophages 
(Figure 4.29C). Taken together, these results suggest BMDM derived NOX2 




Figure 4.29. Bone marrow macrophage derived H2O2 is required for 
mitochondrial DNA transfer.  
CBA lineage negative cells were co-cultured with PepCboy BMSCs for 24 hours with 
conditioned media from LPS treated C57BL/6J or Cybb bone marrow derived 
macrophages for 1 hour. The CBA lineage negative cells were removed and analysed 
for PepCboy by TaqMan qPCR. (B) The mtDNA copy number of PepCboy mtDNA in 
CBA lineage negative cells after treatment with conditioned media from C57BL/6J 
bone marrow derived macrophages (B) The mtDNA copy number of PepCboy mtDNA 
in CBA lineage negative cells after treatment with conditioned media from Cybb bone 
marrow derived macrophages. Data shown are means ± SD ** p<0.01 *** p<0.001 
 
Figure 4.43. Bon  marrow macrophages roduce the NOX2 derived 
superoxide required for mitochondrial transfer. CBA lineage negative cells were 
co-cultured with PepCboy BMSCs for 24 hours with conditioned media from LPS 
treated C57BL/6 or Cybb bon  marro  derived macrophages for 1 hour. The 
lineage negative cells were removed and anal sed for mtDNA in CBA lineage 
negative cells by TaqMan qPCR. (B) The mtDNA copy number of PepCboy mtDNA
in CBA lineage-negative cells after treatment with conditioned media from C57BL/6 
bone marrow derived macrophages (B) The mtDNA copy number of PepCboy
mtDNA in CBA lineage-negative cells after treatment with conditioned media from 






Analysis for C57 


































































To investigate the role of BM macrophage derived NOX2 superoxide in vivo 
C57BL/6J mice were injected daily with control or clodronate liposomes for 3 
days to deplete the BM macrophages. The animals were then infected with S. 
typhimurium for 72 hours, the mice were sacrificed, and the BM was extracted 
and analysed using flow cytometry (Figure 4.30).  
 
 
Figure 4.30. Schematic of experimental design.  
Schematic diagram of experimental design. C57BL/6J mice were injected with 
clodronate liposomes for 3 days prior to S.typhimurium infection for 72 hours. The 
mice were sacrificed, and the bone marrow extracted and analysed for GR1, CD115, 
F4/80 expression or H2DCFDA, Mitotracker green (MTG), Sca 1, CD117, CD48, 
CD150 and CD34 expression. 
 
Following S. typhimurium infection, to confirm BM macrophages were 
depleted the number of BM macrophages were assessed using flow 
cytometry. There was a significant decrease in the number of BM 
macrophages in the S. typhimurium and clodronate treated animals compared 
to S. typhimurium alone (Figure 4.31).  
 
 
Figure 4.31. Bone marrow macrophages are depleted with clodronate 
liposomes.  
C57BL/6J mice were injected with clodronate liposomes for 3 days prior 
to S.typhimurium infection for 72 hours. The mice were sacrificed and the bone 
marrow extracted and analysed for GR1, CD115, F4/80 expression. Relative 
macrophage cell count of S.typhimurium infected mice verses clodronate 
and S.typhimurium mice. Data shown are means ± SD of 4 mice in each group 
*p<0.05 
Figure 4.44. Schematic of experimental design. Schematic diagram of 
experimental design. C57BL/6 mice were injected with clodronate liposomes for 3 
days prior to S.typhimurium infection for 72 hours. The mice were sacrificed and the 
bone marrow extracted and analyzed for GR1, CD115, F4/80 expression 


























Figure 4.45. Bone marrow macrophages are depleted with clodronate 
liposomes. C57BL/6 mice were injected with clo ronat  liposomes f r 3 days prior 
to S.typhimurium infection for 72 hours. The mice were sacrificed, and the bone 
marrow extracted and analyzed for GR1, CD115, F4/80 expression. Relative 
macrophage cell count ofS.typhimurium infected mice verses clodronate 
andS.typhimuriummice n=4.  Data shown are means ± SD of 4 mice *p<0.05
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Next, to determine if the absence of macrophages in the BM caused a 
decrease in ROS in the HSPC populations following infection, ROS levels 
were measured using the DCF assay. Increases in ROS levels in the LSK, 
HSC, ST-HSC and LT-HSC were shown to be inhibited in clodronate treated 
animals inoculated with S.typhimurium compared to control (non-clodronate 
treated) S.typhimurium inoculated animals (Figure 4.32).  
 
 
Figure 4.32. Macrophage depletion inhibits HSPC ROS increase in 
response to infection. 
C57BL/6J mice were injected with clodronate liposomes for 3 days prior 
to S.typhimurium infection for 72 hours. The mice were sacrificed and the bone 
marrow extracted and analysed for H2DCFDA (DCF), Sca 1, CD117, CD48, CD150 
and CD34 expression to analyse ROS in specific populations n=4 each group. Data 
shown are means ± SD *P < 0.05 
 
Furthermore, depletion of macrophages inhibited the S.typhimurium elicited 
increase in mitochondrial content within the LSK, HSC, ST-HSC and LT-HSC 































* * * * * *
* *
LSK HSC ST-HSC LT-HSC
Figure 4.46. Bone marrow derived macrophage produce superoxide in 
response to infection. C57BL/6 mice were injected with clodronate liposomes for 3 
days prior to S.typhimurium infection for 72 hours. The mice were sacrificed and the 
bo e marrow extracted and analyzed for H2DCFDA (DCF), Sca 1, CD117, CD48, 
CD150 nd CD34 expression to analyse ROS in specific populations n=4. Data 




Figure 4.33. Macrophage derived ROS coordinates mitochondrial 
content increase in the HSC in response to infection.   
C57BL/6J mice were injected with clodronate liposomes for 3 days prior 
to S.typhimurium infection for 72 hours. The mice were sacrificed and the bone 
marrow extracted and analysed for Mitotracker green (MTG), Sca 1, CD117, CD48, 
CD150 and CD34 expression to analyse mitochondrial content in specific populations 
n=4 in each group. Data shown are means ± SD *P < 0.05 **P < 0.01 
 
Figure 4.34 confirms an significant increase in cell number of the LSK, HSC, 
ST-HSC and LT-HSC populations following S.typhimurium infection. However, 
this increase in cell number was not observed in the clodronate treated 
animals inoculated with S.typhimurium (Figure 4.34).  
 
 
Figure 4.34. Macrophages coordinate HSCs expansion in  response to 
infection.   
C57BL/6J mice were injected with clodronate liposomes for 3 days prior 
to S.typhimurium infection for 72 hours. The mice were sacrificed, the bone marrow 
extracted and analysed for Sca 1, CD117, CD48, CD150 and CD34 expression to 



































FI * * * *
** **
* *
LSK HSC ST-HSC LT-HSC
Figure 4.47. Bone marrow  
macrophage derived superoxide coordinates mitochondrial content increase 
in HSCs in response to infection. C57BL/6 mice were injected with clodronate 
liposomes for 3 days prior to S.typhimurium infection for 72 hours. The mice 
were sacrificed, and the bone marrow extracted and analyzed for Mitotracker green 
(MTG), Sca 1, CD117, CD48, CD150 and CD34 expression to analyse 
mitochondrial content in specific populations n=4. Data shown are means ± SD  



































LSK HSC ST-HSC LT-HSC
* * * *
* ** *
Figure 4.48. Bone marrow  macrophages coordinates HSCs expansion  
in response to infection. C57BL/6 mice were injected with clodronate liposomes 
for 3 days prior to S.typhimurium infection for 72 hours. The mice 
were sacrificed, and the bone marrow extracted and analyzed for Sca 1, CD117, 
CD48, CD150 and CD34 expression to analyse cell number n=4. Data shown are 
means ± SD  *P < 0.05
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Overall, these data indicate the increase in NOX2 derived superoxide following 
infection is generated by macrophages and results in transfer of mitochondrial 
DNA to the HSC. Without macrophages, HSCs do not have an increased ROS 
and mitochondrial content following S.typhimurium infection, limiting the 
expansion of the HSC.  
 
4.6 Gap junctions regulate the movement of mitochondria from the 
BMSC to the HSC during infection  
 
I next aimed to establish the mechanism by which mitochondria move from the 
BMSC to the HSC during infection. Previous literature describing 
mitochondrial transfer have shown the most commonly reported mechanism 
of transfer is via TNTs (362). Therefore, to assess if TNTs were facilitating the 
mitochondrial transfer to the HSCs, I used the TNT inhibitor, Cytochalasin B 
(CytoB). The maximum dose of intraperitoneal CytoB tolerated was selected 
to inhibit the formation of TNTs (363). First, C57BL/6J mice were pre-treated 
with CytoB for 1 hour before treatment with LPS for 2 hours. The mice were 
sacrificed, and the BM was extracted and assessed by flow cytometry (Figure 
4.35A). Figure 4.35B shows LPS caused a significant increase in 
mitochondrial mass within the LSK, HSC, ST-HSC and LT-HSC populations. 
Pre-treatment with CytoB did not inhibit the LPS elicited increase in 
mitochondrial mass. There was a significant increase in mitochondrial content 
observed in the HSPC populations from animals treated with CytoB and LPS 
compared to the control animals (Figure 4.35B).  It was also observed 
treatment with CytoB prior to LPS did not inhibit the expansion of the HSPC 
populations (Figure 4.35C). Taken together, these data suggest TNTs do not 
directly regulate the movement of mitochondria to the HSC during infection. 
However, it is not clear if the dose of the inhibitor chosen was sufficient enough 








Figure 4.35. Cytochalasin B does not inhibit mitochondrial content 
increase after LPS treatment. 
(A) C57BL/6J mice were pre-treated with 25 mg/kg cytochalasin B (CytoB) for 1 hour 
before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green 
(MTG). (B) Mitochondrial content (MTG mean fluorescence intensity (MFI)) in specific 
LSK, HSC, ST-HSC and LT-HSC populations n=5 (C) Cell count of LSK, HSC, ST-
HSC and LT-HSC populations n=5 in each group. Data shown are means ± SD *P < 
0.05 
 
It has also been reported that intracellular mitochondria transfer can occur 
through gap junctions (364). To investigate if gap junctions mediate 
mitochondrial transfer to the HSCs in response to LPS I used the gap junction 
inhibitor carbenoxolone (CBX). C57BL/6J mice were pre-treated with CBX for 
1 hour before treatment with LPS for 2 hours. The mice were sacrificed, and 
the BM was extracted and assessed by flow cytometry (Figure 4.36A). Pre-
treatment with CBX led to reduced mitochondrial content in the LSK, HSC, ST-
Figure .49. Cytochalasin B does not inhibit mitochondrial content increase after LPS 
treatment (A)C57BL/6J mice were pre-treated with cytochalasin B (CytoB) for 1 hour before 
treatment with 1mg/kg LPS for 2 hours. The animals were sacrificed, the bone marrow was 
extracted stained with a panel of antibodies and Mitotracker green (MTG). (B) Mitochondrial 
content (MTG MFI) in specific LSK, HSC, MPP, ST-HSC and LT-HSC populations n=5 (C) Cell 





































































































HSC and LT-HSC populations compared to LPS treatment alone (Figure 
4.36B). Moreover, pre-treatment with CBX inhibited the LPS induced increase 




Figure 4.36. Carbenoxolone inhibits mitochondrial content increase after 
LPS treatment.  
(A) C57BL/6J mice were pre-treated with 50 mg/kg carbenoxolone (CBX) for 1 hour 
before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green 
(MTG). (B) Mitochondrial content (MTG mean fluorescence intensity (MFI)) in specific 
LSK, HSC, ST-HSC and LT-HSC populations n=5 (C) Cell count of LSK, HSC, ST-
HSC and LT-HSC populations n=5 in each group. Data shown are means ± SD *P < 
0.05 
To determine the functional consequences of the inhibition of mitochondrial 
content increase caused by the CBX, C57BL/6J mice were treated with control 
PBS or LPS for 2 hours. The animals were sacrificed, and the BM was 
































































































Figure 4.50. Carbenoxolone inhibits mitochondrial content increase after LPS treatment 
(A)C57BL/6J mice were pre-treat d with carbenoxolone (CBX) for 1 hour before t eatment with 
1mg/kg LPS for 2 hours. The animals were sacrificed, the bone marrow was extracted stained 
with a panel of antibodies and Mitotracker green (MTG). (B) Mitochondrial c ntent (MTG MFI) in 
specific LSK, HSC, MPP, ST-HSC and LT-HSC populations n=5 (C) Cell count of LSK, HSC, 






4.37 shows a significant decrease in mitochondrial potential in the CBX and 
LPS treated LSKs, HSCs and ST-HSCs, compared to the LPS alone. There 
were no observed changes in mitochondrial potential in the LT-HSCs (Figure 
4.37). 
 
Figure 4.37. Carbenoxolone inhibits increase in mitochondrial potential 
after LPS treatment.  
C57BL/6J mice were pre-treated with 50 mg/kg carbenoxolone (CBX) for 1 hour 
before treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted, stained with a panel of antibodies and Tetramethylrhodamine, 
methyl ester (TMRM) to assess mitochondrial health (TMRM mean fluorescence 
intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in each 
group. Data shown are means ± SD *P < 0.05 
 
 
To confirm that gap junctions are involved in the intercellular communication 
between BMSCs and HSCs, I used the mobile dye, calcein (365). Calcein 
enters the cell via gap junction therefore, I stained BMSC with calcein and then 
cultured these with lineage negative cells. The cocultures were treated with 
CBX or vehicle and then treated with H2O2. Results show there was an 
increase in calcein dye uptake into the lineage negative cells cultured with 
BMSC in the presence of H2O2 compared to the control treated cultures. 
Moreover, this uptake of calcein was reduced when the coculture were treated 





































Figure 4.51. Carb noxolone inhibits increase in mitochondrial potential after LPS 
treatment. C57BL/6J mice w re pre-trea ed with carbenoxolone (CBX) for 1 hour before 
treatm nt wi h 1 g/kg LPS for 2 hours. The animals were s crificed, the bone marr w was 
extracted, stained with a panel of antibodies and Tetramethylrhodamine, met yl ester (TMRM) to 
assess mitochondrial health (TMRM MFI) in specific LSK, HSC, MPP, ST-HSC and LT-HSC 




Figure 4.38. Carbenoxolne inhibits the transfer of calcein from BMSC to 
lineahe negative cells following H2O2 treatment.  
mBMSC were pretreated with calcein for 30 minutes. Lineage negative cells were 
then cultured with the calcein stained BMSC and treated with 10 µM H2O2 or 50 µM 
carbenoxolone (CBX) and 10 µM H2O2 for 24 hours. The lineage negative cells were 
removed and analysed for calcein using flow cytometry and mean fluorescence 
intensity (MFI). *P < 0.05 
 
To determine if CBX had an effect on mitochondrial DNA transfer I used the 
coculture assay which took advantage of the SNP differences in the mtDNA 
described in Figure 4.17 and 4.18. Figure 4.39 shows there is a significant 
decrease in transfer of mtDNA to the lineage negative cells when cultured in 
the presence of CBX and H2O2 compared to H2O2 alone.  
 
 
Figure 4.39. Mitochondrial DNA transfer from the BMSC is inhibited by 
carbenoxolone.  
CBA lineage-negative cells (recipient) were cocultured with PepCboy BMSCs (donor) 
with 10 µM H2O2 or carbenoxolone and 10 µM H2O2 for 24 hours. The lineage 
negative cells were removed and analysed for PepCboy SNP mtDNA in CBA lineage 
negative cells by TaqMan PCR using ND3 probes. PepCboy donor mtDNA copy 
number in CBA lineage negative cells. CBA gDNA was used to standardise mtDNA 








Figure 4.53. Carbenoxolne inhibits the increase in calcein expression 
observed following LPS treatment. Flow cytometry analysis of lineage-negative 
cells coculture  with mBMSC a d treated wi h 10 µM H2O2 or carb oxolone and10 
µM H2O2 for 24 hours. The lineage-negative cells were removed stained with calcein








Figure 4.54. Mitochondrial transfer from the BMSC is inhibited by 
carbenoxolone. CBA lineage-negative cells (recipient) were cocultured with 
PepCboy BMSCs (donor) with 10 µM H2O2 or carbenoxolone and 10 µM H2O2 for 24 
hours. The lineage-negative cells were removed and analysed for PepCboy SNP 
mtDNA in CBA lineage-negative cells by TaqMan PCR using ND3 probes. The 
percentage of PepCboy mtDNA in CBA lineage-negative cells. CBA gDNA was used 






























































Next, to visualise the block on mitochondrial transfer from the BMSC to the 
HSPCs, primary mBMSC were transduced with an rLV.EF1.mCherry lentivirus 
for stable incorporation of mCherry protein tagged mitochondria. Lineage 
negative cells were stained with CD45-APC and cultured on the mBMSCs for 
24 hours with H2O2 or H2O2 and the CX43 memetic peptide Gap27. The cells 
were fixed and stained with CX43 (green) and DAPI (blue) and imaged using 
fluorescence microscopy (Figure 4.40A). BMSC labelled mitochondria transfer 
to the lineage negative cells was inhibited in the presence of H2O2 and Gap27, 
quantified by the acquisition of the mCherry fluorescence in the lineage 
negative cells (Figure 4.40B). 
 
 
Figure 4.40. Gap junctions regulate mitochondrial transfer from BMSCs 
to HSCs.  
(A) Representative confocal microscopy images of lineage negative cells stained with 
membrane CD45-APC (yellow) cultured with mBMSCs transduced with 
rLV.EF1.mCherry-Mito-9 (mitochondria (red)) in cocultured with 10 µM H2O2 with and 
without pretreatment with GAP27 (100 µM). The cells were fixed and stained with 
DAPI (blue) and CX43 (green) (magnification 63X) (B) Quantification of 
rLV.EF1.mCherry-Mito-9 in lin- cells from images shown taken from 3 independent 
experiments and 20 lineage cells from each experiment. Data shown are means ± SD 
*P < 0.05 
Figure 4.55. Gap junctions regulate mitochondrial transfer from BMSCs to 
HSCs. (A) Representative confocal microscopy images of lin- cells stained with 
CD45-APC cultured with mBMSCs transduced with rLV.EF1.mCherry-Mito-9 in 
cocultured with 10 µM H2O2 with and without pretreatment with GAP27 (100 µM). 
The cells were fixed and stained with DAPI and CX43-FITC (magnification 63X) (B) 
Quantification of rLV.EF1.mCherry-Mito-9 in lin- cells from images shown taken from 
3 independent experiments and 20 lineage cells from each experiment. Data shown 
are means ± SD *P < 0.05









To determine if mitochondrial transfer was regulated by CX43 gap junctions I 
used the coculture assay which took advantage of the SNP differences in the 
mtDNA described in Figure 4.17 and 4.18. There is a significant decrease in 
mtDNA transfer to the lineage negative cells when cultured in the presence of 
GAP27 and H2O2 compared to H2O2 alone (Figure 4.41). Taken together, 
using methods to inhibit gap junctions, these results show CX43 gap junctions 
regulate mitochondrial transfer from the BMSC to the HSC populations in 
models of acute infection. 
 
 
Figure 4.41. Mitochondrial DNA transfer from the BMSC is inhibited by 
CX43 blocking peptide GAP27.  
CBA lineage-negative cells (recipient) were cocultured with PepCboy BMSCs (donor) 
with 10 µM H2O2 alone or 100 µM GAP27 and 10 µM H2O2 for 24 hours. The lineage 
negative cells were removed and analysed for PepCboy SNP mtDNA in CBA lineage 
negative cells by TaqMan PCR using ND3 probes. Donor PepCboy mtDNA copy 
number in CBA lineage negative cells. CBA gDNA was used to standardise mtDNA 
copy number. Data shown are means ± SD *P < 0.05 
 
 
4.7 ROS activates phosphorylation of AKT to enable mitochondrial 
transfer by PI3K 
 
Increased ROS levels have previously been shown to be associated with 
increased signalling of phosphoinositide-3,4,5-trisphosphate (PIP3) and 
subsequent activation of  phosphoinositide 3-kinase (PI3K) (366, 367). The 
PIP3 also activates downstream signalling of the protein kinase AKT (pAKT) 
which is vital for cell survival (368). Therefore, I next quantified AKT 
Figure 4.55. Mitochondrial transfer from the BMSC is inhibited by CX43 
blocking peptide GAP27. CBA lineage-negative cells (recipient) were cocultured 
with PepCboy BMSCs (donor) with 10 µM H2O2 or 100 µM GAP27 and 10 µM 
H2O2 for 24 hours. Th  lin age-negative cells were re oved and analysed for 
PepCboy SNP mtDNA in CBA lineage-negative cells by TaqMan PCR using ND3 
probes. The percentage of PepCboy mtDNA in CBA lineage-negative cells. CBA 




phosphorylation (S473) in the HSC after treatment with S.typhimurium (72 
hours) or LPS (2 hours). AKT phosphorylation was significantly elevated in the 
LSK, HSC, ST-HSC and LT-HSC population after both S.typhimurium infection 
and LPS treatment compared to the untreated control (Figure 4.42A-C). 
 
 
Figure 4.42. pAKT expression is elevated in the haematopoietic stem and 
progenitor populations after S.typhimurium infection and LPS treatment.  
(A) Gating strategy used is shown (B) C57BL/6J mice were infected with 
S.typhimurium (Sal) for 72 hours, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies. The cells were then fixed and stained 
with pAKT-PE and assessed by flow cytometry n=6. (C) C57BL/6J mice were treated 
with LPS for 2 hours, the animals were sacrificed, the bone marrow was extracted 
and stained with a panel of antibodies. The cells were then fixed and stained with 
pAKT-PE and assessed by flow cytometry n=5 in each group. Data shown are means 































































































































Next, to examine the effects of infection on AKT phosphorylation in the BMSC 
in vivo C57BL/6J mice were treated with LPS for 2 hours or infected with 
S.typhimurium for 72 hours. The mice were sacrificed, and the BMSCs were 
analysed for pAKT expression using flow cytometry. pAKT was significantly 
increased in the BMSC after both S.typhimurium and LPS treatment compared 
to the untreated control (Figure 4.43A-C). 
 
 
Figure 4.43. pAKT expression is elevated in the BMSC after 
S.typhimurium infection and LPS treatment.  
(A) Gating strategy used is shown (B) C57BL/6J mice were infected with 
S.typhimurium (Sal) for 72 hours, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to analyse the BMSC population. 
The cell were then fixed and stained with pAKT-PE and assessed by flow cytometry 
n=6. (C) C57BL/6J mice were treated with LPS for 2 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies to 
analyse the BMSC population. The cell were then fixed and stained with pAKT-PE 
and assessed by flow cytometry n=5 in each group. Data shown are means ± SD *P < 
0.05 
 
Next, to confirm increased ROS causes AKT phosphorylation in vivo C57BL/6J 
mice were treated with BSO for 2 hours. The mice were sacrificed, and the 
HSPCs were analysed for pAKT expression using flow cytometry (Figure 
4.44A). Figure 4.44B shows pAKT was significantly increased in the LSK HSC, 












































Figure 4.58. pAKT expression is elevated in the BMSC after S. 
typhimurium and LPS treatment. (A) C57BL/6J mice were infected with S. 
typhimurium (Sal) for 72 h, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to analyse the BMSC 
population. The cell were then fixed and stained with pAKT-PE and assessed by 
flow cytometry n=6. (B) C57BL/6J mice were treated with LPS for 2 hours, the 
animals were sacrificed, the bone marrow was extracted and stained with a panel 
of antibodies to analyse the BMSC population. The cell were then fixed and 
stained with pAKT-PE and assessed by flow cytometry n=5. Data shown are 































Figure 4.44. BSO induces an increase in pAKT expression in the 
haematopoietic stem and progenitor populations.  
(A) C57BL/6J mice were treated with 100 mg/kg L-buthionine-sulfoximine (BSO) for 
2 hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and pAKT-PE. (B) pAKT expression (pAKT (mean fluorescence 
intensity (MFI)) in the specific populations of all animals examined. n=5 in each group. 
Data shown are means ± SD *P < 0.05 
 
To investigate if ROS also induced pAKT in the BMSC C57BL/6J mice were 
treated with 100 mg/kg BSO for 2 hours. pAKT was significantly increased in 




Figure 4.45. BSO induces an increase in pAKT expression in the BMSC.  
(A) C57BL/6J mice were treated with 100 mg/kg L-buthionine-sulfoximine (BSO) for 
2 hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and pAKT-PE. (B) pAKT expression (pAKT (mean fluorescence 
intensity (MFI)) in all animals examined. n=5 in each group. Data shown are means 
± SD *P <0.05 
Figure 4.59. BSO induces an increase in pAKT expression in the 
haematopoi tic stem and p ogenitor population . (A) C57BL/6J mice were 
treated with 100mg/kg L-buthionine-sulfoximine (BSO) for 2 hours, the animals were 
sacrificed, the bone marrow was extracted stained with a panel of antibodies and 
pAKT-PE. (B) pAKT expression (pAKT(mean fluorescence intensity (MFI)) in the 





















































Figure 4.60. BSO induces an increase in pAKT expression in the BMSC. (A)
C57BL/6J mice w re tr ated with 100mg/kg L-buthionine-sulfoximine (BSO) for 2 
hours, the animals were sacrificed, the bone marrow was extracted stained with a 
panel of antibodies and pAKT-PE. (B) pAKT expression (pAKT(mean fluorescence 
intensity (MFI)) in all animals examined. n=5. Data shown are means ± SD *P <0.05
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Next, to confirm the increase in phosphorylation of AKT in the HSC I cocultured 
BMSC and lineage negative cells in the presence of H2O2 and assessed 
phosphorylation of AKT (pAKT-S473) by western blotting. Figure 4.46 shows 
an increase in AKT phosphorylation in the lineage negative cells when cultured 
with BMSC in the presence of H2O2. 
 
 
Figure 4.46. pAKT expression is elevated in the lineage negative cells 
after coculture with BMSC with H2O2.  
Western bot analysis of lineage negative (lin-) cells co-cultured with mBMSCs. The 
co-culture was treated with 10 µM H2O2 for 30 minutes, the lin- cells were removed 
and analysed for pAKT expression. 
 
 
AKT is phosphorylated as part of the PI3K pathway, where PI3K is converted 
into PIP3 which binds to AKT (369, 370). AKT is then phosphorylated by mTOR 
(371) or DNA-dependent protein kinase (372) which initiates full AKT activity. 
To determine if PI3K had an effect on mitochondrial transfer I used the PI3K 
delta (PI3Kδ) inhibitor Cal 101. I used the coculture assay which took 
advantage of the SNP differences in the mtDNA described in Figure 4.17 and 
4.18. Figure 4.47 shows there is a significant decrease in mtDNA transfer to 
the lineage negative cells when cultured in the presence of Cal 101 and H2O2 
compared to H2O2 alone.  
 
Figure 4.61. pAKT expression is elevated in the lineage negative cells after 
coculture with BMSC with H2O2. Western bot analysis of lin- cells co-cultured with 
mBMSCs. The co-culture was treated with 10 µM H2O2 for 30 minutes, the lin- cells 













Figure 4.47. Mitochondrial DNA transfer from the BMSC is inhibited by 
Cal 101.  
CBA lineage-negative cells (recipient) were cocultured with PepCboy BMSCs (donor) 
with 10 µM H2O2 or 25 µM Cal 101 and 10 µM H2O2 for 24 hours. The lineage negative 
cells were removed and analysed for PepCboy SNP mtDNA in CBA lineage negative 
cells by TaqMan PCR using ND3 probes. Donor PepCboy mtDNA copy number in 
CBA lineage negative cells. CBA gDNA was used to standardise mtDNA copy 
number. Data shown are means ± SD *P < 0.05 
 
To assess if PI3K inhibition was involved with gap junctions regulation I used 
the mobile dye, calcein (365). Consistent with previous results, in the presence 
of H2O2 there was an increase in calcein dye uptake into the lineage negative 
cells compared to the control. However, this uptake of calcein was reduced 
when the coculture was treated with the PI3Kδ inhibitor Cal 101 prior to H2O2 
addition (Figure 4.48). 
 
 
Figure 4.48. Cal 101 inhibits the increase in calcein expression observed 
following LPS treatment.  
mBMSC were pretreated with calcein for 30 minutes. Lineage negative cells were 
then cultured with the calcein stained BMSC and treated with 10 µM H2O2 and 25 µM 
Cal 101 or 10 µM H2O2 alone for 24 hours. The lineage negative cells were removed 
and analysed for calcein using flow cytometry and mean fluorescence intensity (MFI). 
*P < 0.05 

























Figure 4.63. Mitochondrial transfer from the BMSC is inhibited by Cal 101. CBA 
lineage-negative cells (recipient) were cocultured with PepCboy BMSCs (donor) with 
10 µM H2O2 or Cal 101 and  µM H2O2 for 24 h urs. The lineage-negative cells 
w re removed an alysed for PepCboy SNP mtDNA in CBA lineage-  cells 
by TaqMan PCR using ND3 probes. The percentage of PepCboy mtDNA in CBA 
lineage-negative cells. CBA gDNA was used to standardize mtDNA copy number. 















Figure 4.62. Cal 101 inhibits the increase in calcein expression observed 
following LPS treatment. Flow cytometry analysis of lineage-negative cells 
cocultured with mBMSC and treated with 10 µM H2O2 or Cal 101 and 10 µM 
H2O2 for 24 hours. The lineage-negative cells were removed stained with calcein
and analysed for calcein mean fluorescence intensity (MFI).
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To investigate if PI3K mediates mitochondrial content increase in the HSCs in 
response to LPS, C57BL/6J mice were pre-treated with Cal 101 for 1 hour 
before treatment with LPS for 2 hours. The mice were sacrificed, and the BM 
was extracted and assessed by flow cytometry (Figure 4.49A). Pre-treatment 
with Cal 101 led to a reduced mitochondrial content in the LSK, HSC, ST-HSC 




Figure 4.49. Cal 101 inhibits mitochondrial content increase after LPS 
treatment.  
(A) C57BL/6J mice were pre-treated with 30 mg/kg Cal 101 for 1 hour before 
treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green 
(MTG). (B) Mitochondrial content (MTG mean fluorescence intensity (MFI)) in specific 
LSK, HSC, ST-HSC and LT-HSC populations n=5 in each group. Data shown are 
means ± SD *P < 0.05 **P < 0.01 
 
Finally, to determine the functional consequences of the inhibition of 
mitochondrial content increase caused by the Cal 101, C57BL/6J mice were 
treated with control PBS or LPS for 2 hours. The animals were sacrificed, and 
the BM was extracted and analysed for mitochondrial potential by flow 






















































Figure 4.63. Cal 101 inhibits mitochondrial content increase after LPS treatment (A) 
C57BL/6J mice were pre-treated with Cal 101 for 1 hour before treatment with 1mg/kg LPS for 2 
hours. The animals were sacrificed, the bone marrow was extracted stained with a panel of 
antibodies and Mitotracker green (MTG). (B) Mitochondrial content (MTG MFI) in specific LSK, 




in the Cal 101 and LPS treated LSK, HSC and ST-HSCs, compared to the LPS 
alone. There were no observed changes in mitochondrial potential in the LT-
HSC (Figure 4.50). Taken together, these data show PI3K signaling mediates 




Figure 4.50. Cal 101 inhibits mitochondrial membrane potential increase 
after LPS treatment.  
(A) C57BL/6J mice were pre-treated with 30 mg/kg Cal 101 for 1 hour before 
treatment with 1 mg/kg LPS for 2 hours. The animals were sacrificed, the bone 
marrow was extracted stained with a panel of antibodies and Mitotracker green 
(MTG). (B) Mitochondrial content (MTG mean fluorescence intensity (MFI)) in specific 
LSK, HSC, ST-HSC and LT-HSC populations n=5 in each group. Data shown are 
means ± SD *P < 0.05  
 
4.8 Summary  
 
In this chapter I have shown that mitochondria are transferred from the BMSC 
to the HSC in response to infection. Moreover, I have identified mitochondria 
move via gap junctions and this is stimulated by NOX2 superoxide, causing 
oxidative stress in HSC and the BMSC. This elevated superoxide in the BM is 
generated by the macrophages and facilitates mitochondrial movement to the 
HSC. Finally, I have identified that the increase in superoxide regulates PI3K 
activation and subsequent phosphorylation of AKT which drives transfer of 





























































Figure 4.65. Cal 101 inhibits increase in mitochondrial potential after LPS treatment. 
C57BL/6J mice were pre-treated with Cal 101 for 1 hour before treatment with 1mg/kg LPS for 2 
hours. The animals were sacrificed, the bone marrow was extracted, stained with a panel of 
antibodies and Tetramethylrhodamine, methyl ester (TMRM) to assess mitochondrial health 
(TMRM MFI) in specific LSK, HSC, MPP, ST-HSC and LT-HSC populations n=5 . Data shown 
are means ± SD *P < 0.05
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5 Enhanced free fatty acid uptake via CD36 promotes a 
metabolic switch to β-oxidation by haematopoietic stem 
cells in response to bacterial infection 
 
5.1 Introduction 
In chapter 3 and 4 I have shown that mitochondria are transferred from the 
BMSC to the HSC in response to acute infection. I next wanted to examine 
what fuels the HSCs TCA cycle in response to infection. The TCA cycle 
integrates many fuels sources including fatty acids, glucose and glutamine to 
generate ATP and functions as an assembly point for cellular respiration and 
metabolism (373). The HSC is supported by cells of the BM microenvironment 
and the BM has a high fat content which increases with age (165). Recent 
studies have shown, metabolic pathways are central in regulating 
haematopoiesis, and HSC metabolism can determine cell differentiation or 
maintenance of quiescence (374). Specifically, FAO has been shown to be 
utilised to aid self-renewal and differentiation in both committed progenitors 
and the more primitive HSCs (26). Moreover, the inhibition of FAO can reduce 
stem cell differentiation capacity (26).  
In malignant haematopoiesis, several studies have shown fatty acids are key 
in fuelling leukaemia. A study by Ye et al. 2016 showed there is elevated levels 
of FFA in the serum of leukaemic mice. Moreover, the LSC induced lipolysis 
in the BMAT to fuel the LSC by FAO (17). A study from our lab group has also 
shown that FFA are taken up by AML blasts for increased proliferation due to  
increased β-oxidation (17, 42). Therefore, I hypothesise that the metabolic 
switch towards β-oxidation dependency in AML originates from the 
physiological HSC response to stress and HSC take up FFAs in response to 
infection. 
In this chapter, I will examine acquisition of FFAs by HSCs following S. 
typhimurium or LPS infection. Furthermore, I will investigate the mechanisms 
regulating fatty acid transport to the HSC and immunometabolic 




5.2 S.typhimurium infection drives uptake of long chain fatty acids 
in the HSC 
 
It has previously been shown FFA levels in the serum are elevated in response 
to infection (375, 376). To determine if FFA were elevated in models of acute 
bacterial infection C57BL/6J mice were infected with S.typhimurium for 72 
hours or treated with LPS for 16 hours. The 16-hour LPS time point was 
chosen as the cells still have an increased mitochondrial content, an IL 6 
response and it just after the cells begin to cycle. Figure 5.1 shows there was 
an increase in serum FFA levels from S.typhimurium and LPS treated mice 
compared to control mice. 
 
 
Figure 5.1. Elevated levels of FFA in the serum of S.typhimurium and LPS 
treated mice.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours or LPS for 16 
hours. Blood was taken from the animals by cardiac puncture and the serum was 
assessed for levels of FFA. n=5 in each group. Data shown are means ± SD *P < 
0.05 
 
Next, to investigate if the elevated FFAs following infection were taken up by 
the haematopoietic cells, I developed a transplant model to track real time fatty 
acid uptake in vivo. PepCboy CD45.1 lineage negative (lin-), CD117 positive 
(LK) cells were isolated and transduced with a firefly luciferase virus (LK+FF). 
The cells were then transplanted into busulfan treated C57BL/6J CD45.2 
animals (Figure 5.2A). Engraftment and transduction of the LK+FF cells were 
monitored using D-luciferin by in vivo bioluminescent imaging (Figure 5.2B). 
12 weeks post transplantation the CD45.1 LK+FF engrafted CD45.2 animals 
were injected with a probe containing a long chain FFA conjugated to luciferin 
Figure 5.1. Elevated levels of FFA in the serum of S. typhimurium and LPS treated mice 
C57BL/6J mice were infected with S. typhimurium (Sal) for 72 h or LPS for 16 hours. Blood was 
taken from the animals by cardiac puncture and the serum was assessed for levels of FFA. n=5 


















































molecule (FFA-luc) through a cleavable disulphide bond (Figure 5.2C and D). 
The probe is stable extracellularly however, once internalised into the cells 
following lipid uptake, the disulphide bond is cleaved by glutathione. The 
luciferin molecule reacts with the luciferase and fluorescence can be observed 
by bioluminescent imaging (377). One week later after the mice had recovered 
the animals were injected with LPS for 16 hours. Following LPS treatment, 
there was activation of luciferase in the BM compartment signifying long chain 









Figure 5.2. Treatment with LPS drives fatty acid uptake in the 
haematopoietic compartment.  
(A) Schematic diagram of the experimental design. PepCboy CD45.1 lineage 
negative, CD117 positive (LK) cells were isolated and transduced with a firefly 
luciferase virus (LK+FF) and transplanted into CD45.2 animals. (B) Mice were 
bioluminescence imaged using luciferin to confirm engraftment. (C) Mice were 
injected with control PBS for 16 hours then treated with FFA-SS-luc and imaged using 
bioluminescence (FFA-luciferin). One-week later mice were injected LPS for 16 hours 
then treated with FFA-SS-luc and imaged using bioluminescence (FFA-
luciferin+LPS). Representative images of control and LPS treated mice. (D) 
Densitometry of the bioluminescent images in (C) to determine fluorescence intensity 
in vehicle and LPS treated animals. n=4 in each group. Data shown are means ± SD 








Figure 5.2. Infection with LPS drives fatty acid uptake in the hematopoietic 
compart ent. (A) Sche atic diagram of the experimental design. PepCboy
CD45.1 lineage negative, kit positive (LK) cells were isolated and transduced 
with a firefly luciferase virus (LK+FF ) and transplanted into CD45.2 animals. (B) 
Mice were bioluminescence imaged using luciferin to confir  engraftment. (C) 
Mice w re injected with LPS or cont ol PBS for 16 ours then treated with FFA-
SS-luc and imaged using bioluminescence. Representative images of control 
and LPS treated mice. (D) Densitometry of the bioluminescent images in (C) to 
determine fluorescence intensity in vehicle and LPS treated animals. n=4 in each 













































To assess the specific HSPC populations with increased lipid content during 
infection, C57BL/6J mice were infected with S.typhimurium for 72 hours. The 
HSPC populations were analysed for lipid content with a panel of cell surface 
antibodies and Bodipy 493/503 using flow cytometry (Figure 5.3A). This 
included all colour compensations and the gating strategy to isolate the 
specific cell populations of interest is shown in Figure 5.3B. All gating was 
determined using fluorescence minus one controls. 
 
 
Figure 5.3. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and 
LT-HSC.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, and the bone marrow was extracted. The cells were stained with a 
panel of antibodies to analyse specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC 
populations. (B) The gating strategy used is shown. 
 
Figure 5.4 shows that the LSK (Lin- Sca 1+ CD117+), MPPs (Lin- Sca 1+ 
CD117+ CD150+ CD48+), total HSCs (Lin- Sca 1+ CD117+ CD150+ CD48-), 
ST-HSCs (Lin- Sca 1+ CD117+ CD150+ CD48- CD34+) and LT-HSCs (Lin- 
Sca 1+ CD117+ CD150+ CD48- CD34-) (68) populations within the BM all 
have an increased intracellular neutral lipid staining after S.typhimurium 
infection compared to the control non-infected animals.  
Figure 5.3. Gating strategy for mouse Lin-, LSK, HSC, MPP, ST-HSC and LT-
HSC (A) C57BL/6J mice were infected with S. typhimurium (Sal) for 72 h, the 
animals were sacrificed, and the bone marrow was extracted. The cells were 
stained with a panel of antibodies to analyse specific Lin-, LSK, HSC, MPP, ST-HSC 




































































































Figure 5.4. S.typhimurium induces an increase in lipid content in the 
haematopoietic populations.  
C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and Bodipy 493/503 to analyse lipid content (Bodipy 493/503 mean 
fluorescence intensity (MFI)) in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC 
populations. n=6 in each group. Data shown are means ± SD **P < 0.01 ***P < 0.001 
 
Similarly, following 16 hours of LPS treatment HSPC populations within the 
BM have an increased lipid content after treatment with LPS (Figure 5.5).  
 
 
Figure 5.5. LPS induces an increase in lipid content in the 
haematopoietic populations.  
C57BL/6J mice were treated with 1 mg/kg LPS for 16 hours, the animals were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies and 
Bodipy 493/503 to analyse lipid content (Bodipy 493/503 mean fluorescence intensity 
(MFI)) in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations. n=5 Data 
shown are means ± SD *P <0.05 **P < 0.01  
 
Next, to investigate if the increase in lipid content was due to uptake of FFA, 
C57BL/6J mice were infected with S. typhimurium for 72 hours or treated with 
LPS for 16 hours. The LK cells were isolated and incubated with Bodipy FL-
C12 (a FFA tagged to Bodipy) for 30 minutes. There was an increase in FFA 
uptake observed in the LK cells from S.typhimurium or LPS compared to LKs 
from untreated mice (Figure 5.6). 
Figure 5.4 S. yphimurium induces a  increase in lipid content in the 
haematopoietic populations. C57BL/6J mice were infected with S. 
typhimurium (Sal) for 72 h, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies and Bodipy 493/503 to analyse lipid 
content (Bodipy 493/503 mean fluorescence intensity (MFI)) in specific Lin-, LSK, 
HSC, MPP, ST-HSC and LT-HSC populations. n=6 in each group. Data shown are 









































Figure 5.5. LPS induces an increase in lipid content in the haematopoietic 
populations. (A) C57BL/6J mice were treate  with 1mg/kg LPS for 16 hours, the 
animals were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies and and Bodipy 493/503 to analyse lipid content (Bodipy 493/503 mean 
fluorescence intensity (MFI)) in specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC 


















































Figure 5.6. LPS and S.typhimurium induce an uptake of FFA in the 
haematopoietic progenitor populations.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours or LPS for 16 
hours. The animals were sacrificed and the bone marrow extracted. LK cells were 
isolated and incubated with Bodipy FL-C12 and fluorescence was measured. n=5 in 
each group Data shown are means ± SD *P < 0.05 
 
To visualise the uptake of FFA LK cells isolated from the BM of control or S. 
typhimurium infected (72 hours) C57BL/6J mice were stained with Bodipy 
493/503, Hoechst 33342 and Sca 1-APC membrane stain for 30 minutes and 
imaged using fluorescence microscopy (Figure 5.7A). LK cells positive for Sca 
1-APC membrane stain were then classified as LSKs. LSK cells from 
S.typhimurium infected mice had an increased lipid content quantified by 
Bodipy 493/503 fluorescence (Figure 5.7B). Taken together these results 
demonstrates HSPCs take up FFA in response to infection and this leads to 
an increased lipid content in the cell. 
Figure 5.7. LPS induces an uptake of FFA in the h ematopoietic progenitor
populations. C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours
or LPS for 16 hours. Th animas were sacrificed, and the bone marrow extracted.
LK cells were isolated and incubated with Bodipy FL-C12 and fluorescence was




















































Figure 5.7 S.typhimurium infection induces uptake of FFA in LSK cells.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours (A) 
Representative live cell fluorescent microscopy images of LSK cells isolated from the 
mice, Sca 1 membrane stain (red), Bodipy 493/503 (green) and Hoechst 33342 
(blue). Data shown are means ± SD of n=5 mice. (B) Quantification of Bodipy 493/503 
fluorescence in LSK cells from images shown, 20 LK cells from each mouse in each 
condition. Data shown are means ± SD *P < 0.05 
 
5.3 S.typhimurium infection increases OCR and dependency on β-
oxidation in HSPCs 
 
To understand the metabolic consequences of the increase in FFA in the 
HSCs response to infection I used the mitochondrial extracellular flux assay to 
measure oxygen consumption. LSKs isolated from S.typhimurium (72 hours) or 
LPS (16 hours) treated animals had an increased OCR at both basal and 
maximal respiration compared to the control LSK cells (Figure 5.8A and B).  
 
Figure 5.8 Inf ction w th LPS induces uptake of FFA. (A) C5 BL/6J mice were 
infected wi h S. typhim rium (Sal) for 72 hours (A) Representative live cell 
fluorescent microscopy images of LK cells isolated from the mice, red-Sca1 
membrane stain, green-Bodipy 493/503 and blue Hoechst 33342. Data shown are 
means ± SD of n=5 mice. (B) Quantification of Bodipy 493/503 fluorescence in LK 
cells from images shown, 20 LK cells from each experiment. Data shown are means 




























Figure 5.8. LSK have increased OCR levels after LPS treatment or 
S.typhimurium infection.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the BM was extracted and stained with a panel of antibodies to isolate 
the LSK population by FACS. Basal (normalised to rotenone) and maximal OCR 
levels were measured by OCR. n=5 in each group. (B) C57BL/6J mice were treated 
with PBS or LPS for 2 hours, the animals were sacrificed, the BM was extracted and 
stained with a panel of antibodies to isolate the LSK population by FACS. Basal 
(normalised to rotenone) and maximal OCR levels were measured by the extracellular 
flux assay. n=5 in each group. Data shown are means ± SD **P < 0.01***P < 0.001 
 
To assess the changes in glycolysis after S.typhimurium (72 hours) infection 
or LPS (16 hours) treatment. I used the extracellular flux assay to analyse 
ECAR (Figure 5.9A). Whilst there was an increase in basal OCR there was no 
observed increase in basal glycolysis (ECAR) following S.typhimurium (72 
hours) infection or LPS (16 hours) treatment (Figure 5.9B). 
 
Figure 5.9. LSK have increased OCR levels after LPS and S. typhimurium infection. (A) 
C57BL/6J mice were infected with S. typhimurium (Sal) for 72 hours, the ani als were 
sacrificed, the bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK population by FACS. Basal (normalised to rotenone) and maximal OXPHOS levels were 
measured by OCR. n=5 in each group. (B) C57BL/6J mice were tre ted with PBS or LPS for 2 
hours, the animals were sacrifice , the bone marrow was extracted and stained with a p nel of 
antibodies to isolate the LSK pop lation by FACS. Basal ( ormalised to rotenone) and maximal 
OXPHOS levels were measured by OCR. n=5 in each group. Data shown are means ± SD  






























































































































Figure 5.9. LSK have no change in basal glycolysis after LPS treatment 
or S.typhimurium infection.  
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours or treated with 
LPS for 16 hours, the animals were sacrificed, the bone marrow was extracted and 
stained with a panel of antibodies to isolate the LSK population by FACS. Glycolysis 
levels were measured by ECAR. (B) Basal OCR (normalised to rotenone) vs Basal 
ECAR of LSK after S.typhimurium and LPS treatment. n=5 in each group. Data shown 
are means ± SD 
 
 
Cells utilise pyruvate, long chain FAs and glutamine as the major substrates 
to generate ATP to support cellular metabolism. The Seahorse XF Mito Fuel 
Flex Test uses inhibitors of these pathways to identify the ability of the cell to 
switch between oxidative pathways, to meet the basal metabolic demands. I 
used the assay to monitor the contribution of FAO or β-oxidation to maintain 
basal metabolism in LSKs from LPS (16 hours) treated animals. Figure 5.10 
shows, LSK from LPS treated C57BL/6J mice have an increased dependency 
on FAO as a source of energy compared to LSKs from control mice.  
Figure 5.10. LSK have no change in basal glycolysis  after LPS n S. 
typhimurium infection. (A) C57BL/6J mice were infected with S. typhimurium (Sal) 
for 72 hours or LPS for 16 hours, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to isolat  t e LSK population by 
FACS. Glycolysis levels were measured by ECAR. (B) Basal OCR vs Basal ECAR of 
LSK after S. typhimurium and LPS treatment (normalised to rotenone). n=5 in each 















































Figure 5.10. LPS treatment drives increased dependency on fatty acid 
oxidation in the LSK population.  
C57BL/6J mice were treated with LPS for 16 hours, the animals were sacrificed, the 
BM was extracted and stained with a panel of antibodies to isolate the LSK population 
by FACS. The LSK population was analysed for the reliance on fatty acids to maintain 
baseline respiration. n=5 in each group. Data shown are means ± SD *P < 0.05 
 
 
Next, to establish the role of β-oxidation on OCR, C57BL/6J mice were treated 
with LPS for 16 hours. The animals were sacrificed and the LSKs were isolated 
by FACS and treated ex vivo with an inhibitor of mitochondrial CPT1, etomoxir 
(ETX) to inhibit β-oxidation. Seahorse XF Mito stress test analysis showed ex 
vivo treatment ETX inhibited the LPS elicited increase in basal and maximal 
OCR but did not affect the control cells (Figure 5.11A and B). 
 
Figure 5.11. LPS tre tment drives increased dependency on fatty acid 
oxidation in the LSK population. C57BL/6 mice were treated with LPS for 16 
hours, the animals were sacrificed, the bone marrow was extracted and stained with 
a panel of antibodies to isolate the LSK population by FACS. The LSK population 
was analysed for the reliance on fatty acids to maintain baseline respiration. n=5 in 





























Figure 5.11. LSKs have an increased dependency on β oxidation 
following LPS treatment.  
C57BL/6J mice were treated with LPS for 16 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to isolate the LSK 
population by FACS. The LSKs were treated with the β-oxidation inhibitor, etomoxir 
(ETX) and oxygen consumption rate (OCR) levels were measured by the extracellular 
flux assay. (B) Basal mitochondrial respiration (normalised to rotenone) of LSK cells 
from control and LPS treated animals with and without ETX. Maximal mitochondrial 
respiration LK cells from control and LPS treated animals with and without ETX. Data 
shown are means ± SD of n=5 mice in each group. *P < 0.05 
 
To understand the importance of β-oxidation in the HSCs response to infection 
in vivo, C57BL/6J mice were pre-treated ETX for 1 hour before administration 
of S.typhimurium. The mice were then treated with ETX daily, 72 hours post 
S.typhimurium administration the animals were scarified and the BM was 
analysed by flow cytometry (Figure 5.12A). Figure 5.12B shows LSK, HSC, 
ST-HSC, and LT-HSC cell cycling were all significantly reduced in the ETX 
and S.typhimurium treated animals compared to S.typhimurium alone.  























































































































Figure 5.12. LSKs have an increased dependency on β oxidation following  
LPS treatment. C57BL/6 mice were treated with LPS for 16 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to is late the LSK popul tion by FACS. The LSKs were treated with the 
β-oxidation inhibitor, etomoxir (ETX) and OXPHOS levels were measured by OCR. 
(B) Basal mitochondrial respiration (normalised to rotenone) of LSK cells from 
control and LPS treated animals with and without ETX. Maximal mitochondrial 
respiration LK cells from control and LPS treated animals with and without ETX. 





Figure 5.12. Etomoxir inhibits Ki67 positive cells following S. 
typhimurium infection.  
(A) Schematic diagram of experimental design in which C57BL/6J mice were infected 
with S.typhimurium (Sal) for 72 hours and Etomoxir (ETX). The BM was extracted, 
and the cells were analysed by flow cytometry for LSK, HSC, ST-HSC and LT-HSC 
populations. (B) Percentage of cycling cells as measured by Ki67 positive cells after 
S. typhimurium and ETX treatment. Data shown are means ± SD of >4 mice in each 
group *p<0.05. 
 
Next, to examine if the decrease in cell cycling correlated with a decrease in 
cell number, I examined the cell count per 100,000 BM cells after ETX and 
S.typhimurium. As expected the S.typhimurium treated animals had a 
significant increase in LSK, HSC, ST-HSC and LT-HSC cell number. However, 
in the ETX and S.typhimurium treated group there was no change in HSPC 
cell count compared to the control (Figure 5.13).   
 
 
Figure 5.13. Etomoxir inhibits cell cycling after S. typhimurium infection (A) 
Schematic diagram of experimental design in which C57/BL6 mice were infected 
with S. typhimurium (Sal) for 72 hours and Etomoxir (ETX). The BM was extracted, 
and the cells were analysed by flow cytometry for LSK, HSC, ST-HSC and LT-HSC 
populatio s. (B) Percentage of cycling cells s measured by Ki67 positi  cells after 















































































Figure 5.13. Etomoxir inhibits cell number increase after S.typhimurium 
infection.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours and Etomoxir 
(ETX). The BM was extracted, and the cells were analysed for cell count per 100 000 
cells by flow cytometry for LSK, HSC, ST-HSC and LT-HSC populations. Data shown 
are means ± SD of >4 mice in each group *p<0.05 **p<0.01 
 
To confirm the effect of ETX on cell count and cell cycling following 
S.typhimurium infection was not due to a decrease in lipid content in the cell I 
used Bodipy 493/503 staining. Figure 5.14 shows that lipid content is 
significantly increased in the LSK, HSC, ST-HSC and LT-HSC in both the 




Figure 5.14. Etomoxir does not inhibit lipid content increase in the HSC 
after S.typhimurium infection.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours and Etomoxir 
(ETX). The BM was extracted and stained with a panel of antibodies and Bodipy 
493/503 to analyse lipid content (Bodipy 493/503 mean fluorescence intensity (MFI)) 
in specific LSK, HSC, ST-HSC and LT-HSC populations. Data shown are means ± 

















































Figure 5.14. Etomoxir inhibits cell number increase after S. typhimurium
infection C57/BL6 mice were infected with S. typhimurium (Sal) for 72 hours and 
Etomoxir (ETX). The BM was extracted, and the cells were analysed for cell count 
per 100 000 cells by flow cytometry for LSK, HSC, ST-HSC and LT-HSC 















































Figure 5.15. Etomoxir does not inhibit lipid content increase in the HSC after S. 
typhimurium infection. C57/BL6 mice were inf cted with S. typhimurium (Sal) for 
72h and Etomoxir (ETX). he BM was extracted and stained ith a panel of 
antibodies and Bodipy 493/503 to analyse lipid content (Bodipy 493/503 mean 
fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC 




To establish the role of β-oxidation on OCR following S.typhimurium infection, 
the LSKs from control and S.typhimurium were isolated by FACS and treated 
ex vivo with ETX. Seahorse XF Mito stress test analysis showed ex vivo 
treatment ETX inhibited the S.typhimurium induced increase in both basal and 
maximal OCR. ETX did not affect OCR in the LSKs from control animals 
(Figure 5.15A and B). 
 
 
Figure 5.15. LSKs have a decreased OCR following etomoxir and 
S.typhimurium infection.  
C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours and etomoxir 
(ETX). The bone marrow was extracted and stained with a panel of antibodies to 
isolate the LSK population by FACS. (A) The LSKs were treated with the β-oxidation 
inhibitor, ETX and oxygen consumption rate (OCR) levels were measured by 
extracellular flux assay. (B) Basal mitochondrial respiration (normalised to rotenone) 
of LSK cells from control and LPS treated animals with and without ETX. Maximal 
mitochondrial respiration LK cells from control and LPS treated animals with and 













































































Figure 5.16. LSKs have a decreased OCR following etomoxir and S. 
typhimurium infection. C57/BL6 ice were infected with S. typhi urium (Sal) for 
72h and Etomoxir (ETX). The bone marrow was extracted and stained with a panel 
of antibodies to isolate the LSK population by FACS. The LSKs were treated with 
the β-oxidation inhibitor, etom xir (ETX) and OXPHOS levels were m asured by 
OCR. (B) Basal mitochondrial respiration (norm lised t  rotenone) of LSK cells from 
control and LPS treated animals with and without ETX. Maximal mitochondrial 
respiration LK cells from control and LPS treated animals with and without ETX. 
Data shown are means ± SD of n>4 mice in each group. *P < 0.05
221 
 
To next determine if ETX inhibited the HSC response to LPS treatment 
C57BL/6J mice were pre-treated with ETX for 1 hour before 16 hours of LPS 
treatment. The mice were sacrificed, and the BM was analysed by flow 
cytometry (Figure 5.16A). ETX inhibited the LPS elicited increase in LSK, HSC 
and LT-HSC cell cycling (Figure 5.16B). ST-HSC cell cycling was not 
significantly reduced by ETX pre-treatment compared to LPS alone, however, 
there was a trend towards a decreased cell cycling (Figure 5.16B).  
 
 
Figure 5.16. Etomoxir inhibits increase in Ki67 positive cells after LPS 
treatment.  
(A) Schematic diagram of experimental design in which C57BL/6J mice were pre-
treated with etomoxir (ETX) for 1 hour before LPS treatment (16 hours). The BM was 
extracted, and the cells were analysed by flow cytometry for Ki67 staining in the LSK, 
HSC, ST-HSC and LT-HSC populations. (B) Percentage of cycling cells as measured 
by Ki67 positive cells after and ETX and LPS treatment. Data shown are means ± SD 























































ST- HSC LT- HSC
Figure 5.17. Etomoxir inhibits increase in cell cycling after LPS treatment (A) 
Schematic diagram of experimental design in which C57/BL6 mice were pretreated
with etomoxir (ETX) for 1 hour before LPS treatment (16 hours). The BM was 
extracted, and the cells were analysed by flow cytometry for LSK, HSC, ST-HSC 
and LT-HSC populations. (B) Percentage o f cycling cells as measured by Ki67 
positive cells after and ETX and LPS treatment. Data shown are means ± SD of 5 
mice in each group *p<0.05 **p<0.01.
222 
 
To determine whether ETX pre-treatment before LPS, had an effect on HSPC 
cell count, the BM was stained with a HSC antibody panel and cell number per 
100 000 BM cells was assessed by flow cytometry. Figure 5.17 confirms a 
significant increase in cell number of the LSK, HSC, ST-HSC and LT-HSC 
populations following LPS treatment. However, this increase in cell number 




Figure 5.17. Etomoxir inhibits cell number increase after LPS treatment.  
C57BL/6J mice were pre-treated with etomoxir (ETX) for 1 hour before LPS treatment 
(16 hours). The BM was extracted, and the cells were analysed for LSK, HSC, ST-
HSC and LT-HSC cell number by flow cytometry. Data shown are means ± SD of 5 
mice in each group *p<0.05 **p<0.01. 
 
Next, to understand the colony forming ability of the haematopoietic cells after 
ETX and LPS treatment, C57BL/6J mice were treated with control PBS, LPS 
alone or ETX and LPS for 16 hours. The animals were sacrificed, the BM was 
extracted, seeded in a semisolid Methocult for 7 days. Pre-treatment with ETX 
significant reduced expansion of the granulocyte monocyte progenitor 





























































Figure 5.18. Etomoxir inhibits cell number increase after LPS treatment 
C57/BL6 mice were pretreated with etomoxir (ETX) for 1 hour before LPS treatment 
(16 hours). The BM was extracted, and the cells were analysed for LSK, HSC, ST-
HSC and LT-HSC cell number by flow cytometry. Data shown are means ± SD of 5 




Figure 5.18. Etomoxir inhibits the LPS induced expansion of the 
granulocyte monocyte progenitor populations.  
C57BL/6J mice were pre-treated with etomoxir (ETX) for 1 hour before LPS treatment 
(16 hours), the animals were sacrificed, the bone marrow was extracted. 1 x 104 bone 
marrow cells were seeded in a semisolid Methocult for 7 days. Granulocytic 
progenitor (G), granulocyte monocyte progenitor (GM), and granulocyte monocyte 
megakaryocyte progenitor (GEMM) colonies were then counted. Data shown are 
means ± SD of n=5 in each group *P < 0.05 
 
 
ETX is an inhibitor of CPT1 which is located on the inner wall of the outer 
mitochondrial membrane (378). CPT1 is an enzyme responsible for acyl 
carnitines formation which is vital for the transportation of fatty acyl chains from 
the cytosol into the mitochondria, a step which is crucial for FAO (379). 
Therefore, I next confirmed CPT1A expression was increased on the HSC 
following LPS treatment. C57BL/6J mice were treated with LPS for 16 hours, 
the mice were sacrificed, and the HSC population was isolated by FACS. 
Figure 5.19 shows that HSC from LPS treated mice have a significantly 
increased expression of CPT1A compared to HSCs from control mice.  
 
 
Figure 5.19. Etomoxir inhibits the LPS induced expansion of the granulocyte 
monocyte progenitor populations. C57/BL6 mice were pre-treated with etomoxir 
(ETX) for 1 hour before LPS treatment (16 hours), the animals were sacrificed, the 
bone marrow was extracted. 1 x 104 bone marrow cells were seeded in a semisolid 
Methocult for 7 days. Granulocytic progenitor (G), granulocyte monocyte progenitor 
(GM), and granulocyte monocyte megakaryocyte progenitor (GEMM) colonies were 


















Figure 5.19. CPT1A is upregulated in the HSC at 16 hours post LPS 
treatment.  
C57BL/6J mice were treated with LPS for 16 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to isolate the HSC 
population by FACS. RNA was analysed for CPT1A gene expression by qPCR. n=5 
in each group. Data shown are means ± SD *P < 0.05 
 
ETX has previously been reported to have off-target effects, when used at high 
concentrations. These off target effects include inhibition of complex 1 in the 
mitochondria (380) and induction of severe oxidative stress (381) which could 
have an effect on the HSC response to infection. Therefore, to investigate the 
specific function of CPT1A in the haematopoietic compartment following LPS 
treatment, LK cells were isolated from WT CD45.1 mice and transduced with 
control KD (LK (con KD)) or CPT1A KD (LKCPT1A KD) (Figure 5.20A). Figure 5.20B 
confirms CPT1A was successfully knocked down on average by 70% in the 
LKCPT1A KD. The LKCPT1A KD cells were then transplanted into WT CD45.2 mice 
and 14-weeks post transplantation the animals were treated with LPS for 16 
hours (Figure 5.20A). The mice were then sacrificed, the BM was extracted, 
and stained with CD45.1 PE to monitor engraftment. Figure 5.20C confirms 
equal engraftment of CD45.1 cells in recipient CD45.2 mice within both 
treatment groups.  
Figure 5.20 CPT1A is upregulated in the HSC at 16 hours post LPS treatment. 
C57BL/6 ice were treated with LPS for 16 hours, the animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to isolate the 
HSC population by FACS. RNA was analysed for CPT1A gene expression by 






















Figure 5.20. CD45.1 engraftment is seen in the bone marrow of transplant 
mice.  
(A) Schematic diagram of the experimental design, CD45.1 lineage negative, CD117 
positive (LK) cells were transduced with a CPT1A knockdown lentivirus (LKCPT1A KD) 
and transplanted into CD45.2 animals. Post engraftment mice were treated with LPS 
for 16 hours and the bone marrow assessed by flow cytometry. (B) Relative CPT1A 
expression in control knockdown (conKD) and CPT1A knockdown (CPT1AKD) LK 
cells before transplantation. (C) 16 hours post LPS treatment the animals were 
sacrificed, and the BM was extracted, the cells were analysed by flow cytometry for 
CD45.1 expression to confirm engraftment. Data shown are means ± SD of >4 mice 
in each group.  
 
In addition to engraftment the BM was also stained with a panel of antibodies, 
permeabilised and fixed to assess HSPC cycling by flow cytometry. The gating 
strategy to identify cell cycling in the specific cell populations of interest is 

















































Figure 5.21. CD45.1 engraftment is seen in the bone marrow of transplant 
mice. (A) Schematic diagram of the experime tal design, CD45.1 lineage negative, 
kit positiv  (LK) cells were transduced with a CPT1A knock down lentivirus (LKCPT1A 
KD) and transplanted into CD45.2 animals. Post engraftment mice were treated with 
LPS for 16 hours and the bone marrow assessed by flow cytometry. (B) Relative 
CPT1A expres io  in control knockdown (conKD) and CPT1A knockdown 
(CPT1AKD) LK cells before transplantation. (C) 16 hours post LPS treatment the 
animals were sacrificed, and the BM was extracted, the cells were analyzed by flow 
cytometry for CD45.1 expression to confirm engraftment. Data shown are means ±
SD of >4 mice in each group. 
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one controls. Figure 5.21B and C shows there was no change in LSK and HSC 
cell cycling in the LKCPT1A KD transplant animals in response to LPS.  
 
 
Figure 5.21. Ki67 positive cells increase following LPS treatment is 
inhibited in the CPT1AKD HSC.  
CD45.1 lineage negative, CD117 positive (LK) cells were transduced with a CPT1A 
knockdown lentivirus (LKCPT1A KD) and transplanted into CD45.2 animals. Post 
engraftment mice were treated with LPS for 16 hours and the bone marrow assessed 
by flow cytometry for percentage of Ki67 positive cells. (A) The gating strategy used 
is shown. (B) Representative histogram plot of Ki67-FITC expression in the LSK and 
HSC population. (C) Percentage of cycling cells as measured by Ki67 positive cells. 
Data shown are means ± SD of >4 mice in each group.  
 
There was also no observed increase in LSK, HSC, ST-HSC and LT-HSC 
count per BM 100 000 cells in the LPS treated LKCPT1A KD transplant animals 


























































Figure 5.22. CPT1AKD HSC inhibits cell number increase after LPS 
treatment.  
CD45.1 lineage negative, CD117 positive (LK) cells were transduced with a CPT1A 
knockdown lentivirus (LKCPT1A KD) and transplanted into CD45.2 animals. Post 
engraftment mice were treated with LPS for 16 hours and the bone marrow assessed 
by flow cytometry for cell number per 100 000 cells. Data shown are means ± SD of 
>4 mice in each group.  
 
To ensure the CPT1A KD did not affect lipid transport into the cell the BM was 
stained with a panel of antibodies and Bodipy 493/503. Lipid content was 
significantly increased in the LSK, HSC, ST-HSC and LT-HSC of the LKCPT1A 
KD transplant mice following LPS treatment (Figure 5.23). Together, these 
results demonstrate HSCs have an increased dependency on β-oxidation for 




Figure 5.23. CPT1AKD does not inhibit lipid content increase after LPS 
treatment.  
CD45.1 lineage negative, CD117 positive (LK) cells were transduced with a CPT1A 
knockdown lentivirus (LKCPT1A KD) and transplanted into CD45.2 animals. Post 
engraftment mice were treated with LPS for 16 hours. The bone marrow was 
extracted and stained with a panel of antibodies and Bodipy 493/503 to analyse lipid 
content (Bodipy 493/503 mean fluorescence intensity (MFI)) in specific LSK, HSC, 
ST-HSC and LT-HSC populations. Data shown are means ± SD of >4 mice in each 
group *p<0.05  
 
Figure 4.48. Bone marrow  macrophages coordinates HSCs expansion  
in response to infection. C57BL/6 mice were injected with clodronate liposomes 
for 3 days prior o S.typhimurium infecti n for 72 h urs. The mice 
































Figure 5.23. CPT1AKD HSC inhibits cell number increase after LPS treatment 
CD45.1 lineage negative, kit positive (LK) cells were transduced with a CPT1A 
knock down lentivirus (LKCPT1A KD) and transplanted into CD45.2 animals. Post 
engraftment ice wer  treated with LPS for 16 hours and the bone marrow 
assessed by flow cytometry for cell number per 100 000 cells. Data shown are 






























Figure 5.24. CPT1AKD does not inhibit lipid content increase after LPS 
treatment CD45.1 lineage negative, kit positive (LK) cells were transduced with a 
CPT1A knock down lentivirus (LKCPT1A KD) and transplanted into CD45.2 animals. 
Post engraftment mice were treated with LPS for 16 hours. The BM was extracted
and stained with a panel of antibodies and Bodipy 493/503 to analyse lipid content 
(Bodipy 493/503 mean fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC 






5.4 CD36 regulates uptake of long chain free fatty acid by the HSC in 
response to infection 
 
I next examined the mechanism regulating the uptake of FFA to the HSC in 
response to infection. Numerous membrane proteins have been shown to be 
associated with lipid uptake including fatty acid-binding proteins (FABPs), fatty 
acid transport proteins (FATPs) which are also known as solute carrier 27 
(SLC27). To investigate how FAs are transported into the HSC following LPS 
treatment  or S.typhimurium infection, I assessed the gene expression of 
several membrane proteins known to be involved with lipid trafficking (262). 
Figure 5.24 shows that mRNA expression of the lipid transporters CD36, 
Slc27a2, Slc27a4 and Fabp3 were all upregulated in the HSCs isolated from 
LPS (2 and 16 hours) or S.typhimurium (72 hours) treated animals compared 
to control HSCs. There was no change in the expression of Slc27a5, Fabp1, 
Fabp4 and LDLR in the HSC from LPS or S.typhimurium infected mice. HSC 
expression of Slc27a1, Fabp5 and Msr1 were downregulated following LPS or 




Figure 5.24. Fatty acid transporter genes expression in HSC in response 
to S.typhimurium  infection or LPS treatment.   
C57BL/6J mice were treated with S.typhimurium  (72 hours) or LPS for 2 or 16 hours, 
the animals were sacrificed, the bone marrow was extracted and stained with a panel 
of antibodies to isolate the HSC population by FACS. RNA was analysed for gene 














































Figure 5.25. Fatty acid transporter genes expression in response to 
S.typhimurium and  LPS stimulation in the HSC. C57BL/6J mice were treated 
with ofS.typhimurium (72 hours) LPS for 2 or 16 hours, the animals were 
sacrificed, the bone marrow was extracted and stained ith  panel of antibodies 
to isolate the HSC population by FACS. RNA was analysed for gene expression 
of fatty acid transporter genes by qPCR. n=5 in each group. 
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It has previously been shown, the LSCs take up FFA to support increased 
proliferation. Furthermore, LSCs expressing the fatty acid transporter CD36 
demonstrated high levels of fatty acid oxidation, providing those LSCs with a 
survival advantage (17). Therefore, I focused on CD36 expression and 
function in the HSC. To confirm CD36 expression was elevated during 
infection C57BL/6J mice were infected with S.typhimurium for 72 hours or LPS 
for 16 hours and assessed for CD36 by flow cytometry. Increased protein 
expression of CD36 was observed in the LSK, HSC, ST-HSC and LT-HSC 
from both S.typhimurium and LPS treated mice compared to the control mice 
(Figure 5.25A and B). Although still elevated CD36 protein expression (Figure 
5.25) was not as significantly elevated compared to the mRNA expression of 
CD36 (Figure 5.24). One possible explanation for this difference is that levels 
of mRNA expression do not always translate to protein expression. This may 
be because of timing of the experiments or the fact I am just observing the 










Figure 5.25. CD36 expression in the HSC is elevated after S.typhimurium 
infection or LPS treatment.   
(A) C57BL/6J mice were infected with S.typhimurium (Sal) for 72 hours, the animals 
were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to analyse CD36 expression in specific LSK, HSC, ST-HSC and LT-HSC 
populations. n=6 in each group. (B) C57BL/6J mice were treated with 1 mg/kg LPS 
for 16 hours, the animals were sacrificed, the bone marrow was extracted stained 
with a panel of antibodies to analyse CD36 expression in specific populations n=5 in 
each group. Data shown are means ± SD *P < 0.05 **p<0.01. 
 
 
To test the importance the role of CD36 in FFA uptake and the impact on HSC 
expansion following infection, C57BL/6J mice were pre-treated with the CD36 
inhibitor sulfosuccinimidyl oleate (SSO) for 1 hour before LPS treatment for 16 
hours (Figure 5.26A). Figure 5.26B confirms CD36 expression was inhibited 
in the LPS and SSO treated mice compared to LPS alone.  
 
Figure 5.26. CD36 expression in the HSC is elevated after 
S.typhimurium and LPS infection (A) C57BL/6J mice were infected with S. 
typhimurium (Sal) for 72 h, the animals were sacrificed, the bone marrow was 
extracted and stained with a panel of antibodies to analyse CD36 expression in 
specific LSK, HSC, ST-HSC and LT-HSC population . n=6 in each group. (B) 
C57BL/6J mice were treated with 1mg/kg LPS for 16 hours, the animals were 
sacrificed, the bone marrow was extracted stained with a panel of antibodies to 
analyse CD36 expression in specific populations n=5 in each group. Data shown 






































































Figure 5.26. Sulfosuccinimidyl oleate inhibits CD36 expression increase 
after LPS treatment.  
(A) Schematic of experimental design. C57BL/6J mice were pre-treated with 40 mg/kg 
sulfosuccinimidyl oleate (SSO) for 1 hour before treatment with 1 mg/kg LPS for 16 
hours. The animals were sacrificed, the bone marrow was extracted stained with a 
panel of HSC antibodies. (B) CD36 expression (CD36 mean fluorescence intensity 
(MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in each group. 
Data shown are means ± SD *P < 0.05 **P < 0.01 
 
 
I next examined the consequence of CD36 inhibition on lipid content in the 
HSPCs following infection. SSO pre-treatment inhibited the LPS elicited 
increase in lipid content within the HSC, ST-HSC and LT-HSC populations 
(Figure 5.27). In the LSK population lipid content was not significantly reduced 
by SSO pre-treatment compared to LPS alone, however, there was a trend 





























































Figure 5.27. Sulfosuccinimidyl oleate inhibits CD36 expression increase 
after LPS treatment (A) Schematic of exp rimental design. C57BL/6J mice 
were pre-treated wi h Sulfosuccinimidyl oleate (SSO) for 1 hour before treatment 
with 1mg/kg LPS for 16 hours. The animals were sacrificed, the bone marrow 
was extracted stained with a panel of HSC antibodies. (B) CD36 expression 
(CD36 MFI) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in each 




Figure 5.27. Sulfosuccinimidyl oleate inhibits LPS induced increase in 
lipid content in the HSC.  
C57BL/6J mice were pre-treated with 40 mg/kg sulfosuccinimidyl oleate (SSO) for 1 
hour before treatment with 1mg/kg LPS for 16 hours. The animals were sacrificed, 
the bone marrow was extracted stained with a panel of HSC antibodies and Bodipy 
493/503 to analyse lipid content (Bodipy 493/503 mean fluorescence intensity (MFI)) 
in specific LSK, HSC, ST-HSC and LT-HSC populations. n=5 in each group. Data 
shown are means ± SD *P < 0.05 
 
 
To assess if the decrease in lipid content in the HSPCs from the LPS and SSO 
treated animals was due to a decrease in FA uptake into the cells, the LK 
population was isolated and incubated with Bodipy FL-C12 for 30 minutes. 
There was a reduced FFA uptake observed in the LK cells from LPS and SSO 






































































Figure 5.28. Sulfosuccinimidyl oleate inhibits LPS induced increase in lipid 
content in the HSC. C57BL/6J mice were pre-treated with Sulfosuccinimidyl
oleate (SSO) for 1 hour befor  reatment with 1mg/kg LPS for 16 hours. The 
animals were sacrificed, the bone marrow was extracted stained with a panel of 
HSC antibodies and Bodipy 493/503 to analyse lipid content (Bodipy 493/503 
mean fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC 




Figure 5.28. Sulfosuccinimidyl oleate inhibits LPS induced fatty acid 
uptake into the LK cells.  
C57BL/6J mice were pre-treated with 40 mg/kg sulfosuccinimidyl oleate (SSO) for 1 
hour before treatment with 1 mg/kg LPS for 16 hours. The animals were sacrificed, 
the bone marrow and LK cells were isolated. The LK cells were incubated with Bodipy 
FL-C12 and fluorescence was measured. n=5 in each group Data shown are means 
± SD *P< 0.05 
 
I next determined if the SSO induced reduction in lipid uptake and subsequent 
lipid content within the HSPCs following LPS treatment had an effect on cell 
cycling. Figure 5.29A shows LSK, HSC, ST-HSC, and LT-HSC cell cycling 
were all significantly reduced in the SSO and LPS treated animals compared 
to LPS alone. 
 
 
Figure 5.29. Sulfosuccinimidyl oleate inhibits Ki67 positive cell 
expression in the HSC after LPS treatment.  
C57BL/6J mice were pre-treated with 40 mg/kg sulfosuccinimidyl oleate (SSO) for 1 
hour before treatment with 1 mg/kg LPS for 16 hours. The animals were sacrificed, 
the bone marrow was extracted stained with a panel of HSC antibodies and Ki67 to 
analyse cell cycling. Percentage of cycling cells was measured by Ki67 positive cells 
























Figure 5.29. Sulfosuccinimidyl oleate inhibits LPS induced fatty acid uptake 
into the K cells. C57BL/6J mice were pre-treated with Sulfosuccinimidyl
oleate (SSO) for 1 hour before treatment with 1mg/kg LPS for 16 hours. The 
animals were sacrificed, the bone marrow and LK cells were isolated. The LK 
cells were incubated with Bodipy FL-C12 and fluorescence was measured. n=5 
in each group Data shown are means ± SD  *P < 0.05










































Figure 5.30. Sulfosuccinimidyl oleate inhibits cell cycling in the HSC after 
LPS treatment C57BL/6J mice were pre-treated with Sulfosuccinimidyl
oleate (SSO) for 1 hour before treatment with 1mg/kg LPS for 16 hours. The 
animals were s crificed, the bone marrow was extracted st ined with a panel of 
HSC antibodies and Ki67 to analyse cell cycling. Percentage of cycling cells was  
measured by Ki67 positive cells after LPS and SSO treatment. n=5 in each 
group. Data shown are means ± SD  *P < 0.05
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To examine if the decrease in cell cycling was correlated with a decrease in 
cell number, I examined the cell count per 100 000 BM cells after SSO and 
LPS. As previously ovserved, the LPS treated animals had a significant 
increase in LSK, HSC, ST-HSC and LT-HSC cell number. However, in the 
SSO and LPS treated mice there was no change in HSPC cell count compared 
to the control (Figure 5.30).  
 
 
Figure 5.30. Sulfosuccinimidyl oleate inhibits increase in HSC cell count 
after LPS treatment.  
C57BL/6J mice were pre-treated with 40 mg/kg sulfosuccinimidyl oleate (SSO) for 1 
hour before treatment with 1 mg/kg LPS for 16 hours. The animals were sacrificed, 
the bone marrow was extracted assessed by flow cytometry for cell number per 100 
000 cells. n=5 in each group. Data shown are means ± SD *P < 0.05 
 
Next, to establish the role of FA uptake on OCR, the LSKs from control, LPS 
alone and SSO and LPS treatment mice were isolated by FACS. Seahorse XF 
Mito stress test analysis showed pre-treatment with SSO inhibited the LPS 
induced increase basal and maximal OCR but did not affect the control cells 
(Figure 5.31A and B).  However, in this experiment the basal respiration was 
very low and not consistent with multiple previous experiments in the control 
and LPS treated LSKs. Moreover, the oligomycin was not observed to 
decrease OCR which is an expected respiration dynamic due to ATP synthase 
inhibition. This could be due to the wrong oligomycin concentration in the 
assay or the length of time the LSKs took to sort from the BM for the assay 
therefore, these results are not reliable.  
 




































Figure 5.31. Sulfosuccinimidyl oleate inhibits increase in HSC cell count 
after LPS treatment C57BL/6J mice were pre-treated with Sulfosuccinimidyl
oleate (SSO) for 1 hour before treatment with 1mg/kg LPS for 16 hours. The 
animals were sacrificed, the bone marrow was extracted assessed by flow 
cytometry for cell number per 100 000 cells n=5 in each group. Data shown are 




Figure 5.31. LSKs have a reduced OCR following SSO and LPS treatment.  
C57BL/6J mice were pre-treated with 40 mg/kg sulfosuccinimidyl oleate (SSO) for 1 
hour before treatment with 1 mg/kg LPS for 16 hours. The animals were sacrificed, 
the bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK population by FACS and oxygen consumption rate (OCR) levels were measured 
by  extracellular flux assay. (B) Basal (normalised to rotenone) and maximal 
mitochondrial respiration of LSK cells from control, LPS or LPS and SSO treated 
animals. Data shown are means ± SD of n=5 mice in each group. **P < 0.01 
 
 
To confirm the effects of pharmacological inhibition of CD36 in response to 
infection was consistent with genetic knockout of CD36 we used CD36 
deficient mice (CD36-/-). CD36-/- mice or WT CD36+/+ mice were treated with 
LPS for 16 hours (Figure 5.32A). LPS treated WT CD36+/+ animals had a 
significant increase in lipid content in the LSK, HSC, ST-HSC, and LT-HSC 
compared to the control mice (Figure 5.32B). However, there was no observed 
increase in lipid levels in the LPS treated CD36-/- mice compared to baseline 
control CD36-/- mice (Figure 5.32B).  
 
 





























































Figur 5.32. LSKs have a reduced OCR following SSO and LPS treatment. 
C57BL/6J mice were pre-treated wit  Sulfosuccinimidyl ole te (SSO) for 1 hour 
before treatment with 1mg/kg LPS for 16 hours. The animals were sacrificed, the 
bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK populati  by FACS and OXPHOS levels were measured by OCR. (B) Basal 
(normalised to rot none) and maximal mitochondrial respiration of LSK cells from 
control, LPS or LPS and SSO treated animals Data shown are means ± SD of n=5 





Figure 5.32. CD36-/- mice have reduced lipid content after LPS treatment.  
(A) Schematic of experimental design. CD36-/- or WT (CD36+/+) mice were treated 
with 1 mg/kg LPS for 16 hours, the animals were sacrificed, the bone marrow was 
extracted stained with a panel of antibodies and Bodipy 493/503 (B) Lipid content 
(Bodipy 493/503 mean fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC 
























































































































Figure 5.33. CD36KO mice h v  reduced lipid content aft r LPS tr atment 
(A) Schematic of experimental design. CD36 knock out mice (CD36-/-) or WT 
(CD36+/+) mice were treated with 1mg/kg LPS for 16 hours, the animals were 
sacrificed, the bone marrow was extracted stained with a panel of antibodies  
and Bodipy 493/503 MFI. (B) Lipid content (Bodipy 493/503 mean fluorescence 
intensity (MFI)) in specific LSK, HSC, ST-HSC and LT-HSC populations n=5 in 
each group. Data shown are means ± SD  *P < 0.05
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Unlike the WT CD36+/+ animals, LK cells from LPS treated CD36-/- mice did 
not have an increased lipid uptake compared to LK cells from control CD36-/- 




Figure 5.33. CD36-/- mice have reduced fatty acid uptake into the LK cells 
after LPS treatment.  
CD36-/- or WT (CD36+/+) mice were treated with 1 mg/kg LPS for 16 hours. The 
animals were sacrificed, the bone marrow and LK cells were isolated. The LK cells 
were incubated with Bodipy FL-C12 and fluorescence was measured. n=5 in each 
group Data shown are means ± SD *P < 0.05 
 
 
Figure 5.34 shows there was no change in LSK, HSC, ST-HSC, and LT-HSC 
cell cycling in the CD36-/- mice treated with LPS compared to control untreated 
CD36-/- mice. In contrast, LPS treated WT CD36+/+ animals had a significant 






























Figure 5.34. CD36KO ice have reduced fatty acid uptake into the LK cells 
after LPS treatment CD36 knock out mice (CD36-/-) or WT (CD36+/+) mice 
were treated with 1mg/kg LPS for 16 hours. The animals were sacrificed, the 
bone marrow and LK cells ere isolated. The LK cells were incubated with 
Bodipy FL-C12 and fluorescence was measured. n=5 in each group Data shown 




Figure 5.34. CD36-/- mice have reduced HSC cell cycling after LPS 
treatment.  
CD36-/- or WT (CD36+/+) mice were treated with 1 mg/kg LPS for 16 hours. The 
animals were sacrificed, the bone marrow was extracted stained with a panel of HSC 
antibodies and Ki67 to analyse cell cycling in the LSK, HSC, ST-HSC and LT-HSC 
population. Percentage of cycling cells was measured by Ki67 positive cells after LPS 
treatment. n=5 in each group. Data shown are means ± SD *P < 0.05 
 
 
To monitor the contribution of FAO or β-oxidation in maintaining basal 
metabolism in CD36-/- mice I used the Seahorse XF Mito Fuel Flex Test. CD36-
/- mice were treated with LPS for 16 hours, the mice were sacrificed and the 
LSK were isolated from the BM by FACS. Figure 5.35 shows, LSK from LPS 
treated CD36-/- mice have no change in dependency on FAO as a source of 
energy compared to LSKs from control CD36-/- mice. Moreover, the 
dependency on FAO as a source of energy in CD36-/- mice is lower than the 













































































































Figure 5.35. CD36KO mice have reduced HSC cell cycling after LPS 
treatment CD36 kno k out mic  (CD36-/-) o  WT (CD36+/+) mice were treated 
with 1mg/kg LPS for 16 hours. The animals were sacrificed, the bone marrow 
was extracted stained with a panel of HSC antibodies and Ki67 to analyse cell 
cycling in the LSK, HSC, ST-HSC and LT-HSC population. Percentage of cycling 
cells was measured by Ki67 positive cells after LPS treatment. n=5 in each 




Figure 5.35. CD36-/- mice have a low dependency on fatty acid oxidation 
in the LSK population.  
CD36-/- were treated with LPS for 16 hours, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to isolate the LSK 
population by FACS. The LSK population was analysed for the reliance on fatty acids 
to maintain baseline respiration. n=5 in each group. Data shown are means ± SD 
 
 
Next, to confirm FFA uptake was impaired in the CD36-/- mice following LPS 
treatment was specific to the HSPC compartment I used the transplant model 
to track real time fatty acid uptake in vivo. CD36-/- CD45.2 LK cells were 
isolated and transduced with a firefly luciferase virus (CD36-/- LK+FF). The cells 
were then transplanted into busulfan treated PepCboy CD45.1 animals (Figure 
5.36A). Engraftment and transduction of the CD36-/- LK+FF cells were 
monitored using D-luciferin by in vivo bioluminescent imaging (Figure 5.36B). 
14 weeks post transplantation the CD36-/- LK+FF engrafted CD45.1 animals 
were injected with FFA-luc (Figure 5.36C and D). One-week later, after the 
mice had recovered the animals were injected with LPS for 16 hours. Following 
LPS treatment, there was no activation of luciferase in the BM compartment 
signifying long chain FFA are not taken up by CD36-/- haematopoietic cells in 




































Figure 5.36. CD36KO mice have dependency n fatty acid oxidation in the LSK 
population. CD36 knock out mice (CD36-/-) were treated with LPS for 16 hours, the 
animals were sacrificed, the bone marrow was extracted and stained with a panel of 
antibodies to isolate the LSK population by FACS. The LSK population was 
analysed for the reliance on fatty acids to maintain baseline respiration. n=5 in each 




Figure 5.36. Treatment with LPS does not drives fatty acid uptake in the 
haematopoietic compartment of CD36-/- mice.  
(A) Schematic diagram of the experimental design. CD36-/- lineage negative, CD117 
positive (LK) cells were isolated and transduced with a firefly luciferase virus (LK+FF) 
and transplanted into WT (CD36+/+) CD45.2 animals. (B) Mice were bioluminescence 
imaged using luciferin to confirm engraftment. (C) Mice were injected with control 
PBS for 16 hours then treated with FFA-SS-luc and imaged using bioluminescence 
(FFA-luciferin). One-week later mice were injected LPS for 16 hours then treated with 
FFA-SS-luc and imaged using bioluminescence (FFA-luciferin+LPS). Representative 
images of control and LPS treated mice. (D) Densitometry of the bioluminescent 
images in (C) to determine fluorescence intensity in vehicle and LPS treated animals. 




































































To test the importance of CD36 in FFA uptake following S.typhimurium 
infection, WT CD36+/+ and CD36-/- were infected with S.typhimurium for 72 
hours (Figure 3.37A). Figure 5.37B confirms lipid levels were significantly 
increased in the WT CD36+/+ LSK, HSC, ST-HSC and LT-HSC following 
S.typhimurium infection. Surprisingly LSK, HSC, and ST-HSC from 
S.typhimurium treated CD36-/- mice also had an increase in lipid content 
compared to control mice (Figure 5.37B). CD36 regulates the uptake of long 
chain FAs, it is expected following infection cells take up long chain FAs as 
they are more efficient energy source compare to short or medium chain FAs. 
Bodipy 493/503 staining is a measure of total lipid content in the cell therefore, 
the increase in lipid content observed in the could be due to an abundance of 
short or medium chain FAs. There was no difference in LT-HSC lipid levels 









Figure 5.37. Lipid content is elevated in the CD36-/- HSC after 
S.typhimurium infection.  
(A) Schematic of experimental design. CD36-/- or WT (CD36+/+) mice were infected 
with S.typhimurium (Sal) for 72 hours, the animals were sacrificed, the bone marrow 
was extracted stained with a panel of antibodies and Bodipy 493/503. (B) Lipid 
content (Bodipy 493/503 mean fluorescence intensity (MFI)) in specific LSK, HSC, 
ST-HSC and LT-HSC populations n=6 in each group. Data shown are means ± SD 
*P < 0.05 
 
Next, to visualise uptake of FFA within the LK cells following infection, LK cells 
isolated from the BM of control or S. typhimurium infected (72 hours) WT 
CD36+/+ and CD36-/- mice. The cells were stained with Bodipy 493/503, 
Hoechst 33342 and Sca 1-APC membrane stain for 30 minutes and imaged 
using fluorescence microscopy (Figure 5.38A). LK cells positive for Sca 1-APC 
membrane stain were classified as LSKs. LSK cells from S. typhimurium 
















































































































































































Figure 5.38. Lipid content is elevated in the HSC after S. typhimurium
infection (A) Schematic of exp rimental design. CD36 knock out mice (CD36-/-) 
or WT (CD36+/+) mice were were infected with S. typhimurium (Sal) for 72 
hours, the animals were sacrificed, the bone marrow was extracted stained with 
a panel of antibodies  and Bodipy 493/503 MFI. (B) Lipid co tent (Bodipy
493/503 mean fluorescence intensity (MFI)) in specific LSK, HSC, ST-HSC and 
LT-HSC populations n=6 in each group. Data shown are means ± SD  *P < 0.05
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493/503 fluorescence (Figure 5.38B). However, LSK cells from CD36-/- mice 
infected with S. typhimurium had a significantly reduced lipid content 
compared to control mice (Figure 5.38B). 
 
 
Figure 5.38. Infection with S.typhimurium does not drive fatty acid uptake 
in the LSK of CD36-/- mice.  
CD36-/- or WT (CD36+/+) mice were infected with S.typhimurium (Sal) for 72 hours. (A) 
Representative live cell fluorescent microscopy images of LK cells isolated from the 
mice, Sca 1-APC membrane stain (red), Bodipy 493/503 (green) and Hoechst 33342 
(blue). Data shown are means ± SD of n=5 mice. (B) Quantification of Bodipy 493/503 
fluorescence in LK cells from images shown, 20 LK cells from each mouse in each 
condition. Data shown are means ± SD *P < 0.05 
 
To understand the importance of CD36 expression on HSPC metabolism in 
response to infection, LSK from CD36+/+ and CD36-/- S.typhimurium infected 
mice were isolated by FACS. Seahorse XF Mito stress test analysis showed, 
in contrast to WT CD36+/+, CD36-/- LSKs from S.typhimurium infected mice 
have no change in basal or maximal OCR compared to CD36-/- LSKs from 
control mice (Figure 5.39A and B).  
CD36-/- con CD36-/-Sal































Figure 5.39. Infection with S. typhimurium does not drive fatty acid uptake 
in the LKS of CD36 knock out mice. CD36 knock out ice (CD36-/-) or WT 
(CD36+/+) mice wer  were inf cted with S. typhimurium (Sal) f r 72 hours. (A) 
Representative live cell fluorescent microscopy images of LK cells isolated from 
the mice, red-Sca1 membrane stain, green-Bodipy 493/503 and blue Hoechst 
33342. Data shown are means ± SD of n=5 mice. (B) Quantification of Bodipy
493/503 fluorescence in LK cells from images shown, 20 LK cells from each 




Figure 5.39. LSK from CD36-/- mice do not have increased OCR after 
S.typhimurium infection.  
(A) CD36-/- or WT (CD36+/+) mice were infected with S.typhimurium (Sal) for 72 hours. 
The bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK population by FACS and OCR levels were measured by the extracellular flux 
assay. (B) Basal mitochondrial respiration (normalised to rotenone) and maximal 
mitochondrial respiration of LSK cells from control and S. typhimurium treated 
animals. Data shown are means ± SD of n=6 mice in each group. *P < 0.05 
 
To assess the changes in glycolysis in the WT CD36+/+ and CD36-/- mice after 
S.typhimurium (72 hours) infection I used the extracellular flux assay to 
analyse ECAR (Figure 5.40A). In the WT CD36+/+ mice there was an increase 
in basal OCR but was no observed increase in basal glycolysis (ECAR) 
following S. typhimurium (72 hours) infection (Figure 5.40B). Conversely, 
CD36-/- LSK have increased basal ECAR but no changes in basal OCR 
response to S.typhimurium infection (Figure 5.40B). Together, these data 
show that CD36 is essential for the uptake of FFA and subsequent cell cycling 























































































Figure 5.40. LSK from CD36 knock out mice do not have increased OCR 
after S. typhimurium infection. (A)CD36 knock out mice (CD36-/-) or WT 
(CD36+/+ mice were were infected with S. typhimurium (Sal) f r 72 hours. The 
bone marrow was extracted and stained with a panel of antibodies to isolat  the 
LSK population by FACS and OXPHOS levels were measured by OCR. (B) 
Basal mitochondrial respiration (normalised to rotenone) and maximal 
mitochondrial respiration of LSK cells from control and S. typhimurium treated 




Figure 5.40. LSK from CD36-/- mice have an increased reliance on 
glycolysis after S.typhimurium infection.  
(A) CD36-/- or WT (CD36+/+) mice were infected with S.typhimurium (Sal) for 72 hours. 
The bone marrow was extracted and stained with a panel of antibodies to isolate the 
LSK population by FACS. ECAR was measured by the extracellular flux assay. (B) 
Basal OCR (normalised to rotenone) vs Basal ECAR of CD36-/- and CD36+/+ LSKs 
after S. typhimurium infection. Data shown are means ± SD of n=6 mice in each 
group.  
 
Next, to understand the importance of CD36 specifically in the haematopoietic 
compartment in response to infection, I used a transplantation model. LK cells 
from WT CD36+/+ (CD45.2) mice were isolated and transplanted into recipient 
WT (CD45.1) animals, these were termed WT(CD36+/+). LK cells were also 
isolated from CD36-/- (CD45.2) mice and transplanted into recipient WT 
(CD45.1) animals, these were termed WT(CD36-/-). 14 weeks post 
transplantation WT(CD36+/+) and WT(CD36-/-) were infected with S. typhimurium 
for 4 days (Figure 5.41). The longer time point was chosen to assess the 
differences in the severity of the infection between the WT(-/-CD36) and the 






















































Figure 5.41. LSK fro  CD36 knock out mice have an increased reliance on 
glycolysis after S. typhimurium infection. (A) CD36 knock out mice (CD36-/-) 
or WT (CD36+/+) mice were were infected with S. typhimurium (Sal) for 72 
hours. The bone marrow was extracted and stained with a panel of antibodies to 
isolate the LSK population by FACS. Glycolysis levels were measured by ECAR. 
(B) Basal OCR (normalised to rotenone) vs Basal ECAR of CD36-/- and 
CD36+/+ LSKs aft r S. typhimurium infection. Data shown are means ± SD of 
n=6 mice in each group. 
























Figure 5.41. Schematic of experimental design.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT(+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S. typhimurium for 96 hours.  
 
WT(-/-CD36) transplanted animals infected with S. typhimurium had a 
significantly increased weight loss compared to WT(+/+CD36) transplanted 
animals, a hallmark of more advanced S. typhimurium infection (Figure 5.42A). 
WT(-/-CD36) also had enhanced mortality compared to WT(+/+CD36) transplanted 
animals (4.42B). 
 
Figure 5.42. WT(-/-CD36) mice have increased weight loss and increased 
susceptibility to S.typhimurium infection.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT(+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S.typhimurium for 96 hours. (A) Percentage 
weight loss at 96 hours post S.typhimurium infection. (B) Kaplan-Meier survival curve. 











Figure 5.42. Schematic of experimental design . CD36+/+ CD45.2 or CD36-/-
CD45.2 lineage negative, kit positive cells were isolated and transplanted into 
WT CD45.1 a im ls WT(+/+CD36) or  WT(-/-CD36). Post engraftment mice were 
treated with S. typhimurium for 96 hours. 




























Figure 5.43. WT(-/-CD36) mice have increased weight loss and increased 
susceptibility to S. ty himurium infection. CD36+/+ CD45.2  CD36-/- CD45.2 
lineage egative, kit positive cells were isolated and transplanted into WT
CD45.1 animals WT(+/+CD36) or  WT(-/-CD36). Post engraftment mice were treated 
with S. typhimurium for 96 hours. (A) Percentage weight loss at 96 hours post S. 
typhimurium infection. (B) Kaplan-Meier survival curve. n>5 in each group. Data 
shown are means ± SD  *P < 0.05
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To determine engraftment mice were sacrificed, the BM was extracted and 
stained with CD45.2 FITC for flow cytometry analysis. Figure 5.43 confirms 
equal engraftment of WT CD36+/+ (CD45.2) and CD36-/- (CD45.2) into WT 
CD45.1 mice.  
 
 
Figure 5.43. CD45.2 cell engraftment is seen in the bone marrow of 
transplant mice.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT(+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S.typhimurium. 96 hours post S. typhimurium 
treatment the animals were sacrificed, and the BM was extracted, the cells were 
analysed by flow cytometry for CD45.1 expression to confirm engraftment. n>5 in 




Following 96 hours of S.typhimurium infection blood was taken from the 
WT(+/+CD36) and WT(-/-CD36) mice. The serum was isolated and assessed for 
levels of FFA. Figure 5.44 shows there was an increase in serum FFA levels 
from S.typhimurium treated WT(-/-CD36) mice compared to S.typhimurium 





















Figure 5.44. CD45.2 cell engraftment is seen in the bone marrow of 
transplant mice. CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, kit 
positiv  cells w re isolated and transplanted into WT CD45.1 animal  WT(+/+CD36)
or  WT(-/-CD36). Post engraftment mice were treated with S. typhimurium. 96 hours 
post S. typhimurium treatment the animals were sacrificed, and the BM was 
extracted, the cells were analysed by flow cytometry for CD45.1 expression to 




Figure 5.44. Elevated levels of FFA in the serum of WT(-/-CD36) mice 
following S.typhimurium infection.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT (+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S.typhimurium for 96 hours. Blood was taken 
from the animals by cardiac puncture and the serum was assessed for levels of FFA. 
n>5 in each group. Data shown are means ± SD **P < 0.01 
 
I next determined the importance of CD36 expression on the haematopoietic 
compartment on lipid levels following S.typhimurium infection. Figure 5.45 
show lipid levels were significantly decreased in the WT(-/-CD36) LSK, HSC, ST-
HSC, and LT-HSC compared to the WT(+/+CD36) HSPCs following 
S.typhimurium infection.  
 
 
Figure 5.45. WT(-/-CD36) mice have a reduced lipid content in the HSC 
following S.typhimurium infection.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT(+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S.typhimurium for 96 hours. The animals were 
sacrificed, the bone marrow was extracted stained with a panel of antibodies and 
Bodipy 493/503. Lipid content (Bodipy 493/503 mean fluorescence intensity (MFI)) 
was assessed in specific LSK, HSC, ST-HSC and LT-HSC populations by flow 




























Figure 5.45. Elevated levels of FFA in the serum of WT(-/-CD36) mice following 
S. typhimurium infection. CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, 
kit positive cells ere isol ted and transplanted into WT CD45.1 animals 
WT(+/+CD36) or  WT(-/-CD36). Post engraftment mice were treated with S. 
typhimurium for 96 hours. Blood was taken from th  animals by cardiac puncture 
and the serum was assessed for levels of FFA. n>5 in each group. Data shown 




























































































Figure 5.46. WT(-/-CD36) mice have a reduc d lipid content in the HSC 
following S. typhimurium infection. CD36+/+ CD45.2 or CD36-/- CD45.2 lineage 
negative, kit positive cells were isolated and transplanted into WT CD45.1 
animals WT(+/+CD36) or  WT(-/-CD36). Post engraftment mice were treated with S. 
typhimurium for 96 hours. The animals were sacrificed, the bone marrow as 
extracted stained with a panel of antibodies and Bodipy 493/503 MFI. Lipid 
content (Bodipy 493/503 mean fluorescence intensity (MFI)) was assessed in 
specific LSK, HSC, ST-HSC and LT-HSC populationsby flow cytometry. n>5 in 
each group. Data shown are means ± SD *P < 0.05
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Alongside lipid level quantification, the BM was also stained with a panel of 
antibodies, permeabilised and fixed to assess cell cycling by flow cytometry. 
There was a significant decrease in LSK, HSC, ST-HSC and LT-HSC cell 
cycling from WT(-/-CD36) animals treated with S.typhimurium compared to the 




Figure 5.46. WT(-/-CD36) mice have a reduced HSC Ki67 positive expression 
following S.typhimurium infection.  
CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, CD117 positive cells were 
isolated and transplanted into WT CD45.1 animals WT(+/+CD36) or WT(-/-CD36). Post 
engraftment mice were treated with S.typhimurium for 96 hours. The animals were 
sacrificed, the bone marrow was extracted stained with a panel of HSC antibodies 
and Ki67 to analyse cell cycling in the LSK, HSC, ST-HSC and LT-HSC population. 
Percentage of cycling cells was measured by Ki67 positive cells after S.typhimurium 
treatment. n>5 in each group. Data shown are means ± SD *P < 0.05 **P < 0.01 
 
 
Finally, to determine if the uptake of FFA in response to infection is specific to 
HSCs I developed a transplant model in which WT CD45.1 LK cells were 
isolated and transplanted into CD36-/- mice. Therefore, these animals were 
CD36 knockout but had a WT haematopoietic system. 14 weeks post 
transplantation the animals were treated with LPS for 16 hours (Figure 5.47A). 
The mice were then sacrificed, the BM was extracted, and stained with CD45.1 
PE to monitor engraftment. Figure 5.47B and Appendix Figure 8.1 and 8.3 
confirms equal engraftment of CD45.1 WT cells in recipient CD45.2 CD36-/- 






































































Figure 5.47. WT(-/-CD36) mice have a reduced HSC cell cycling following S. 
typhimurium infection. CD36+/+ CD45.2 or CD36-/- CD45.2 lineage negative, kit 
positive cells were isolated and transplanted into WT CD45.1 animals WT(+/+CD36)
or  WT(-/-CD36). Post engraftment ice were treated with S. typhimurium for 96 
hours. The animals were sacrificed, the bone marrow was extracted stained with 
a panel of HSC antibodies and Ki67 to analyse cell cycling in the LSK, HSC, ST-
HSC and LT-HSC population. Percentage of cycling cells was measured by Ki67 
positive cells aft r S. typhimurium treatment. n>5 in each group. Data shown are 




Figure 5.47. CD45.1 cell engraftment is seen in the bone marrow of CD36-
/- mice transplanted with CD36+/+ LK cells.  
(A) Schematic diagram of experimental design. CD36+/+ CD45.1 lineage negative, 
CD117 positive cells were isolated and transplanted into CD36-/- CD45.2 animals. 
Post engraftment mice were treated with LPS for 16 hours and cells were analysed 
by flow cytometry. (B) 16 hours post LPS treatment the animals were sacrificed and 
the bone marrow was extracted, the cells were analysed for CD45.1 expression to 
confirm engraftment. n>5 in each group. Data shown are means ± SD 
 
 
I next looked at the effect treatment with LPS had on CD36 expression in the 
HSPCs from the transplant mice. CD36 expression was elevated in the WT 
HSC LSK, HSC, ST-HSC and LT-HSC transplanted into CD36-/- mice after 




























Figure 5.48. CD45.1 cell engraftment is seen in the bone marrow of 
transplant mice. (A) Schematic diagram of experimental design. CD36+/+ 
CD45.1 lineage negative, kit positive (LK) cells were isolated and transplanted 
into CD36-/- CD45.2 animals. Post engraftment mice were treated with LPS for 16 
hours and cells were analysed by flow cytometry. 16 hours post LPS treatment 
the animals were sacrificed, and the BM was extracted, the cells were analysed
for CD45.1 expression to confirm engraftment. n>5 in each group. Data shown 




Figure 5.48. CD36 expression is elevated in CD36-/- mice transplanted 
with CD36+/+ LK cells following LPS treatment.  
CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS for 16 hours. The animals were sacrificed, the bone marrow was extracted and 
stained with a panel of antibodies to analyse CD36 expression in specific LSK, HSC, 
ST-HSC and LT-HSC populations. n>5 in each group. Data shown are means ± SD 
*P < 0.05 **P < 0.01 
 
Moreover, lipid content within the LSK, HSC, ST-HSC and LT-HSC was 
significantly increased in the WT CD36+/+ into CD36-/- mice in response to LPS 
treatment. This increase in lipid content observed was similar to the WT 
response to LPS (Figure 5.49). 
 
 
Figure 5.49. LPS induces an increase in lipid content in the 
haematopoietic populations of the CD36-/- mice transplanted with CD36+/+ 
LK cells.  
CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS for 16 hours. The bone marrow was extracted and stained with a panel of 
antibodies and Bodipy 493/503 to analyse lipid content (Bodipy 493/503 mean 
fluorescence intensity (MFI)) in specific Lin-, LSK, HSC, ST-HSC and LT-HSC 



































Figure 5.49. CD36 expr ssion s elevated in transplant mice following LPS 
treatment. CD36+/+ CD45.1 lineage negative, kit positive (LK) cells were isolated 
and transplanted into CD36-/- CD45.2 animals. Post engraftment mice were 
treated with LPS for 16 hours. The animals were sacrificed, the bone marrow 
was extracted and stained with a panel of antibodies to analyse CD36 
expression in specific LSK, HSC, ST-HSC and LT-HSC populations. n>5 in each 





































Figure 5.50. LPS induces an increase in lipid content in the haematopoietic 
populations of the transplant mice. CD36+/+ CD45.1 lineage negative, kit 
positive (LK) cells were isolated and transplanted into CD36-/- CD45.2 animals. 
Post engraftment mice were treated with LPS for 16 hours. The bone marr w 
was extracted and stained with a panel of antibodies and Bodipy 493/503 to 
analyse lipid content (Bodipy 493/503 mean fluorescence intensity (MFI)) in 
specific Lin-, LSK, HSC, MPP, ST-HSC and LT-HSC populations.n>5 in each 
group. Data shown are means ± SD *P < 0.05 **P < 0.01
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Next, to determine if the increase in lipid content was due to uptake of FFA, 
LK cells were isolated from the transplant mice and incubated with Bodipy FL-
C12 for 30 minutes. Similar to the WT animal, increased FFA uptake was 
observed in the LK cells from the LPS treated transplant mice compared to 




Figure 5.50. LPS induces an uptake of FFA in the haematopoietic 
progenitor populations of the CD36-/- mice transplanted with CD36+/+ LK 
cells.  
CD36+/+ CD45.1 lineage negative, CD117 positive (LK) cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS for 16 hours. The animals were sacrificed, and the bone marrow extracted. LK 
cells were isolated and incubated with Bodipy FL-C12 and fluorescence was 
measured. n>5 in each group. Data shown are means ± SD *P < 0.05 
 
In addition to engraftment, CD36 expression and lipid content, the BM was 
also stained with a panel of antibodies, permeabilised and fixed to assess 
HSPC cycling. Figure 5.51 shows there was increased LSK, HSC, ST-HSC 






















Figure 5.51. LPS induces an uptake of FFA in the haematopoietic progenitor 
populations of the transplant mice. CD36+/+ CD45.1 lineage negative, kit 
positive (LK) cells were isolated and transplanted into CD36-/- CD45.2 animals. 
Post engraftment mice were treate  wit  LPS for 16 hours. The animas were 
sacrificed, and the bone marrow extracted. LK cells were isolated and incubated 
with Bodipy FL-C12 and fluorescence was measured. n>5 in each group. Data 




Figure 5.51. LPS increases Ki67 expression in HSC in the CD36-/- mice 
transplanted with CD36+/+ LK cells.  
CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS. Following 16 hours of LPS treatment, the animals were sacrificed, and the bone 
marrow extracted. The bone marrow was stained with a panel of HSC antibodies and 
Ki67 to analyse cell cycling in the LSK, HSC, ST-HSC and LT-HSC population. 
Percentage of cycling cells was measured by Ki67 positive cells after LPS treatment. 
n>5 in each group. Data shown are means ± SD *P < 0.05 **P < 0.01 
 
To investigate if the increase in cell cycling was associated with an increased 
cell number, HSPC cell count per 100 000 BM cells was assessed by flow 
cytometry. Comparable to the WT response to infection, Figure 5.52 confirms 
a significant increase in cell number of LSK, HSC, ST-HSC and LT-HSC 
populations per 100 000 BM cells following and LPS treatment. 
 
 
Figure 5.52. LPS increases HSC numbers per 100 000 BM cells counted 
in CD36-/- mice transplanted with CD36+/+ LK cells. 
CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS. Following 16 hours of LPS treatment, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to analyse cell number 
per 100 000 bone marrow cells in specific LSK, HSC, ST-HSC and LT-HSC 








































Figure 5.51. LPS induces HSC cell cycling in the transplant mice. CD36+/+ 
CD45.1 lineage negative, kit positive (LK) cells were isolated and transplanted 
into CD36-/- CD45.2 animals. Post engraftme t mice w re treated with LPS. 
Following 16 hours of LPS treatment, the animals were sacrificed, and the bone 
marrow extracted. The bone marrow stained with a panel of HSC antibodies and 
Ki67 to analyse cell cycling in the LSK, HSC, ST-HSC and LT-HSC population. 
Percentage of cycling cells was measured by Ki67 positive cells after LPS 
































Figure 5.52. LPS incre s s HSC numbers per 100,000 BM cells c unted in 
transplant mice. CD36+/+ CD45.1 lineage negative, kit positive (LK) cells were 
isolated and transplanted into CD36-/- CD45.2 animals. Post engraftment mice 
were treated with LPS. Follo ing 16 hours of LP  treatment, the animals were 
sacrificed, the bone marrow was ex racted and stained with a panel of antibodies 
to analyse cell number per 100 000 bone marrow cells in specific LSK, HSC, ST-




Next to understand the metabolic changes in the HSPCs from the transplant 
mice after LPS treatment, I used the mitochondrial extracellular flux assay. 
LSKs isolated from LPS treated transplant animals had an increased basal 
and maximal respiration compared to the control LSKs (Figure 5.53A and B).  
 
 
Figure 5.53. LSKs from CD36-/- mice transplanted with CD36+/+ LK cells  
have an increased OCR following LPS infection.  
(A) CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS. Following 16 hours of LPS treatment, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to isolate the LSK 
population by FACS and OCR levels were measured by extracellular flux assay. (B) 
Basal mitochondrial respiration (normalised to rotenone) and maximal mitochondrial 
respiration of LSK cells from control and LPS treated transplant mice. n>5 in each 































































Figure 5.53. LSKs from transplanted mice have an incr ase  OCR following 
LPS infection. (A) CD36+/+ CD45.1 lineage negative, kit positive (LK) cells were 
is lated and transplanted into CD36-/- CD45.2 animals. Post engraftment mice 
were treated with LPS. Following 16 hours of LPS treatment, the animals were 
sacrificed, The bone marrow was extracted and stained with a panel of 
antibodies to isolate the LSK population by FACS and OXPHOS levels were 
measured by OCR. (B) Basal mitochondrial respiration (normalised to rotenone) 
and maximal mitochondrial respiration of LSK cells from control and LPS treated 
transplant mice. n>5 in each group. Data shown are means ± SD
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Next, to assess glycolysis in the LSK from the control and LPS treated 
transplant animals, ECAR was measured. Similar to WT animals, glycolysis 
was not significantly upregulated in the LSKs from the LPS treated transplant 
animals compared to control transplant animals (Figure 5.54A and B). 
Together these data show that CD36 on the HSC is essential for the 
haematopoietic response to infection. 
 
 
Figure 5.54. LSKs from CD36-/- mice transplanted with CD36+/+ LK cells 
no change in basal ECAR after LPS infection.  
(A) CD36+/+ CD45.1 lineage negative, CD117 positive cells were isolated and 
transplanted into CD36-/- CD45.2 animals. Post engraftment mice were treated with 
LPS. Following 16 hours of LPS treatment, the animals were sacrificed, the bone 
marrow was extracted and stained with a panel of antibodies to isolate the LSK 
population by FACS. ECAR was measured by extracellular flux assay (B) Basal OCR 
(normalised to rotenone) vs basal ECAR of control and LPS treated transplant mice. 
n>5 in each group. Data shown are means ± SD  




























Figure 5.54. LSKs from tr nsplanted m c no change in basal glycolysis  
after LPS infection. (A) CD36+/+ CD45.1 lineage negative, kit positive (LK) cells 
were isolated an  tran planted into CD36-/- CD45.2 animals. Post engraftment 
mice were treated with LPS. Following 16 hours of LPS treatment, the animals 
were sacrificed, The bone marrow was extracted and stained with a panel of 
antibodies to isolate the LSK population by FACS. Glycolysis levels were 
measured by ECAR. (B) Basal OCR (normalised to rotenone) vs Basal ECAR of
control and LPS treated transplant mice. n>5 in each group. Data shown are 





In the final results chapter of my thesis I have presented data to show HSCs 
have an increased lipid content following infection. This lipid increase is due 
to the acquisition of FFA into the cells and causes a metabolic shift in the HSCs 
towards a dependency on β-oxidation as a source of energy. Moreover, the 
inhibition of β-oxidation leads to decreased OCR and subsequent reduction of 
Ki67 positive cells. I have also shown the acquisition of FFA into the HSC is 
regulated by the membrane fatty acid transporter CD36. Without CD36 
expression on the HSC during infection, there is an impaired uptake of FFA 
and an increased use of glycolysis as the metabolic pathway to generate ATP. 
There is also a decreased cell cycling which leads to an increased 
susceptibility to the infection and enhanced mortality. Overall, HSCs take up 
FFA into the cell via CD36 which leads to an increased dependency on β-












6 Discussion and Conclusions 
 
6.1 General discussion 
 
Infectious diseases have been a major selective pressure in mammalian 
evolution and are still a leading cause of global mortality. Of the top 10 causes 
of global death in 2019, two are communicable or infectious diseases, 
diarrhoeal diseases and lower respiratory infections (382). The innate immune 
response to the challenge of infection must be rapid and robust to generate 
significant numbers of leukocytes in a short space of time. The most abundant 
leukocyte found in mammals are neutrophils and they contribute to infection 
resolution by activation of other lymphocytes, capturing microbes within 
extracellular traps, phagocytosis and enzyme mediated lysis (383). During 
infection neutrophil and other immune cell turnover is colossal, there is an 
increased demand and the haematopoietic system responds by rapidly 
switching from steady-state haematopoiesis to emergency granulopoiesis 
(384). This transition involves interactions between both haematopoietic and 
non-haematopoietic cells of the BM microenvironment including exchange of 
cytokines and growth factors (385-387). BMSC specifically have previously 
been shown to support the increased demand for haematopoiesis during 
inflammatory conditions, preventing HSC exhaustion (388). The change from 
steady-state to emergency haematopoiesis places substantial metabolic 
demand on the haematopoietic system.  A better understanding of the 
metabolic changes in the HSC during normal physiological stress can help in 
understanding how these processes can become dysregulated in diseases 
such as ageing and cancer.   
 
In this thesis I have described the process of mitochondrial transfer from 
BMSC to haematopoietic progenitors to support the innate immune response 
to acute infection. Additionally, I have identified a mechanism regulating this 
transfer and subsequent onset of emergency haematopoiesis by an increase 
in mitochondrial content causing a metabolic change in the HSC before 
mitochondrial biogenesis can occur. I have also identified a substrate used by 
the mitochondria during infection, the HSCs take up FFA to support the 
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increased metabolic demand. Moreover, this study established the 
mechanisms governing the uptake of the FFA into the HSC, without which 
leads to an enhanced susceptibility to the infection causing mortality.  
 
6.2 Key findings 
 
6.2.1 Mitochondrial transfer in the bone marrow 
In this thesis, I have shown mitochondria are trafficked from the BMSC to the 
HSC during infection, adding to the many cells types which undergo 
intercellular mitochondrial transfer.  
HSCs have previously been shown to be utilise glycolysis as opposed to 
mitochondrial OXPHOS to meet their energy demands, a metabolic adaptation 
influenced by their hypoxic niche (245). This preference for glycolysis reflects 
the low metabolic demands of the quiescent HSC as OXPHOS is the most 
efficient pathway for energy production (389). The reduced reliance on 
mitochondrial function in the HSC allows for maintenance of low ROS levels, 
as HSCs are vulnerable to oxidative stress (351, 390). Furthermore, it has 
been shown that HSC mitochondria are relatively inactive (287) and ROS 
associated with mitochondrial activity is lower in the HSC compared to the 
more committed progenitors (245, 288). This suggests HSCs require a rapid 
burst of mitochondrial metabolism for differentiation. Whilst it is known that 
HSCs switch from glycolysis to OXPHOS for the increased energy demand 
required for differentiation, the mechanisms regulating this switch remains to 
be elucidated. However, it is probable, the metabolic change is more complex 
than a switch from one metabolic pathway to another. This metabolic switch in 
the HSC may have evolved from an increase in energy demand for rapid 
differentiation in response to exogenous stress. Here I find pathogenic stress 
initiates an increase in mitochondrial mass within the HSC prompting a 





Notably, it has been shown that HSCs undergoing self-renewal need to 
minimise mitochondrial activity to remain quiescent (247, 286, 391). Moreover, 
these HSCs have been shown to have a higher long term multilineage 
reconstituting ability in both primary and secondary transplants compared to 
HSCs with increased mitochondria membrane potential, indicating 
mitochondrial biogenesis (392). This may suggest, whilst I find HSCs have an 
increased mitochondrial mass during infection there may be a subset of HSCs 
which do not have an increased mitochondrial content to maintain self-renewal 
and replenish the HSC pool without exhaustion.   
 
Given the supporting data on increased mitochondrial activity in the more 
committed progenitor cells it would be expected that these cells also have an 
increased mitochondrial content during infection. However, I find two hours 
following LPS treatment there is no increase in the mitochondrial content in 
the committed progenitor populations. Mitochondrial respiration occurs in 
immune cells however, the rate of consumption is dependent on the specific 
cells state of reactivity. It has previously been reported that activated immune 
cells could favour glycolysis due to it generating ATP more rapidly than 
OXPHOS (393). Moreover, the metabolic profile of the committed progenitors 
differs from that of the HSCs (247). Therefore, this could be the reason why 
the more committed progenitors do not have an increased mitochondrial mass 
following infection.  
 
Intercellular mitochondrial transfer is increasingly becoming recognised as a 
fundamental process occurring in both malignant and non-malignant tissue. In 
a malignant setting the mitochondrial trafficking to the tumour cells increases 
ATP production through enhanced OXPHOS which enables the progression 
of lung (293), breast (394), melanoma (298) and ovarian (394) cancer. In 
addition, my lab group has shown that mitochondria are transferred from the 
BMSC to the AML blasts in a NOX2 dependent manner. The mitochondrial 
transfer promoted an increase in OXPHOS in the AML and inhibition of NOX2 
prevented the transfer of mitochondria decreasing AML survival (41). 
Moreover, this caused an upregulation of PGC-1α driven mitochondrial 
biogenesis in the BMSC (395). Non- malignant cells have also been shown to 
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acquire mitochondria from an adjacent cell. BM derived stromal cells protect 
against acute injury by mitochondrial transfer to the pulmonary alveoli following 
LPS treatment (295). In the first chapter of my thesis I established 
mitochondrial transfer occurs in a non-malignant haematological system 
following pathogenic stress. Therefore, suggesting that mitochondrial transfer 
to AML is a process which has been hijacked from the highly evolved normal 
HSC physiological response to infection. It also provides a paradigm in which 
other malignant cells, established to be dependent on mitochondrial transfer 
for survival, have evolved from the non-malignant counterpart which use 
mitochondrial transfer in response to stress. It is also likely many non-
malignant cells which have a strong association with adjacent cells may 
undergo mitochondrial transfer.  
 
6.2.2 Mitochondrial biogenesis and infection  
 
Importantly in this study I found that this mitochondrial transfer occurred from 
the BMSC to the HSC before the onset of mitochondrial biogenesis. It has 
previously been shown the transition from quiescent to active HSCs is 
inherently associated with increased mitochondrial biogenesis (396-399). 
During the transition, mitochondrial health is tightly regulated by mitochondrial 
unfolded protein response (UPRmt). Moreover, SIRT7 a vital component of 
UPRmt can supress mitochondrial biogenesis to conserve the HSC pool under 
stress (400). These data highlight the HSCs ability to activate numerous 
mechanisms to regulate metabolic activity, which is a fundamental 
determinant of HSC maintenance and cell fate. It also suggests HSCs critically 
need to increase their mitochondrial mass prior to undergoing differentiation. 
In context, I find within two hours of LPS infection mitochondrial biogenesis is 
not upregulated, therefore the mitochondrial transfer to the HSC is vital to 
increase mitochondrial mass for HSC activation in response to the infection.  
 
Whilst I found biogenesis was not upregulated two hours after infection, I did 
find PGC-1α mRNA was upregulated. PGC-1α is a co-transcriptional activator 
which is a central regulator of mitochondrial biogenesis (401). PGC-1α 
activates various transcription factors including NRF1 and NRF2, which in turn 
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promotes Tfam expression driving transcription and replication of mtDNA 
(402). However, PGC-1α has also been highlighted to regulate ROS levels 
within the cell by elevating the expression of various ROS-detoxifying 
enzymes. Excess ROS within the cell can cause damage to DNA, lipids and 
proteins. St-Pierre et al. 2003 reported expression of PGC-1α in muscle cells 
increased the expression of superoxide dismutase 2 (SOD2) and glutathione 
peroxidase 1 (GPX1), which remove superoxide and hydrogen peroxide 
respectively (403). Moreover, PGC-1α expression improved cell survival in 
oxidative stress conditions (404) whilst reduced expression sensitised cells to 
oxidative stress (405). This suggests the alongside the initiation of 
mitochondrial biogenesis, the increased expression of PGC-1α seen at 2 
hours following LPS infection may be to maximise ATP production whilst 
preventing oxidative damage in the cell. 
 
Furthermore, there is increasing evidence to suggest PGC1α also regulates 
the intrinsic properties of the mitochondria, which can impact oxidative 
metabolism and gene expression changes (401). Mitochondria isolated from 
muscle cells of transgenic mice ectopically expressing PGC1α had a greater 
capability for substrate oxidation compare to wild type mice (403). Therefore, 
the new mitochondria that are imported in the presence of PGC1α following 
infection, could have different properties including a higher ability to oxidise 
substrates compared to the original organelles.  
 
6.2.3 BMSC and stressed haematopoiesis  
 
It is becoming more apparent that HSCs heavily rely on the supportive BM 
microenvironment for HSC maintenance and differentiation. BMSC 
specifically, can support haematopoiesis through both direct and indirect 
mechanisms and therefore, are a key component of the HSC cell niche (406). 
My results contribute to the evidence, I have shown during infection BMSC 
donate their mitochondria to the HSCs for an increased metabolic capacity. It 
has also been shown this process occurs from the HSC to the BMSC through 
CX43 mediated gap junctions (324). The mitochondria were shown to be 
transferred to the BMSC to modulate ROS within the HSC. However, this 
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research was a conference abstract therefore, limited conclusions can be 
made. Nonetheless, it is clear mitochondrial transfer between HSC and the 
microenvironment is a fundamental process that occurs to support 
haematopoiesis.  
 
Mitochondrial transfer involving BMSCs has also been reported in many 
malignant haematopoietic cells including AML (41) and ALL (407) to enhance 
proliferation and survival. Moreover, AML stimulates mitochondrial biogenesis 
in BMSCs ensuring the BMSCs remain a viable, continual source of 
mitochondria (408). Although not researched in this thesis, I believe a similar 
process occurs in BMSCs following infection to ensure a constant supply of 
mitochondria to the HSC. Taken together the BMSC is a key supportive cell in 
both malignant and non-malignant haematopoiesis.  
 
6.2.4 ROS and infection 
 
It has been well reported that ROS production is rapidly increased in response 
to infection. This acts to facilitate clearance of the pathogen and activate 
signalling cascades associated with cell proliferation and inflammation (409, 
410). The two sources of ROS which have been well characterised during host 
cell- microbial interaction are the mitochondrial electron transport chain and 
membrane associated NOX complex. The NOX complexes are typically 
associated with phagocytic cells which have a rapid respiratory burst 
mechanism to generate ROS (411). NOX machinery has also been found in 
numerous non-phagocytic cell types including epithelial and endothelial cells 
(412, 413). NOX2 specifically, located on monocytes/macrophages is vital in 
the immune response to bacterial infection and defects in the enzyme leads to 
CGD (233). It has been shown that BM microenvironment myeloid cell derived 
NOX2 ROS plays a crucial role in facilitating emergency granulopoiesis during 
infection (414). Moreover, it is known that NOX2 activation is crucial for 
microbial management, however the direct mechanism linking the initiation of 
the complex and pathogen elimination is not yet clear. In this study I have 
shown the production of NOX2 derived ROS by the macrophages increases 
oxidative stress in BMSC and the HSC driving mitochondrial transfer. 
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Moreover, mitochondrial transfer from the BMSC to the HSC was reduced in 
mice with the inability for phagocytic NOX2 production. Overall this suggest 
that NOX2 derived ROS is vital for the immune response to acute infection. 
 
6.2.5 Macrophages in the HSC niche 
 
Macrophages play a significant defensive role in combatting infection by 
responding to systemic signals via expression of many cytokines and 
chemokines (415). Many studies have shown that macrophages also play a 
key role in the regulation of HSCs. Tissue specific BM macrophages promote 
HSC retention by regulating osteolineage cells and BMSCs, thus 
antagonising the SNS-mediated inhibition of HSC retention in the BM (77, 
355, 356, 416). In vivo depletion of macrophages using genetic models or 
clodronate-loaded liposomes promotes the mobilization of HSPCs into the 
blood (355). Furthermore, BM CD169+ macrophages promote the retention 
of HSCs in the BM by inducing the expression of CXCL12 (77). Moreover, a 
rare population of macrophages that are α-smooth muscle actin positive, 
localized adjacent to HSCs, may protect HSCs from exhaustion by limiting 
the production of ROS under stress (417). My research shows in the 
absence of macrophages there is a significant decrease in macrophage 
generated NOX2 ROS following infection. This leads to a reduction of 
mitochondrial mass and subsequent block on cell number increase within 
the HSPC populations. Therefore, regulation of HSC mitochondrial content 
by production of NOX2 derived ROS can be added to the list of key roles of 
the macrophage during acute infection.  
 
6.2.6 Gap junctions; the mitochondrial transporter 
Mitochondria have previously been shown to be transferred intercellularly by 
TNTs (293, 394, 418, 419), extracellular vesicles (296) and gap junctions 
(295). During infection I found mitochondria was transferred from the BMSC 
to the HSC via CX43 mediated gap junction. The gap junction inhibitor CBX 
and the CX43 memetic peptide Gap27 reduce mitochondrial transfer between 
BMSC and the HSCs. Interestingly, whilst AML is the malignant counterpart to 
264 
 
the HSPCs the mechanism of mitochondrial transfer differed. Transfer of 
mitochondria from the BMSC to the AML was shown to be facilitated by TNTs 
and inhibition of TNT formation by CytoB blocked this mitochondrial transfer 
(41). I found that inhibition of TNT formation by CytoB has no effect on 
mitochondrial content in the HSC. This could be due to the HSC residing in 
close proximity to the BMSC within the niche allowing for gap junction 
formation between these cells (420). CytoB is commonly used for inhibiting 
TNTs however it works by inhibiting actin therefore is not specific to inhibiting 
the formation of TNTs. Thus, mitochondria could move through TNTs to the 
HSC however the gap junction’s formation is the critical mechanism in 
regulating mitochondrial transfer during infection. 
Gap junctions are plasma membrane channels that allow for the direct 
interchange of cytoplasmic components between adjacent cells (319). They 
enable the exchange of small molecules including ions, second messengers 
(e.g. Ca2+, IP3, cAMP), metabolites, individual amino acids and short peptides 
through a regulated gate (320). This raises the question during infection what 
else moves between the BMSC and the HSC besides mitochondria? To further 
understand the physiological response to infection, it would be interesting to 
determine the extent of the transfer between HSC and BMSC. Unfortunately, 
this was not in the scope of my PhD but hopefully will be investigated in the 
future.  
It has been reported that mitochondrial transfer is bi-directional and 
mitochondria transfer from T-ALL cells to BMSC via TNTs (421). This transfer 
was found to reduce levels of ROS in the T-ALL cells. This was similar to Golan 
et al. 2016, where mitochondria were transferred to the BMSCs to modulate 
ROS within the HSC (324). High levels of mitochondrial ROS have been 
associated with dysfunctional mitochondria (422) therefore in these studies the 
transferred mitochondria could be dysfunctional. It would be interesting to 
investigate if HSCs are exporting dysfunctional mitochondria during infection 




6.2.7 PI3K and infection  
 
PI3Ks are a family of lipid kinases key in mediating many intracellular 
signalling cascades involved in proliferation and survival (423). PI3Ks are 
comprised of a catalytic subunit and a regulatory subunit, the regulatory 
subunit stabilises and blocks the catalytic subunit (424). PI3K phosphorylates 
phosphoinositide and produces phosphoinositide-3,4,5-trisphosphate (PIP3), 
this then recruits the downstream signalling factor protein kinase AKT (368). 
Previous studies have shown increased ROS is linked to an increased PIP3 
signalling and subsequent AKT signalling (367). PI3Ks have also been shown 
to modulate NOX complex’s by regulation of Rac activity (425). In my thesis I 
have shown that phosphorylated AKT (pAKT) is upregulated in the BMSCs 
and the HSCs following acute infection and ROS alone can cause this 
upregulation.  
 
Moreover, I find PI3K regulates the movement of mitochondria from the 
BMSCs to the HSC. Inhibition of PI3Kδ by Cal 101, significantly reduces 
mitochondrial transfer and leads to a dysfunctional immune response to acute 
infection. Cal 101 is also used as a second line drug in the treatment of chronic 
lymphocytic leukaemia (CLL) (426). It was reported however, Cal 101 caused 
serious adverse effects including death, mostly due to infection (427). This 
suggests inhibition of mitochondrial transfer may have been the cause of the 
increased susceptibility to infection.  
 
6.2.8 Fatty acid uptake 
 
In the past several years, the metabolic requirements for HSC function have 
been investigated (245, 428-431). However, many studies have focused on 
glycolysis and the maintenance of HSCs under normal conditions and the 
contribution of lipid metabolism under stress has not been fully appreciated. 
The HSC energy requirements during differentiation and expansion following 




For optimal use of all substrates available and to optimise energy requirements 
cells can reprogramme protein localisation, turnover and gene expression 
(432). The first stage in nutrient homeostasis is uptake of the nutrient by the 
cells, which often involves many specific membrane receptors. This is  
followed by a downstream network of proteins for intracellular nutrient traffic 
or signal transduction (433). Long chain fatty acids are a common nutrient 
found in the diet and a major source of energy for many cells (434, 435). Fatty 
acids can also regulate the expression of genes by transcription factors such 
as peroxisome proliferator-activated receptors (PPARs) (436, 437) which 
regulate numerous metabolic genes (438) and FoxO1 (439) important for 
adapting to low nutrient availability (440). The liver and adipocyte tissue are 
the only tissues which possess the ability for de novo fatty acid synthesis, all 
other cells depend on fatty acid uptake for their metabolic needs (441). This 
emphasises the physiological importance of fatty acid uptake into cells. In this 
study I have identified that HSCs take up FFA in response to acute infection 
and this uptake is critical to the immune response.   
 
FFA uptake is now commonly recognised as an essential process, sustaining 
cell metabolism in both malignant and non-malignant cells. In a non-malignant 
setting, quiescent HSCs have a high rate of fatty acid oxidation, and inhibition 
of fatty acid oxidation leads to HSC dysfunction (26). Furthermore, in 
malignant cells FFA are used as a major energy source in ovarian (442) and 
prostate cancers (443). This  process is similar to observations in AML, FFAs 
are taken up by the AML blasts to enhancing proliferation through a 
mechanism which increases β-oxidation in the blast (42). This, therefore, 
suggests that FFA uptake by AML is again a process which has been hijacked 
from the normal physiological response to stress.  
 
6.2.9 Metabolic switch during infection   
 
When HSCs undergo differentiation in response to stress, I have shown there 
is a metabolic switch towards mitochondrial OXPHOS which is associated with 
elevated ROS. The question still remains what fuels the TCA cycle in response 
to infection. Single cell gene expression analysis has shown that FAO plays a 
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crucial role in HSC expansion (335). FAO has also been associated with HSC 
maintenance via the PML-Peroxisome proliferator-activated receptor delta 
(PPARδ) pathway by regulating asymmetric division (26). Inhibition of FAO 
causes HCSs to undergo symmetric divisions leading to HSC exhaustion and 
depletion of the stem cell pool (26). FAO has also been shown to be pertinent 
in sustaining ATP production in breast epithelial cells when contact is lost with 
the extracellular matrix (444). Therefore, this suggests increased ATP 
production by FAO may protect HSCs following differentiation when contact is 
lost with the BM niche. Moreover, a recent study has shown when mice 
undergo short term starvation there is a decrease in the number of HSC (445). 
This data further suggested HSC differentiation is reliant on FAO as a loss in 
HSC number may be attributed to an increased FAO during starvation causing, 
the HSC to undergo differentiation initiating a loss of the HSC pool.  
 
It has not yet been investigated if FAO is the preferred metabolic pathway in 
HSC differentiation. Models using Drosophila have demonstrated FAO is 
critical for the differentiation of blood cell progenitors and the progenitors are 
unable to differentiate in the absence of FAO (446). Interestingly it has been 
reported that muscle stem cells (447), endothelial precursors (448), intestinal 
stem cells (449) and neural stem cells (450) all have a metabolic dependence 
on FAO. In this study I add HSCs to the list of cells that are dependent on FAO 
metabolism. I show during infection HSCs take up FFA this in turn causes a 
rapid shift from baseline, quiescent glycolytic metabolism to increased 
dependency on FAO. Furthermore, mitochondria are the main site for FAO 
where the fatty acids are broken down to generate ATP (451). This suggests 
the imported mitochondria in the HSC following infection could be using the 
acquired fatty acids to fuel FAO. 
 
6.2.10 CD36; the fatty acid transporter 
In this thesis I have reported HSCs take up FFA during infection and this is 
through upregulation of the fatty acid translocase or CD36 located on the cell 
surface. CD36 is a scavenger receptor class B family of proteins involved in 
metabolism, immunity, angiogenesis and atherosclerosis (452). It is a 
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membrane glycoprotein which is present on, mononuclear phagocytes, 
platelets, hepatocytes, myocytes, adipocytes, and other haematopoietic cells 
(453). CD36 binds and facilitates the transport of long chain fatty acids and 
can function as a regulator of these processes (454, 455). 
In the past few years CD36 has been studied considerably for its role in 
mediating  fatty acid uptake and subsequent oxidation in the pathophysiology 
of the liver (456) and the heart (457) associated with dysregulated fatty acid 
metabolism (458). Moreover, the presence of CD36 on pluripotent stem cell 
derived cardiomyocytes was found to be a marker of maturation and can be 
used to define more mature cells (459). This suggests during infection 
upregulation of CD36 could be used as a marker of HSC differentiation. In fact, 
because CD36 is expressed on numerous cell types, and the plurality of the 
disease phenotypes related to CD36 function, to study CD36 function in HSCs 
I decided to develop the transplant model system. This model used CD36 
knockout on HSCs transplanted into wild type animals, rather than using CD36 
global knockout animals for this study. In context, I find cell-autonomous 
requirement of CD36 upregulated in the HSCs facilitates fatty acid uptake, 
allowing HSC expansion and enabling the immune response to infection. 
CD36 has also been implicated in adipocyte differentiation, upregulation of 
CD36 was correlated with enhanced differentiation  and adipogenesis and 
silencing of  CD36 impaired these processes (453). This could suggest if there 
is upregulation of CD36 on the adipocytes following infection this could 
function to increase adipogenesis, creating more adipocytes for the release of 
FFAs. However, due to the lack of ability to look at adipocytes in the bone 
marrow I was unable to study this but hopefully this can be investigated in the 
future.  
CD36 has numerous functions other than fatty acid uptake including 
recognition and internalisation of pathogens. Macrophages deficient of CD36 
have demonstrated a reduced Staphylococcus aureus (S.aureus) 
internalisation and a marked reduction in IL 12 and tumour necrosis factor-α 
and production (460). This resulted in an inability to clear the S.aureus causing 
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the presence of the bacteria in the bloodstream (460). This data complicates 
the interpretation of the survival studies in the transplant CD36-/- mice in terms 
of the role of HSC FAO. As this is a transplant model in which the 
haematopoietic system is CD36 knockout there would be a number of tissue 
macrophages which remained WT however they also would also be CD36 
deficient macrophages in the model. Therefore, the impaired response to 
infection may also be due to CD36 knockout macrophages inability to respond 
to the pathogenic stress. However, in this model during infection we do see an 
activation of glycolysis in the HSC which is not seen in control cells suggesting 
the cells are actively trying to generate ATP. Moreover, it has been found at 
early stages of infection with malaria wild type mice have a higher circulatory 
proinflammatory cytokines and lower anti-inflammatory cytokines than CD36 
knockout mice. However, at later stages of infection the inflammatory profile 
was comparable between wildtype and CD36 knockout mice. I do find HSCs 
have an increased CD36 expression which facilitates fatty acid uptake into the 
cells following infection. However, to test the specific effect of fatty acid uptake 
in the HSC following infection, I would need a mouse model in which is CD36 
could be knocked out in only the HSCs prior to infection.  
Notably following infection, the gene expression of numerous fatty acid 
transporters were up-regulated. Long chain fatty acid rapidly diffuse across the 
phospholipid membrane (461) and this is regulated by many integral or 
membrane associated proteins (462, 463). The fatty acid transporter proteins 
(Slc27a1, Slc27a4, Slc27a5) (265, 266) are located on the plasma membrane 
and function by coupling fatty acid uptake to the first reaction in FA utilisation 
(263, 463). During infection I find SCL27A4 is upregulated in the HSC during 
infection and therefore may play a role in the trafficking of FFA into the cell. 
FA binding proteins (Fabp1, Fabp3, Fabp4, Fabp5) are also known to be 
important in fatty acid transport (264). FABPs are the plasma membrane 
isoforms of the mitochondrial aspartate aminotransferase which is an enzyme 
involved in maintaining the cytoplasmic/mitochondrial NADH/NAD ratios (464). 
Following infection, I find that FABP3 is upregulated in the HSC, this could be 
a result of cellular redox shuttling to regulate oxidative metabolism. It is 
interesting to note AML utilises FABP4 to support the survival and proliferation 
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of the malignant cells (42) however, I did not find FABP4 to be upregulated in 
the HSC during infection. It is also highly likely there is more than one channel 
through which fatty acids can be transported into the HSC. However, due to 
time restraints I was unable to look at the specific role of these transporters 




Despite the results attained in this thesis, and the progress made in 
understanding the HSC response to infection there are a number of limitations 
which should be considered. The number of mice used in each experiment 
was relatively low, this was to keep in line with the 3Rs (Replacement, 
Reduction and Refinement) to perform more humane animal research. An 
increased number of mice may have led to increased significance in the data 
sets.  
 
Another of the main limitations in this study is the difficultly in assessing the 
true HSC. A lot of the metabolic work was focused on the LSK or the LK, this 
was due to the difficulty in sorting a large number of HSCs from the BM. I also 
encountered problems with availability of the sorter and breakdown of the 
equipment. The length of time the cells are out of the microenvironment could 
also affect the metabolic capacity of these cells. Therefore, the study would 
have greatly benefited from technology to rapidly isolate true HSCs from the 
BM. 
 
Preferably, the isolation of BMSCs from both mouse and humans could have 
been more specific. Mouse BMSC were isolated from the adherent population 
of the BM and characterised as CD45, Ter119 and CD31 negative, CD140a 
and CD105 positive BMSC therefore very heterogeneous population. It would 
be interesting to investigate the specific BMSC population that transferred 
mitochondria to the HSC. Improved techniques in single cell sequencing has 
found there are many different types of BMSCs (141, 142) it would be 
interesting to isolate these populations and analyse mitochondrial transfer to 
the HSC. I was also unable to look at whether in vivo BMSC donate their 
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mitochondria to the HSC during infection. It would be of interest to use a model 
in which the BMSCs specifically have a fluorescent tag on the mitochondria 
and see if following infection, the HSC acquire the tagged mitochondria. 
However, even with this model the tag or mRNA for the tag could be being 
transferred and not the mitochondria themselves.  
Many interpretations in this study have been drawn based on inhibition by 
pharmacological agents. This can be a concern due to non-specific off target 
effects even at steady state haematopoiesis. Where possible I have tried to 
use genetic approach’s either a knockout model or knockdown by shRNA to 
complement the work using pharmacological agents. However, this was not 
possible in every case due to limitations of mouse models or shRNA viruses 
available. 
 
Another limitation is that the majority of the work was undertaken in mouse 
models to represent the true microenvironment. However, it is difficult to know 
how translatable these processes are to humans. It is almost impossible to 
study the microenvironment interactions with the HSC during infection in 
humans, therefore the mouse is the closest model available we can use to 
understand the physiologic processes occurring in humans. The NSG mouse 
model used was also subject to limitations. NSG mice are severely 
immunocompromised allowing the engraftment of human cells without 
rejection. However, the lack of functional B and T cells would undoubtedly 
have an effect on the response to infection. To circumnavigate this issue, I 
used both in vivo and in vitro models to support the conclusion that HSCs 
acquire mitochondria from the BMSC following infection.  
 
It has been shown by many groups investigating stem cells under inflammation 
that HSC marker expression is changed upon acute inflammation. This makes 
the HSC population difficult to analyse when gating flow cytometry data. To 
combat this, I used the additional marker CD34 to gate for the quiescent HSC 





The body’s response to LPS and Salmonella infection differs, whole bacterial 
cells secrete many virulence factors and activate numerous TLRs and PRR to 
regulate the immune response whilst LPS alone activates a TLR4 immune 
response. Therefore, LPS alone may not be truly representative of a bacterial 
infection, however, it is useful in assessing the kinetics of the host response 
to infection. To try and assess the same phase of the inflammatory response 
between LPS and Salmonella on fatty acid uptake I used a time point which 
had similar IL 6 expression in the serum.  
 
6.4 Future work  
 
Although the main aims and objectives of this studied were accomplished, 
there are a few areas which can be developed in the future. Firstly, the 
functionality of the HSC after infection would be of interest. Low mitochondrial 
membrane potential and activity have been shown to be key features of the 
self-renewing human and murine HSCs (392, 465). These HSC also possess 
higher multilineage reconstituting capacity long-term in both primary and 
secondary transplantations (392). I have shown HSCs have an increased OCR 
and mitochondrial potential during infection, however it would be interesting to 
perform secondary transplantation with these HSCs and assess their 
reconstitution capacity and if they exhibit any have any lineage skewing.  
 
I find during infection there is a switch within the HSC from glycolytic 
metabolism towards OXPHOS and β-oxidation. I showed this occurred by 
seahorse metabolic analysis however to understand the significance of this 
switch and the transcriptional change regulating this, it would need to be 
confirmed by more sophisticated biochemical and molecular characterizations 
such as RNA sequencing or single cell RNA sequencing.  
 
In this study I did not look at the source of the FFA during infection. BM adipose 
tissue (MAT) function as an energy source and an endocrine organ which 
accounts for around 70% of the BM in humans (109). Furthermore, the number 
of BM adipocytes increase in both human and mice with age (108, 466). These 
adipocytes have been implicated in many processes including regulation of 
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the haematopoietic niche (121), inflammation (467), osteoporosis (468) and 
bone metabolism (469). Moreover BM adipocytes support the proliferation of 
numerous tumours including AML (42), multiple myeloma (470) and metastatic 
solid tumours (471). Therefore, understanding the role of BM adipocytes in 
supporting the mammalian response to infection remains an important 
question.  
CD36 deficient mice haave a different metabolic profile to wildtype mice it 
would be interesting to investigate if this affects the differentiation ability of 
CD36 deficient HSCs at both steady state and during infection. It would also 
help to determine if the HSC defects are reflected in the number of functional 
myeloid cells already at steady state or specifically found during infection. This 
could be achieved by transplanting control or LPS treated CD36 knockout 
HSCs and testing their multilineage reconstitution potentials. 
 
In this thesis I have underlined the process of FFA uptake and mitochondrial 
transfer to the HSC as the physiological immune response to infection, these 
techniques can now be applied for use in conditions of stress. It would be 
interesting to see if and how these processes are dysregulated in ageing, 
obesity, in adipocyte rich areas, chronic or repeated infection and whether 



















Overall in my thesis I have reported that mitochondrial transfer and FFA uptake 
to the HSC forms part of the complex system modulating how HSCs 
differentiate and sustain haematopoiesis during stress. This process initiates 
a switch within the HSCs from baseline glycolytic metabolism towards 
OXPHOS and β-oxidation to facilitate proliferation and differentiation. The 
mitochondrial transfer occurs early on in the immune response before the 
transcriptional changes for mitochondrial biogenesis transpires, in a system 
evolved to support the rapid requirement for the granulocytic response to 
infection. Moreover, macrophage derived NOX2 ROS acts as the mediator of 
mitochondrial transfer from the microenvironment to the HSC. Mechanistically, 
the ROS facilitates the opening of CX43 gap junctions and is regulated by 
PI3K activation, allowing mitochondrial transfer from the BMSCs to the HSCs. 
In addition, at a later stage of infection transcriptional changes in the HSC, 
initiate upregulation of the fatty acid transporter CD36 facilitating the uptake of 
FFAs. Furthermore, without mitochondrial transfer or FFA uptake HSCs 
cannot switch from glycolysis to OXPHOS and β-oxidation and therefore do 
not enter the cell cycle. This leads to an increased susceptibility and mortality 
to infection. Taken together, the increased mitochondria acquired from the 
BMSCs may provide the extra machinery to metabolise the acquired fatty 
acids. The combination of OXPHOS and FAO have the ability to provide HSC 
with huge amounts of ATP which can be used for rapid proliferation following 
infection. Overall, these data provide new insights into the metabolic changes 
occurring in the haematopoietic system which underpin immune cell 
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Fabp4 GTAAATGGGGATTTGGTCAC  TATGATGCTCTTCACCTTCC
Fabp5 ATGAAAGAGCTAGGAGTAGG TACAAGAGAACACAGTCGTC
CD36 CATTTGCAGGTCTATCTACG CAATGTCTAGCACACCATAAG 
Msr1 GCGGATCAAGATCACTATAAC GGTGAAAGGTCTTTTAAGGAG
LDLR CATCTTCTTCCCTATTGCAC ATGCTGTTGATGTTCTTCAG
CPT1A GGGAGGAATACATCTACCTG GAAGACGAATAGGTTTGAGTTC 
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Taqman®  assay Target Gene Fluorophore Assay Specifics
Human mtDNA ND1 FAM Hs02596873_S1 ND1



















Target Forward Primer Reverse Primer 
COX3 and ND3_1 GGCTACTGGATTCCATGGACTCC TGTGTTCATTCATATGCTAGGCCT
COX3 and ND3_2 TGGTTCTACATTCTTCATGGCTACTGG TTTTGTGTTCATTCATATGCTAGGCCT
ND4_1 ACACTTCTATGACAAACCGACGAA GGAGCTTCAACATGGGCTTTTGG
ND4_2 AACCAGCCTAACACTTCTATGACAA GCAATTGGAGCTTCAACATGGGC
Taqman® assays used for mouse and human mtDNA assessment. 
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ND4_1 ACACTTCTATGACAAACCGACGAA GGAGCTTCAACATGGGCTTTTGG
ND4_2 AACCAGCCTAACACTTCTATGACAA GCAATTGGAGCTTCAACATGGGC
Taqman® assays used for mouse and human mtDNA assessment. 





Figure 8.1. Gating strategy for CD4, CD8 and GR1 positive cells.   
C57BL/6J mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein 
injections of PepcBoy lineage negative, CD117 positive donor cells. The peripheral 
blood was monitored at 4 weeks and 8 weeks after transplantation and assessed by 
flow cytometry. (A) The gating strategy for CD4 and CD8 cells is shown. (B) The 






















































Figure 8.2. CD45.1 engraftment in the peripheral blood of CD45.2 
C57BL/6J animals.  
C57BL/6J mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein 
injections of PepcBoy lineage negative, CD117 positive donor cells. The peripheral 
blood was monitored at 4 weeks and 8 weeks after transplantation and assessed by 
flow cytometry. (A) Engraftment was determined by percentage of CD45.1-APC 
expression on the lymphocytes in the peripheral blood (PB) detected by flow 
cytometry analysis. Percentage of CD45.2-FITC expressing lymphocytes in the PB. 
(B) Percentage of CD45.1-APC positive cells in the CD4-PeCy7 positive population. 
Percentage of CD45.2-FITC positive cells in the CD4-PeCy7 positive population. (C) 
Percentage of CD45.1-APC positive cells in the CD8-PeCy5 positive population. 
Percentage of CD45.2-FITC positive cells in the CD8-PeCy5 positive population. (D) 
Percentage of CD45.1-APC positive cells in the GR1-PeCy5 positive population. 























































































































































Figure 8.3. CD45.1 engraftment in the peripheral blood of CD45.2 CD36-/-  
animals.  
CD36-/- mice were treated with 25 mg/kg busulfan for 3 days prior to tail-vein injections 
of PepcBoy lineage negative, CD117 positive donor cells. The peripheral blood was 
monitored at 4 weeks and 8 weeks after transplantation and assessed by flow 
cytometry. (A) Engraftment was determined by percentage of CD45.1-APC 
expression on the lymphocytes in the peripheral blood (PB) detected by flow 
cytometry analysis. Percentage of CD45.2-FITC expressing lymphocytes in the PB. 
(B) Percentage of CD45.1-APC positive cells in the CD4-PeCy7 positive population. 
Percentage of CD45.2-FITC positive cells in the CD4-PeCy7 positive population. (C) 
Percentage of CD45.1-APC positive cells in the CD8-PeCy5 positive population. 
Percentage of CD45.2-FITC positive cells in the CD8-PeCy5 positive population. (D) 
Percentage of CD45.1-APC positive cells in the GR1-PeCy5 positive population. 
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